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Abstract
Darier’s Disease (DD) is a rare autosomal dominantly inherited skin disorder in which 
co-occurrence of neuropsychiatric abnormalities has been frequently reported by 
dermatologists. The disease is caused by mutations in a single gene, ATP2A2, which maps to 
12q23-q24.1 and is expressed in the skin and brain. This gene encodes SERCA2 
(sarco/endoplasmic reticulum Ca2+ ATPase isoform 2), a calcium pump involved in 
intracellular calcium transport.
This study aimed to conduct the first systematic investigation of the neuropsychiatric 
phenotype in DD, investigate possible genotype-phenotype correlations, and compare the 
neuropsychiatric features in DD individuals and their first-degree unaffected relatives.
One hundred unrelated individuals with DD and 24 of their unaffected relatives were 
assessed using a battery of standardised neuropsychiatric measures. The relationship between 
the mutations detected in the ATP2A2 gene and the presence/severity of neuropsychiatric 
phenotypes was examined.
DD individuals reported high rates of mood disorders, specifically major depression 
(30%), suicide attempts (13%) and suicidal thoughts (31%), and these were significantly more 
common in DD when compared with normative population data. Further, individuals with DD 
reported higher scores on measures of neuropsychiatric dysfunction than their unaffected 
relatives. These associations cannot be explained by psychosocial factors. Mutations found 
among individuals with similar neuropsychiatric phenotypes clustered in certain locations 
within the SERCA2b protein. Together, these findings support the hypothesis that mutations 
inATP2A2 confer susceptibility to neuropsychiatric dysfunction, in particular mood disorders, 
in individuals with DD.
These findings highlight the need for assessment and recognition of psychiatric 
symptoms in DD. The findings may also have implications for identification of other genetic 
factors involved in conferring susceptibility to neuropsychiatric features in individuals 
without DD. Further research is needed into other neuropsychiatric phenotypes in DD and 
into the specific functional effects of mutations in ATP2A2 and the relationship of these to the 
presence of certain neuropsychiatric phenotypes.
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1 OVERVIEW OF THESIS
Darier’s Disease (DD) is a rare, genetic skin disorder characterised by a rash mainly 
affecting seborrheic areas. It is caused by mutations in a single gene, ATP2A2, which encodes 
a protein involved in intracellular calcium signalling. A range of neuropsychiatric features, 
including depression, bipolar disorder, epilepsy and learning difficulties, have been reported 
to co-occur in individuals and families with DD. The psychological consequences of having a 
chronic skin disorder are likely to contribute to, but cannot fully explain, this association. 
There is evidence to suggest that mutations in ATP2A2 could have pleiotropic effects in the 
skin and brain suggesting neuropsychiatric features may be part of the DD phenotype. To date 
there has been no systematic investigation of the neuropsychiatric phenotype in DD using 
standardised assessment measures.
The reported association between DD and neuropsychiatric symptoms has obvious 
implications for management and treatment of individuals with DD. Furthermore, 
investigations into the extent and causes of the relationship between neuropsychiatric features 
and DD may identify both genetic and non-genetic factors involved in conferring 
susceptibility to neuropsychiatric disorders in individuals without DD.
This thesis investigates the neuropsychiatric phenotype in DD. The three main aims are:
1. To conduct a systematic investigation of the neuropsychiatric characteristics in a sample of 
100 unrelated individuals with DD using a battery of standardised neuropsychiatric measures.
2. To investigate possible genotype-phenotype correlations between the type and/or locations 
of pathogenic mutations detected in th &ATP2A2 gene and neuropsychiatric features observed 
in this sample.
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3. To compare the presence of neuropsychiatric features in this sample of individuals and their 
first-degree relatives, unaffected by DD.
A brief overview of the thesis is given below:
Chapter 2 describes the clinical and genetic features of DD. This is followed by a review 
of the literature reporting the presence of neuropsychiatric features among individuals with 
DD. The possible explanations for the co-occurrence of neuropsychiatric features in DD are 
then discussed. Finally, the main aims of the thesis are outlined in further detail.
Chapters 3 to 5 are concerned with describing and discussing the investigations carried 
out to examine the clinical features and prevalence of neuropsychiatric features in 100 
unrelated individuals with DD (Aim 1).
Chapter 6 provides a more detailed introduction to the genetics of DD, describing the 
single gene, ATP2A2, in which mutations causing DD have been found to occur and 
describing the protein, SERCA2, which is encoded by ATP2A2.
Chapters 7 to 9 describe the investigations carried out into the relationship between the 
type and/or location of DD causing mutations detected within ATP2A2 and the 
neuropsychiatric phenotypes observed (Aim 2).
Chapters 10 to 12 describe and discuss the investigations carried out to compare the 
presence of neuropsychiatric features in a subset of individuals with DD and their unaffected 
relatives (Aim 3).
Chapter 13 summarises the key findings of the investigations, discusses the limitations 
and implications of these findings, and makes suggestions for further research.
2
2 INTRODUCTION TO DD AND REVIEW OF THE 
NEUROPSYCHIATRIC FEATURES REPORTED IN DD
2.1 Introduction to DD
2.1.1 DD Clinical Features
Darier’s Disease (DD), also known as Darier-White Disease / keratosis follicularis 
(Online Mendelian Inheritance in Man (OMIM) 124200), is a rare autosomal dominantly 
inherited skin disorder. Estimates of prevalence range from 1 in 100 000 (Svendsen & 
Albrectsen, 1959) to 1 in 55 000 (Wilkinson et a l , 1977) to 1 in 30 000 (Tavadia et a l, 
2002). Based on these estimates, there are between 600 and 2000 individuals in the UK with 
DD. The disorder is characterised by a rash of hyperkeratotic/warty papules, which can 
coalesce to form large plaques, predominantly present in seborrheic areas (central truck, neck, 
scalp, hair margins and flexures). Additional features include distinctive nail abnormalities 
including fragile nails with red and white lines and V-shaped notches at the free end. Pits 
and/or keratotic papules, which can be present on the palms or soles, are also a characteristic 
feature of the disease. Histological features include loss of cell-cell adhesion between cells in 
the epidermis (acantholysis) and abnormal, premature keratinisation of epithelial cells 
(dyskeratosis) with abnormal keratinocytes (called corps ronds). Age of onset is generally 
between 11 and 20 years of age and the disorder is equally prevalent in males and females and 
across all ethnic groups. The course of the disorder is characterised by remissions and 
relapses, which can be triggered by heat, sweating, infections, friction and sun exposure 
(Burge & Wilkinson, 1992). The severity of DD varies greatly between individuals including 
those in the same family, ranging from individuals having a few scattered papules or mild nail 
abnormalities to individuals with severe DD having widespread itchy, malodorous plaques. In 
addition to the classical form of DD described above, a small number of individuals have 
different clinical forms including a haemorrhagic form of the disorder, characterised by
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red/black lesions on the palms and soles, and a vegetating form affecting the flexures. DD is 
currently clinically diagnosed by a skin biopsy and is commonly and most effectively treated 
with topical or oral retinoids (Cooper & Burge, 2003). Examples of classic DD affecting the 
back and neck are shown in Figure 2.1 and Figure 2.2 respectively. The characteristic nail 
fragility, ridging and splitting observed in the majority of individuals is illustrated in Figure 
2.3. The haemorrhagic lesions observed on the palms of individuals with the haemorrhagic 
form of the disorder are illustrated in Figure 2.4.
Figure 2.1 DD Affecting the Back
Photograph taken by the author of the current thesis after obtaining consent
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Figure 2.2 DD Affecting the Neck
Figure 2.3 Nail Fragility, Ridging and Splitting in DD
Photographs taken by the author of the current thesis after obtaining consent
Figure 2.4 Haemorrhagic Lesions on Palms
Photograph taken by the author of the current thesis after obtaining consent
2.1.2 Genetics of DD
DD is autosomal dominantly inherited with high penetrance although phenotypic 
expression is variable (Munro, 1992). The disease rarely, if ever, skips a generation (Cooper 
& Burge, 2003) although some family members may have very mild features and be unaware 
that they have the condition. Most individuals with DD will report a family history and/or will 
be found to have relatives with mild disease (Munro, 1992) although spontaneous de novo 
mutations can arise. Linkage analysis mapped DD to chromosome 12q23-q24.1 (Bashir et al., 
1993; Craddock et al., 1993) and the disease was subsequently shown to be caused by 
mutations in a single gene ATP2A2 (Sakuntabhai et al., 1999b). ATP2A2 encodes the 
sarco/endoplasmic reticulum Ca2+ ATPase isoform 2 (SERCA2), a calcium pump involved in 
intracellular calcium signalling (MacLennan et al., 1997). The ATP2A2 gene spans 21 exons 
and has three splice variants (a, b and c) encoding three isoforms of the SERCA2 protein 
namely SERCA2a, SERCA2b and SERCA2c (Gelebart et al., 2003; Lytton & MacLennan,
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1988; Lytton et a l , 1992; Verboomen et a l , 1994). These three isoforms differ in their end 
amino acid sequences (carboxyl termini) and show different tissue expression patterns, 
summarised in Table 2.1. Both the SERCA2a and SERCA2b isoforms have been found to be 
present in the epidermis although the SERCA2b isoform predominates (Ruiz-Perez et al., 
1999; Tavadia et a l , 2004).
Table 2.1 Three Isoforms of SERCA2
Isoform Length 
(amino acids)
Expression
SERCA2a 997 Heart and slow-twitch skeletal muscle
SERCA2b 1042 Smooth muscle and all non-muscle tissue including the epidermis. 
Ubiquitously expressed -‘Housekeeping isoform’
SERCA2c 999 Epithelial, mesenchymal & hematopoietic cell lines and monocytes
All three isoforms are identical up to amino acid 993.
2.1.3 The Sarco/Endoplasmic Reticulum Ca2+ ATPase Isoform 2 
(SERCA2)-Function & Structure
The sarco/endoplasmic reticulum Ca2+ ATPase isoform 2 (SERCA2) is a calcium pump 
located in the endoplasmic reticulum (ER) membrane. SERCA2 belongs to a family of 
SERCA pumps, which includes two other members namely SERCA1 and SERCA3 that are 
encoded by 2 different genes (Lytton et a l , 1992). The pump actively transports calcium ions 
(Ca2+) against a concentration gradient from the cell cytosol into the lumen of the ER by using 
ATP hydrolysis. (MacLennan et a l , 1997), see Figure 2.5. The pump is therefore responsible 
for maintaining low cytostolic and high ER Ca2+ concentrations. The ER constitutes the main 
intracellular Ca2+ store and plays a central role in Ca2+ homeostasis.
The predicted secondary structure of the SERCA2 protein is based on functional studies 
and the published X-ray crystal structures of the SERCA 1 pump (Toyoshima & Mizutani, 
2004; Toyoshima et al., 2000; Xu et a l , 2002). The structure of the SERCA2 protein and its 
functional domains are described in further detail in Chapter 6.
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Figure 2.5 Basic Function of SERCA2
2.1.4 Dual Role of SERCA2
The SERCA2 protein plays a role both in intracellular Ca2+ signalling and in the synthesis 
and post-translational modification of proteins within the ER. These are described briefly 
below.
2.1.4.1 Intracellular Ca2+ Signalling
In response to external stimuli, Ca2+ ions are released from the ER. This release is 
counterbalanced by the SERCA2 pump actively transporting Ca2+ ions back into the ER. 
Repeated cycles of Ca2+ release and reuptake generate Ca2+ oscillations in the cytosol. These 
complex fluctuations in the intracellular concentration of Ca2+ are responsible for controlling 
many cellular functions including cell differentiation and proliferation and gene transcription 
(Berridge et al., 2000).
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2.1.4.2 Protein Synthesis and Post-translational Modification of Proteins in
the ER
By maintaining high Ca2+ concentrations in the ER lumen, SERC A2 plays an essential 
role in protein synthesis and post-translational modifications of proteins. These processes, 
which take place in the ER and include protein folding, assembly and trafficking, require a 
Ca2+ rich environment as several of the ER resident chaperone proteins are Ca2+ dependent. 
Disruption of Ca2+ homeostasis in the ER leads to impaired protein synthesis, protein mis- 
folding and abnormal trafficking of proteins. The accumulation of unfolded proteins in the ER 
causes ER stress and the activation of the unfolded protein response (UPR) (Zhang & 
Kaufman, 2004). The UPR involves increasing the protein folding capacity of the ER and has 
been found to include up-regulation of SERCA2b expression (Caspersen et al., 2000). In 
severe circumstances prolonged ER stress can lead to cell apoptosis (Schroder & Kaufman, 
2005).
2.1.5 Mutations in ATP2A2 Cause DD
Mutations in ATP2A2 have been shown to cause DD (Sakuntabhai et a l , 1999b). To date, 
143 ATP2A2 mutations have been reported in 175 unrelated individuals with DD in the 
literature (Chao et al., 2002; Dhitavat et a l , 2003b; Dode et a l , 2003; Foggia et a l , 2006; 
Godic et al., 2004; Ikeda et a l , 2003; Jacobsen et a l , 1999; Jones et a l, 2002; Onozuka et a l, 
2004; Racz et a l, 2005; Racz et a l, 2004; Ren et a l, 2006; Ringpfeil et a l, 2001; Ruiz-Perez 
et a l, 1999; Sakuntabhai et a l, 1999a; Sakuntabhai et a l, 2000; Sakuntabhai et a l, 1999b; 
Takahashi et a l, 2001; Wada et a l, 2003; Wang et a l, 2006; Yang et a l, 2004; Yang et a l, 
2001). These mutations, which have been found to be distributed across the gene, are 
described in further detail in Chapter 6.
There have been no reports in the literature of individuals with DD being homozygous for 
mutations in ATP2A2 and mice studies have found that mice homozygous for null mutations
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in the gene are not produced (Zhao et al., 2001). Therefore as individuals with DD are 
heterozygous for mutations in ATP2A2, one normal allele continues to encode a normal 
SERCA2b protein. Recent functional studies looking at the effects of specific mutations in 
ATP2A2 on the functioning of the SERCA2b protein have found the majority lead to a
9+‘mutant’ SERCA2b with very limited or loss of Ca transport activity due to a lack of protein 
expression and/or function (Ahn et al., 2003; Dode et al., 2003; Miyauchi et al., 2006; Sato et 
al., 2004). This suggests that the expression of wild type pump from the single normal allele 
is not sufficient to provide normal function (haploinsufficiency) resulting in an increase in
^ I ^ |
cytoplasmic Ca and a decrease in ER lumenal Ca .
The exact cause of DD remains uncertain but accumulating evidence suggests that 
reduced Ca2+ concentrations in the lumen of the ER may impair the processing and trafficking 
of newly synthesised proteins that are needed for normal adhesion between skin cells. This is 
supported by the finding that trafficking of desmoplakin, a plasma membrane protein 
involved in cell adhesion, is impaired in DD keratinocytes (Dhitavat et al., 2003a). It has also 
been proposed that a further consequence of the impaired processing of proteins in DD 
keratinocytes could be the accumulation of misfolded proteins in the ER, leading to ER stress 
and the unfolded protein response (UPR). In such circumstances, DD epidermal cells would 
have a limited capacity to increase the level of functional SERCA2 pumps and be unable to 
control the UPR which, if it remained persistent, would lead to apoptosis of epidermal cells 
(Hovnanian, 2004). The round dyskeratotic keratinocytes (corps ronds) which are highly 
specific to DD have been suggested to be apoptotic keratinocytes (Foggia & Hovnanian, 
2004). A recent study provided evidence for the possible role of ER stress in the pathogenesis 
of DD by finding when ER stress was induced in keratinocytes from an individual with DD, 
the cells showed an increased expression of three proteins involved in the UPR compared to 
normal keratinocytes from a control individual (Onozuka et al., 2006). These findings suggest
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that the pathological pathway from mutations in ATP2A2 to the clinical features of DD is 
complex and probably involves abnormal trafficking of proteins involved in cell to cell 
adhesion, the UPR and the induction of apoptosis (Hovnanian, 2004).
SERCA2 is widely expressed however, the reasons why mutations in ATP2A2 produce a 
disease that appears to be largely limited to the skin are still unclear. One reason could be that 
the relative importance of SERCA2 may vary in different tissues. SERCA2 pumps may be 
more critical in the epidermis than in other tissues and as a result epidermal cells may be more 
susceptible to a reduction in SERCA2 activity. Another explanation is that certain tissues 
could compensate for the loss of SERCA2 activity by the up-regulation of other members of 
the SERCA pump family such as SERCA3. Cells in the epidermis have been found to lack 
SERCA3, which may indicate a decreased ability of these cells to compensate for loss of 
SERCA2 function (Tavadia et al., 2004). It is also possible that factors that trigger DD such 
as friction, sun exposure and temperature affect the skin most predominantly as it is exposed 
to the external environment whereas internal organs are protected.
2.2 Review of Neuropsychiatric Features in DD
The following sections provide review of the literature reporting neuropsychiatric features 
in individuals with DD including mood/affective disorders (including bipolar affective 
disorder and major depressive disorder) and psychosis, learning difficulties, epilepsy and 
other neurological features. Evidence for the co-occurrence of neuropsychiatric features in 
DD has come from a small number of case series of unrelated individuals with DD in addition 
to family studies and individual case reports. These studies are summarised in Table 2.2, 
Table 2.3 and Table 2.4 and are discussed in the following sections.
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Table 2.2 Summary of Reports of Neuropsychiatric Features in DD- Cases Series
Reference Sample Neuropsychiatric Features
Svendsen &
Albrectsen
(1959)
51 cases (included 12 
members of one family 
and 15 sporadic cases). 
Identified through 
dermatology 
departments across 
Denmark.
22 (43%) individuals described as being either 'mentally 
subnormal’, ‘mentally deranged or psychopaths’ or 
‘destitutes’. One individual had been admitted to a 
psychiatric hospital with psychosis and another had 
committed suicide.
Medansky &
Woloshin
(1961)
5 cases (1 family and 2 
sporadic cases) 
identified from a review 
of dermatology records 
at a Chicago hospital, 
US.
A mother and two children with neuropsychiatric 
abnormalities including depression, ‘unrealistic thinking’, 
‘schizophrenic delusions’ and ‘mild cerebral deterioration’ 
Female described as a ‘high grade mental defective with 
intermittent symptoms of depression’
Male ‘of low average intelligence, anxious and depressed’.
Denicoff et 
al. (1990)
11 cases of DD and 
control group of 11 
individuals with skin 
disorders of equal 
severity.
Prevalence of psychiatric illness did not differ between the 
groups. Histoiy of suicidal thoughts was higher in the DD 
group (64%) than the controls (27%). Most individuals 
with DD reported that their suicidal ideation was not 
necessarily due to their DD.
Burge &
Wilkinson
(1992)
163 cases from 107 
families recruited via 
dermatologists in the 
UK.
7 patients from 6 families had epilepsy, one of these 
individuals also had BPAD. 8 individuals, 2 from the same 
family, had learning difficulties. 2 females had been 
treated for depression.
Munro (1992) 75 adult cases 
(including 13 families 
with two or more cases) 
recruited via 
dermatologists in north­
east England.
2 cases of learning difficulties including a female with 
severe learning difficulties and epilepsy of unknown 
cause. Individuals from 2 families had been treated for 
fits. One individual and her mother had required 
admissions to psychiatric hospitals. Neuropsychiatric 
features were noted to be inconsistent within families.
Ringpfeil et 
al (2001)
50 cases from 24 
families in Germany 
and the US.
A high incidence of depression, suicide, and suicide 
attempts was reported as well as individual cases of 
schizophrenia, seizure disorder, learning difficulties, 
hospitalisation for psychiatric diagnoses not otherwise 
specified and violent behaviour. Several suicides were 
reported in one family and substance abuse was a problem 
for a number of individuals in another family.
Racz et al. 
(2004)
Eight unrelated cases 
identified through a 
dermatology 
department in Hungary.
One female with learning difficulties 
One female with mild depression and a history of 
temporary losses of consciousness, she also had 
endocrinological symptoms. This case was described in 
further detail in (Racz et al., 2006).
Goh et al. 
(2005)
24 unrelated cases of 
DD in Singapore 
identified through the 
National Skin Centre.
Neuropsychiatric disorders recorded in three patients: 
epilepsy, major depressive disorder and severe antisocial 
personality disorder.
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Table 2.2 Continued
Reference Sample Neuropsychiatric Features
Miljkovic et 
al. (2005)
28 cases of DD (9 
families and 13 
sporadic cases) 
identified through major 
dermatological 
departments in 
Slovenia.
3 cases of learning difficulties, 2 patients reported to have 
periodic epileptic seizures and one case of affective 
psychosis. An impairment of memory and concentration 
was observed in the majority of patients.
Zeglaoui et 
a/.(2005)
12 cases (from 1 family 
and 7 sporadic cases) 
identified through a 
dermatology 
department in Tunisia.
One case of learning difficulties.
Table 2.3 Summary of Reports of Neuropsychiatric Features in DD- Family Studies
Reference Neuropsychiatric Features
Getzler & Flint 
(1966)
20 fam ily members, 3 generations,; eight out of the 12 members with DD had 
multiple neuropsychiatric problems including alcoholism, below average 
intelligence, ‘schizophrenic episodes’ and ‘depressive psychosis’. Two out of 
the six unaffected family members also had neuropsychiatric problems.
Craddock et al. 
(1994b), Craddock 
eta l .  (1994a)
17 fam ily  members, 3 generations; all six family members with DD had an 
affective illness including bipolar disorder and major depression. All unaffected 
relatives did not have a history of mood disorder.
Si den berg et al. 
(1994)
17 fam ily members, 2 generations: Multiple family members with DD and 
schizophrenia although not always found together.
Venencie et al. 
(1996)
4 fam ily members, 2 generations; both family members with DD had a slowly 
progressive encephalopathy. Their unaffected family members had normal 
clinical examinations.
Cordeiro et al. 
(2000)
7 fam ily  members, 2 generations; all three family members with DD had a 
diagnosis of depression including a male with associated mood congruent 
psychotic symptoms. All unaffected relatives had no history of affective illness.
Jones et al. (2002) 17 fam ily  members, 4 generations,; all of the six family members with DD in 
addition to 4 unaffected relatives had a lifetime diagnosis of affective disorder 
including bipolar disorder and major depression.
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Table 2.4 Summary of Reports of Neuropsychiatric Features in DD- Case Reports
Reference Neuropsychiatric Features
Pendlebury (1964) Female with epilepsy. Attacks of hysteria noted whilst receiving inpatient 
hospital treatment for DD.
Peck et al. (1976) Male with a unique variant of DD, disabled by large painful cutaneous horns on 
all extremities. Chronically depressed with suicidal ideation.
Clark etal. (1986) Female experienced her first manic episode following childbirth and a further 
episode 6 months later. Lithium treatment exacerbated DD.
Milton et al. 
(1990)
Female diagnosed with BPAD had also made multiple suicide attempts. Lithium 
treatment exacerbated DD.
Rubin (1995) Young male diagnosed with BPAD. Lithium treatment induced symptoms of 
DD.
Hellwig et al. 
(1996)
Female with schizophreniform psychosis, auditory hallucinations, depression, 
suicidal ideation. Temporal relationship between DD and psychotic symptoms.
Jones etal. (1996) Female diagnosed with BPAD. Lithium treatment exacerbated DD.
Koutroumanidis et 
al. (1998)
Male with tonic-clonic epileptic seizures.
al-Homrany et al. 
(1997)
Male with learning difficulties, epilepsy, chronic renal failure, cataract and 
corneal opacities.
Ehrt & Brieger 
(2000)
Female with diagnosed with BPAD. Lithium treatment exacerbated DD.
Lange (2000) Male diagnosed as having a psychotic disorder. Temporal relationship observed 
between DD and psychotic symptoms.
Mei et al. (2000) Male with Vesiculo-Bullous DD and diagnosis of BPAD.
Wang et al. (2002) Male diagnosed with BPAD.
Dhitavat et al. 
(2003b)
Male with learning difficulties and depression.
Dortzbach et al. 
(2003)
Male developed DD at the age of 74 , which appeared in conjunction with other 
serious problems including metastatic carcinoma and an unusual progressive 
fibroproliferative process. Subsequently became severely depressed and 
committed suicide.
Chopra et al. 
(2004)
Female developed DD at the age of 46 following radiotherapy treatment for 
carcinoma of the cervix. This was associated with marked mood variations 
characterised by extreme phases of elation and depression.
Godic et al. (2004) Male with a severe case of DD also “complained about learning difficulties and 
being moody”.
Yang etal. (2004) Female with an unspecified mood disorder.
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Table 2.4 Continued
Reference Neuropsychiatric Features
Racz et al (2005) Female with childhood temporal epilepsy, brother with DD had been 
hospitalised for aggressive behaviour.
Racz et al (2005) Male with dysthymic disorder.
DD; Darier’s Disease, BPAD; Bipolar Affective Disorder
2.2.1 Mood Disorders and Psychosis
The presence of psychiatric symptoms, in particular mood disorders and suicidal ideation, 
in DD has frequently been reported in the literature although the prevalence of psychiatric 
illness in the case series studies of unrelated individuals with DD varies greatly.
Case Series - In an examination of 51 individuals with DD, identified through 
dermatology departments across Denmark, 22 (43%) individuals were described as being 
either 'mentally subnormal’, ‘mentally deranged or psychopaths’ or ‘destitutes’. More 
specifically one patient had been diagnosed with ‘psychosis’ and another had committed 
suicide (Svendsen & Albrectsen, 1959). Medansky & Woloshin (1961) administered a battery 
of psychological measures to five individuals with DD identified from a review of 
dermatology records at a Chicago hospital in the US. A mother, her son and daughter were 
described being ‘extremely suspicious’, ‘a chronic paranoid schizophrenic’ and having 
‘unrealistic thinking, compatible with that of an underlying schizophrenic process’ 
respectively. A further unrelated female and male were described as having ‘intermittent 
symptoms of depression’ and being ‘ anxious and depressed’ respectively. More recently, 
larger studies of individuals with DD have reported small numbers of psychiatric illness. Out 
of 163 individuals with DD in the UK studied by two dermatologists, Burge & Wilkinson 
(1992), two individuals had been treated for depression and another had a diagnosis of bipolar 
affective disorder (BPAD). Similarly, of 75 individuals with DD living in the north-east of 
England interviewed by a dermatologist, one individual and an additional affected family
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member had been admitted to a psychiatric hospital (Munro, 1992). In a study of 24 unrelated 
individuals with DD in Singapore, one individual had major depressive disorder and another 
is reported as having an antisocial personality disorder (Goh et a l , 2005). Racz et a l (2004) 
studied eight unrelated cases of DD recruited through a dermatology department in Hungary 
with one female being reported as having mild depression. One case of affective psychosis 
was found in an examination of 28 cases of DD in Slovenia (Miljkovic et a l , 2005). In 
contrast, Ringpfeil et al (2001) assessed 50 individuals with DD from 24 German and US 
families and noted a high incidence of depression, suicide, and suicide attempts. Individual 
cases of schizophrenia, hospitalisation for psychiatric diagnoses not otherwise specified and 
hospitalisation for violent behaviour were also reported. Several suicides were reported in one 
family and substance abuse was a problem for a number of individuals in another family.
Denicoff et al (1990) compared the psychiatric histories of 11 patients with severe DD 
and a control group of 11 individuals with other skin disorders of equal severity. Prevalence 
of psychiatric illness did not differ between the groups. Four individuals with DD had a 
psychiatric diagnosis including one individual with BPAD, two with depression and one 
individual with an adjustment disorder. In the control group two individuals had a history of 
major depression and another had a history of an adjustment disorder with depressed mood. 
History of suicidal ideation was higher in the DD group (64%) than the controls (27%), which 
was thought to be clinically significant. Although the study did not examine the relationship 
between DD severity and the presence of suicidal ideation, most individuals did not relate 
their suicidal ideation to their DD. However, the authors noted that DD might indirectly lead 
to suicidal ideation by causing problems such as job and relationship difficulties.
Family Studies -  Several families have been reported in which there is co-occurrence of 
mood spectrum disorders and DD. Getzler & Flint (1966) studied three generations of a large 
family with multiple family members with DD. Information was obtained regarding 20 family
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members, and the authors reported eight out of the 12 family members with DD had multiple 
neuropsychiatric features including alcoholism, ‘schizophrenic episodes' and ‘depressive 
psychosis’. However, two of the six unaffected family members studied, including the mother 
of the second generation, had also been admitted to ‘an institution’. Sidenberg et al (1994) 
identified a large Canadian family with DD during an ongoing linkage study of schizophrenia. 
Of the 17 family members that were studied, multiple members were found to have DD and 
schizophrenia although these were not always found together. The authors did not report the 
proportion of individuals with and without DD who also had a diagnosis of schizophrenia. 
Cordeiro et a l (2000) report on a family in which three family members with DD had a 
diagnosis of depression, which in one case was associated with mood congruent auditory 
hallucinations. Four unaffected relatives did not have any history of affective illness.
Craddock et al (1994b), from our research group, administered a standardised 
psychiatric interview to available adult members of three generations of a family with DD in 
the UK. All five family members with DD also had a lifetime diagnosis of major affective 
illness according to two sets of psychiatric diagnostic criteria, including one family member 
with a diagnosis of BPAD (see Figure 2.6a). All unaffected relatives did not have a history of 
mood disorder. At follow-up an unaffected family member displayed very mild features of 
DD, which they had never been aware of (Craddock et a l, 1994a), the individual later 
developed a severe mood disorder (Green et a l, 2005). The authors note that it is unlikely that 
the co-occurrence seen in this family was due to chance or a psychological reaction to having 
DD since individuals did not relate their mood symptoms to their skin disorder. This is 
particularly highlighted by the individual found to have mild features of DD at follow-up who 
subsequently developed a mood disorder despite being unaware that they had DD. In addition, 
there was no temporal relationship between worsening of skin symptoms and the symptoms 
of affective illness. Jones et a l (2002), also from our research group, used a modified
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standardised psychiatric interview to assess 17 members from four generations of one family 
with DD. Ten family members, including six individuals with DD, had a lifetime diagnosis of 
affective disorder according to standard diagnostic criteria, including BPAD spectrum illness
and major depressive disorder, shown in Figure 2.6b.
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Figure 2.6 Two Families Displaying Co-occurrence of Major Affective Disorder and DD
Investigated by our Research Group. Figure a; Craddock?/ al. (1994a), Figure b; Jones et al., 
(2002)
Case Reports - In the literature there are reports of individuals with DD also having mood 
disorders including depression (Dhitavat et al., 2003b; Dortzbach et a l , 2003; Peck et a l , 
1976; Yang et a l, 2004), dysthymic disorder (Racz et a l ,  2005) and BPAD (Clark et a l,
1986; Ehrt & Brieger, 2000; Jones et a l ,  1996; Mei et a l ,  2000; Milton et a l ,  1990; Rubin, 
1995; Wang et a l ,  2002). Treatment with lithium for BPAD has been reported to exacerbate 
(Burge & Wilkinson, 1992; Clark et a l ,  1986; Ehrt & Brieger, 2000; Milton et a l ,  1990) and 
induce (Rubin, 1995) the symptoms of DD. In the case of one male reported to be
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chronically depressed with suicidal ideation (Peck et al., 1976) and another male who 
committed suicide (Dortzbach et al., 2003), their psychiatric symptoms are reported as being 
a psychological reaction to the severity of the symptoms of DD.
Further case reports have suggested a possible temporal relationship between the 
presence of psychiatric symptoms and a worsening of the symptoms of DD. Hellwig et al. 
(1996) describe a female with DD who developed a psychotic syndrome shortly after an 
admission to hospital for depression. The onset of psychosis, including delusions and auditory 
hallucinations, occurred simultaneously with an exacerbation of her DD. A further psychotic 
relapse, in which she made multiple suicide attempts, was also associated with a worsening of 
her DD symptoms, which improved as her psychotic symptoms subsided. The authors 
suggested the temporal relationship between the occurrence of psychotic symptoms and 
exacerbation of DD may be non-random. A further case report describes a male who began 
‘talking only in riddles and puns’, displaying blunting of affect and poverty of thought three 
days after developing symptoms of DD (Lange, 2000). Chopra et al (2004) report the case of 
a female who developed DD at the age of 46 following radiotherapy treatment for carcinoma 
of the cervix. The development of the symptoms of DD was associated with marked mood 
variations characterised by extreme phases of elation and depression.
2.2.2 Learning Difficulties
Case Series - Learning difficulties (LD) were frequently noted among individuals with 
DD in early studies of unrelated individuals with DD in the literature although the criteria 
used were not specified (Medansky & Woloshin, 1961; Svendsen & Albrectsen, 1959). 
Svendsen & Albrectsen (1959) suggested that individuals with DD differed from ‘normal’ in 
terms of their mental development and described 22 (43%) of the 51 individuals examined as 
being either 'mentally subnormal’, ‘mentally deranged or psychopaths’ or ‘destitutes’. Three 
unrelated individuals out of the five assessed by Medansky & Woloshin (1961) were
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described as being ‘a borderline mental defective’, ‘a high grade mental defective’ and ‘of 
low average intelligence’ respectively. In contrast, during a thorough examination of 163 
patients from 107 unrelated families with DD, only eight patients (two from the same family) 
were found to have learning difficulties (Burge & Wilkinson, 1992). In another recent 
examination of 75 cases of DD there were only two reports of learning difficulties (Munro, 
1992). Of the 50 individuals from 24 families with DD examined by Ringpfeil et al (2001), 
one individual with mild DD had learning difficulties. Higher frequencies of LD in 
individuals with DD have been found in more recent studies, one individual was found to 
have LD out of 12 patients with DD in Tunisia (Zeglaoui et al., 2005) and one case was 
reported in a study of eight cases of DD in Hungary (Racz et a l, 2004). In an examination of 
28 individuals from 22 families with DD in Slovenia by Miljkovic et a l (2005) three patients 
were reported to have learning difficulties and the majority of individuals were found to have 
an impairment of memory or concentration although it is not reported how these features were 
measured. Evaluation of educational level in this sample revealed 61% had only finished a 
primary or vocational school.
Family Studies- Getzler & Flint (1966) reported below average intelligence in several of 
the individuals with DD in the family they investigated. Venencie et a l (1996) describe two 
siblings with DD and a slowly progressive encephalopathy including moderate learning 
difficulties.
Case Reports- Further reports of individuals with DD also having learning difficulties are 
reported in the literature (al-Homrany et a l, 1997; Dhitavat et a l, 2003b; Godic et a l, 2004). 
In a few cases individuals with DD and LD have been found to have additional neurological 
abnormalities and psychiatric symptoms. The three individuals described by Medansky & 
Woloshin (1961) as being a “borderline mental defective”, “a high grade mental defective” 
and “of low average intelligence” all had additional psychiatric symptoms including
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“unrealistic thinking compatible with that of an underlying schizophrenic process”, anxiety 
and depression. The sample collected by Munro (1992) included a woman with learning 
difficulties in addition to epilepsy of an unknown cause. One individual with LD and DD 
interviewed by Burge & Wilkinson (1992) also had spinocerebellar dysfunction, pes cavus 
and scoliosis and another had congenital hydronephrosis, partial spina bifida and 
hemitransitional vertebrae. In the large family reported by Getzler & Flint (1966), two family 
members described as having below average intelligence were also described as being 
“emotionally labile” and having “schizophrenic episodes” respectively. The two siblings 
described by Venencie et a l (1996) are described as having LD in addition to a slowly 
progressive encephalopathy. In addition to LD and DD, the patient described by al-Homrany 
et a l (1997) had multiple additional problems including chronic renal failure, epilepsy, 
cataract and corneal opacities. Two further males in the literature reported to have DD and LD 
are also reported to have depression (Dhitavat et a l , 2003b) and complaints of “being moody” 
(Godic et a l , 2004). Together these studies suggest that severe LD is present in a minority of 
individuals and/or families with DD and in some cases may be associated with additional 
complications. Whether mild LD or problems in particular areas of learning, such as memory 
or concentration affects a larger proportion of individuals with DD, as suggested by Miljkovic 
et a l (2005), remains unclear.
2.2.3 Epilepsy and Other Neurological Features
Case Series- In the data collected from 163 patients with DD by Burge & Wilkinson 
(1992), seven individuals from six families were found to have epilepsy. The authors 
highlighted that the prevalence of epilepsy in the sample (42.9 /1000) was higher than that for 
the general population (7 /1000) (Wade & Hewer, 1987). The other case series studies of 
unrelated individuals with DD found cases of epilepsy in their samples in varying small 
frequencies. Of 75 individuals interviewed by Munro (1992), epilepsy of an unknown cause
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was found in one patient with severe learning difficulties and individuals from two further 
families had been treated for fits. Individuals in one of the 24 families examined by Ringpfeil 
et a l (2001) were found to have a range of neuropsychiatric problems including depression, 
schizophrenia and a case of seizure disorder. One case of epilepsy was found in 24 unrelated 
cases of DD in Singapore (Goh et a l, 2005). Two of the 28 individuals examined by 
Miljkovic et al (2005) were reported to have periodic epileptic seizures.
Case Reports- Further case reports in the literature have described individuals with DD 
also having epilepsy (al-Homrany et a l, 1997; Koutroumanidis et a l, 1998; Pendlebury, 
1964; Racz et a l, 2005). Pendlebury (1964) described a female with DD and grand mal 
epilepsy who is also described as having attacks of hysteria whilst receiving hospital 
treatment for her DD. One member of a Hungarian family with DD was found to have 
temporal childhood epilepsy and her brother with DD had been hospitalised for aggressive 
behaviour (Racz et a l, 2005). As previously reported, the individual with DD and epilepsy 
described by al-Homrany et al (1997) also suffered from learning difficulties, chronic renal 
failure, cataract and corneal opacities.
Studies of unrelated individuals with DD suggest the prevalence of epilepsy may be 
higher in DD than in the general population, but is not a common feature of the disease. In a 
small number of cases, individuals with DD and epilepsy may have additional 
neuropsychiatric features.
2.2.4 Summary of Review of Neuropsychiatric Features in DD
This review of the literature indicates that a range of neuropsychiatric features including 
psychiatric illness, epilepsy and learning difficulties are consistently reported in case series 
studies of unrelated individuals with DD. However, the reported prevalence rates of 
neuropsychiatric features in these studies vaiy greatly. This variation is likely to be a result of 
methodological differences in the measurement and/or reporting of such features in these
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studies. Studies reporting additional neuropsychiatric features in a relatively small proportion 
of individuals have tended to report more severe features requiring treatment (Burge & 
Wilkinson, 1992; Munro, 1992). In contrast, case series studies reporting a much higher 
prevalence have tended to include reports of milder features such as mild learning difficulties 
(Miljkovic et al., 2005) and depression (Ringpfeil et al., 2001). Studies reporting 
neuropsychiatric features in families with multiple family members with DD have 
consistently reported a greater prevalence of neuropsychiatric features in family members 
with DD than family members without DD, including families with complete co-segregation 
of DD and neuropsychiatric features (Cordeiro et al., 2000; Craddock et al., 1994a; Venencie 
et al., 1996). The small number of case reports in the literature highlight the range of 
neuropsychiatric features found to co-occur in individuals with DD. Of particular interest are 
the reports of individuals where there has been a temporal relationship between the presence 
of severe psychiatric symptoms and a worsening of the symptoms of DD. The next section 
discusses the possible explanations for the co-occurrence of neuropsychiatric features in DD.
2.3 Explanations for the presence o f Neuropsychiatric Features in 
DD
There are several possible explanations for reported co-occurrence of neuropsychiatric 
abnormalities in DD including a chance association, psychosocial factors, genetic linkage 
between DD and a susceptibility gene for neuropsychiatric illness and pleiotropic effects of 
mutations in A TP2A2 in the skin and brain. These are discussed below.
2.3.1 Chance Relationship
The first possibility is a chance co-occurrence between DD and neuropsychiatric 
features. The most common neuropsychiatric features that have been reported to co-occur 
with DD are mood disorders and mild learning difficulties, which are also relatively common
23
in the general population. It is therefore possible that the many reports of a co-occurrence of 
DD and neuropsychiatric features are due to chance and/or ascertainment bias. However, 
there are a large number of reports of neuropsychiatric features among individuals with DD in 
the literature and the reports of families where multiple family members with DD have 
additional neuropsychiatric symptoms provide evidence against a chance relationship.
2.3.2 Psychosocial Effects of Skin Disease
The psychological consequences of having a chronic skin disorder are likely to contribute 
to the reported association between DD and neuropsychiatric features, in particular symptoms 
of depression. Onset of the symptoms of DD during adolescence could also lead to greater 
psychosocial impairments than might be expected if the symptoms started later in adult life. 
The perceived impact the disorder has on various aspects of everyday functioning, rather than 
the severity of DD, may be related to the presence of depressive symptoms. This is supported 
by Harris et al. (1996) who found a poor correlation between patient self-rated scores on the 
Dermatology Life Quality Index (DLQI) and clinicians9 ratings of DD severity. This indicates 
that for some individuals a mild form of the disease may cause severe impairment. In 
addition, the onset of a skin disorder at a young age may affect performance at school and 
could contribute to the reports of poor school performance in individuals with DD.
Denicoff et al. (1990) reported that of the 64% individuals with DD in their study who 
had a history of suicidal thoughts, most did not relate their suicidal ideation to their DD. 
Similarly the family members with mood disorders and DD interviewed by Craddock et al. 
(1994b) did not relate their mood symptoms to their skin disorder and one family member 
with very mild features of DD which they were never aware of, later developed a severe mood 
disorder (Green et al., 2005). Also, anecdotally, dermatologists report that DD patients in 
general differ in terms of their behaviour from their other patients with similar dermatological 
morbidity. These findings suggest that for a proportion of individuals with DD the additional
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presence of mood disorders and suicidal ideation may be due to factors other than a 
psychological reaction to having a chronic skin disorder.
2.3.3 Genetic Linkage
Genetic linkage between DD and a susceptibility gene for affective illness has been 
proposed as an explanation for the reported association between DD and affective illness. 
Recent genome-wide scans have provided evidence for the presence of a susceptibility locus 
for affective disorders on chromosome 12 in the region of the ATP2A2 gene including bipolar 
disorder (Shink et al., 2005) and major depressive disorder (Abkevich et al., 2003; McGuffin 
et al., 2005). Genetic linkage is a possibility in families where DD co-segregates with 
affective illness however, it cannot explain the majority of the reported associations between 
DD, affective disorders and other neuropsychiatric phenotypes. This is because most DD 
mutations are specific to families and therefore the majority would not be in linkage 
disequilibrium (very closely linked) with a variant that predisposes to susceptibility to mood 
disorders.
2.3.4 Pleiotropic Effects of Mutations in ATP2A2 in the Skin and Brain
A further explanation is that mutations in the ATP2A2 gene itself, in addition to causing 
DD, confer susceptibility to neuropsychiatric features (pleiotropy). This is supported by the 
fact that SERCA2b has been found to be highly expressed in the brain (Baba-Aissa et al.,
• ^ j
1998). The role of intracellular Ca signalling in a range of neuronal functions including 
neuronal excitability, neurotransmitter release, gene expression neuronal growth and synaptic 
plasticity (Berridge, 2002; Berridge et al., 1998; Verkhratsky, 2005) also supports this 
suggestion.
Furthermore, there is evidence suggesting the role of ER function in the pathophysiology 
and treatment of affective disorders. A recent study has found that ER stress responses were
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impaired in B lymphocyte cell lines from a small sample of individuals with bipolar disorder 
compared to controls (So et al., 2007). In addition, in primary cultured rat cerebral cortical 
cells, two mood stabilizing drugs, lithium and valproate have been shown to regulate the 
expression of proteins involved in the ER stress response (Shao et al., 2006). As previously 
reported, the SERCA2 protein is located in the ER membrane and has been implicated to be 
involved in ER stress pathways (Caspersen et al., 2000). The finding that ER stress pathways 
have also been suggested to be disrupted in bipolar affective disorder and are a potential target 
of pharmacological agents used to treat mood disorders, further supports the suggestion that 
mutations in ATP2A2 may be involved in conferring susceptibility to neuropsychiatric 
features, in particular mood disorders, in individuals with DD.
Interestingly, another disorder reported to have associated neuropsychiatric features, 
Wolfram Syndrome, has been found to be caused by mutations in a single gene encoding a 
protein located in the ER membrane (WFS1) (Strom et al., 1998; Takeda et al., 2001). This 
protein, expressed in various tissues including the brain and pancreas, has recently been 
indicated to play a role in regulating cellular Ca2+ homeostasis, in part by modulating the 
filling state of the ER Ca2+ store (Takei et al., 2006). WFS1 deficiency has also been shown to 
increase ER stress in pancreatic p-cells (Yamada et al., 2006). Wolfram Syndrome is a rare 
autosomal-recessive disorder characterised by juvenile onset diabetes mellitus and optic 
atrophy. Individuals with Wolfram Syndrome have been described as having a diverse range 
of neuropsychiatric abnormalities including severe psychiatric symptoms (Swift et al., 1990), 
learning difficulties and seizures (Kinsley et al., 1995). In one study of 68 individuals with 
the disorder, 60% of individuals were found to have severe psychiatric symptoms including 
severe depression, psychosis, organic brain syndrome or impulsive aggression with 25% of 
individuals requiring an admission to a psychiatric hospital and/or making a suicide attempt 
(Swift et al., 1990). Reports of a high prevalence of neuropsychiatric features among
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individuals with a disorder caused by mutations in a gene encoding a protein located in the 
ER membrane with a very similar function to SERCA2, also provides support for the 
hypothesis that mutations in the ATP2A2 gene itself, in addition to causing DD, confer 
susceptibility to neuropsychiatric features.
The pleiotropy hypothesis suggests that mutations in ATP2A2 could confer susceptibility 
to a wide range of different neuropsychiatric features including major depressive disorder, 
bipolar affective disorder, psychotic episodes, schizophrenia, epilepsy and learning 
difficulties that might be expected to have different aetiologies. However, there is evidence 
that a number of these neuropsychiatric phenotypes have overlapping pathogenic 
mechanisms. For example, first-degree relatives of individuals with bipolar affective disorder 
appear to have an increased risk of developing both bipolar affective disorder and major 
depressive disorder suggesting the two disorders have shared susceptibility factors (McGuffin 
& Katz, 1989). Similarly, family studies have suggested the presence of overlapping 
susceptibility factors in affective disorders and schizophrenia including the finding of high 
rates of major depressive disorder in the relatives of individuals with schizophrenia (Maier et 
al., 1993). The prevalence of schizophrenia (Turner, 1989) and mood disorders (Hurley,
2006) have also been reported as increased in individuals with learning difficulties A review 
of studies assessing the type and prevalence of psychiatric disorders in individuals with 
epilepsy found that reports of the lifetime prevalence of affective disorders in individuals with 
epilepsy ranged from 24% to 72% (Gaitatzis et al., 2004). In addition, family history of 
depression is frequently observed among individuals with both epilepsy and depression 
(Kanner & Balabanov, 2002).
Further support for mutations in ATP2A2 having pleiotropic effects in both the skin and 
brain would come from a population-level association between neuropsychiatric features and 
DD. As discussed above, such an association has not been consistently or robustly found in
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the case series studies of unrelated individuals with DD. However, these studies have had 
methodological problems and small sample sizes. Previous case series of DD have been 
undertaken by dermatologists untrained in neuropsychiatric assessment and have been mainly 
based on recording individuals’ general medical history and treatment. Systematic 
investigations using standardised measures of neuropsychiatric features in large samples of 
individuals with DD are required to confirm and determine the extent of the relationship 
between DD and neuropsychiatric features.
Genotype-phenotype correlations between the types and/or locations of mutations within 
the ATP2A2 gene and the presence of neuropsychiatric phenotypes would also provide 
support for the pleiotropic hypothesis and one study has reported such a correlation (Jacobsen 
et a l , 1999). This study, and others investigating genotype-phenotype correlations in DD are 
described in further detail in Chapter 6.
The aims of this thesis are to address these two questions by conducting a systematic 
investigation of the neuropsychiatric phenotypes in a large sample of individuals with DD, 
and to look for correlations between the neuropsychiatric phenotypes observed and ATP2A2 
mutations within this sample. The three main aims of this thesis are:
1. To conduct a systematic investigation of the neuropsychiatric characteristics in a sample of 
100 unrelated individuals with DD using a battery of standardised neuropsychiatric measures. 
This will include investigations ofpossible relationships between the clinical features o f DD, 
such as severity and age o f  onset, and neuropsychiatric features observed. (Chapters 3 to 5).
2. To investigate possible genotype-phenotype correlations between the type and/or locations 
of pathogenic mutations detected in the ATP2A2 gene and neuropsychiatric features observed 
in a large sample of unrelated individuals with DD. This will include investigations o f
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possible relationships between the mutations and type and severity o f neuropsychiatric 
phenotypes. (Chapters 6-9).
3. To compare the presence of neuropsychiatric features in a sample of individuals with DD 
and their first-degree relatives, unaffected by DD. This method will allow controlling for 
additional genetic and non-genetic factors that could influence the presence o f  
neuropsychiatric features in individuals with DD. (Chapters 10-12).
The following chapter (Chapter 3) describes the recruitment and clinical and neuropsychiatric 
assessment of 100 unrelated index participants with DD.
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3 DEMOGRAPHICS, CLINICAL AND NEUROPSYCHIATRIC 
FEATURES IN 100 INDIVIDUALS WITH DD: METHODS
This chapter describes the recruitment and clinical and neuropsychiatric assessment of 
100 unrelated index participants with DD. First, the systematic and non-systematic 
approaches to recruiting study participants are described. This is followed by a description of 
the clinical and neuropsychiatric assessment of participants, which included an assessment of 
demographic characteristics, clinical features of DD and impact on quality of life, lifetime 
neuropsychiatric features, IQ and family history of neuropsychiatric features. Finally a 
summary is provided of the analyses carried out to investigate possible relationships between 
the clinical features of DD and the neuropsychiatric features observed. The study was 
approved by the Multi-Centre Research Ethics Committee for Wales (MREC) Reference: 
03/9/08. Additional information relating to this chapter can be found in section A of the 
Appendix starting at pg. 276, and will be referenced throughout the chapter.
3.1 Recruitment o f Participants
The recruitment of participants took place between January 2004 and May 2006. In order 
to assess the neuropsychiatric features in a representative sample of individuals with DD, 
participants were recruited on the basis of having DD mainly through dermatologists and a 
UK support group for DD. Both systematic and non-systematic approaches were used to 
recruit participants, described below.
3.1.1 Systematic Approaches to Recruiting Participants
The main systematic recruitment of participants was achieved with the help of a 
Consultant Dermatologist, Dr Susan Burge (Dermatology Department, Churchill Hospital, 
Oxford). Dr Burge has extensively researched DD including conducting a study investigating 
the clinical features of 163 individuals with DD in the UK (Burge & Wilkinson, 1992). Dr
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Burge is in contact clinically with a large number of individuals with DD in the UK and wrote 
to those individuals that she was in recent clinical contact with asking if they would be willing 
to participate in the current study. Invitation letters were sent to 135 individuals between the 
ages of 18 and 75 years (51 males (38%) and 84 females (62%)). The letter provided brief 
details about the research and asked if individuals may be willing to take part (shown in 
Appendix A.i. pg. 276). Individuals who were interested in receiving further information 
about the study were asked to complete an attached contact form, to be returned in the 
stamped addressed envelope enclosed with the letter. Individuals were given the opportunity 
to refuse by ticking a box on the form indicating that they did not wish to take part in the 
research.
The numbers of individuals responding to the invitation letter are summarised in Figure 
3.1. After one month a reminder letter was sent to individuals who had not responded to the 
initial invitation letter. In total, 67 individuals (50%) replied indicating that they would be 
interested in receiving further information about taking part in the study. 14 individuals (10%) 
refused. The address details were incorrect for 9 individuals (7%). The remaining 45 
individuals (33%) did not respond to either the initial or reminder invitation letter.
Figure 3.1 Systematic Recruitment of Index Participants with DD via Dr. Burge
7 Refusals
Refusals
7 Refusals
9 [7%J 
Wrong 
address
9 Interested in 
receiving further 
information
45 [33%] No response 
following initial letter 
and reminder letter
58 Interested in receiving 
further information
67 [50%] Interested in 
receiving further 
information
61 No response- sent reminder letter
135 invitation letters sent to unrelated individuals with DD
Individuals were also systematically recruited with the help of Dr Sherine Tavadia and 
Professor Colin Munro (Department of Dermatology, Southern General Hospital, Glasgow). 
Dr Tavadia and Professor Munro have also carried out extensive research into DD including a 
survey of the prevalence of the disorder in the west of Scotland (Tavadia et al., 2002). They 
sent 20 invitation letters, identical to the letter sent by Dr Burge, to individuals with DD with 
whom they were currently in contact. Three individuals (15%) replied indicating that they 
would be interested in receiving further information about taking part in the study.
3.1.2 Non-Systematic Approaches to Recruiting Participants
The non-systematic approaches to recruiting individuals included approaching members 
of the UK Darier’s Support Group, contacting dermatologists in the Midlands Area, a study 
webpage and the referral of a small number of individuals from medical disciplines other than 
dermatology. The main non-systematic recruitment of index participants was achieved by 
contacting members of the DD Support Group, which is currently run by Mrs Jenny Davies. 
Individuals usually contact the group after being given the details by their dermatologist, 
seeing a poster in a dermatology waiting room or finding the details on the internet. The 
current role of the support group is to provide individuals with further information about DD 
in the form of information leaflets and answering queries over the telephone and email. Mrs 
Davies sent out 60 letters to members of the support group with information about the 
research. Individuals who were interested in receiving further information about the study 
were asked to complete an attached contact form, which could be returned in the stamped 
addressed envelope enclosed with the letter. A copy of the letter is shown in Appendix A.i. 
pg. 277). Letters were not sent to members of the support group who had already expressed an 
interest in the research after receiving an invitation letter from Dr Susan Burge.
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A further non-systematic approach to recruiting participants was achieved by writing to 
dermatologists in the Midlands area asking whether they had any patients with DD who they 
would be willing to write to and provide information about the research. Willing 
dermatologists were emailed the standard template invitation letter (Appendix A.i. pg 276). 
Eight individuals receiving letters from their dermatologist replied indicating they would be 
interested in receiving further information about taking part in the study.
Three individuals expressed an interest in the research after reading about the research 
on the internet. The information contained on the website is shown in Appendix A.i. pg. 278. 
A further three individuals were recruited for the study from three other disciplines namely 
medical genetics, neurology/learning disability service and psychiatry. It should be noted that 
the individual who was recruited from psychiatry was a family member of an individual who 
received an invitation letter from Dr Burge. Therefore this family/individual could have 
potentially been recruited systematically on the basis of having DD rather than being treated 
for a psychiatric condition.
A summary of the numbers of individuals expressing an interest in the research 
according to method of recruitment is displayed in Table 3.1.
Table 3.1 Frequencies of Individuals Expressing an Interest in the Research according to 
Method of Recruitment
Method Of Recruitment Frequency of 
individuals
%
Dr Susan Burge, Oxford 67 58
Support Group 32 26
Dermatologists in Midlands Area 8 7
Internet 3 3
Professor Colin Munro and Dr Sherine 
Tavadia, Glasgow
3 3
Referral from other medical disciplines 3 3
Total 116 100
Individuals expressing an interest in the research were sent a letter from myself along 
with a detailed participant information sheet with further details about the study and what
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taking part would involve (shown in Appendix A.i. pg. 279). The letter also informed 
individuals that they would be contacted by telephone around one week after they had 
received the letter to answer any questions they may have and to discuss whether they would 
be interested in taking part in the research. During the telephone conservation individuals 
were briefly screened to check that they had been diagnosed with DD by a dermatologist and 
were over 18. Individuals were asked if they had any further questions about the research 
before being asked if they would be willing to participate. Once individuals had said they 
would be willing to participate, a convenient time and place for an interview to take place was 
arranged. In all cases participants were visited in their own homes.
A summary of the frequencies of individuals agreeing to participate in the research 
and the reasons for individuals not participating are summarised in Table 3.2. Of the 116 
individuals initially expressing an interest in the research 102 individuals agreed to participate 
and were visited in their homes. A further two individuals were willing to participate in the 
research but unfortunately due to their location (North Scotland) it was not possible for them 
to participate. Five individuals who initially expressed an interest in the study could not be 
contacted by telephone to discuss participating in the study. One individual became too 
physically unwell, not related to their DD, to be able to participate in the study and six 
individuals decided that they would not like to take part.
Table 3.2 Frequencies of Individuals Agreeing to Participate in the Research and Reasons for 
Individuals not Participating
Frequency
Participated in study 102
Unable to participate due to location (N. Scotland) 2
Unable to contact via telephone to discuss participating in 
the research
5
Became physically too unwell 1
Decided not to participate 6
Total 116
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102 unrelated individuals with a diagnosis of DD participated in the research. Two of 
these individuals had to be excluded from the study. One male participant who had previously 
been told he might have DD actually had a diagnosis of another skin disorder, Hailey-Hailey 
disease, and did not have DD. This diagnosis was confirmed by his dermatologist. A further 
male participant was excluded due to the limited amount of information that was obtained 
during his interview. The remaining 100 individuals were included in the study.
3.2 Clinical & Neuropsychiatric Assessment o f Participants
The following section describes the clinical and neuropsychiatric assessment of the 100 
index participants with DD. I interviewed all individuals in their homes in one session lasting 
approximately 2-2 Vi hours. All participants gave written informed consent (see Appendix A.i. 
pg. 281 for copy of the consent form). A summary of the clinical and neuropsychiatric 
assessment carried out with 100 unrelated individuals with DD is displayed in Figure 3.2 pg. 
36. All data were entered into a relational Microsoft Windows Access Database that I 
designed.
3.2.1 Demographic Characteristics of the Sample
Information was collected on a selection of demographic variables including current age, 
gender, marital status, current social circumstances, main lifetime occupation and highest 
level of educational qualifications.
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Figure 3.2 Clinical and Neuropsychiatric Assessment of Individuals with DD
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3.2.2 Assessment of Clinical Features of DD and Impact on Quality of 
Life
A series of structured questions were asked to obtain data on the clinical features of 
DD including age of onset and duration, severity, symptoms, aggravating factors and the 
impairment caused by having DD and the impact on quality of life. Photographs of areas of 
skin currently affected by DD were taken once consent to take a photograph had been 
obtained. A copy of the DD clinical assessment is displayed in Appendix A.ii pg. 282.
3.2.2.1 Age of Onset and Duration of DD
Individuals were asked to recall the age when their symptoms of DD first appeared. The 
number of years individuals had had DD for was subsequently calculated.
3.2.2.2 Lifetime Severity of DD
Individuals were classified as having mild, moderate or severe DD according to the 
descriptions given in Table 3.3. This classification of severity has been used in previous 
published studies of DD (Sakuntabhai et al., 1999a).
Table 3.3 Classification of Severity of DD
Severity Description
Mild Keratotic papules scattered sparsely over the trunk or flexures or 
disease limited to one or two areas (e.g. hands)
Moderate More extensive papular lesions or localised verrucous plaques
Severe Coalescent verrucous plaques involving most of the trunk or grossly 
hypertrophic flexured disease
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3.2.2.3 Symptoms and Aggravating Factors of DD
Individuals were asked if they had ever experienced pain, itching or malodour due to their 
DD, rated as either yes, no or unknown. Individuals were also asked whether factors including 
stress, sunlight and heat or sweating made the symptoms of their DD worse, rated as yes, no, 
unknown or not applicable.
3.2.2.4 Impairment caused by DD
To assess the impairment caused by having DD, individuals were asked whether they had 
ever required inpatient treatment for their DD and if so how many times. Individuals were 
asked how much time they had taken off work due to the symptoms of their DD and if they 
had ever had to stop work due to their DD. Individuals were also asked to rate on a scale of 
mild, moderate, severe, not applicable or unsure, how much impact having DD had had on 
their school life, work/career, relationships and social activities.
3.2.2.5 Dermatology Life Quality Index (DLQI)
Individuals were asked to complete the Dermatology Life Quality Index (DLQI), a brief 
validated questionnaire designed to assess the impact of skin conditions on quality of life 
(Finlay & Khan, 1994). This measure was included in the assessment battery to allow 
investigations of possible relationships between quality of life, the severity of DD and, the 
presence of neuropsychiatric symptoms.
The DLQI consists of 10 questions relating to the impact of having a skin disorder on 
six domains of quality of life ‘Symptoms and feelings ’, ‘Daily activities ‘L e i s u r e ‘ Work 
and school ', ‘Personal relationships ’ and ‘Treatment Each of the 10 items relates to the last 
week and has four possible responses “not at all", “a little ", “ a lot" and “very much ” 
scored as 0 ,1,2 3 respectively. Total scores can range from 0 (no impairment of life quality) 
to 30 (maximum impairment of life quality). The questionnaire has been used in over 137
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studies with 36 different skin conditions (Lewis & Finlay, 2004) and has previously been 
completed by 137 individuals with DD (Harris et a l , 1996). For the purposes of the current 
study the questionnaire was adapted to create a second version of the DLQI where the items 
related to the worst week ever. Both versions of the DLQI were used in the present study and 
are displayed in Appendix A.iii pg. 284.
3.2.2.6 Family History of DD
Individuals were asked if they had any known family history of DD rated as either none, 
possible, definite or unknown.
3.2.3 Assessment of Lifetime Psychiatric Features- Interview
3.2.3.1 Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 
Interview
All individuals were asked a series of brief screening questions to assess whether they 
had a history of experiencing or receiving treatment for psychiatric illness including anxiety 
and panic attacks, depression, mania, psychosis, obsessive-compulsive symptoms, eating 
disorders and history of alcohol or substance abuse/dependence (displayed in Appendix A.iv 
pg. 286). If individuals responded affirmatively to one or more screening questions, the 
presence of these features was examined in further detail using the relevant sections of the 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview (Wing et al., 1990). 
The SCAN is a semi-structured interview designed to elicit the presence of symptoms and 
behaviours associated with major psychiatric disorders. In the present study the standard 
SCAN sections were modified to reduce the length of the interview. This was achieved by 
selecting the questions assessing the presence of clinical features required for a lifetime 
diagnosis of a psychiatric disorder according to standard diagnostic criteria. Careful 
questioning was needed in the depression section of the interview due to the potential
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difficulties in distinguishing between symptoms of depression and symptoms which were a 
direct result of having a skin disorder (e.g. itchiness during the exacerbation of the symptoms 
of DD could potentially affect an individual’s sleep pattern). Information obtained regarding 
the presence of psychiatric symptoms during the interview was supplemented by inspecting 
individuals’ psychiatric notes and/or relevant GP notes.
3.2.3.2 Subjective Relationship between DD and Lifetime Psychiatric 
Features
Individuals reporting a history of psychiatric illness were asked whether they felt there 
had been a lifetime and/or temporal relationship between the symptoms of their DD and the 
occurrence of episodes of psychiatric illness.
3.2.4 Assessment of Lifetime Psychiatric Features- Consensus Ratings
Information regarding the presence of lifetime psychiatric symptoms collected at 
interview and from inspecting available medical case notes was combined to produce a 
clinical vignette for each individual. The vignettes were used to make a number of psychiatric 
lifetime ratings on the features outlined in the following sections (see Appendix A.v. pg. 287 
for a copy of the rating sheet). In all cases, Dr Lisa Jones, Professor Nick Craddock and I 
made the psychiatric lifetime ratings independently and consensus was reached by discussing 
all ratings.
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3.2.4.1 Best-Estimate Lifetime Psychiatric Diagnoses
Best-estimate lifetime psychiatric diagnoses were made according to the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) 
(American Psychiatric Association, 2000). In cases where individuals were diagnosed as 
having more than one lifetime psychiatric disorder, the disorder judged to have caused the 
most impairment was recorded as the main lifetime psychiatric disorder.
3.2A.2 History of Suicidal Thoughts and Suicide Attempts
Lifetime history of suicidal thoughts and attempts was rated on a 5-point scale ranging 
from Absent (0) to Multiple suicide attempts likely to result in death (5), displayed in Table 
3.4.
Table 3.4 Rating of Lifetime History of Suicidal Thoughts and Suicide Attempts
Rating
Absent 0
Tedium Vitae {feelings that life is not worth living that lacks the active, intrusive 
quality of suicidal ideation)
1
Suicidal Ideation 2
Suicide attempt unlikely to result in death 3
Suicide attempt likely to result in death 4
Multiple suicide attempts likely to result in death 5
3.2.4.3 Key Psychiatric Clinical Ratings and Psychiatric Rating Scale
Other key psychiatric clinical variables were rated where relevant including:
• Age of onset of any psychiatric illness and age of onset of specific psychiatric 
illnesses causing clinically significant impairment (including self-sought treatment, 
being referred for treatment and disruption to work, family or social life)
• Number of episodes of affective illness
• Longest duration of affective illness
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3.2.5 The Bipolar Affective Disorder Dimension Scale (BADDS)
The Bipolar Affective Disorder Dimension Scale (BADDS) is a measure designed to allow 
lifetime ratings to be made on four domains of psychopathology relevant to individuals with 
bipolar spectrum illness namely Mania (M), Depression (D), Psychosis (P) and Incongruence 
(I) (Craddock et al., 2004). The main advantage of the scale is that it allows richer 
information to be obtained regarding an individual’s psychopathology than can be obtained 
using standard diagnostic systems. In the present study the Mania (M) and Depression (D) 
dimensions of BADDS were rated in index individuals with DD. Based on all available 
information, including information obtained from the semi-structured SCAN interview and 
case notes, each dimension is rated on a scale of 0 (no evidence of manic/depressive 
symptoms) to 100 (evidence of 10 or more incapacitating episodes of mania/depression). A 
copy of the BADDS ratings guidelines is provided in Appendix A.vi pg. 289.
3.2.5.1 Reliability of Lifetime Psychiatric Ratings
Reliability of the lifetime psychiatric ratings made by myself, Dr Jones and Professor 
Craddock was assessed using Cohen’s Kappa (categorical variables) and intra-class 
correlation coefficient (continuous variables) and are displayed in Table 3.5 and Table 3.6 
respectively. Inter-rater reliability was high with mean kappa statistics of 0.86 and 0.93 for 
DSM-IV diagnoses and suicidal ideation respectively and mean intra-class correlation 
coefficients for other key psychiatric clinical variables ranging from 0.82-1.
Table 3.5 Inter-Rater Reliability of Lifetime DSM-IV Diagnoses and History of Suicidal 
Thoughts and Suicide Attempts
Mean Kappa 95% Cl
Lifetime DSM-IV Diagnoses 0.86 0.85-0.86
History of Suicidal Thoughts 
and Attempts
0.93 0.8-1.00
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Table 3.6 Inter-Rater Reliability of Key Psychiatric Clinical Variables
Mean Intra-class 
Correlation
95% Cl
Age of Onset of any Psychiatric Disorder 0.86 0.54-1
Age of Onset of Depression 0.82 0.39-1
Age of Onset of any Anxiety Disorder 1 -
Age of onset of Mania 1 -
Number of Episodes of Mania 0.99 0.98-1
Number of Episodes of Depression 0.99 0.98-1
Longest Duration of Mania 0.99 098-1
Longest Duration of Depression 0.91 0.54-1
BADDS Mania 0.99 0.96-1
BADDS Depression 0.92 0.84-1
BADDS; Bipolar Affective Disorder Dimension Scale.
3.2.6 Other Neuropsychiatric Features
3.2.6.1 Lifetime History of Neurological Features and Investigations
Lifetime history of neurological features and neurological investigations was assessed 
using a brief checklist (Appendix A.vii pg. 295) to obtain information on the presence of 
neurological symptoms and disorders, including headaches, episodes of loss of consciousness, 
epilepsy, memory difficulties and infections of the brain. Individuals responding affirmatively 
to any of the items in the checklist were asked for further information including dates the 
symptoms occurred, whether any treatment was received and the degree of impairment caused 
by the symptoms. Information obtained regarding the presence of neurological disorders 
and/or symptoms during the interview was supplemented by inspecting individuals’ available 
hospital notes and/or relevant GP notes.
3.2.6.2 Learning Difficulties
Lifetime history of learning difficulties was assessed by the following:
• Asking individuals whether they had ever had a diagnosis of dyslexia and/or whether 
they received extra help at school for problems with reading and/or writing and/or 
spelling and/or sums/numbers. It was likely that responses to these questions would
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depend on the participants’ age, with older participants being less likely to have been 
given a diagnosis of dyslexia and/or received extra help whilst at school.
• Due to the likelihood that the frequencies of individuals diagnosed with dyslexia 
would vary according to age groups, a brief questionnaire was also used to screen for 
dyslexia in the sample, The Adult Dyslexia Checklist (Vinegrad, 1994). The dyslexia 
checklist contains 20 (yes/no) items e.g. “Is your spelling poor?”, “Do you mix up bus 
numbers like 95 and 59?” (Appendix A.viii. pg. 297). Scores are calculated by adding 
up the number of “YES” answers, with 9 or more YES responses reported as being a 
powerful indicator of difficulty. The dyslexia checklist was not initially part of the 
clinical assessment therefore the questionnaire was posted to individuals at a later date 
along with a stamped addressed envelope in which the questionnaire could be 
returned.
3.2.7 IQ Scores
IQ was assessed using the Wechsler Abbreviated Scale of Intelligence (WASI) (The 
Psychological Corporation, 1999). The WASI is a battery of four subsets of the full WAIS 
(Wechsler Adult Intelligence Scale) namely, Similarities, Compensation, Block Design and 
Matrix Reasoning. It is possible to administer either a four- or two-subset form of the 
measure. Due to time constraints, the two-subset version of the WASI, which includes the 
Comprehension and Matrix Reasoning subsets, was administered in the present study. An 
advantage of this measure is that it provides an estimate of general intellectual ability and can 
be administered in approximately 15 minutes. A disadvantage is that it only provides a full 
scale IQ score and not separate verbal and performance IQ scores, which can be obtained 
when using the four-subset version.
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3.2.8 Family History of Neuropsychiatric Features
Information was collected regarding known family history of probable neuropsychiatric 
illness in first-degree relatives (parents, siblings, children) with and without DD. Psychiatric 
illnesses were recorded if they could be included in one of the five following categories of 
psychiatric illness:
• Major Depression for which individuals had received treatment and/or the symptoms 
of which had caused significant impairment including time off work and causing 
family problems.
• Other psychiatric illnesses -anxiety disorders, alcohol misuse/dependence, substance 
misuse/dependence, obsessive compulsive disorder, eating disorders for which 
individuals had received treatment and/or the symptoms of which had caused 
significant impairment.
• Bipolar Disorder
• Schizophrenia
• Other Severe Psychiatric Disorders- psychiatric illnesses where the diagnosis was 
uncertain but the symptoms were severe enough to require treatment by psychiatric 
services and/or inpatient psychiatric treatment.
3.2.9 Personality, Temperament and Current Mood State Questionnaires
At the end of the clinical and neuropsychiatric assessment, individuals were asked if 
they would be willing to have a pack of personality, temperament and current mood state 
questionnaires to be completed in their own time and returned in a stamped addressed 
envelope. The questionnaires included in the pack are listed in Table 3.7 below. Further 
descriptions of these questionnaires are given in Chapter 10, which describes the measures
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and design used to compare the presence of neuropsychiatric features in a smaller subset of 
individuals with DD and their unaffected relatives.
Table 3.7 Personality, Temperament and Current Mood State Questionnaires
Reference
Beck Depression Questionnaire (BDI) (Beck & Steer, 1987)
Altman Self-Rating Scale for Mania Scale 
(ASRM)
(Altman et al., 1997)
Rosenberg Self-Esteem Scale (RSE) (Rosenberg, 1965)
Eysenck Personality Questionnaire (EPQ) (Eysenck & Eysenck, 1975)
Temperament Evaluation of Memphis, Pisa, 
Paris and San Diego-autoquestionnaire version 
(TEMPS-A)
(Akiskal et al., 2005)
Kings Schizotypy Questionnaire (KSQ) (Jones etal., 2000; Williams, 1993)
A small number of individuals (N=9) did not wish to complete the questionnaire pack. 
The pack was not given to a further three individuals as they reported having a reading 
disability and would have found it difficult to complete the questionnaires. A questionnaire 
pack was left with the remaining 88 individuals. A reminder letter with a further copy of the 
questionnaire pack and another stamped addressed envelope was sent to individuals if the 
questionnaires had not been returned within 2 weeks. Seventy-three individuals returned the 
questionnaire pack, figures are summarised in Table 3.8.
Table 3.8 Returned Questionnaire Packs
Frequency
Returned questionnaire pack 73
Returned- incomplete 1
Not returned 14
Declined- not given 9
Not suitable- not given 3
Total 100
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3.3 Analysis o f Demographics, Ciinical and Neuropsychiatric 
Features in 100 Individuals with DD
Analysis of the demographic characteristics, clinical features of DD and neuropsychiatric 
features was conducted in the following ways:
1. Describing the demographic characteristics, clinical features of DD, neuropsychiatric 
features, IQ scores and family history of neuropsychiatric features in 100 unrelated 
individuals with DD. Including:
• Examining the relationship between the perceived impact of DD on quality of life 
and DD severity.
• Describing the prevalence of neuropsychiatric features to allow comparisons to be 
made to the prevalence of these features in other populations reported in the 
literature to assess whether there is evidence for a population-level association 
between DD and neuropsychiatric features.
• Comparing the prevalence of DD among first-degree relatives with a history of 
psychiatric illness and epilepsy and identifying any families displaying co­
segregation of DD and neuropsychiatric features.
2. Investigating the presence of multiple neuropsychiatric features in individuals with 
DD, which may provide support for the hypothesis that mutations in ATP2A2 have 
pleiotropic effects.
3. Investigating possible relationships between DD clinical features, psychiatric features, 
learning difficulties and IQ scores. Including:
• Investigating possible subjective and objective relationships between the clinical 
features of DD (including severity and age of onset) and lifetime history of 
psychiatric symptoms. Such relationships (particularly subjective relationships) 
may provide support for the contribution of psychosocial factors in the presence of
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psychiatric features in individuals with DD but objective relationships may also 
provide support for pleiotropy (certain mutations in ATP2A2 may lead to the 
presence of both severe DD and severe neuropsychiatric features including 
psychiatric features).
• Investigating possible relationships between the perceived impact of having DD on 
everyday functioning and lifetime history of psychiatric symptoms which again 
may provide support for the contribution of psychosocial factors in the presence of 
psychiatric features in individuals with DD.
• Investigating relationships between age of onset and severity of DD and IQ scores 
and learning difficulties. Such relationships may support the role of psychosocial 
factors (severe symptoms of DD from an early age may affect school attendance 
and subsequently school performance) but may also provide support for pleiotropy 
(certain mutations in ATP2A2 may lead to the presence of both severe DD and 
severe neuropsychiatric features including learning difficulties).
3.4 Statistical Analysis
Data were extracted from the study Access database into the statistical package SPSS 
version 12.0.1 (SPSS Inc., 2003). Normality of the data was assessed using the Kolmogorov- 
Smimov Test. The majority of the data were not normally distributed so non-parametric 
statistical tests were used, outlined below. Statistical tests were considered significant at the 
p<0.05 level, (two tailed).
Continuous data:
• Differences between two groups were assessed using Mann-Whitney U tests (in 
one case where data were found to be normally distributed, an independent 
samples /-test was used).
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• Differences between 3+ groups were assessed using Kruskal-Wallis Analysis of 
Variance. If a significant difference was found, post hoc comparisons were 
performed on each pair of groups using Mann-Whitney U tests.
• Correlations between two continuous variables were assessed using Spearman’s 
rho.
Categorical data
• Relationships between two categorical variables were assessed using 2x2 and 2x3 chi- 
square tests. In cases where 20% or more of the cells in a chi-square table had an 
expected count of less than five, Fisher’s exact tests (2x2 tables) and exact 
significance tests for Pearson’s chi-square (2x3 tables and greater) were used. For 2x3 
chi-square tables, if a significant relationship was found, post hoc comparisons were 
performed on each pair using 2x2 chi-square tests.
Due to the modest size of the sample and limited power, corrections were not routinely 
made for multiple testing. Therefore, any significant findings were treated with caution and an 
emphasis was placed on looking for trends in the relationships between the clinical features of 
DD and the neuropsychiatric features observed.
The following chapter (Chapter 4) describes the demographic, clinical and 
neuropsychiatric features observed among 100 unrelated individuals with DD.
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4 DEMOGRAPHICS, CLINICAL AND NEUROPSYCHIATRIC 
FEATURES IN 100 INDIVIDUALS WITH DD: RESULTS
This chapter describes the demographic, clinical and neuropsychiatric features of 100 
unrelated individuals with DD. First the demographic characteristics of the sample are 
described followed by the clinical features of DD and impact on quality of life. This is 
followed by a description of the lifetime prevalence of neuropsychiatric features in the 
sample. The final part of the chapter reports investigations of possible relationships between 
the clinical features of DD and the presence and severity of lifetime neuropsychiatric features 
observed in the sample. Additional information relating to this chapter can be found in section 
B of the Appendix starting at pg. 298, and will be referenced throughout the chapter.
4.1 Demographic Characteristics
The demographic characteristics of the sample are summarised in Table 4.1 and Table 
4.2. The mean age of the sample was 48.2 years and participants were predominantly female 
(71%). The majority of the sample were UK Caucasian (92%). Most individuals (63%) were 
living in their own home with a spouse and/or children. Fifty-one percent of individuals were 
working either full or part time and 23% of individuals were retired. Sixteen percent of 
individuals were currently not working and receiving benefits. The most frequent category of 
main lifetime occupation was service, shop and market worker (30%).
The frequencies and percentages of the highest level of educational qualifications 
individuals achieved by age group are summarised in Table 4.2. A large proportion of the 
sample had no qualifications (41%). Similar proportions of individuals had obtained other 
qualifications, which included CSEs and GCSE grades D-G (13%), GCSE grades A-C or 
equivalent (17%) and A Levels or equivalent (12%). Fourteen percent of individuals had 
obtained higher educational qualifications including teaching and nursing qualifications and
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degrees. A higher proportion of individuals in the 55-64 and 65-74 age groups had no 
qualifications, 69% and 50% respectively, compared to individuals in the 18-34 and 35-44 
age groups, 14.3 % and 18.2% respectively.
Table 4.1 Demographic Characteristics of 100 Individuals with DD
Demographics Descriptives and Percentages
Age (years)
Mean (95% Cl) 48.2 (45.8-50.7)
Standard Deviation 12.4
Range 20-71
%
Female 71
Ethnic Origin
UK Caucasian 92
Other Caucasian 6
Asian 2
Marital Status
Has married/lived as married 88
Has never married/lived as married 12
Current Social Circumstances
Lives in own home with spouse and/or children 63
Lives alone 14
Lives in home of parents or children 13
Lives with partner at least one year but not married 7
Other 3
Current Employment Status
Employed full time 34
Employed part time 17
Not working-receiving benefits 16
Full-time student 2
Homemaker 8
Retired 23
Main Lifetime Occupation
Legislator/senior officials, managers and professionals 18
Technicians & associate professionals (& civil servants) 9
Clerks 18
Service workers & shop & market workers 30
Craft & related trade workers 7
Plant & machinery operators and assemblers 9
Elementary occupations 7
Never worked 1
Full-time student 1
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Table 4.2 Highest Level of Educational Qualifications by Age Groups
Age at Interview
18-34
N=14
35-44
N=22
45-54
N=28
55-64
N=26
65-74
N=10
All
N=100
N % N % N % N % N % %
No
qualifications
2 14.3 4 18.2 12 42.9 18 69.2 5 50.0 41
Other
qualifications*
4 28.6 5 22.7 2 7.1 2 7.7 0 0.0 13
GCSE A-C or 
equivalent
3 21.4 4 18.2 7 25.0 3 11.5 0 0.0 17
A Level or 
equivalent
2 14.3 3 13.6 4 14.3 0 0 3 30 12
Teaching, HND, 
Nursing
1 7.1 3 13.6 1 3.6 3 11.5 2 20 10
Degree 1 7.1 1 4.5 2 7.1 0 0 0 0.0 4
Unknown 1 7.1 2 9.1 0 0 0 0 0 0.0 3
* Other qualifications include CSEs and GCSE grades D-G.
4.2 DD Clinical Features and Impact on Quality o f Life
A clinical diagnosis of DD was confirmed in 95 cases either by obtaining copies of 
individuals’ dermatology records or by the fact that they were recruited for the study through 
a dermatologist on the basis of having a diagnosis of DD. The remaining five individuals 
reported that they had been given a diagnosis of DD by a dermatologist and four could recall 
their diagnosis had been confirmed with a biopsy. Two individuals had a diagnosis of 
unilateral/segmental DD affecting one side of the body only.
4.2.1 Age of Onset and Duration of DD
Age of onset of DD was known for ninety-six individuals. The descriptives and 
distributions are summarised in Table 4.3 and Figure 4.1 respectively. The median age of 
onset of DD in the sample was 14 years. The youngest age of onset was a female who had 
been bom with DD and the oldest was a female who had no symptoms until the age of 48.
The peak age of onset of DD was between the ages of 11-20 (49% of individuals). The
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median duration of having DD in the sample was 31 years and ranged from 3 to 60 years 
(Table 4.3).
Table 4.3 Age of Onset and Duration of DD (Years)- Descriptives
N Median Range Inter quartile 
range
Age of onset of DD 96 14 0-48 10
Duration of DD 96 31 3-60 21
0-10 11-20 21-30 31-40 41-50 Unsure
Age of onset of Darier's Disease (Years) 
Figure 4.1 Age of Onset of DD- Distributions
Q  Male 
■  Female
4.2.2 Severity of DD
Table 4.4 displays the severity of the cases of DD using the classification criteria 
described in Chapter 3 Table 3.3 pg.37. The majority of individuals (67) were classified as 
having moderate DD. Twenty-two individuals were classified as having mild DD and 11 were 
classified as having severe DD. The distribution of mild, moderate and severe DD was similar 
in males and females.
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Table 4.4 Severity of DD -Frequencies and Percentages
Total Male Female
N=100 N=29 N==71
N N % N %
Mild 22 7 24 15 21
Moderate 67 19 66 48 68
Severe 11 3 10 8 11
4.2.3 Symptoms and Aggravating Factors of DD
Ninety-two individuals reported itching as a symptom of their DD, 54 individuals 
reported that their skin could be painful and 60 reported they had noticed body malodour as a 
result of their DD. The frequencies of symptoms reported in DD are summarised in Figure 4.2 
pg. 56. Twenty-two individuals reported that their skin could at times be completely clear 
whereas the majority of individuals reported their skin had never been completely clear since 
the onset of the condition.
Eighty-two individuals reported that heat or sweating made their skin worse while 52 
stated sunlight caused exacerbations. Sixty-eight individuals felt that their skin was worse 
under times of stress. The frequencies of common aggravating factors reported in DD are 
summarised in Figure 4.3 pg. 56. One individual reported a severe flare of their DD after 
using a sun bed. Three individuals’ dermatology notes indicate that they experienced an 
outbreak of DD following surgery. Two individuals who had taken the mood stabiliser lithium 
in the past felt this had possibly made their skin worse. This was supported by evidence from 
their medical notes that their skin seemed to improve when lithium was stopped. It is also 
noted in one of these individual’s case notes that their skin flared whilst they were taking 
carbamazepine, another mood stabiliser. Another individual’s dermatology case notes 
reported that their DD flared the same time their antidepressant, mirtazapine, was increased.
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4.2.4 Impairment and Impact on Quality of Life
The numbers of individuals who had been admitted to hospital for treatment of their DD 
are summarised in Table 4.5 pg. 56. The majority of individuals had not required inpatient 
treatment (67 individuals). Twenty-three individuals had been treated in hospital between one 
and four times and 10 individuals had required an admission to hospital on five or more 
occasions. Nine individuals reported having to stop work due to the severity of their DD and a 
further 15 individuals had taken a total of months off work due their skin condition (shown in 
Table 4.6).
The subjective impairment individuals felt having DD had had on their school life, 
work/career, relationships and social activities are summarised in Figure 4.4 pg. 57. Twenty- 
eight individuals reported that they felt having DD had an impact on their school life (either 
mildly, moderately or severely). Areas of school life affected were the comments of other 
children and bullying, sports and swimming lessons and having to take time off due to the 
severity of their skin condition. Thirty individuals reported having DD had caused 
relationship problems, 35 individuals reported problems at work and in their career and 53 
individuals reported social activities being impaired by having DD.
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Reported 
□  No
■  Yes
■  Unsure
_l   !  -----
M alodor Itch ing  P a in
Symptom of DD 
Figure 4.2
Reported
Unsure
A p p l i c a b l e
Heat or 
sweating
Aggravating Factors
Figure 4.3
Figure 4.2 Frequencies of Individuals Reporting Malodour, Itching and Pain as a Symptom of 
DD
Figure 4.3 Frequencies of Individuals Reporting Heat, Sun and Stress as an Aggravating Factor 
of DD
Table 4.5 Number of Admissions to Hospital for Treatment of DD
Number of Admissions Frequency
0 67
1-4 23
5+ 10
Total 100
Table 4.6 Total Amount of Time Taken Off Work due to the Symptoms of DD
Time Taken Off Work Frequency
None 51
Days 11
Weeks 11
Months 13
Greater than one year 2
Stopped work due to DD 9
Not applicable 3
Total 100
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39 .0%
82 .0%
Effect on 
School
H  None
□  Mild
gj Moderate 
0  Severe 
Not
Applicable 
as DO
□  symptoms 
started after 
leaving 
school
Effect on 
Relationships 
B None
□  Mild
□  Moderate
□  Severe
□ NotLJ Applicable 
□  Unsure
Effect on 
Social 
Activities 
B None
□  Mild
E3 Moderate
□  Severe
□  Unsure
Effect on 
W ork/Career
□  None
□  Mild
□  Moderate
□  Severe 
Not
LJ Applicable
□  Unsure
Figure 4.4 Subjective Impairment of DD on School Life, Work/Career, Relationships and Social 
Activities
4.2.4.1 Dermatology Life Quality Index
Ninety-nine individuals completed two versions of the Dermatology Life Quality 
Index (DLQI) relating to the last week and the worst week ever respectively. The measure has 
been previously described in Chapter 3 section 3.2.2.5 pg. 38. The descriptives and 
distributions of DLQI total scores are summarised in Table 4.7 and Table 4.8. The median 
total score on the last week and worst week version of the questionnaire was 4 (13% of the 
maximum score of 30) and 15 (50% of the maximum score of 30) respectively.
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Fifty-nine individuals had scores of 0-5 on the last week version of the questionnaire 
indicating that their DD had caused little impact on their everyday lives during the last week. 
Only three individuals had a score of over 20 indicating that during the last week they felt the 
symptoms of DD had caused a significant impact on their quality of life. In contrast only 12 
individuals reported no or limited impact on quality of life during the worst week of DD 
symptoms indicating the majority of individuals felt that having DD had caused impairment at 
some point in their lives.
Table B-l pg. 298 summarises DLQI last week and worst week median domain scores as 
a percentage of each domain total score. The highest scores on both versions of the DLQI 
related to the domain of symptoms and feelings. The median symptoms and feelings domain 
score on the last week version of the questionnaire was 2 (33.3 % of the maximum score of 
that domain). The median symptoms and feelings domain score on the worst week version of 
the questionnaire was 5 (83% of the maximum score of that domain). This domain relates to 
two items asking individuals within the time period how itchy, sore, painful or stinging their 
skin has been and how embarrassed or self-conscious they have been because of their skin.
Table 4.7 Dermatology Life Quality Index Total Score- Last Week and Worst Week- 
Descriptives
N Median Range Inter quartile 
range
Last Week 99 4 0-28 8
Worst Week 99 15 0-30 12
Table 4.8 Distribution of Dermatology Life Quality Index Total Scores -  Last Week and Worst 
Week
Number of Individuals
DLQI Score Last Week Worst Week
0-5 59 12
6-10 23 17
11-15 9 21
16-20 5 20
>20 3 29
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4.2.5 Relationship between Impact on Quality of Life and DD Severity
The relationship between DLQI last and worst week total scores and DD severity is 
illustrated in Figure 4.5. Kruskal-Wallis H test indicated that there was a significant 
difference between the total median DLQI last week scores of individuals with mild, 
moderate and severe DD (H =11.496, df=2, p=0.003). Mann-Whitney U tests indicated that 
individuals with moderate and severe DD scored significantly higher on the DLQI last week 
version than individuals with mild DD (5 vs. 1.5; U=387, n=88, p=0.001) and (9 vs. 1.5; 
U=65.5, n=33, p=0.032) respectively. There was no significant difference between the DLQI 
last week scores of individuals with moderate and severe DD (5 vs. 9; U=308, n=77, 
p=0.422).
There was also a significant difference between the total median DLQI worst week 
scores of individuals with mild, moderate and severe DD (H= 19.051, df=2, p<0.001). 
Mann-Whitney U tests indicated that individuals with moderate and severe DD scored 
significantly higher on the DLQI worst week version than individuals with mild DD (17 vs. 
10.5; U=336.5, n=88, p<0.001) and (18 vs. 10.5; U=17, n=33, p<0.001) respectively. There 
was no significant difference between the DLQI worst week scores of individuals with 
moderate and severe DD (17 vs. 18; U=279.5, n=77, p=0.224).
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Figure 4.5 Relationship between Last Week and Worst Week Dermatology Life Quality Index 
Scores and DD Severity
4.2.6 Family History of DD
The numbers o f individuals with a definite, possible or no known family history of 
DD are summarised in Table 4.9. Fifty-three individuals reported a definite family history of 
DD. A further 15 felt that another family member probably had DD either because they had 
observed that they had a similar skin condition to themselves that had not been diagnosed or 
another family member had mentioned that they had a similar looking skin condition. 
Twenty-six individuals reported no family history of DD despite knowing or having 
information on all other immediate family members. Six individuals were unsure if they had a
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family history of DD, four of these individuals had been adopted and had no information on 
either of their parents and two individuals had no information about their fathers.
Table 4.9 Family History of DD - Frequencies
Frequency
Definite 53
Probable 15
None 26
Unknown 6
Total 100
4.2.7 Section Summary
This section has described the clinical features of DD in the sample and the level of 
impairment the disorder has had on various aspects of individuals’ everyday lives. The 
following section describes the prevalence of lifetime psychiatric symptoms in the sample.
4.3 Lifetime Psychiatric Features
4.3.1 Main Best-Estimate Lifetime DSM-IV Diagnoses
The frequencies and percentages of the main best-estimate lifetime DSM-IV 
psychiatric diagnoses of individuals in the sample are summarised in Table 4.10 and Table 
4.11. Fifty-five individuals had a lifetime DSM-IV diagnosis. In the case of a further eight 
individuals (classified as unknown) there was a suggestion of a history of psychiatric illness 
but not enough symptoms could be elicited to make a definite lifetime DSM-IV diagnosis. A 
significantly higher percentage of females than males had a history of psychiatric illness (65% 
vs. 31%; X2 = 9.478, df= 1, p=0.002).
Thirty individuals in the sample had a history of Major Depressive Disorder, which 
was the most common category of psychiatric illness. One individual with a diagnosis of 
Major Depressive Disorder developed hypomanic symptoms for one month after being treated 
with antidepressant medication, the symptoms stopped after her GP discontinued the
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medication. Two individuals had a diagnosis of Dysthymic Disorder and twelve individuals 
had a lifetime diagnosis of Depression Not Otherwise Specified (NOS). This category is used 
for individuals with a history of depressive features that do not reach the criteria for other 
depressive disorders. Four individuals had a lifetime diagnosis of Bipolar I Disorder and a 
further individual was diagnosed as having Cyclothymic Disorder. Three individuals had 
history of Panic Disorder and a further three individuals had a diagnosis of Anxiety NOS.
Table 4.10 Summary of Main Best-Estimate Lifetime DSM-IV Diagnoses
Total Male Female
N=100 N=29 N==71
% N % N %
Any DSM-IV Disorder 55 9 31.0 46 64.8
Unknown 8 4 13.8 4 5.6
No DSM-IV Disorder 37 16 55.2 21 29.6
Table 4.11 Main Best-Estimate Lifetime DSM-IV Diagnoses
Total
N=100
DSM-IV Diagnosis N
Major Depressive Disorder 30
Recurrent Episodes 24
Single Episode 6
Dysthymic Disorder 2
Depression NOS 12
Bipolar I Disorder 4
Cyclothymic Disorder 1
Panic Disorder 3
With Agoraphobia 1
Without Agoraphobia 2
Anxiety Disorder NOS 3
Unknown 8
Unaffected 37
NOS; Not otherwise specified
4.3.2 Co-morbid DSM-IV Diagnoses
Table 4.12 summarises the co-morbid DSM-IV diagnoses of eleven individuals. Ten 
individuals whose main diagnosis was a depressive disorder also had a history of an anxiety 
disorder and one individual with a main diagnosis of an anxiety disorder also had a history of 
a depressive disorder. Table 4.13 and Table 4.14 summarise the percentages of all best
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estimate lifetime DSM-IV diagnoses in the sample and includes the individuals with two co- 
morbid diagnoses twice. In total 50 individuals had a lifetime diagnosis of a mood disorder 
and 16 individuals were diagnosed as having a history of an anxiety disorder.
Table 4.12 Co-morbid DSM-IV Diagnoses
Main DSM-IV Diagnosis Second DSM-IV Diagnosis Number of 
Cases
Major Depressive Disorder (R) Panic Disorder without agoraphobia 3
Major Depressive Disorder (R) Panic Disorder with agoraphobia 1
Major Depressive Disorder (R) Generalised anxiety disorder 1
Major Depressive Disorder (R) Anxiety Disorder NOS 1
Major Depressive Disorder (S) Anxiety Disorder NOS 1
Dysthymic Disorder Panic Disorder without agoraphobia 1
Depression NOS Panic Disorder with agoraphobia 1
Panic Disorder with agoraphobia Depression NOS 1
Panic Disorder without agoraphobia Anxiety Disorder NOS 1
R; recurrent episode, S; single episode, NOS; not otherwise specified. 
Table 4.13 All Best-Estimate Lifetime DSM-IV Diagnoses
Total
N=100
DSM-IV Diagnosis N
Major Depressive Disorder 30
Recurrent 24
Single 6
Dysthymic Disorder 2
Depression NOS 13
Bipolar I Disorder 4
Cyclothymic Disorder 1
Panic Disorder 9
With Agoraphobia 3
Without Agoraphobia 6
Generalized Anxiety Disorder 1
Anxiety Disorder NOS 6
Unknown 8
Unaffected 37
NOS; not otherwise specified.
Table 4.14 Summary of all Lifetime DSM-IV Diagnoses
Total
N=100
N
Any DSM-IV Mood 50
Disorder
Any DSM-IV Anxiety 16
Disorder
63
4.3.3 History of Suicidal Thoughts and Suicide Attempts
The frequencies and percentages of individuals with a history of suicidal thoughts and 
suicide attempts are summarised in Table 4.15 and illustrated in Figure 4.6. Individuals are 
only included in one category so for example an individual with a past history of suicidal 
thoughts who had also made a suicide attempt is only included in the category for suicide 
attempt. Thirteen individuals had made a suicide attempt in their lifetime.
Brief descriptions of the suicide attempts made by thirteen individuals are summarised 
in Table 4.16. One individual, classified as having severe DD, made a suicide attempt during 
an episode of depression, which was in reaction to a worsening of the symptoms of their DD. 
For the remaining twelve individuals there was no subjective or objective temporal 
relationship between their suicide attempts and the symptoms of DD.
Table 4.15 History of Suicidal Thoughts and Suicide Attempts
Total
N=100
N
Multiple suicide attempts likely to result in death 1
Suicide attempt likely to result in death 3
Suicide attempt unlikely to result in death 9
Suicidal Thoughts 18
Unsure 6
None 63
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Lifetime Prevalence 
of Suicidal Ideation 
and Suicide 
Attempts 
0  None
□  Suicidal Ideation
□  Suicide Attempt
□  Unknown
Figure 4.6 Summary of History of Suicidal Ideation and Suicide Attempts - Frequencies
Table 4.16 Descriptions of Suicide Attempts by Thirteen Individuals
Study ID Description
DAR4-1 M ultiple overdoses over a 20-year period. M edical notes report 
attempts to be impulsive and in response to dom estic difficulties. 
Described as having an emotionally unstable personality disorder.
DAR70-1 One serious overdose following marital problems. Described as having 
a cyclothymic personality.
DAR85-1 Impulsive suicide attempts over a month period following a 
relationship breakdown.
DAR55-1 M ultiple overdoses over a 15-year period. Described in medical notes 
as having somatoform disorder.
DAR46-1 Two overdoses following domestic difficulties.
DAR39-1 Impulsive overdose following a situational crisis.
DARI 9-1 Overdose on one occasion.
DARI 8-1 Diagnosis o f  bipolar disorder. Admitted to hospital on a section 
following an overdose, mood described as being elated at the time.
DAR7-1 Overdose as a teenager following a relationship breakdown.
DAR30-1 M ultiple overdoses often in response to domestic situations. Described 
in medical notes as having a dependent personality.
DAR58-1 Overdose in late teens.
DAR52-1 Suicide attem pt during episode o f depression in reaction to a flare up o f 
DD.
DARI 7-1 Overdose during an episode o f  depression in relation to a number o f  
stressful life events.
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4.3.3.1 Relationship between Lifetime DSM-IV Diagnosis and History of 
Suicidal Thoughts and Suicide Attempts
The relationship between lifetime DSM-IV diagnosis and history of suicidal thoughts 
and suicide attempts are shown in Table B-2 pg. 298. All of the individuals with a history of 
suicidal thoughts or suicide attempts either had a positive DSM-IV lifetime diagnosis of 
psychiatric illness or there was a suggestion of a history of psychiatric illness but not enough 
symptoms could be elicited to make a definite lifetime DSM-IV diagnosis (classified as 
Unknown DSM-IV).
4.3.4 Lifetime Treatment for Psychiatric Illness
Table 4.17 summaries the types of treatment individuals had received for psychiatric 
illness in their lifetime. Individuals who had received more than one type of treatment, for 
example had consulted their GP for symptoms of depression, received antidepressants and 
been referred to secondary psychiatric services, are included in more than one treatment 
category. Almost half of the sample (49 individuals) had at some stage in their lives consulted 
their GP for psychiatric symptoms. Forty-six individuals on at least one occasion in their lives 
had been offered or received antidepressant, anxiolytic or hypnotic medication by their GP for 
treatment of psychiatric symptoms. Five individuals in the sample had been treated with a 
mood stabilizer, these included the four individuals in the sample with diagnosis of Bipolar I 
Disorder and another individual with a lifetime diagnosis of Major Depressive Disorder who 
had taken multiple overdoses over a 15 year period and had an extensive psychiatric history. 
The four individuals with Bipolar I Disorder had also been treated with antipsychotic 
medication on at least one occasion. Twenty-five individuals had been referred by their GP to 
secondary psychiatric services. Nine individuals had received psychiatric inpatient treatment
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for episodes of depression (3 individuals), suicide attempts (3 individuals), manic episodes (2 
individuals) and both episodes of mania and depression (1 individual).
Table 4.17 Lifetime Treatment for Psychiatric Illness
Total
N=100
N
Consulted GP for physical symptoms 
thought by GP to be related to symptoms 
of anxiety or depression
2
GP consultation for psychiatric symptoms 49
Offered/received antidepressants, 
anxiolytics or hypnotics for psychiatric 
symptoms
46
Received mood stabilisers 5
Received antipsychotic medication 4
Referred by GP to psychiatric services 25
Psychiatric inpatient 9
Individuals who had received more than one type o f treatment are included in more than one category.
4.3.5 Key Psychiatric Clinical Variables
The 55 individuals with a lifetime DSM-IV diagnosis of any psychiatric illness were 
also given additional ratings on key psychiatric clinical variables namely age of onset of 
psychiatric illness, number of episodes of affective illness and longest duration of affective 
episodes. In some cases there was not enough information regarding individuals' psychiatric 
history to make a rating on these variables (this is reflected in the N columns in the tables).
4.3.5.1 Age of Onset of Psychiatric Illness
Descriptive data for the age of onset of psychiatric illness causing impairment of 39 
individuals is summarised in B-3 pg. 298. The median age of onset of the 39 individuals with 
any lifetime psychiatric illness and the 35 individuals with a lifetime depressive disorder was 
25 years and ranged from 14 to 58 years. The median age of onset of the four individuals with 
a lifetime history of bipolar disorder was 23 years and ranged from 15 to 52 years.
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4.33.2 Number of Episodes of Affective Illness
Descriptive data for the number of episodes of affective illness among individuals with 
a lifetime DSM-IV diagnosis of a mood disorder are summarised in Table B-4 pg. 299. The 
30 individuals with a diagnosis of Major Depressive Disorder had a median of four episodes 
of depression (range; 1 to 20 episodes). One female diagnosed with Major Depressive 
Disorder had experienced two episodes of sub clinical mania following the births of both of 
her children. A further individual with Major Depressive Disorder developed a hypomanic 
episode after being treated with antidepressant medication. Two individuals with a lifetime 
diagnosis of Dysthymic Disorder had both experienced one chronic period of depressed mood 
that did not reach criteria for an episode of major depression. Nine of the 13 individuals with 
a lifetime diagnosis of Depression NOS had a median of two episodes of depression (range; 1 
to 130 episodes). It was not possible to determine the number of episodes in the other four 
cases. Three of the four individuals with Bipolar I Disorder had a median of 10 episodes of 
depression (range; 1 to 50 episodes) and six episodes of mania (range; 1 to 20 episodes). It 
was not possible to determine the number of episodes in the other case of Bipolar I Disorder.
4.33.3 Longest Duration of Affective Illness
Descriptive data for the length of the longest episode of affective illness in weeks 
among individuals with a lifetime DSM-IV diagnosis of a mood disorder is summarised in B- 
5 pg. 299. It was possible to determine the length of the longest episode of depression in 29 
individuals with a lifetime diagnosis of Major Depressive Disorder. The median length of the 
longest episode of depression was 26 weeks and ranged from two weeks to 260 weeks (five 
years). The two individuals with a lifetime diagnosis of Dysthymic Disorder had experienced 
chronic periods of depression lasting 312 weeks (six years) and 780 weeks (15 years) 
respectively. The median length of the longest episode of depression among nine individuals 
with Depression NOS was three weeks and ranged from four days to 130 weeks (2 Vi years).
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For two individuals with Bipolar I Disorder the median length of the longest episode of 
depression was 14 weeks (range; 12 to 15 weeks) and the median length of the longest 
episode of mania was five weeks (range; 2 to 50 weeks).
4.3.6 Section Summary
This section has described the prevalence of lifetime psychiatric symptoms in the sample 
including lifetime DSM-IV diagnosis, history of suicidal thought and attempts and treatment 
for psychiatric illness. The following section describes the prevalence of other 
neuropsychiatric features in the sample.
4.4 Other Neuropsychiatric Features
4.4.1 Lifetime Prevalence of Epilepsy
Three individuals in the sample had a lifetime diagnosis of epilepsy, described in 
Table 4.18. One individual with a lifetime diagnosis of tonic-clonic epilepsy was currently 
receiving treatment for epilepsy. Two individuals with a lifetime diagnosis of idiopathic 
epilepsy and petit mal epilepsy respectively were not currently receiving any treatment for 
epilepsy.
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Table 4.18 Individuals with a Lifetime Diagnosis of Epilepsy
Type of Epilepsy Details Investigations
Tonic-Clonic
Epilepsy
Tonic clonic seizures starting around the age of 
eight. Currently being treated with anti-epileptic 
medication.
Also absence seizures starting in childhood.
EEGs dramatically abnormal with 
frequent generalised epileptic 
discharges (from medical notes).
Idiopathic Epilepsy Admitted at the age 18 for investigations of 
epilepsy. Grand mal fits observed. Treated with 
anti-epileptic medication for 40 years, stopped 12 
months ago after not having a fit for 15 years.
EEG showed no specific 
epileptiform pattern. Further 
EEG showed a generalised excess 
of slow rhythms (from medical 
notes).
Petit Mal Epilepsy Age 6-13; absence/petite mal episodes- lasting for a 
few minutes a couple of times a week.
Investigated and diagnosed by a 
neurologist (reported by 
participant).
4.4.2 Lifetime Prevalence of Investigations for Blackouts and Brief 
Periods of Loss of Consciousness
Thirteen individuals had had investigations for blackouts, periods of loss of 
consciousness or fainting episodes, summarised in Table 4.19. In eleven of these cases 
individuals either reported they were unsure of the results of the investigations or they and/or 
their medical notes reported no neurological abnormalities were found. A CT revealed some 
mild atrophic changes in an individual aged 40 who received neurological investigations after 
collapsing. An individual with a lifetime diagnosis of bipolar disorder was given 
investigations for an episode of loss of consciousness aged 55, which revealed a possible 
aneurysm or medial sphenoid ridge meningoma.
4.4.3 Summary of all Neurological Investigations and Treatments
In total thirty-six individuals had been referred to a neurologist and had neurological 
investigations or had been treated for a neurological condition, summarised in Table 4.20. 
Four individuals who had been treated or investigated for two different neurological 
conditions are included in the table twice. This included an individual who had petit mal 
epilepsy in childhood who also had viral meningitis aged 43, a 51 year old individual who had
70
been given a CT scan to investigate memory problems and an audiogram for hearing 
difficulties, a 58 year old individual who had a CT scan to investigate headaches and had also 
had an audiogram to investigate hearing problems and a 39 year old individual who had had 
investigations for migraines and problems with peripheral vision. Sixty-one individuals had 
consulted their GP for possible neurological symptoms, summarised in Table 4.21. Twenty- 
three individuals who had consulted their GP for two or more possible neurological symptoms 
on separate occasions are included in the table more than once.
Table 4.19 Investigations for Blackouts, Periods of Loss of Consciousness o r Fainting Episodes
Study ID Details Investigations
DAR72-1 Query o f Temporal Lobe Epilepsy 
GP notes report ‘temporal lobe epilepsy or 
vasovagal attacks
At interview reported having brain scans 
to investigate blackouts.
DARI 7-1 Query o f Petit Mal Epilepsy 
Reported periods of loss of 
concentration/daydreaming at school.
At interview reported having an EEG -  
unsure of results.
DAR27-1 Query o f Epileptic Fit
GP notes report ‘query epileptic f i t ’.
Reported having unusual falls/blackouts.
Unsure.
DAR18-1 Query o f Epileptic fit
GP notes report ‘loss o f consciousness which 
may have been grand mal in nature '.
From notes: EEG was suggestive of 
focal activity from the left posterior 
temporal region. CT scan showed an 
increased density lesion. Thought to be 
either an aneurysm or medial sphenoid 
ridge meningoma.
DAR99-1 Reported fainting episodes since teenage years 
occurring anywhere.
Reported having EEG and CT scans.
DAR91-1 Hospital notes report a history of headache and 
fainting episodes and one episode of ‘transient 
loss o f consciousness lasting 3-4 minutes no 
associated convulsions or incontinence'.
From hospital notes: EEG and head CT 
within normal range.
DAR55-1 Reported having one blackout. Reported investigations, including brain 
scans, were normal.
DAR52-2 Reported a 2 week period of blackouts whilst 
being treated in hospital for a flare of her DD.
Reported blood tests and brain scans 
were all normal.
DAR92-1 Reported fainting on a few occasions, first age 
15.
Reported CT scan taken following one 
episode was normal.
DAR48-1 From GP notes: investigations after collapsing, 
having headaches at the time.
From GP notes: CT scan showed some 
atrophic changes.
DAR28-1 Reported fainting attacks since the age of 11 
also recorded in medical notes.
In medical notes: CT scan for syncopal 
attacks normal.
DAR4-1 Reported periods of collapsing with associated 
with numbness one side of the body and slurred 
speech, episodes recorded in medical notes.
From medical notes: neurologist 
reported no abnormal neurological signs.
DAR23-1 Faint feelings and light-headedness recorded in 
GP notes.
Referred to a neurologist - no 
neurological symptoms found.
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Table 4.20 Investigations of Neurological Symptoms by a Neurologist and/or Neurological 
Investigations
Type of neurological condition investigated by 
neurologist or neurological procedure
Frequency
Epilepsy 3
Blackouts, periods of loss of consciousness or fainting 
episodes
13
Headaches 6
Hearing Problems 9
Other* 9
Total** 40
* Viral encephalitis; viral meningitis; other meningitis; CT scan or peripheral vision; head MR1 investigations 
for slight paralysis; investigations for left sided weakness following 3 possible strokes; CT scan poor memory; 
halting gait; loss of feeling in leg whilst driving.
**Four individuals who had been treated or investigated for two different neurological conditions are included in 
the table twice.
Table 4.21 GP Consultation for Neurological Symptoms
Type of neurological condition Frequency
Epilepsy 3
Fits, Faints, blackouts 24
Headaches 33
Hearing Problems 14
Other* 13
Total** 87
* Viral encephalitis; viral meningitis; other meningitis; CT scan or peripheral vision; head MRI investigations 
for slight paralysis; investigations of left sided weakness following 3 possible strokes; CT scan poor memory; 
halting gait; loss of feeling in leg whilst driving; dizziness; hand shaking; positional vertigo; twitching legs. 
**23 individuals who had consulted their GP for two or more possible neurological symptoms are included in 
the table more than once.
4.4.4 Learning Difficulties
The frequencies of individuals diagnosed with dyslexia and individuals who received 
extra help at school are summarised in Table 4.22. Five individuals reported that they had 
been given a diagnosis of dyslexia and a further nine individuals reported that they received 
extra help at school for problems with reading and/or spelling and/or maths. This included an 
individual aged 29 who had attended a school for children with behavioural and learning 
difficulties and an individual aged 21 with a lifetime diagnosis of tonic-clonic epilepsy who 
was diagnosed with a language area based learning difficulty at the age of 11.
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Fifty-nine individuals returned the Adult Dyslexia Checklist (ADC) (previously 
described in Chapter 3 section 3.2.6.2 pg. 43). Eleven individuals (18.6%) gave nine or more 
YES responses on the questionnaire indicating difficulty. The numbers of individuals with a 
diagnosis of dyslexia, receiving extra help at school and scoring nine or more YES responses 
on the ADC are shown in Table 4.23. In total 21 individuals had either a diagnosis of 
dyslexia, received extra help at school or scored nine or more on the ADC or a combination of 
the three.
Table 4.22 Individuals Diagnosed with Dyslexia and/or Reported Receiving E xtra Help a t School
Frequency
Diagnosis of dyslexia 5
Received extra help at school 13
Four Individuals diagnosed with dyslexia and received extra help at school are included in the table twice.
Table 4.23 Summary of Measures of Learning Difficulties
Measure of Learning Difficulties Frequency
Diagnosis of dyslexia only 1*
Received extra help at school only 7
(includes 4*)
> 9 YES responses on the ADC only 7
Diagnosis of dyslexia AND received extra help at school 2
only (includes 1*)
Diagnosis of dyslexia AND > 9 YES responses on the ADC 
only
0
Received extra help at school AND > 9 YES responses on 
the ADC only
2
Diagnosis of dyslexia AND received extra help at school 
AND ;> 9 YES responses on the ADC
2
TOTAL 21
n* = number of individuals not returning the Adult Dyslexia Checklist. ADC= Adult Dyslexia Checklist.
4.4.5 Section Summary
This section has described the lifetime prevalence of additional neuropsychiatric features in 
the sample including epilepsy, neurological investigations and treatments and learning 
difficulties. The following section describes the IQ scores of the sample.
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4.5 IQ Scores
Eighty-five individuals completed the two-subset version of the Weschsler 
Abbreviated Scale of Intelligence (WASI) (previously described in chapter 3 section 3.2.7 pg. 
44). The descriptives and distributions of IQ scores are summarised in Table 4.24 and Table 
4.25 & Figure 4.7 respectively. The reasons for the remaining 15 individuals not completing 
the IQ measure are reported in Table 4.26. The mean IQ score was 100, which is within the 
average range of IQ. Seventy-eight individuals (92%) had IQ scores within the range 
classified as being average. Two individuals (2.4%) had scores within the superior IQ range. 
Four individuals (4.7%) had scores within the borderline category and one individual had a 
score within the extremely low category.
Table 4.24 IQ Scores -Descriptives
N Mean Std.
Deviation
95% Cl Range
85 100.38 13.143 97.54-103.21 67-125
Table 4.25 IQ Scores-Distributions
IQ Score Classification Frequency %
120-129 Superior 2 2.4
110-119 High Average 18 21.2
90-109 Average 48 56.5
80-89 Low Average 12 14.1
70-79 Borderline 4 4.7
69 and below Extremely Low 1 1.2
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Figure 4.7 Distribution of IQ Scores
Table 4.26 Reasons Fifteen Individuals did not complete the IQ Measurement
N
English not first language 2
Time constraints/not feasible 7
Not happy to complete 3
Unable to concentrate due to  slightly high mood 1
Unable to concentrate due to current medication 1
Too anxious 1
Total 15
4.5.1 Relationship of IQ with Age and Gender
There was a significant positive correlation between IQ and age at interview (r=0.270, 
n=85, p=0.012). Descriptive data for the IQ scores of males and females are summarised in 
Table B-6 pg. 299. There was no significant difference between the mean IQ scores o f males 
and females (t=0.111, df=83, p=0.912).
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4.5.2 Section Summary
This section has described the distribution of IQ scores in the sample. The following 
section summaries the lifetime prevalence of all neuropsychiatric features in the sample 
including psychiatric illness, neurological investigations and treatments, learning difficulties 
and below average IQ.
4.6 Summary o f Lifetime Prevalence o f Neuropsychiatric Features
Table 4.27 summaries the numbers of individuals in the sample with a lifetime history 
of any DSM-IV diagnosis, being referred to psychiatric services, being referred for 
neurological investigations or treatments, learning difficulties and having a below average IQ 
(<80). Fifty-two individuals had either been referred to secondary psychiatric services and/or 
been referred to a neurologist at some point in their life. In total 78 individuals in the sample 
had a lifetime history of any of the lifetime neuropsychiatric phenotypes examined in this 
study.
Table 4.27 Frequencies of Individuals with Specific Lifetime Neuropsychiatric Features and any 
Neuropsychiatric Phenotype
Lifetime Neuropsychiatric Feature N
Any lifetime DSM-IV disorder 55
Referred to psychiatric services 25
Referred for neurological investigations or treatments 36
Learning difficulties 21
Below average IQ (<80) 6
Referred to psychiatric services OR referred for neurological investigations or 
treatments
52
*Any neuropsychiatric phenotype 78
* Number of individuals with a lifetime history of any DSM-IV disorder OR being referred to psychiatric 
services OR being referred for neurological investigations or treatments OR learning difficulties OR IQ <80.
The following section describes the prevalence of family history of neuropsychiatric features 
including psychiatric illness and epilepsy in the sample.
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4.7 Family History o f Neuropsychiatric Features
4.7.1 Family History of Psychiatric Illness and Epilepsy in 1st Degree 
Relatives
The numbers of individuals having first-degree relatives with a history of psychiatric 
illness and epilepsy are displayed in Table 4.28. In total 43 individuals reported they knew of 
a first-degree relative who had received treatment for a psychiatric illness or had experienced 
psychiatric symptoms causing significant impairment. This included thirteen individuals with 
multiple (two or more) first-degree relatives with a history of psychiatric illness. Six 
individuals had a first-degree relative with a diagnosis of epilepsy and one individual had two 
first-degree relatives diagnosed as having epilepsy.
Table 4.28 Family History of Psychiatric Illness and Epilepsy
No First Degree Relative 
with Known History
1st Degree Relative with 
History
Multiple 1st Degree 
Relatives with History
Psychiatric Illness 57 30 13
Epilepsy 93 6 1
Figures are the numbers/ percentages of the 100 individuals with DD.
The numbers of individuals having first-degree relatives with a history of specific 
psychiatric illnesses are summarised in Table 4.29. The most common type of psychiatric 
illness in first-degree relatives was major depression. Thirty-two individuals had a family 
history of major depression. Two individuals reported that they had a first degree relative with 
a diagnosis of bipolar disorder, and a further two individuals gave descriptions of their 
relatives’ psychiatric symptoms that were thought to be bipolar disorder, these are described 
in Table 4.30. Three individuals reported they had a first-degree relative with a diagnosis of 
schizophrenia. Three individuals had a first degree relative with a histoiy of a severe 
psychiatric illness including episodes of psychosis and other psychiatric illnesses requiring 
admission to a psychiatric hospital. Eight individuals had a first-degree relative with other
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psychiatric illnesses including anxiety disorders alcohol misuse/dependence and obsessive- 
compulsive disorder.
The 43 individuals with a first-degree relative with a history of psychiatric illness had 
a total of 64 first-degree relatives with a positive psychiatric history. Of these 64 relatives, 34 
(53.1%) also had a diagnosis of DD, 23 (35.9%) did not have DD and in seven cases (10.9%) 
it was unknown whether or not they had DD (summarised in Table B-7 pg. 300). The seven 
individuals with a first-degree relative with a history of epilepsy had a total eight first-degree 
relatives with epilepsy. Of these eight relatives six (75%) had DD, one (12.5%) did not have 
DD and in one case (12.5) it was unknown whether or not they had DD (summarised in Table 
B-8 pg. 300).
Table 4.29 Family History of Psychiatric Illness - by Diagnosis
Diagnosis in 1“ Degree 
Relatives of Individuals 
with DD
No First Degree 
Relative with Known 
Illness
1st Degree Relative with 
Illness
Multiple Affected 1st 
Degree Family 
Members
Major Depression 68 22 10
Bipolar Affective Disorder 96 4 0
Schizophrenia 97 3 0
Other Severe Psychiatric 
Disorder
97 2 1
Other Psychiatric Illness 92 6 2
Figures are the numbers/percentages of the 100 individua s with DD.
Individuals are only included positively in the table once for each of their relatives e.g. an individual with a 1st 
degree relative with schizophrenia and substance abuse is only rated as 1st degree relative with schizophrenia, an 
individual with one first degree relative with schizophrenia and another relative with substance abuse problems 
is rated as 1" degree relative with schizophrenia and 1st degree relative with other psychiatric illness.
Table 4.30 Descriptions of Family Members with a Definite or Possible History of Bipolar 
Disorder
Diagnosis of
Index
Individual
Family
Member
DD Description
Unaffected Mother No Admitted to a psychiatric hospital aged 40 and 50, 
described as being ‘high’ with grandiose ideation.
Bipolar I Mother Yes Described as seeing a psychiatrist for depression 
and anxiety, in daughters’ medical notes described 
as having a bipolar illness.
Unaffected Sister Yes Diagnosis of Bipolar Disorder.
Unaffected Sister No Has seen a psychiatrist and has periods when her 
behaviour is very out of character. On lithium.
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Examples of families with multiple members with neuropsychiatric features are displayed 
in Figure 4.8 to Figure 4.11 .In family one (Figure 4.8) the index individual was a female who 
had a hypomanic episode following antidepressant treatment, she reported that her mother 
who also had DD had been admitted to a psychiatric hospital on numerous occasions. She had 
three sons with a diagnosis of heroin abuse/dependence. Two had a diagnosis of DD and had 
both suffered from depression and also blackouts and photoflash epilepsy respectively. Her 
younger son in his early 20s who did not have DD had an episode of psychosis following a 
period of sleep deprivation. In family two (Figure 4.9) four siblings all with DD also all had a 
history of neuropsychiatric features including, depression, bipolar disorder, an episode of 
psychosis following childbirth and a form of childhood epilepsy. Their father who also had 
DD had experienced depression and the same type of childhood epilepsy as his son. In family 
three (Figure 4.10) four siblings had a history of depression and/or suicide attempts. Three of 
these individuals also had DD. Their father who had DD also had a history of depression. The 
30-year-old daughter of the index individual had a diagnosis of DD and no history of 
psychiatric illness. The index individual in family four (Figure 4.11) was a female in her late 
50’s with a history of depression and anxiety her medical notes also reported a short period of 
paranoia which did not reach delusional intensity. She reported that her sister who she did not 
think had DD had also experienced symptoms of anxiety. She was unsure whether her father 
had DD although remembered him seeing a dermatologist, thought that he had had a possible 
breakdown. One adult son without DD had received treatment for anxiety and depression and 
had made suicide attempts. Her other son with DD had a diagnosis of schizophrenia and 
depression and had also made suicide attempts. She was unsure whether her adult daughter 
had DD but felt she had probably suffered from depression.
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4.7.2 Section Summary
This section has described the prevalence of family history of neuropsychiatric features in 
sample including psychiatric illness and epilepsy. The following section investigates the 
relationships between lifetime neuropsychiatric features, IQ scores and family history of 
psychiatric illness among individuals in the sample.
4.8 Relationship between Lifetime Neuropsychiatric Features, IQ 
Scores and Family History of Psychiatric Illness
The relationships between lifetime DSM-IV diagnosis of psychiatric illness, history of 
investigations for blackouts/loss of consciousness, lifetime diagnosis of epilepsy, family 
history of psychiatric illness, below average IQ score and history of learning difficulties 
among individuals in the sample is displayed in Table B-9 pg 300. Three significant 
relationships are printed in bold and the frequencies and percentages of these are displayed in 
Table B-10 to Table B-l 1 pg. 301. Significantly more individuals with a history of 
investigations for blackouts/loss of consciousness had a lifetime DSM-IV diagnosis of 
psychiatric illness (85% vs. 53%; %2=4.411, df=l, p=0.036) and a family history of psychiatric 
illness (69% vs. 40%; ^=3.781, df=l, p=0.052). Significantly more individuals with learning 
difficulties had a below average IQ score (45% vs. 12%; Fisher’s, p=0.003).
4.8.1 Section Summary
This section has described the relationships between lifetime neuropsychiatric features, 
IQ scores and family history of psychiatric illness among individuals in the sample. The 
following section investigates subjective and objective relationships between the clinical 
features of DD and the presence and severity of lifetime psychiatric symptoms observed in the 
sample.
4.9 Relationship between DD Clinical Features and Lifetime 
Psychiatric Features
This section investigates the relationship between DD clinical features and the 
presence and severity of lifetime psychiatric features in the sample. Individual’s subjective 
thoughts regarding the relationship between the psychiatric features they had experienced and
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the features of DD are reported in section 4.9.1. The relationship between age of onset of DD 
and age of onset of psychiatric symptoms and illness is reported in section 4.9.2. 
Relationships between the clinical features of DD, including age of onset and duration, 
severity, symptoms (pain and malodour), impact on quality of life and family history of DD, 
and lifetime psychiatric features, including history of a lifetime DSM-IV diagnosis, history of 
suicidal thoughts and/or attempts and key psychiatric variables (age of onset of psychiatric 
illness, number of episodes of depression and longest episode of depression), are investigated 
in sections 4.9.3 to 4.9.7. A summary of all the trends and significant relationships found is 
presented in section 4.9.8.
4.9.1 Subjective Relationship between DD and Psychiatric Features
Individuals who reported a history of psychiatric illness were asked whether they felt 
there had been a lifetime and/or temporal relationship between the symptoms of their DD and 
the occurrence of episodes of psychiatric illness. A positive lifetime relationship indicated 
individuals felt that all the episodes of psychiatric illness they had experienced were due to 
having DD. A positive temporal relationship indicated that individuals had experienced 
episodes of psychiatric illness that they felt were due to the symptoms of DD although 
individuals did not attribute all episodes of psychiatric illness as being due to having DD.
As it has been shown in 4.3.1 pg. 61, 50 individuals in the sample had a DSM-IV 
lifetime diagnosis of mood disorder. All of these individuals had a history of depressive 
symptoms. The frequencies and percentages of individuals reporting subjective lifetime 
and/or temporal relationships between episodes of depression and the symptoms of DD are 
summarised in Table B-12 pg. 301 and displayed in Figure 4.12. Three individuals (six 
percent) with lifetime DSM-IV diagnoses of Major Depressive Disorder (Recurrent), 
Dysthymic Disorder and Depression Not otherwise Specified respectively reported a lifetime 
relationship indicating that they felt all the episodes of depression they had experienced were
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directly caused by the symptoms of DD. Nineteen individuals (38%) reported a temporal 
relationship indicating that they felt some episodes of depression they had experienced were 
caused by the symptoms of DD, although they had experienced other episodes o f depression 
that they did not relate to having DD.
Fifteen individuals in the sample had a DSM-IV lifetime diagnosis o f anxiety 
disorder. One of these individuals with a DSM-IV diagnosis of panic disorder reported a 
possible lifetime relationship and definite temporal relationship between panic episodes and 
the symptoms of DD. All other individuals did not relate their symptoms of anxiety to the 
symptoms of DD.
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Figure 4.12 Percentages of Individuals Reporting a Lifetime and Temporal Relationship 
between Episodes of Depression and the Symptoms of DD
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4.9.2 Age of Onset of DD and Age of Onset of Psychiatric Symptoms and 
Illness
To investigate the relationship between age of onset of DD and the age of onset of 
psychiatric illness, the number of individuals for which the onset of DD preceded or occurred 
at the same age as the onset of psychiatric illness was compared with the number of 
individuals in whom the onset of psychiatric illness preceded the onset of DD. Of the 55 
individuals with a DSM-IV diagnosis, the age of onset of DD was known for 53 individuals. 
Of these individuals, the age of onset of any psychiatric symptoms and the age of onset of any 
psychiatric illness causing impairment could be determined for 42 and 37 individuals 
respectively. In the majority of cases the onset of DD preceded or occurred at the same age as 
the onset of psychiatric symptoms (34 out of 42 individuals, 81%) and the onset of psychiatric 
illness causing impairment (31 out of 37 individuals, 84%).
This section has described the number cases in which the onset of psychiatric 
symptoms and illness occurred before or after the onset of DD. The following section (4.9.3) 
investigates the relationship between age of onset and duration of DD and additional lifetime 
psychiatric features including history of a DSM-IV diagnosis, history of suicidal thoughts 
and/or attempts and other key psychiatric clinical variables (age of onset of any psychiatric 
illness, number of episodes of depression and longest duration of depression). This is then 
followed by investigations of the relationship between further clinical features of DD and the 
presence and severity of lifetime psychiatric features in sections 4.9.4 to 4.9.7.
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4.9.3 Age of Onset and Duration of DD - Relationship with Psychiatric 
Features
4.9.3.1 Lifetime DSM-IV Diagnosis and History of Suicidal Thoughts and 
Suicide Attempts
Descriptives for the age of onset and duration of DD among individuals with and without 
a lifetime DSM-IV diagnosis and among individuals with and without a history of suicidal 
thoughts or attempts are shown in Table B-13 pg. 302. Individuals with and without a lifetime 
DSM-IV diagnosis did not significantly differ in their median age of onset of DD (13 vs. 14 
years; U=840.5, n=90, p=0.250) or the median duration of their DD (31 vs. 30 years;
U=911.5, n=90, p=0.571). Similarly, individuals with a history of no suicidal thoughts or 
attempts, suicidal thoughts and suicide attempts did not significantly differ in their median 
age of onset (14 vs. 14 vs. 14.5 years; H= 0.783, df =2, p= 0.676) or the median duration of 
their DD (29 vs. 36 vs. 32 years; H= 2.262, df= 2, p= 0.323).
4.9.3.2 Key Psychiatric Clinical Variables
Correlations between the age of onset and duration of DD and key psychiatric clinical 
variables (age of onset of any psychiatric illness, number of episodes of depression and 
longest duration of depression) are shown in Table B-14 pg. 302. There were no significant 
correlations between age of onset and duration of DD and any of the key psychiatric clinical 
variables.
4.9.4 DD Severity - Relationship with Psychiatric Features
4.9.4.1 Lifetime DSM-IV Diagnosis and History of Suicidal Thoughts and 
Suicide Attempts
Comparisons of the percentages of individuals with a lifetime DSM-IV diagnosis and 
a history of suicidal thoughts or attempts among individuals with mild, moderate and severe
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DD are shown in Table B-15 pg. 303. There was no significant difference in the percentage of 
individuals with a positive DSM-IV diagnosis among individuals with mild, moderate and 
severe DD (50% vs. 63% vs. 60%; x2=l-047, df=2, p=0.592). There was also no significant 
difference in the percentages of individuals with a history of suicidal thoughts and attempts 
among individuals with mild, moderate and severe DD (%2= 6.79, df=4, p=0 .143). However, 
there was a trend for the prevalence o f suicidal thoughts, but not suicide attempts, to increase 
with DD severity (see Figure 4.13).
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Figure 4.13 Percentage of Individuals with a History of Suicidal Thoughts and Suicide Attempts 
among Individuals with Mild, Moderate and Severe DD
4.9.4.2 Key Psychiatric Clinical Variables
Descriptives for key psychiatric clinical variables among individuals with mild, 
moderate and severe DD are shown in Table B-16 pg. 303. Individuals with mild, moderate 
and severe DD did not significantly differ in their median age of onset of psychiatric illness 
(H= 0.229, df =2, p = 0.892), the median number o f episodes of depression (H=0.030, df =2, p 
=0.985) or the median longest duration o f depression they had experienced (H=2.525, df =2 p 
=0.283).
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4.9.5 Symptoms of DD - Relationship with Psychiatric Features
4.9.5.1 Lifetime DSM-IV Diagnosis and History of Suicidal Thoughts and
Suicide Attempts
Comparisons of the percentages of individuals with a lifetime DSM-IV diagnosis and 
a history of suicidal thoughts or attempts among individuals who reported pain and malodour 
as being a symptom of their DD are shown in Table B-17 pg. 304. As almost all individuals in 
the sample reported itching was a symptom of their DD, the relationship between this 
symptom and the presence and severity of psychiatric features was not investigated. More 
individuals reporting pain as a symptom of their DD had a lifetime DSM-IV diagnosis 
compared to individuals not reporting pain, but this did not quite reach significance (70% vs. 
50%; x2 =3.643, df=l, p=0.056) (see Figure 4.14). There was no significant relationship 
between individuals reporting malodour as a symptom of DD and having DSM-IV lifetime 
diagnosis (x2 = 1.035, df=l, p= 0.309). There was no significant relationship between 
individuals reporting pain (x2= 1.887, df=2, p= 0.389) or malodour (x2 = 4.043 df=2, p= 
0.132) as a symptom of their DD and having a history of suicide thoughts or suicide attempts.
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Pain R eported a s  a Sym ptom  of DD
Figure 4.14 Percentage of Individuals with a Lifetime DSM-IV Diagnosis among Individuals Not 
Reporting and Reporting Pain as a Symptom of Their DD
4.9.5.2 Key Psychiatric Clinical Variables
Descriptives for key psychiatric variables among individuals not reporting and reporting 
pain and malodour as a symptom of their DD are shown in Table B-18 pg. 304. Individuals 
reporting and not reporting pain and malodour as symptoms of their DD did not significantly 
differ in their age of onset o f psychiatric illness, the number of episodes o f depression or the 
longest duration o f depression they had experienced.
4.9.6 Impairment Caused by DD and Impact on Quality of Life- 
Relationship with Psychiatric Features
4.9.6.1 Lifetime DSM-IV Diagnosis and History of Suicidal Thoughts and
Suicide Attempts
Comparisons of the percentages of individuals with a lifetime DSM-IV diagnosis and 
a history of suicidal thoughts or attempts among individuals reporting an impact of DD on 
their school life, work/career, relationships, and social activities are shown in Table B-19 pg. 
305. There were no significant relationships between lifetime DSM-IV diagnosis and the 
subjective impact of DD on school life (%2= 2.771, df=3, p= 0.428), work/career (x2 = 1.778, 
df=2, p= 0.411), relationships (X2 = 2.689, df=2, p= 0.261) and social activities (X2 = 2.916, 
df=2, p= 0.233). There were also no significant relationships between lifetime history of 
suicidal thoughts and suicide attempts and the subjective impact of DD on school life (x2 = 
4.325 df=6, p= 0.653), relationships (X2 = 4.585, df=4, p= 0.337) and social activities (X2 = 
6.161, df=4, p= 0.193). There was a significant relationship between lifetime history of 
suicidal thoughts and suicide attempts and the subjective impact of DD on work/career (x2 =
11.595, df=4, p= 0.021). Further 2x2 chi-square analyses revealed that a significantly higher 
proportion of individuals reporting DD had a mild impact on their work/career had made a 
suicide attempt compared to individuals reporting no impact of DD on their work/career 
(36.4% vs. 7.1% Fisher’s exact test, p= 0.025), shown in Figure 4.15.
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Figure 4.15 Percentage of Individuals with a History of Suicidal Thoughts and Suicide Attempts 
among Individuals Reporting Varying Degrees of Impact of DD on their Work/Career
Descriptives for DLQI last and worst week scores among individuals with and without 
a DSM-IV lifetime diagnosis and among individuals with no history o f suicidal thoughts or 
suicide attempts, a history o f suicidal thoughts and a history o f suicide attempts are 
summarised in Table B-20 pg. 306. Individuals with and without a lifetime DSM-IV 
diagnosis did not significantly differ in their median scores on the DLQI-Last week (5 vs. 3; 
U= 846.000, n= 91, p = 0.215) or DLQI-Worst week (16.5 vs. 14; U= 841.500, n = 91, p = 
0.203). Individuals with a history o f no suicidal thoughts or attempts, suicidal thoughts and 
suicide attempts did not significantly differ in their median scores on the DLQI-Last week 
(H= 2.146, d f =2, p = 0.342) but did significantly differ in their median scores on the DLQI -  
Worst week (H = 7.120, d f = 2, p = 0.028). Further Mann-Whitney U tests indicated that 
individuals with a history o f suicidal thoughts had significantly higher median scores on the 
DLQI-Worst week than individuals with no history of suicidal thoughts/suicide attempts (U = 
333, n =  80, p = 0.017), shown in Figure 4.16.
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Figure 4.16 DLQI - Worst Week Scores among Individuals with and without a History of 
Suicidal Thoughts and Attempts
4.9.6.2 Key Psychiatric Clinical Variables
Descriptives for key psychiatric variables among individuals reporting the impact of 
having DD on their school life, work/career, relationships and social activities as being none, 
mild, moderate or not applicable are shown in Table B-21 pg. 307 and Table B-22 pg. 308. In 
all of these four domains, individuals subjectively reporting the impact o f having DD as being 
none, mild, moderate, severe or not applicable did not significantly differ in their age of onset 
psychiatric illness, the number o f episodes of depression or the longest duration of depression 
they had experienced. Correlations between DLQI last week and worst week scores and key 
psychiatric variables are shown in Table B-23 pg. 309. There was no significant correlation 
between DLQI last week and worst week scores and any of the key psychiatric variables.
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4.9.7 Family History of DD - Relationship with Psychiatric Features
4.9.7.1 Lifetime DSM-IV Diagnosis and History of Suicidal Thoughts and 
Suicide Attempts
Comparisons o f the percentages o f individuals with a lifetime DSM-IV diagnosis and 
a history of suicidal thoughts or attempts amongst individuals with and without a family 
history of DD are shown in Table B-24 pg. 309 and displayed graphically in Figure 4.17 and 
Figure 4.18. Significantly more individuals with a family history of DD had lifetime DSM-IV 
diagnosis compared to individuals not reporting a family history (69% vs. 40%, x2=6.175, 
df=l, p=0.013). There was also a significant relationship between family history of DD and 
history of suicidal thoughts and suicide attempts (x2= 10.803, df=2, p=0.003). Further 2x2 chi- 
square analyses revealed a significantly higher proportion o f individuals with a family history 
of DD had a lifetime history o f suicidal thoughts compared to individuals with no family 
history of DD (27% vs. 0%; X*=9.503, df= l, p=0.002).
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Family History of DD
Figure 4.17 Percentage of Individuals with a Lifetime DSM-IV Diagnosis among Individuals 
with and without a Known Family History of DD
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Figure 4.18 Percentage of Individuals with a History of Suicidal Thoughts and Suicide Attempts 
among Individuals with and without a Known Family History of DD
4.9.7.2 Key Psychiatric Clinical Variables
Descriptives for key psychiatric variables among individuals with and without a family 
history of DD are shown in Table B-25 pg. 310. Individuals with and without a family history 
did not significantly differ in their median age o f onset of psychiatric illness (U=74, n=37, 
p=0.433), the median number o f episodes of depression (U=89.500, n=41, p=0.562) or the 
median longest duration o f depression they had experienced (U=80.500, n=39, p=0.470).
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4.9.8 Section Summary
Table 4.31 summarises the significant relationships between DD clinical features and 
lifetime psychiatric features. Overall the majority of the clinical features of DD, including age 
of onset, duration, severity, and symptoms of DD were not significantly associated with the 
presence or severity of lifetime psychiatric features.
Table 4 .31 Significant Relationships between DD Clinical Features and Lifetime Psychiatric 
Features
DD C lin ic a l 
F e a tu re s
Lifetime DSM-IV 
Diagnosis
History of Suicidal Thoughts and 
Suicide Attempts
Key Psychiatric 
Clinical Variables
Age of Onset and 
Duration
“ - -
Severity “ - -
Symptoms (pain 
and malodour)
♦ * - -
Subjective 
Impairment and 
Impact on Quality 
of Life
A significantly higher proportion of 
individuals reporting a mild impact of 
DD on their work/career had a history 
of suicide attempts compared to 
individuals reporting no impact of 
DD on their work/career. 
Individuals with a history of suicidal 
thoughts had significantly higher 
scores on the DLQI-Worst week than 
individuals with no histoiy of suicidal 
thoughts or suicide attempts.
Family History A significantly higher 
proportion of 
individuals with a 
family history of DD 
had a lifetime 
psychiatric illness 
compared to 
individuals with no 
family history of DD
A significantly higher proportion of 
individuals with a family history of 
DD had a lifetime history of suicidal 
thoughts compared to individuals 
with no family history of DD.
** Relationship almost reached significance; a higher proportion of individuals reporting pain a as a symptom of
their DD had a lifetime DSM-IV diagnosis compared to individuals not reporting pain (70% vs. 50%; x2 =3.643, 
df=l, p=0.056). DLQI; Dermatology Life Quality Index.
The following section investigates the relationship between the clinical features of DD and 
history of learning difficulties and IQ scores.
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4.10 Relationship between DD Clinical Features and Learning 
Difficulties and IQ scores
This section investigates the relationship between DD clinical features, including age of 
onset, severity and family history of DD and history of learning difficulties and IQ scores.
4.10.1 Age of Onset and Duration of DD - Relationship with Learning 
Difficulties
Descriptives for the age of onset of DD among individuals with and without learning 
difficulties are summarised in Table B-26 pg. 310. Individuals with and without learning 
difficulties did not significantly differ in their median age of onset of DD (13 vs. 14 years; 
U= 605.0, n=96,p = 0.244).
4.10.2 DD Severity-Relationship with Learning Difficulties
There was no significant difference in the percentage of individuals with learning 
difficulties among individuals with mild, moderate and severe DD (23% vs. 19% vs. 27%; 
3^=0.403, df=2, p=0.805) (see Table B-27 pg. 310).
4.10.3 Subjective Impact of DD on School Life- Relationship with
Learning Difficulties
There was no significant difference in the percentage of individuals with learning 
difficulties among individuals reporting the impact of DD on their school life as not 
applicable, none, mild or moderate/severe (15% vs. 24% vs. 27% vs. 24%; y?= 1.277, df=3, 
p= 0.758) (see Table B-28 pg 311).
4.10.4 Family History of DD-Relationship with Learning Difficulties
There was no significant difference in the percentage of individuals with learning 
difficulties among individuals reporting and not reporting a family history of DD although
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there was a trend for a higher percentage of individuals reporting a family history of DD to 
have learning difficulties (24% vs. 15%; x2=0.745, df=l, p=0.388) (see Table B-29 pg 311.).
4.10.5 Age of Onset of DD- Relationship with IQ Scores
There was a significant positive correlation between age of onset of DD and IQ Scores 
(rho= 0.240, n=82, p=0.030). As previously reported, there was a positive correlation between 
IQ score and age at interview (r=0.270, n=85, p=0.012). When controlling for age at interview 
there was no significant correlation between age of onset of DD and IQ scores (r=0.117, 
df=79, p=0.299).
4.10.6 DD Severity- Relationship with IQ Scores
Descriptives of IQ scores among individuals with mild, moderate and severe DD are 
summarised in Table B-30 pg. 311. Individuals with mild, moderate and severe DD did not 
significantly differ in their median IQ scores (107 vs. 102 vs. 92; H=5.256, df=2, p=0.072) 
although there was a trend for IQ scores to decrease with an increase in DD severity, which 
almost reached significance, shown in Figure 4.19.
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Figure 4.19 IQ Scores among Individuals with Mild, Moderate and Severe DD
4.10.7 Subjective Impact of DD on School Life - Relationship with IQ 
Scores
Descriptives of IQ scores among individuals reporting the impact of DD on their school 
life as not applicable, none, mild or moderate/severe are summarised in Table B-31 pg. 311. 
Individuals reporting the impact as being not applicable, none, mild or moderate/severe did 
not significantly differ in their median IQ scores (105 vs. 105 vs. 99.5 vs., 96; H=2.955, df=3, 
p=0.399). However, there was a trend for IQ scores to decrease with an increase in the 
reported impact of DD on school.
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4.10.8 Family History of DD- Relationship with IQ Scores
Descriptives for IQ scores among individuals with and without a family history of DD are 
shown in Table B-32 pg. 312. Individuals with and without a history of DD did not 
significantly differ in their median IQ scores (104 vs. 102; U=636.500, n=79, p=0.935).
4.10.9 Section Summary
This section has described the relationship between a number of clinical features of DD 
and history of learning difficulties and IQ scores. The following section provides a summary 
of Chapter 4.
4.11 Summary o f Chapter 4
This chapter has described the demographic, clinical and neuropsychiatric features of 100 
unrelated individuals with DD. The main findings of the chapter are summarised below.
Clinical Features o f DD
• 33% of individuals had been admitted to hospital on at least occasion for treatment of 
DD, individuals reported an impact of DD on their school life (28%), relationships 
(30%), work and career (35%) and social activities (53%).
• Individuals with moderate and severe DD reported the symptoms of DD had a greater 
impact on quality of life than individuals with a mild form of the disorder.
• 53% of individuals reported a definite family history of DD whereas 26% reported no 
family history of the disorder.
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Lifetime Prevalence o f Neuropsychiatric Illness
The second part of the chapter reported the lifetime prevalence of a number of 
neuropsychiatric features among individuals in the current sample. These figures are 
summarised in Table 4.32. Seventy eight percent of the sample had a lifetime history of any 
of the lifetime neuropsychiatric phenotypes measured in the current study, 55% had a lifetime 
diagnosis of any DSM-IV disorder, four percent had a lifetime diagnosis of Bipolar I 
Disorder, 13% of the sample had made a suicide attempt and 25% had been referred to 
psychiatric services.
Table 4.32 Lifetime Prevalence of Neuropsychiatric Features in 100 Unrelated Individuals with 
DD
Neuropsychiatric Phenotype % Of Sample
Any neuropsychiatric phenotype 78
Any DSM-IV disorder 55
Any DSM-IV mood disorder 50
Major Depressive Disorder 30
Bipolar I Disorder 4
Suicide attempt 13
Suicidal thoughts 18
Referred by GP to secondary psychiatric 
services
25
Admitted to a psychiatric hospital 9
Referred to a neurologist and had neurological 
investigations or had been treated for a 
neurological condition
36
Epilepsy 3
Investigations for blackouts, periods of loss of 
consciousness or fainting episodes
13
Learning Difficulties 21
Below average IQ (<80) 6
Family History o f  Neuropsychiatric Features
The numbers of individuals in the current sample with first-degree relatives with a history 
of psychiatric illness and epilepsy have been reported. Comparisons of the prevalence of DD 
among first-degree relatives with a psychiatric illness and epilepsy found:
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• Of 64 first-degree relatives with a positive psychiatric history, a higher percentage 
were reported to have DD (53.1%) than were not (35.9%).
• Of eight first-degree relatives with a diagnosis of epilepsy a higher percentage were 
reported to have DD (75%) than were not (12.5%).
Relationship between Lifetime Neuropsychiatric Features, IQ Scores and Family History o f 
Psychiatric Illness
Investigations of the relationships between the presence of lifetime neuropsychiatric 
features, below average IQ scores and family history of psychiatric illness among individuals 
in the current sample have been described. The significant findings were:
• More individuals with a history of investigations for blackouts/loss of consciousness 
had a lifetime DSM-IV diagnosis of psychiatric illness and a family history of 
psychiatric illness.
• More individuals with learning difficulties had a below average IQ score
Relationships between DD Clinical Features and Lifetime Neuropsychiatric Features and IQ 
Scores
The final part of the chapter reported the findings of numerous investigations of 
relationships between the clinical features of DD, the presence and severity of lifetime 
neuropsychiatric features and IQ scores. Main findings included:
• Six percent of individuals felt that all the episodes of psychiatric illness they had 
experienced were due to the symptoms of DD and 38% of individuals felt at least 
one episode of psychiatric illness was due to the symptoms of DD.
• In 81% of cases the onset of DD preceded or occurred at the same age as the onset 
of psychiatric symptoms.
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• Overall the majority of the clinical features of DD, including age of onset,
duration, severity, and symptoms of DD were not significantly associated with the 
presence or severity of lifetime neuropsychiatric features or IQ scores. However, 
significant relationships and trends were observed and are summarised in Table 
4.33.
The following chapter (Chapter 5) discusses these findings.
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Table 433 Summary of the Significant Relationships and Trends Between DD Clinical Features and Lifetime Neuropsychiatric Features and IQ 
Scores
DD C l i n i c a l  
F e a t u r e s
Lifetime DSM-IV 
Diagnosis of 
Psychiatric Illness
History of Suicidal Thoughts and Suicide Attempts Key Psychiatric 
Clinical 
Variables
Learning
Difficulties
IQ
Age of Onset 
and Duration
- - - - -
DD Severity Trend for the prevalence o f suicidal thoughts, but not suicide 
attempts, to increase with DD severity.
Trend for IQ 
scores to 
decrease with an 
increase in DD 
severity.
Symptoms
(Pain,
Malodour)
Trend for more 
individuals 
reporting pain as a 
symptom o f their 
DD to have a 
lifetime DSM-IV 
diagnosis.
Subjective 
Impairment and 
Impact on 
Quality of Life
A significantly higher proportion of individuals reporting a mild 
impact of DD on their work/career had a history of suicide attempts 
compared to individuals reporting no impact of DD on their 
work/career.
Individuals with a history of suicidal thoughts had significantly 
higher scores on the DLQI-Worst week than individuals with no 
history of suicidal thoughts or suicide attempts.
Family History A significantly 
higher proportion 
of individuals with 
a family history of 
DD had a lifetime 
psychiatric illness 
compared to 
individuals with no 
family history of 
DD.
A significantly higher proportion of individuals with a family 
history of DD had a lifetime history of suicidal thoughts compared 
to individuals with no family history of DD.
Trend for higher 
proportion o f 
individuals 
reporting a 
family history of 
DD to have 
learning 
difficulties.
Significant relationships are shown in normal text. Trends almost reaching significance are shown in italics.
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5 DEMOGRAPHICS, CLINICAL AND NEUROPSYCHIATRIC 
FEATURES IN 100 INDIVIDUALS WITH DD: DISCUSSION
This chapter will discuss the results presented in Chapter 4. These results and discussions 
relate to the first aim of the thesis, which was to conduct a systematic investigation of the 
neuropsychiatric characteristics in a sample of 100 unrelated individuals with DD using a 
battery of standardised neuropsychiatric measures. After a brief discussion of the 
demographics of the sample, the clinical features of DD in the individuals in the present study 
are compared to those described in previous case series studies of DD. This is followed by a 
comparison of the lifetime neuropsychiatric features in the current sample to the reported rates 
in previous case series studies of DD as well as the reported rates in the general population 
and among individuals with other skin conditions. The prevalence of DD among first-degree 
relatives with a reported history of neuropsychiatric illness is then briefly examined. This is 
followed by a discussion of the investigations into whether specific types of neuropsychiatric 
features appear to co-occur in individuals with DD. The findings of the investigations into the 
relationships between the clinical features of DD and the presence and severity of lifetime 
neuropsychiatric features are then discussed along with the extent to which these findings 
provide support for the contribution of psychosocial and pleiotropic (mutations in the ATP2A2 
gene have effects in the skin and brain) factors in the presence of neuropsychiatric features in 
DD.
5.1 Demographics
Although DD is reported to be equally prevalent among males and females, participants 
in the current study were predominantly female (71%). Although this may be partly due to a 
response bias (females may be more likely to respond to an invitation to take part in a 
research project (Rosenthal & Rosnow, 1991)) both the systematic and non-systematic
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methods of recruitment are likely to have also contributed. The main systematic method of 
recruitment of participants was via one consultant dermatologist, Dr Sue Burge, who sent 
invitation letters to a higher number of females (62%), which is likely to have contributed to 
the predominance of females in the current sample. The proportion of males and females 
among the 60 individuals sent invitation letters from the DD support group is unknown 
although the majority of individuals who responded were female (79%). Since females are 
more likely to engage in self-help behaviours concerning health issues (Galdas et al., 2005) it 
is likely that a higher number of females contact, and remain in contact with, the DD support 
group.
Eighty-eight percent of the sample reported that they had married/lived as married (lived 
with a partner for at least one year) and the majority (86%) were currently living with others, 
mainly with a spouse and/or children. This suggests that, in the sample as a whole, having DD 
does not appear to impair individuals’ ability to form and maintain long -term relationships. 
This is in contrast to an early case series study carried out in Denmark in which the authors 
reported statistically more unmarried individuals among individuals with DD than in the 
normal population (Svendsen & Albrectsen, 1959).
A large proportion of individuals (41%) in the present study reported having no 
qualifications. This figure is over twice as high as the percentage of individuals in the UK 
population of working age (males 16-64, females 16-59) reported to have no qualifications 
(15%) (Office for National Statistics, 2003). The present study included individuals over 
working age (males above 64 and females above 59), which were the age groups with the 
highest proportion of individuals with no qualifications (see Table 4.2 pg. 52). However, 
excluding these individuals does not affect the proportion of individuals in the current sample 
with no qualifications (40%). A recruitment bias may also account for these differences since 
individuals with formal qualifications may be more likely to currently be in full time
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employment and be less likely to participate in a research study due to other commitments. 
However, the finding that a large proportion of the current study had no formal qualifications 
is consistent with the findings of a cases series study of DD carried out in Slovenia where the 
authors highlighted that over half the individuals in their sample had only finished a primary 
or vocational school (Miljkovic et a l , 2005).
5.2 DD Clinical Features and Impact on Quality o f Life
The distribution of the age of onset of DD in the present sample matches that reported in 
a previous large UK case series study of 163 individuals with DD (Burge & Wilkinson, 1992) 
with approximately 75% of individuals in both studies reporting the symptoms of their DD 
started before the age of 20. Since a proportion of the individuals in the present sample were 
also part of this previous UK case series study, similar findings may be expected. 
Epidemiological studies of DD carried out in Denmark (Svendsen & Albrectsen, 1959) and 
Slovenia (Miljkovic et al., 2005) have also reported that age of onset DD occurred before the 
age of 19 in the majority of cases (92% and 67% respectively). The proportions of individuals 
with mild, moderate and severe DD in the present study and the study conducted by Burge & 
Wilkinson (1992) are also similar with the majority (two thirds) of individuals being 
classified as having moderate DD. Conversely, in the case series study of DD conducted in 
Slovenia, which used the same criteria for classifying DD severity, the majority of individuals 
were found to have mild DD. However, in all three studies, individuals classified as having 
severe DD made up the smallest proportion. These comparisons suggest the general clinical 
features of DD in the current sample are representative of those commonly observed in DD.
5.2.1 Impairment and Impact on Quality of Life
The high frequencies of individuals reporting itching (92%), pain (54%) and malodour 
(60%) as symptoms of their DD in the current sample indicates the suffering experienced by
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the majority of individuals with DD. The proportions of individuals reporting itching and 
malodour are similar to the proportions of individuals reporting these symptoms in the UK 
case series sample of DD collected by Burge & Wilkinson (1992). However, the percentage 
of individuals reporting pain in the current sample is twice as high as the figure reported in 
their study. The reasons for this are unclear, although the criteria used by Burge & Wilkinson 
to positively rate the symptom of pain may have been more stringent, though this is not 
reported. In the current sample, impairment in social activities was the aspect of individuals’ 
lives most frequently reported as being affected by having DD (see Figure 4.4 pg. 57). 
Similarly, 63% of individuals in the Burge & Wilkinson study stated that having DD had been 
a social handicap. One third of individuals in the current study reported DD had caused 
impairment in their work/career, although only half this number in the Burge and Wilkinson 
study reported their employment prospects had been affected by DD. The reason for this 
difference is likely to be that the figure in the current study included individuals reporting a 
mild impact of DD on their work/career.
Individuals’ scores on the Dermatology Life Quality Index (DLQI) indicated that the 
majority of individuals in the current study felt that their DD had caused little impact on their 
everyday life during the past week (Table 4.8 pg. 58). The median score on the questionnaire 
(4 out of 30) was identical to the median score found in a previous study in which the DLQI 
was completed by 137 individuals with DD Harris et al (1996). In the current sample, scores 
on the questionnaire significantly increased with DD severity, with individuals with moderate 
and severe DD reporting the symptoms of DD having a greater impact on quality of life over 
the past week than individuals with a mild form of the disorder (see Figure 4.5 pg. 60). This 
trend was also observed by Harris et al (1996). However, the wide range of DLQI scores 
among individuals classified as having mild, moderate and severe DD suggests that other 
factors, in addition to the severity of the disorder, may also contribute to the subjective impact
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the symptoms of DD have on individuals’ everyday lives. For the purposes of the current 
study, the DLQI was also used to measure impairment in the week when individuals felt the 
symptoms of DD had been at their worst. This slightly modified version of the measure was 
used to investigate possible relationships between impact of quality of life caused by DD and 
the presence of neuropsychiatric features, discussed later in this chapter, and there are 
therefore no comparison data for scores on this version of the questionnaire.
Lewis & Finlay (2004) reviewed the use of the DLQI in 37 different skin conditions and 
calculated a ‘mean of means’ DLQI score for each skin condition from previous published 
studies. Table 5.1 summaries the DLQI scores for the four skin conditions in which the DLQI 
has been the most widely used, atopic eczema, acne, psoriasis and vitiligo. The mean DLQI 
scores found across studies of atopic eczema (12.2) and acne (11.9) are considerably higher 
than the median score of 4 found in the current study and by Harris et al. (1996) suggesting in 
general these conditions may cause more impairment than DD. However, some of these 
studies have been carried out in an inpatient setting where the symptoms of these skin 
conditions will be more severe. This is reflected in the range of the mean DLQI scores across 
the studies; for example in atopic eczema the range of mean scores across the studies range 
from 4.5 to 21.4 out of the possible total score of 30.
Table 5.1 DLQI Scores in other Dermatological Conditions
Skin Condition N um ber of studies 
(num ber of 
individuals)
DLQI Scores 
Range of Means 
Across Studies
DLQI Scores 
Mean of Means Across 
Studies
Atopic Eczema 15 (1409) 4.5-21.4 12.2
Acne 8 (838) 4.3-17.7 11.9
Psoriasis 13 (2468) 1.7-18.2 8.8
Vitiligo 5 (856) 4.8-15 5.6
DLQI; Dermatology Life Quality Index. Figures reported by Lewis & Finlay (2004).
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5.2.2 Family History of DD
Although DD is autosomal dominantly inherited with high penetrance, only half of the 
individuals in the current study reported a known family history of DD. This finding is 
consistent with the findings of other case series studies of DD. Of the 163 individuals, from 
107 families interview by Burge & Wilkinson (1992), 46 individuals (47% of the families) 
reported no family history of DD. Similar rates of individuals reporting no family history of 
DD were reported in the case series studies carried out by Munro (1992) (43%) and Zeglaoui 
et al. (2005) (58%). Munro (1992) examined family members of individuals reporting no 
family history of DD and found that around half of these individuals actually did have a 
family history. Munro suggested that the remaining cases where family history was not found 
could be explained either by new cases of DD arising as a result of spontaneous de novo 
mutations in the gene for DD (ATP2A2 had not yet been identified as the DD gene) or cases 
where information regarding parentage was incorrect. Another possibility not discussed in the 
literature is that a proportion of individuals may have the clinical features of DD caused by 
factors other than having a mutation in ATP2A2 i.e. be phenocopies. Such individuals would 
be unlikely to report a family history of DD. In Chapters 8 and 9 of this thesis, the detection 
of mutations in ATP2A2 among individuals reporting and not reporting a family history of DD 
is described and will indicate whether or not this last suggestion could be a possibility.
5.3 Investigations o f a Population-Level Association Between DD 
and Neuropsychiatric Features
Seventy-eight percent of the sample had a lifetime history of any of the lifetime 
neuropsychiatric phenotypes measured in the current study. In addition, just over half of the 
sample had either been referred to secondary psychiatric services and/or been referred to a 
neurologist at some point in their life. These figures appear to suggest a potential population-
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level association between DD and neuropsychiatric features. However, a number of the 
features measured are not uncommon in the general population. The following sections 
compare the lifetime prevalence of neuropsychiatric features in the current sample to the 
reported rates of these features in previous case series studies of DD (see Chapter 2, Table 2.2 
pg. 12 for a brief description of these studies) as well as the reported rates of these features in 
the general population and among samples of individuals with other skin conditions. Such 
comparisons will give an indication of whether certain neuropsychiatric phenotypes do appear 
to occur more commonly in DD than in other populations.
5.3.1 Lifetime Prevalence of Psychiatric Disorders
Over half (55%) of the individuals in the present study had a lifetime diagnosis of a 
psychiatric illness according to the diagnostic criteria DSM-IV and one quarter of the sample 
had been referred to secondary psychiatric services at some point in their life. This finding is 
consistent with a small number of case series studies that have reported a high prevalence of 
psychiatric illness among individuals with DD (Ringpfeil et al., 2001; Svendsen &
Albrectsen, 1959). However, the prevalence of psychiatric illness is much higher than that 
previously reported in two large case series studies carried out in the UK in which very small 
numbers of cases of psychiatric illness were reported (Burge & Wilkinson, 1992; Munro, 
1992). Out of 163 individuals interviewed by Burge & Wilkinson (1992), two individuals had 
been treated for depression and another had a diagnosis of bipolar affective disorder (BPAD) 
and of the 75 individuals interviewed by Munro (1992) one individual and an additional 
affected family member had been admitted to a psychiatric hospital. A likely explanation for 
this finding is that in the current study a standardised semi-structured interview was used to 
elicit the presence of lifetime psychiatric symptoms whereas in the other two previous UK 
case series studies this was assessed on recording individuals’ general medical history and 
treatment. A further explanation could be a bias in the present study towards including
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individuals with a history of psychiatric illness. However, almost all the participants in the 
current study were recruited via a dermatologist or the DD support group i.e. on the basis of 
having DD rather than a psychiatric illness. In addition, a proportion of individuals in the 
current sample were also in the study conducted by Burge & Wilkinson (1992). Of the 
participants in the current study recruited via Dr Sue Burge, 41% were found to have a 
lifetime diagnosis of a psychiatric illness. This suggests that methodological differences 
between the studies, rather than a recruitment bias, accounts for the greater prevalence of 
psychiatric illness in the current study. One third of participants in the current study were 
recruited via the DD support group. It is possible that individuals in contact with the group 
have suffered more as a result of having DD and are more likely to have experienced 
psychiatric symptoms than individuals with DD not in contact with the group. Of the 
participants recruited via the DD support group, 71% had a lifetime diagnosis of a psychiatric 
illness, which is higher than the prevalence of psychiatric illness among individuals who were 
recruited via a dermatologist (46%). This indicates that recruiting participants via the DD 
support group may have biased the sample to contain a higher proportion of individuals with a 
psychiatric illness. However, the majority of participants in the study were recruited via 
dermatologists and almost half of these participants had a history of psychiatric illness.
In the current sample a significantly higher percentage of females than males had a 
history of psychiatric illness (65% vs. 31%). This finding is consistent with that observed in 
large epidemiological studies of psychiatric illness (Alonso et al., 2004; Kessler et a l , 1994). 
There are a number of social and biological factors that are likely account for this finding, 
including the fact that males may be less likely to recognise and/or report the symptoms of 
psychiatric illness.
To my knowledge there are no published data relating to the lifetime prevalence of 
psychiatric illness or contact with psychiatric services in the UK general population that use
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methodology directly comparable to that used in this study. In 2000, the Office for National 
Statistics (www.statistics.gov.uk) carried out a survey of psychiatric morbidity among 8800 
adults aged between 16-74 in private households in Great Britain (Singleton et a l , 2001). 
However, the survey only reports past week prevalence rates of psychiatric illness. A widely 
reported study of lifetime prevalence rates of psychiatric disorders is the US National 
Comorbidity Survey (NCS) (Kessler et a l , 1994). However, this study was carried out in the 
US over 10 years ago and the psychiatric diagnoses were made according to an earlier edition 
of the diagnostic criteria DSM (DSM-III-R) making comparisons with the lifetime prevalence 
of psychiatric illness in the current sample less meaningful. A more closely matched sample 
to the current sample is that collected by the European Study of the Epidemiology of Mental 
Disorders (ESEMeD) (Alonso et a l , 2004). This recent study investigated lifetime and 12- 
month prevalence of mood, anxiety and alcohol disorders in 21,425 individuals across six 
European countries (Belgium, France, Germany, Italy, the Netherlands and Spain) according 
to DSM-IV diagnostic criteria. In the following sections the prevalence of psychiatric 
disorders in the current sample will be compared to the prevalence rates reported in these two 
large epidemiological studies.
5.3.1.1 Mood Disorders
Half of the individuals in the present study had a lifetime diagnosis of a mood disorder 
(see Table 4.14 pg. 63). This figure is over twice as high as the total lifetime prevalence of 
mood disorders reported in the ESEMeD (14%) and NCS (19.3%). However, these two 
surveys had an equal proportion of males and females whereas the present sample was 
predominantly female (71%). Since the current study and these two epidemiological studies 
found females to have a higher prevalence of mood disorders, the predominance of female 
participants will inflate the prevalence of mood disorders in the current sample. However, the 
lifetime prevalence of mood disorders among females only in the ESEMeD (18.2%) and NCS
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(23.9%) remain lower than the 50% total lifetime prevalence observed in the current sample. 
Across the ESEMeD and NCS epidemiological studies the mid-point between the average 
total lifetime prevalence (16.7%) and average female only lifetime prevalence (21%) is 19%. 
Since the proportion of women in both these studies was approximately equal, this mid-point 
between the prevalence of mood disorders in the total samples (comprising of 50% females) 
and the prevalence in the female only samples (comprising of 100% females) is an estimate of 
the prevalence of mood disorders in these studies if the proportion of women was 75%. This 
figure is a more appropriate population prevalence of mood disorders to compare to the 
prevalence of mood disorders in the present sample (comprising of 71% females), as it 
accounts for the higher percentage of females in the current sample. Using this value, the 
prevalence of mood disorders in the present study is significantly higher than the population 
prevalence reported in the two large epidemiological studies (50% vs. 19%; binomial test, p= 
<0.0001).
The most common psychiatric illness observed in the present sample was major 
depression with a prevalence of 30%. This finding is consistent with a previous case series 
study of DD, in which depression was reported as the most commonly observed 
neuropsychiatric phenotype (Ringpfeil et al., 2001). This percentage is again higher than the 
lifetime prevalence of major depression reported in the ESEMeD (total; 12.8%, females; 
16.5%) and NCS (total; 17.1%, females; 21.3%). Based on these figures, the most appropriate 
population prevalence of major depression to compare to the prevalence of major depression 
in the current sample would be 17% i.e. the mid-point between the average total lifetime 
prevalence and average female only lifetime prevalence. Using this value, the prevalence of 
major depression in the present study is significantly higher than the population prevalence 
reported in the two epidemiological studies (30% vs. 17%; binomial test, p=0.0005).
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Four percent of individuals in the present study had a diagnosis of bipolar disorder. Four 
further individuals showed evidence of mood bipolarity including an individual diagnosed 
with cyclothymic disorder, another described in their medical notes as having a cyclothymic 
personality, a female reporting sub-clinical high mood after the births of both her children and 
an individual who developed hypomanic symptoms after taking antidepressants. The 
prevalence of bipolar disorder in the current study is higher than that reported in the previous 
case series studies of unrelated individuals with DD, in which only one case of bipolar 
disorder has been reported (Burge & Wilkinson, 1992). It is possible that bipolar disorder may 
have been under-reported in these studies particularly the older case series studies, where 
individuals with bipolar disorder may have been described as having other conditions such as 
depression, schizophrenia, “emotional problems” or “unrealistic thinking”. This is highlighted 
in the case of a male described as being depressed by Medansky & Woloshin (1961) who is 
also reported to have “spoken at considerable length about his success in business and the big 
deals behind which he was the driving force”. This description sounds indicative of the 
presence of manic symptoms, although the authors do not comment on this.
The lifetime prevalence of mania in the NCS is 1.6% (1.7% in females) (the ESEMeD 
does not report prevalence figures for bipolar disorder). These figures are similar to other 
reported lifetime prevalence rates of bipolar disorder. Bebbington & Ramana (1995) reviewed 
studies reporting the epidemiology of bipolar disorder and found the lifetime prevalence to be 
fairly consistent across the studies and suggested the lifetime prevalence of bipolar disorder 
for males and females was between 1-1.5%. The most appropriate population prevalence of 
bipolar disorder to compare to the prevalence of bipolar disorder in the current sample would 
therefore be 1.5%. Using this value, the prevalence of bipolar disorder in the present study is 
significantly higher than the population prevalence (4% vs. 1.5%; binomial test, p=0.05), 
although this finding would not remain significant after corrections for multiple testing.
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The findings of the current study together with previous case series studies are consistent with 
the existence of a modest population association between bipolar disorder and DD.
5.3.1.2 Anxiety Disorders
In the current study 16% of the sample had a lifetime diagnosis of any anxiety disorder. 
This is similar to the lifetime prevalence of anxiety disorders reported in the ESEMeD (total; 
13.6%, females, 17.5%) and lower than that reported in the NCS (total; 24.9%, females; 
30.5%). Based on these figures, the most appropriate population prevalence of anxiety 
disorders to compare to the prevalence of anxiety disorders in the current sample would be 
22%. Using this value, the prevalence of anxiety disorders in the present study is actually 
significantly lower than the population prevalence reported in the two epidemiological studies 
(16% vs. 22%; binomial test, p=0.03), although this finding would not remain significant after 
corrections for multiple testing. This finding suggests that there is not a non-specific increased 
rate of all psychiatric disorders in the current sample.
5.3.1.3 Suicidal Thoughts and Suicide Attempts
Thirteen individuals in the current sample had made a suicide attempt and a further 18 
reported a lifetime history of suicidal thoughts. Therefore, in total, almost one third of the 
sample (31%) had a lifetime history of suicidal thoughts. This finding is consistent with 
previous studies reporting a high prevalence of suicidal ideation and attempts among 
individuals with DD (Denicoff et al., 1990; Ringpfeil et al., 2001). Similar to the findings of 
Denicoff et al. ,(1990), that most individuals did not relate their suicidal ideation to their DD, 
only one individual in the current study had made a suicide attempt in reaction to a worsening 
of the symptoms of their DD, whereas for the remaining twelve individuals there was no 
subjective or objective temporal relationship between their suicide attempts and the symptoms 
ofDD.
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The survey of psychiatric morbidity among adults in Great Britain carried out by the 
Office for National Statistics (Singleton et a l, 2001) collected data on lifetime suicidal 
thoughts and suicide attempts in 8450 individuals, which were published in a separate report 
(Meltzer et a l, 2002). The lifetime prevalence of suicide attempts (total; 4.4%, females only; 
5.3%) and suicidal thoughts (total; 14.9%, females only; 17.1%) in this general population 
survey is much lower than the prevalence observed in the current DD sample. Just over half 
the individuals in the psychiatric morbidity survey were women. To take into account the 
higher percentage of women in the current study, population prevalence figures of 4.9% for 
suicide attempts and 16% for suicidal ideation were used to compare to the prevalence of 
suicidal thoughts and attempts observed in the current study. Using these values, the 
prevalence of suicide attempts (13% vs. 4.9%; binomial test, p=0.0008) and suicidal ideation 
(31% vs. 16%; binomial test, p=<0.0001) in the current study are significantly higher than 
that observed in the UK general population.
A summary of the prevalence of mood disorders, major depression, bipolar disorder, 
suicide attempts and suicidal ideation in the present study compared to prevalence of these 
features reported in general population samples are summarised in Table 5.2 and Table 5.3. 
These comparisons indicate that the prevalence of mood disorders, specifically major 
depression, suicide attempts and suicidal thoughts are significantly higher in individuals with 
DD than in the general population.
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Table 5 J  Comparison o f the Lifetime Prevalence o f Mood and Anxiety Disorders in the C urrent Study to the Prevalence Reported in Two M ajor 
Epidemiology Studies
Lifetime Prevalence %
C urrent
DD
ESEMeD 
Total (Female only)
NCS
Total (Female only)
*Most Appropriate 
Comparison
Binomial 
Test (P)
Diagnostic Criteria DSM-IV DSM-IV DSM-ffl-R -
Any Mood Disorder 50 14(18.2) 19.3 (23.9) 19 <0.0001
Major Depression 30 12.8(16.5) 17.1 (21.3) 17 0.0005
Bipolar I Disorder 4 - 1.6 (1.7) 1.5** 0.05
ESEMeD; European Study of the Epidemiology of Mental Disorders (Alonso et al, 2004), NCS; National Comorbidity Survey (Kessler et al, 1994), DSM; Diagnostic and 
Statistical Manual of Mental Disorders. DD, Darier’s Disease.
*The mid point between the average total prevalence and average female prevalence across the two epidemiological studies to take into account the predominance of females 
(71%) in the current sample. ** Taking into account the prevalence bipolar disorder commonly reported in other epidemiological studies.
Table 5 3  Comparison of the Lifetime Prevalence of Suicidal Thoughts and Attempts in the C urrent Study to the Prevalence Reported in the Office 
for National Statistics Survey of Psychiatric Morbidity Among Adults in G reat Britain
Lifetime Prevalence %
C urrent
DD
ONS Psychiatric Morbidity 
Survey 
Total (Female only)
** Most Appropriate 
Comparison
Binomial Test (P)
Suicidal
attempts
13 4.4 (5.3) 4.9 0.0008
Suicidal
thoughts*
31 14.9(17.1) 16 <0.0001
ONS; Office For National Statistics Survey of Psychiatric Morbidity (Meltzer et al, 2002), DD, Darier’s Disease, F; lifetime prevalence in females only. 
* Figures include individuals with a lifetime history of suicide attempts.
**The mid point between the total prevalence and female prevalence to take into account the predominance of females (71%) in the current sample.
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5.3.2 Psychiatric Co-morbidity in Other Skin Conditions
Literature relating to psychiatric co-morbidity in other skin disorders indicates that there 
is a high prevalence of psychiatric disorders among dermatology patients. It is commonly 
reported that the overall prevalence of psychiatric co-morbidity in dermatology patients with 
conditions including acne, alopecia, psoriasis and vitiligo, is around 30% with depression and 
anxiety being commonly observed (Gupta & Gupta, 2003; Picardi et a l , 2000). However, for 
a number of reasons, it is not meaningful to compare the prevalence of psychiatric illness 
found in the current sample of individuals with DD to the prevalence reported among 
individuals with other skin conditions in the literature. Firstly, in the current sample, lifetime 
prevalence of psychiatric illness was measured whereas the studies in the literature have 
assessed point prevalence. Secondly, the reported overall prevalence of psychiatric co­
morbidity in dermatology patients has come from studies conducted in both outpatient and 
inpatient dermatology settings whereas all of the individuals in the current study were 
outpatients (although one third had been a dermatology inpatient at some point in their lives). 
Finally, most of the studies reporting psychiatric co-morbidity in dermatology patients have 
assessed the presence of psychiatric symptoms using brief self-rated measures/general 
screening questionnaires whereas the presence of these symptoms in the present sample was 
assessed using a standardised clinical semi-structured interview.
The prevalence of suicidal ideation among psoriasis (5.5%) and acne (5.6%) patients has 
been reported to be twice as high as that reported among general medical patients (Gupta & 
Gupta, 1998). This study measured the point prevalence of suicidal ideation in both inpatients 
and outpatients using a self-rated measure. The findings therefore cannot be compared to the 
lifetime prevalence of suicidal ideation observed in the current sample of individuals with 
DD.
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A limitation of the present study is the lack of a control sample. To further support the 
finding of an increased prevalence of psychiatric illness in DD, a control sample of 
individuals with another skin disorder of a similar severity to DD needs to be collected and 
assessed using a standardised psychiatric clinical interview. Collecting a control sample of 
individuals with another skin condition was considered when the current study was first being 
designed however, due to time constraints this was not possible. The skin condition used as a 
control sample would have to be selected carefully, as complex relationships are likely to 
exist between psychiatric and dermatologic symptoms in a number of skin conditions. As well 
as psychiatric symptoms being a consequence of having a skin disorder, psychosocial stress is 
also reported to play a role in the exacerbation and onset of a number of skin conditions such 
as psoriasis and atoptic dermatitis (Gupta & Gupta, 2003).
5.3.3 Epilepsy and Other Neurological Conditions
Three individuals in the current sample had a lifetime diagnosis of three different types of 
epilepsy (tonic-clonic, idiopathic and petit mal) giving an overall prevalence of 3% (30/1000). 
This prevalence of epilepsy is consistent with a number of other case series studies of DD, for 
example, Burge & Wilkinson (1992) reported the prevalence of epilepsy in their sample as 
42.9 / 1000. A review article of the epidemiology of the epilepsies (Sander & Shorvon, 1996) 
indicates that the reported lifetime prevalence rates of epilepsy in the general population are 
very variable, ranging from 1.5-57/1000 depending on the definitions used, with the average 
prevalence being 10.3/1000 (1.3%). Using this value, the prevalence of epilepsy in the current 
study is not significantly higher than in the general population (3% vs. 1.3%; binomial test, 
p=0.1). The findings of the current study and the previous case series studies do not support a 
population-level association between DD and epilepsy, although the prevalence of epilepsy in 
these studies is higher than the reported population prevalence of epilepsy. These findings
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could suggest that a subgroup of individuals/families with DD may have an increased 
susceptibility to developing epilepsy.
Over one third of individuals in the current study had been referred to a neurologist 
and/or had neurological investigations and almost two thirds had consulted their GP for 
possible neurological symptoms, most common being blackouts/periods of loss of 
consciousness (24% consulted GP, 13% referred for investigations), hearing problems (14% 
consulted GP, 9% referred for investigations) and headaches (33% consulted GP, 6% referred 
for investigations). This rate seems high but it is not clear whether the prevalence of these 
'soft’ neurological symptoms is higher than in the general population. In a large community 
based study in the UK investigating the incidence and lifetime prevalence of neurological 
disorders, migraine, tension headache and ear conditions were all excluded due to resource 
constraints (MacDonald et a l , 2000). The finding that thirteen percent of individuals in the 
current sample had received investigations for blackouts, periods of loss of consciousness or 
fainting episodes is noteworthy. Whether these episodes have an underlying neurological 
cause in any of the reported cases remains unclear, although the majority of investigations 
carried out on these individuals at the time of these episodes were reported to be normal. It is 
also possible that in a proportion of these individuals the episodes of loss of consciousness 
may be part of a somatization disorder.
Lifetime history of the presence of neurological symptoms and disorders in the current 
study was assessed using a brief checklist of questions. Future studies could carry out a more 
detailed assessment of the presence of neurological features in individuals with DD including 
the administration of specific neurological tests such as audiograms and neuroimaging.
120
5.3.4 Lifetime History of Learning Difficulties
Five percent of the current sample reported that they had been given a diagnosis of 
dyslexia. It is not meaningful to compare this figure to the reported prevalence of dyslexia in 
the general population since it is unlikely that older participants in the current sample with 
dyslexia would have ever been given a formal diagnosis. Thirteen percent of the sample 
reported they had received extra help at school although this also likely to be dependent on 
participants’ age and this figure may be an underestimate of individuals in the sample who 
required extra help at school.
In an attempt to overcome these difficulties, 59 individuals completed the self-rated 
Adult Dyslexia Checklist (ADC) with 19% having a score on the questionnaire indicating 
difficulty. The checklist was posted to individuals after they had been visited. Therefore it is 
possible that individuals with greater difficulties with reading and/or spelling may have been 
less likely to return the questionnaire. When this questionnaire was previously completed by 
679 adults in the UK, including 32 with known dyslexia, 10% had scores indicating difficulty 
(The British Dyslexia Association). Comparison of these figures indicates that twice as many 
individuals in the current study had scores indicating difficulty than in the sample of 679 UK 
adults. However, that sample was predominantly comprised of degree course, access course 
and A-level students and is therefore not a very suitable comparison group.
One fifth of individuals in the current sample were classified as having learning 
difficulties (individuals who had a diagnosis of dyslexia and/or received extra help at school 
and/or had a high score in the ADC reflecting difficulty). These findings do not indicate a 
population level association between DD and learning difficulties. This is consistent with the 
findings of the majority of previous case series studies of DD, which have reported relatively 
small numbers of individuals with learning difficulties. However, in a case series study in 
Slovenia, the majority of individuals were noted to have an impairment of memory and
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capacity to concentrate (Miljkovic et al., 2005). Similarly, an early study conducted in 
Denmark suggested that individuals with DD differed from ‘normal’ in terms of their mental 
development (Svendsen & Albrectsen, 1959). It is not clear how these impairments were 
assessed in these two studies. The current study is limited by the methods used to measure 
learning difficulties. Individuals’ responses to the questions regarding dyslexia and receiving 
extra help at school are likely to be dependent on their age group. As previously discussed, a 
high percentage of individuals in the current sample reported having no qualifications. There 
are a number of possible reasons for this finding, including the possibility that individuals 
with DD may be impaired in specific aspects of learning. This needs further investigation 
using standardised neuropsychological measures such as memory and attention tests.
5.3.5 Normative IQ Scores
The mean IQ score of the 85 individuals who completed the Wechsler Abbreviated Scale 
of Intelligence (WASI) measure was 100, which is within the average range of IQ. Just six 
percent of individuals in the current study had a below average IQ. Only one previous small 
case series study of DD has measured IQ (Medansky & Woloshin, 1961). In this study, two 
individuals out of the five assessed were found to have a below average IQ, although it is 
difficult to make comparisons to such a small sample.
A comparison of the distribution of IQ scores in the current sample to the normative 
sample published in the WASI manual is displayed in Table 5.4 The distribution of IQ scores 
in the current DD sample is almost identical to the distribution reported in the normative 
sample, which is reported to be highly representative of the English speaking US population. 
This comparison is limited by the normative sample coming from the US population (a 
specific UK normative sample is not available for the WASI) and also by the fact that almost 
half the sample consisted of children. Despite these limitations, the findings of the current 
study suggest that individuals with DD do not differ from the general population in terms of
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their general level of intellectual functioning. It is, however, possible that individuals with a 
lower level of intellectual functioning may be less likely to respond to an invitation to take 
part in a research study.
Table 5.4 Comparison of the Distribution of IQ  Scores in the C urrent Study to the Distribution 
in the Published Normative Sample
%
IQ Score Classification C urrent DD 
Sample
Published 
Normative Sample
130 and above Very Superior 0 2.0
120-129 Superior 2.4 7.3
110-119 High Average 21.2 15.6
90-109 Average 56.5 50.0
80-89 Low Average 14.1 15.8
70-79 Borderline 4.7 6.8
69 and below Extremely Low 1.2 2.5
IQ scores measured using the Wechsler A bbreviated Scale o f  Intel igence (WASI)
5.4 Family History of Neuropsychiatric Features
Almost half the individuals in the current sample (43%) reported that they had at least 
one first-degree relative with a history of psychiatric illness that had required treatment and/or 
caused significant impairment. Seven individuals in the sample had a family history of 
epilepsy in their first-degree relatives. The first-degree relatives with a history of psychiatric 
illness and epilepsy were more commonly reported as having DD than not having DD. This 
was most apparent for epilepsy where 75% of the first-degree relatives with a diagnosis of 
epilepsy were also reported to have DD. Similarly, of the first-degree relatives with a positive 
psychiatric history, a higher percentage were reported to have DD (53.1%) than were not 
(35.9%).
Previous family studies of DD have consistently reported a greater prevalence of 
neuropsychiatric features in family members with DD than in family members without DD. 
The examples of four families with multiple members with DD and neuropsychiatric illness 
displayed in the present thesis (Figure 4.8-Figure 4.11 pg. 80) also show an increased 
prevalence of neuropsychiatric features among family members with DD, although no cases
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of complete co-segregation between DD and neuropsychiatric features were observed. A 
limitation of the current study is that information regarding family history was obtained from 
the index individual and the majority of first-degree relatives were not seen to confirm the 
absence or presence of a history of neuropsychiatric features or a diagnosis of DD. However, 
it is more likely that an affected first-degree relative with mild DD may have been reported as 
being unaffected than a true unaffected relative being reported as having DD.
There are a number of explanations for the observed increased prevalence of 
neuropsychiatric features among individuals with DD compared to their relatives unaffected 
by DD. The increased prevalence of psychiatric illness in individuals with DD compared to 
their unaffected relatives may reflect a psychological reaction to having a chronic disorder. 
However, in a family displaying complete co-segregation between DD and mood disorders 
interviewed by Craddock et al. (1994b), family members did not relate their mood symptoms 
to their skin disorder. In addition, psychosocial factors would not account for the more severe 
neuropsychiatric features being reported more commonly among first-degree relatives with 
DD. For example, in the family described by Getzler & Flint (1966) neuropsychiatric features 
including ‘schizophrenic episodes’ and ‘depressive psychosis’ were reported more commonly 
among family members with DD. Such severe psychiatric symptoms are unlikely to result 
from a psychological reaction to having a skin disorder. It is possible that in this family a gene 
predisposing individuals to these psychiatric symptoms was in linkage disequilibrium with the 
DD gene. Another possible explanation is that mutations in ATP2A2, in addition to causing 
DD, have effects in the brain and cause individuals with DD to have an increased 
susceptibility to developing neuropsychiatric features. The prevalence of neuropsychiatric 
features in a sample of individuals with DD and their first-degree relatives, unaffected by DD, 
will be investigated and discussed in further detail later in this thesis in Chapters 10 to 12.
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5.5 Relationship between Lifetime Neuropsychiatric Features, IQ
Scores and Family History of Psychiatric Illness
Investigations into whether certain neuropsychiatric features appear to occur more 
commonly together in individuals with DD revealed that significantly more individuals with a 
history of investigations for blackouts/loss of consciousness also had a lifetime DSM-IV 
diagnosis of psychiatric illness and a family history of psychiatric illness compared to 
individuals without a history of having such investigations. It is possible that in these 
individuals the psychiatric features and blackouts/episodes of loss of consciousness have a 
shared pathogenic mechanism therefore providing support for the hypothesis that mutations in 
ATP2A2 have pleiotropic effects in the skin and brain. However, it is also possible that in 
some individuals the episodes of loss of consciousness may be part of the psychiatric 
condition, for example may reflect a severe panic attack, which is not recognised by the 
individual or may be part of a somatization disorder. It is not possible to establish the cause 
for the co-occurrence of psychiatric illness and episodes of loss of consciousness in the 
individuals in the current sample. Neuroimaging investigations on these individuals would 
help to determine whether there is a potential biological cause for the co-occurrence of these 
symptoms. Significantly more individuals with learning difficulties had a below average IQ 
score compared to individuals without learning difficulties. This is an expected finding since 
the two measures are likely to be measuring the same neuropsychiatric phenotype in these 
individuals.
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5.6 Relationship between DD Clinical Features and Lifetime
Neuropsychiatric Features
Relationships, both subjective and objective, between the clinical features of DD and the 
presence and severity of lifetime neuropsychiatric features in the current sample were 
investigated to help determine the extent to which psychosocial and pleiotropic factors may 
play a role in the presence of neuropsychiatric features in DD.
Only a small percentage (6%) of individuals in the current sample felt that all the 
episodes of psychiatric illness they had experienced were due to the symptoms of DD. This 
finding is consistent with previous studies in which individuals with DD have not related their 
psychiatric symptoms to their DD (Craddock et al., 1994b; Denicoff et al., 1990) and suggests 
that in many individuals with DD, the additional presence of psychiatric symptoms may be 
due to factors other than a psychological reaction to having a chronic skin disorder. It is, 
however, possible that individuals may attribute the psychiatric symptoms they have 
experienced to other life events such as relationship problems, which could have resulted 
from them having DD, although this is difficult to assess. Over one third of the current sample 
(38%) did report that they felt at least one episode of psychiatric illness, which in all cases 
was an episode of depression, was directly due to the symptoms of DD. This highlights the 
possibility that episodes of depression experienced by individuals with DD can be a direct 
consequence of the symptoms of DD. In the majority of cases (81%) the onset of DD 
preceded or occurred at the same age as the onset of psychiatric symptoms. This finding was 
expected since the symptoms of DD generally appear between the ages of 11 and 20 and 
would therefore be expected to occur before the emergence of psychiatric symptoms. This 
finding highlights the potential for psychosocial factors to play a large role in the 
development of psychiatric symptoms in DD although this does not exclude the possibility 
that other factors may play an important role. Overall, the majority of the other clinical 
features of DD, including age of onset and duration, severity, impairment and impact on
quality of life were not significantly associated with the presence or severity of lifetime 
neuropsychiatric features. The significant findings from these investigations, and the 
relationships that almost reached significance, are summarised in Table 4.33 pg. 103. A 
limitation of these investigations is the small group sizes, which limit the power to detect 
significant relationships.
A number of relationships that would be expected if psychosocial factors alone accounted 
for the occurrence of neuropsychiatric features in DD were not observed. For example, the 
reported impact on quality of life caused by DD was not found to be associated with a 
presence of a lifetime history of psychiatric illness or with measures of the severity of 
psychiatric illness including numbers of episodes of depression. DD severity was also not 
found to be associated with these psychiatric features, although these findings need to be 
examined in larger samples.
5.6.1.1 Relationships between DD Severity, Impact on Quality of Life and
History of Suicidal Thoughts and Suicide Attempts
Significant relationships were observed between the impairment and impact on quality of 
life caused by DD and history of suicidal thoughts and suicide attempts. Significantly more 
individuals reporting DD to have caused mild impact on their work/career had a history of 
suicide attempts compared to individuals reporting no impact (Figure 4.15 pg. 91). However, 
this significant finding should be treated with caution for a number of reasons. Firstly, if a 
true relationship existed it would be expected that individuals reporting a moderate/severe 
impact on their work/career due to DD would have a greater prevalence of history of suicide 
attempts than individuals reporting a mild impact, although this was not observed. Secondly, 
the reported impact of DD on work/career did not appear to be correlated with other measures 
of the presence or severity of lifetime psychiatric features.
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Individuals with a history of suicidal thoughts reported a significantly greater impact on 
quality of life during the worst week of their DD (measured by the DLQI) compared to 
individuals with no history of suicidal thoughts or attempts (see Figure 4.16 pg. 92). Due to 
the cross sectional design of the current study, it is not possible to establish whether history of 
suicidal thoughts may be primary or secondary to the reported impact of DD on quality of 
life. It is likely that individuals whose quality of life has been severely affected by DD would 
experience suicidal thoughts in reaction to their skin disorder but it is also possible that 
individuals with history of suicidal thoughts may be more likely to retrospectively report that 
DD has had a greater impact on their life. Evidence for suicidal thoughts being experienced as 
a direct consequence of the symptoms of DD is supported by the observed trend for the 
prevalence of history suicidal thoughts, to increase with DD severity (Figure 4.13 pg. 87).
This trend was not observed for suicide attempts. The relationship between quality of life and 
suicidal thoughts in DD requires further investigation in a larger number of individuals and 
would ideally be investigated longitudinally. The presence of an association between quality 
of life and suicidal thoughts would have implications for the management of DD and the 
potential use of quality of life measures to identify individuals with DD who are at risk of 
experiencing suicidal thoughts.
History of suicide attempts was not observed to be associated with DD severity or the 
impact of DD on quality of life. The small sample number of individuals in the present study 
with a history of suicide attempts means that power to detect significant relationships would 
be limited. However, the observation that in all but one of these cases there was no subjective 
or objective temporal relationship between the suicide attempt and the symptoms of DD 
supports the notion that factors other than a direct reaction to the symptoms of DD are likely 
to explain the observed increased prevalence of suicide attempts in DD.
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5.6.1.2 Increased Prevalence of Psychiatric Illness Among Individuals 
Reporting Pain as a Symptom of DD
A  non-significantly higher prevalence of history of psychiatric illness was observed in 
individuals reporting pain as a current or past symptom of their DD (Figure 4.14 pg. 89). This 
finding is difficult to interpret, although experiencing pain as a result of DD could cause 
individuals to become depressed, individuals with a past or current history of depression may 
be more likely to retrospectively report that their DD had been painful in the past. It is 
possible that, due to the number of relationships investigated in the current study, this finding 
could be due to chance. This is supported by the fact that pain as a symptom of DD was not 
observed to be associated with any of the measures of severity of psychiatric symptoms, such 
as the number of episodes of depression individuals had experienced.
5.6.1.3 Increased Prevalence of Psychiatric Illness and Suicidal Thoughts 
Among Individuals Reporting a Positive Family History of DD
Individuals reporting a definite or probable family history of DD had a significantly 
higher prevalence of history of psychiatric illness (Figure 4.17 pg. 93) and suicidal thoughts 
(Figure 4.18 pg. 94) compared to individuals reporting a negative family history of DD. A 
similar trend was also observed for suicide attempts (Figure 4.18 pg. 94). An explanation for 
this observation is that having another family member with DD, especially severe DD, may 
cause individuals to experience depression and possibly suicidal thoughts particularly if they 
are concerned that their DD will become as severe as their relatives’ symptoms. Having a 
child with DD might also lead to feelings of guilt that they have passed on the disorder, which 
may lead to the development of symptoms of depression. It is also possible that the observed 
prevalence of psychiatric symptoms among individuals reporting a family history of DD 
could be providing support for the pleiotropy hypothesis that mutations in ATP2A2 may 
confer susceptibility to psychiatric illness. Certain mutations that may lead to a more severe, 
easily recognised, form of DD in families, may also have effects in the brain and contribute to
individuals developing psychiatric symptoms. It is also possible that a proportion of 
individuals not reporting a family history of DD may not have a mutation in ATP2A2 i.e. they 
may be phenocopies of DD. This possibility is investigated and discussed further in Chapters 
8 and 9.
A non-significant trend was observed for the prevalence of learning difficulties to be 
higher among individuals reporting a positive family history of DD. However, the difficulties 
encountered in measuring learning difficulties in the present study, discussed above, limits the 
conclusions that can be drawn from this finding. No relationship between IQ scores and 
family history of DD were observed in the sample.
5.6.2 Relationship between DD Severity and IQ Scores
A trend for IQ scores to decrease with an increase in DD severity was observed (Figure 
4.19 pg. 98). This relationship almost reached significance despite the small number of 
individuals classified as having severe DD. This association could support the role of 
psychosocial factors, since having severe symptoms of DD from an early age may affect 
school attendance and performance leading to a reduced level of intellectual functioning in 
adulthood. This is supported by the finding that there was also a trend for IQ scores to 
decrease with an increase in the subjective reported impact of DD on school. However, the 
trend for IQ scores to decrease with DD severity could also be providing support for 
pleiotropy hypotheses in that certain mutations in ATP2A2 may lead to the presence of both 
severe DD and severe neuropsychiatric features including a reduced level of intellectual 
functioning.
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5.7 Summary, Limitations and Suggestions for Further Research
This chapter has discussed the findings of the first systematic investigation into the 
neuropsychiatric phenotype in DD using a battery of standardised neuropsychiatric measures. 
A comparison of the prevalence of neuropsychiatric features in the current sample to available 
data regarding the prevalence of these features in the general population, suggests a potential 
population-level association between DD and mood disorders, specifically major depression, 
suicide attempts and suicidal thoughts. This finding is limited by the fact that there are no 
reported lifetime figures for the prevalence of these features in other skin conditions, 
highlighting the need for a control sample of individuals with a skin disorder of similar 
severity to be assessed using a similar battery of standardised neuropsychiatric measures. The 
prevalence of bipolar disorder and epilepsy in the sample is non-significantly higher than the 
prevalence in the general population suggesting that a subset of individuals/families with DD 
may have an increased risk of developing these disorders.
It is difficult to compare the apparently high prevalence of soft neurological symptoms in 
the sample to the prevalence of these features in the general population. This needs to be 
investigated in future studies using specific neurological tests. Similarly, difficulties were 
encountered in assessing true prevalence of learning difficulties in the current sample, which 
requires further investigations using standardised neuropsychological measures. However, the 
findings of the current study do suggest individuals with DD do not differ from the general 
population in terms of their general level of intellectual functioning.
Despite the fact that the majority of individuals in the current study were recruited on the 
basis of having DD, it is possible that there could be a recruitment bias towards individuals 
who have experienced psychiatric symptoms as a consequence of their DD, since these 
individuals may be in more regular contact with a dermatologist and/or the DD support group. 
Conversely, individuals with more severe neuropsychiatric features, including severe
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psychiatric illness and learning difficulties may be less likely to be in regular contact with 
dermatologists and/or respond to an invitation to take part in a research study. Such 
individuals may be underrepresented in this current sample.
The investigations of the relationships between the clinical features of DD and the 
presence and severity of lifetime neuropsychiatric features indicate that psychosocial factors 
alone cannot account for the observed increased prevalence of mood disorders, suicidal 
thoughts and suicide attempts observed in the current sample. In addition, the increased 
prevalence of psychiatric illness and history of suicidal thoughts and attempts among 
individuals reporting a positive family history DD and the trend for IQ scores to decrease with 
an increase in DD severity potentially provides support for the pleiotropy hypothesis that 
mutations in ATP2A2 may confer susceptibility to neuropsychiatric features in individuals 
with DD. A limitation of these investigations is the small group sizes, which limits the power 
to detect significant relationships. There is also the possibility that due to the number of 
relationships examined, some of the significant findings may have been due to chance. 
Possible explanations for the significant relationships observed have been discussed, although 
due to the cross-sectional design of the study it is not possible to make any definite causal 
inferences. These findings require replication in larger samples of individuals with DD, 
ideally in a longitudinal study. Over all, the high prevalence of mood disorders, suicidal 
thoughts and suicide attempts observed in the current sample highlights the need for 
assessment and recognition of psychiatric symptoms in DD, particularly in individuals 
reporting a positive family history of DD.
The following chapters (Chapter 6 to 9) are concerned with addressing the second main 
aim of the thesis, which is to investigate possible genotype-phenotype correlations between 
the type and/or locations of pathogenic mutations detected in the A TP2A2 gene and 
neuropsychiatric features observed in this current sample. Evidence for such correlations
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would support the hypothesis that mutations in the ATP2A2 gene may have pleiotropic effects 
in the skin and brain and therefore confer susceptibility to neuropsychiatric features in 
individuals with DD.
133
6 GENOTYPE-PHENOTYPE CORRELATIONS BETWEEN 
MUTATIONS DETECTED IN ATP2A2 AND 
NEUROPSYCHIATRIC PHENOTYPES: INTRODUCTION
This chapter describes the DD causing mutations in ATP2A2 that have previously been 
reported in the literature. This is followed by a description of the functional domains of the 
sarco/endoplasmic reticulum Ca ATPase isoform 2 (SERCA2) protein, which is encoded by 
the ATP2A2 gene. Finally, previous findings of studies investigating possible relationships 
between the type and/or location of mutations within A TP2A2 and the presence of 
neuropsychiatric features are discussed.
6.1 Mutations Reported in A TP2A2 In the Literature
The ATP2A2 gene spans 21 exons and has three splice variants (a, b and c), which are a 
result of alternative splicing of exon 20. To date, 143 ATP2A2 mutations have been reported 
in 175 unrelated individuals in the literature (Chao et al., 2002; Dhitavat et al., 2003b; Dode 
et al., 2003; Foggia et al., 2006; Godic et al., 2004; Ikeda et al., 2003; Jacobsen et al., 1999; 
Jones et al., 2002; Onozuka et al., 2004; Racz et al., 2005; Racz et al., 2004; Ren et a l, 2006; 
Ringpfeil et al., 2001; Ruiz-Perez et a l, 1999; Sakuntabhai et al., 1999a; Sakuntabhai et al., 
2000; Sakuntabhai et al., 1999b; Takahashi et al., 2001; Wada et al., 2003; Wang et al., 2006; 
Yang et al., 2004; Yang et a l, 2001). These reported mutations are distributed across the 
gene. The types of mutations found and their approximate percentages are summarised in 
Table 6.1. A brief description/definition of each mutation type is given below.
Nonsense mutations: a single base substitution that leads to a premature termination 
codon (PTC) that specifies termination of protein synthesis. These mutations are expected to 
have a dramatic effect on the protein.
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Frameshift mutations: small deletions or insertions of bases leading to a shift in the 
reading frame of the triplet codon system. These mutations can potentially lead to a PTC and 
are expected to have a dramatic effect on the protein.
Missense mutations (non-synonymous mutations): a single base substitution leads to an 
amino acid change. This change can either be conservative, where the amino acids have 
similar properties or non-conservative where they do not. Non-conservative changes result in 
a greater change in the protein properties and have a greater potential to be pathogenic.
In-frame mutations: small deletions or insertions of bases that do not shift the reading 
frame of the triplet codon system. This leads to the deletion or insertion of amino acids. These 
mutations are likely to result in a change in the properties of a protein but are not expected to 
be as damaging as frameshift and nonsense mutations.
Splice site mutations: a single base substitution in the splice donor (first few bases in an 
intron) or splice acceptor (last few bases in an intron) sequences, which flank exons. This may 
lead to retention of large segments of intronic DNA or to entire exons being spliced out and 
can therefore result in a change in the properties of a protein.
Other: include large insertions and deletions of bases, which are likely to have a dramatic 
effect on the protein structure and function.
Table 6.1 Frequencies of Types of M utations Previously Reported \nATP2A2
M utation Type Number %
Nonsense 14 10
Frameshift (insertion/deletion) 33 23
Missense 71 50
In-frame (insertion/deletion) 9 6
Splice Site 12 8
Other 4 3
Total 143 100
The majority of the 143 mutations reported in the literature to date have been found to be 
unique within a single family (83%). Twenty-five mutations (17%) have been reported more
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than once in apparently unrelated individuals. Four separate missense mutations have been 
reported in three or more apparently unrelated families.
6.1.1 Mutation Detection Rates in ATP2A2
Reported disease-causing mutation detection rates in larger scale mutation screens of the 
ATP2A2 gene (10 or more unrelated individuals with DD) range from 50% (Ikeda et al.,
2003) to 70% (Onozuka et al., 2004). Explanations for these findings have included DNA 
quality and/or technical reasons (Ikeda et al., 2003), undetected mutations being located in an 
unscreened region of the ATP2A2 gene (Ringpfeil et al., 2001) and the screening strategies 
used not being able to detect large scale mutations (Ruiz-Perez et al., 1999). A further 
explanation for a DD causing mutation not being detected in individuals is that they could 
have clinical features similar to DD caused by factors other than a pathogenic mutation in 
ATP2A2 i.e. be a phenocopy of DD.
6.2 Domain Structure o f SERCA2
As previously described in Chapter 2, ATP2A2 encodes three isoforms of the SERCA2 
protein (a, b and c), which are identical up to amino acid 993 and differ in their carboxyl 
termini and expression (Table 2.1 pg. 7). Both the SERCA2a and SERCA2b isoforms have 
been found to be present in the epidermis although the SERCA2b isoform predominates 
(Ruiz-Perez et al., 1999; Tavadia et al., 2004). The major role of the SERCA2b isoform in 
the epidermis is supported by a mutation causing DD being found in a region of the protein 
specific to the 2b isoform (Dhitavat et al., 2003b). SERCA2b has also been found to be highly 
expressed in the brain with the highest levels being found in the Purkinje neurons of the 
cerebellum and the pyramidal cells of the hippocampus (Baba-Aissa et a l , 1998).
SERCA2b is 1042 amino acids in length and contains five major domains: the M domain 
which is composed of 11 transmembrane domains (Ml-Ml 1), the S domain, which is
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composed of five stalk domains (S1-S5) and three cytoplasmic domains; the Actuator (A) 
domain, the Nucleotide ATP-binding (N) domain and the Phosphorylation (P) domain. A 
schematic diagram of the functional domains of the SERCA2b protein, based on the 
schematic diagram of the protein published by Dode et al (2003), is shown in Figure 6.1. 
SERCA2b differs from SERCA2a (997 amino acids) and SERCA2c (999 amino acids) by 
having a proposed additional 11th transmembrane domain and a carboxyl terminus that 
extends into the endoplasmic reticulum (ER) lumen (Verboomen et a l , 1994).
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Figure 6.1 Schematic Diagram of the Functional Domains of SERCA2b
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6.2.1 M Domain
The SERCA2 protein has seven Ca2+ binding amino acids within four of the
a  i
transmembrane domains (M4, M5, M6 and M8) which form two Ca binding sites 
(Toyoshima et al., 2000). Site 1 contains amino acids from M5, M6 and M8 and site 2 
contains amino acids from M4 and M6. The SERCA2 protein alternates between two 
conformational states, El and E2, resulting in two Ca2+ ions being transported from the 
cytoplasm into the ER against a concentration gradient (MacLennan et a l, 1997). In the El
^  i______________________________________________________________________________________________________________________________________________________________________
state the Ca binding sites are of high affinity and facing the cytoplasm. After ATP binding, 
the pump is phosphorylated by ATP allowing the protein to undergo a series of 
conformational changes resulting in the E2 state in which the Ca2+ binding sites are of low 
affinity and facing the ER lumen.
6.2.2 A, N and P Domains
The cytoplasmic section of SERCA2 contains three separate functional domains, 
described below.
Actuator (A) domain is involved in transferring the energy from ATP hydrolysis to Ca2+ 
transport. It is also thought to act as a gating mechanism, making bound Ca2+ ions 
inaccessible from either side of the ER membrane before they are released in the ER lumen 
(Toyoshima & Mizutani, 2004).
Nucleotide ATP-binding (N) domain contains amino acids critical for binding to ATP 
allowing phosphorylation of the P domain.
Phosphorylation (P) domain is split into two parts, separated by the N domain, contains 
the amino acid phosphorylated by ATP and additional amino acids critical for ATP 
hydrolysis.
138
A 3-D representation of the SERCA2 protein published in a review article by Foggia & 
Hovnanian (2004) is shown in Figure 6.2.
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Figure 6.2 3-D Schematic Diagram of the Domain Structure of SERCA2 published in Foggia & 
Hovnanian (2004)
6.3 Functional Studies of Effects of ATP2A2 Mutations
As individuals with DD are heterozygous for mutations in A TP2A2, one normal allele 
continues to encode a normal SERCA2b protein. Recent functional studies have investigated 
the effects of 56 specific mutations in ATP2A2 on the functioning of ‘mutant’ SERCA2b 
proteins. These studies have found that the majority of mutations result in a SERCA2b protein 
with very limited or loss of Ca2+ transport activity due to a lack of protein expression and/or 
function (Ahn et al., 2003; Dode et a l ,  2003; Miyauchi et a l , 2006; Sato et a l , 2004). 
However, a small number o f exceptions have been found, described below. Overall the 
functional studies suggests that the expression of the normal wild type SERCA2b protein 
from the single normal allele is not sufficient to provide normal function (haploinsufficiency).
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Ahn et al. (2003) examined the expression and function of 12 SERCA2b proteins 
resulting from DD causing mutations. Ten out of the 12 proteins displayed decreased 
expression and/or stability. Only one mutation, located in the 7th transmembrane (M7) 
domain, resulted in a protein that showed calcium pumping activity (V843F). In addition, five 
mutations were found to lead to ‘mutant’ SERCA2b pumps that interacted with and 
subsequently reduced the activity of the co-expressed wild-type normal SERCA2b pumps. 
Dode et al. (2003) investigated functional effects of 10 missense mutations in SERCA2b. 
Eight of the mutations were found to result in a SERCA2b protein with no significant Ca2+ 
transport. One unique mutation, located in the M8 to M9 cytosolic loop, was found to have an 
enhanced Ca2+transport activity relative to the wild type SERCA2b and had reduced 
sensitivity to inhibition by lumenal Ca2+ (S920Y). Sato et al. (2004) examined the expression 
and function of three SERCA2b proteins resulting from DD causing missense mutations in 
ATP2A2. All three proteins were found to exhibit nearly normal protein expression and Ca2+ 
transport function. One mutation, located in the stalk 4 (S4) domain, was found to result in a 
SERCA2b protein with markedly reduced sensitivity to the feedback inhibition by ER 
lumenal Ca2+ (L321F). It is postulated by the authors that this would bring about an 
abnormally elevated Ca level in the ER lumen which could in turn produce a strong 
feedback inhibition of the wild type SERCA2b pump.
6.4 Genotype-Phenotype Studies
A small number of studies have been conducted to investigate genotype-phenotype 
correlations between mutations detected in ATP2A2 and the neuropsychiatric features 
observed in individuals with DD. Such relationships would provide strong evidence that 
mutations in ATP2A2 do have pleiotropic effects in the skin and brain. Jacobsen et al. (1999) 
investigated genotype-phenotype correlations in 19 unrelated individuals with DD. Seventeen 
distinct mutations were identified with two pairs of individuals being found to have the same
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mutation. The 10 individuals in the study with a lifetime history of neuropsychiatric features 
were all examined by a research psychiatrist and diagnoses were made according to standard 
diagnostic criteria. The neuropsychiatric phenotypes observed included, cyclothymic disorder, 
schizoid personality disorder NOS, bipolar I disorder, major depression and epilepsy. 
Genotype-phenotype correlations were observed. A predominance of missense mutations was 
found in individuals with DD and neuropsychiatric features compared to individuals with DD 
only (70% vs. 38%). The mutations in individuals with a neuropsychiatric phenotype also 
showed a non-random clustering in the last third of the gene, all being located in exons 13-19. 
Interestingly, two apparently unrelated individuals in the study with a lifetime diagnosis of a 
psychiatric disorder were found to have the same missense mutation in the ATP binding ‘N’ 
domain of SERCA2 (C560R). One of these individuals had bipolar I disorder and the other 
individual had a diagnosis of schizoid personality disorder NOS and suffered from a form of 
psychosis. A further missense mutation in the 7th transmembrane (M7) domain of the 
SERCA2b protein (V843F) was found in two unrelated individuals with neuropsychiatric 
features. One of these individuals had epilepsy and the other had experienced blackouts as 
well as an episode of major depression. Although the study had a relatively small sample size, 
the findings did provide evidence of genotype-phenotype correlations between mutations in 
ATP2A2 and the occurrence of neuropsychiatric features in DD. This was highlighted in 
particular by unrelated individuals with the same mutation being found to have similar 
neuropsychiatric phenotypes.
Three further studies have failed to find any relationship between the type and/or location 
of mutations in ATP2A2 and the presence of neuropsychiatric features. Ringpfeil et al (2001) 
investigated genotype-phenotype correlations in 14 families/individuals with DD in whom 14 
distinct mutations were identified. Neuropsychiatric features were assessed by medical and 
family history and considered significant if the disorder resulted in medical care or
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consultation of a specialist. The authors reported no obvious genotype-phenotype correlations. 
However, three families with the most severe clinical features of DD also had severe 
neuropsychiatric features including “severe emotional problems”, suicide attempts and 
depression. Two of these families both had an in-frame deletion mutation each eliminating 
one amino acid in the Stalk 1 (SI) domain (Del L41 and Del P42). A further family classified 
as having severe DD had members with variable neuropsychiatric features including seizure 
disorder, depression and schizophrenia. This family had a missense mutation in the ATP 
binding ‘N’ domain (F487S). Sakuntabhai et al. (1999a) investigated genotype-phenotype 
associations in 22 families/individuals with DD including five families reported in 
Sakuntabhai et al. (1999b). Information regarding neuropsychiatric features was obtained as 
part of the general medical history. The authors reported that neuropsychiatric abnormalities 
were not associated with a specific type of mutation and varied among affected family 
members within the same family. Ruiz-Perez et a l (1999) identified 40 different mutations in 
47 families with DD. To investigate genotype-phenotype correlations between the mutations 
detected and the neuropsychiatric features observed, the authors focused on six 
individuals/families with the clearest evidence of associated neuropsychiatric disorders. This 
included one individual with notably low intelligence, an individual with schizophrenia and 
four families where one or more family members had neuropsychiatric features including 
learning or behavioural difficulties, history of fits and schizophrenia. The authors found that 
these families had different types of mutations and concluded that although neuropsychiatric 
features in individuals with DD did not appear to be associated with certain types of 
mutations they could be an intrinsic, but inconsistent consequence of mutations within the 
ATP2A2 gene.
One limitation of the studies not finding associations between mutations in ATP2A2 and 
the presence of neuropsychiatric features in individuals with DD is that neuropsychiatric
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diagnoses were made based on questions regarding general medical history and treatment 
rather than on systematic and standardised assessment by a trained researcher. In addition, 
investigations of genotype-phenotype correlations were carried out in studies with small 
sample sizes.
Site-directed mutagenesis studies have also provided support for mutations in ATP2A2 
having pleiotropic effects in the skin and brain by highlighting that specific mutations may be 
associated with the presence of neuropsychiatric features. Sato et al. (2004) found a unique 
missense mutation (L321F) in the stalk 4 (S4) domain which led to a SERCA2b protein with 
markedly reduced sensitivity to feedback inhibition by ER Ca2+. This mutation was found in a 
female and her daughter both with severe DD who both also had severe neuropsychiatric 
disorders and behaviour problems. The authors suggested that this mutation could be having 
pleiotropic effects in the skin and brain. A further mutation resulting in reduced sensitivity to 
ER lumenal Ca2+, located in the M8 to M9 cytosolic loop (S920Y), was reported by Dode et 
al. (2003). Interestingly, this mutation has been reported in a family with moderate to severe 
DD and a member with neuropsychiatric problems which included epilepsy and low-normal 
IQ (Jacobsen et al., 1999; Sakuntabhai et a l, 1999a). Ahn et al. (2003) suggest that the 
finding that certain mutations in A TP2A2 result in SERCA2b pumps that can interact with and 
reduce the activity of the wild-type protein, could account for both the variable clinical 
features observed in individuals with DD and the presence of neuropsychiatric features.
Of the 143 DD causing mutations in ATP 2A2 reported in the literature to date, 
approximately one quarter have been reported in individuals who have additional 
neuropsychiatric features. At present, no clear relationship has emerged between presence of 
neuropsychiatric features and the type and/or location of mutations in ATP2A2. This in part 
may be due to small sample sizes and the lack of detailed information reported regarding the 
neuropsychiatric phenotypes and/or how this information has been collected. Previous case
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series studies of DD have been undertaken by dermatologists untrained in psychiatric 
assessment and the presence of neuropsychiatric features has been based on recording general 
medical history and treatment.
6.5 Further Aims of the Thesis
In addition to investigating the prevalence of neuropsychiatric features in 100 individuals 
with DD (described and discussed in Chapters 3 to 5) a further aim of the thesis was to carry 
out investigations into the relationship between mutations detected in ATP2A2 and the 
neuropsychiatric phenotypes observed. The observation of relationships between the type 
and/or location of mutations in A TP2A2 and the presence and/or severity of specific 
neuropsychiatric phenotypes would provide strong evidence that mutations in ATP2A2 have 
pleiotropic effects in the skin and brain. The advantages of the current study compared to 
previous studies are that genotype-phenotype correlations were assessed in a larger sample of 
individuals and the neuropsychiatric features were assessed in detail systematically using 
standardised measures.
A further aim of the current study was to compare the clinical and neuropsychiatric 
features in individuals in whom a DD causing mutation was and was not detected. Differences 
between the two groups could suggest that a proportion of individuals in the sample have a 
skin condition with very similar clinical features to DD caused by factors other than a 
pathogenic mutation in ATP2A2.
The following chapter (Chapter 7) describes methods used to investigate genotype- 
phenotype correlations in a large sample of unrelated individuals with DD.
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7 GENOTYPE-PHENOTYPE CORRELATIONS BETWEEN 
MUTATIONS DETECTED IN ATP2A2 AND 
NEUROPSYCHIATRIC PHENOTYPES: METHODS
This chapter describes the methods used to investigate correlations between the type 
and/or locations of pathogenic mutations detected in the ATP2A2 gene and the 
neuropsychiatric phenotypes observed in a sample of unrelated individuals with DD. The 
collection of DNA samples is described followed by the techniques and processes involved in 
DNA extraction (carried out by two members of the psychiatric genetics laboratories at 
Birmingham and Cardiff Universities) and the detection of variants in the ATP2A2 gene 
(carried out by the laboratory at the Wales Gene Park). The subsequent analysis I carried out 
on the Gene Park data is then described. This included the identification of pathogenic 
mutations vAftim.ATP2A2 and comparison of these to the distribution of previously reported 
ATP2A2 mutations. The comparisons made between individuals in whom a pathogenic 
mutation was and was not detected are then described. Finally, the approaches to investigating 
possible genotype-phenotype correlations between the type and location of the pathogenic 
mutations detected within A TP2A2 and the neuropsychiatric phenotypes observed in 
individuals with DD are described. Additional information relating to this chapter can be 
found in section C of the Appendix starting at pg. 313, and will be referenced throughout the 
chapter.
7.1 DNA Collection and Extraction
7.1.1 DNA Collection
Venous whole blood samples or Oragene™ (Genoteck Inc.) saliva samples were 
collected from 93 index individuals with DD. Samples were also obtained from 11 additional 
affected family members (from 11 separate families- including two cases where no DNA 
could be collected from the index individual) and 17 unaffected family members (from 17
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separate families). The frequencies of blood and saliva samples collected are summarised in 
Table 7.1.
Table 7.1 Frequencies of Blood and Saliva Samples Collected
Blood Samples Oragene Saliva 
Samples
Total
Index Individuals 88 5 93
Affected Family Members 8 3 11
Unaffected Family Members 8 9 17
Total 104 17 121
7.1.2 Known Pathogenic Mutations in ATP2A2
Pathogenic mutations in ATP2A2 were already known for eight of the index individuals 
with DD in the present study. This information was provided by Dr Susan Burge, the 
Consultant Dermatologist who was involved in the recruitment of research participants. DNA 
was collected again from seven of these individuals in the present study for quality control 
purposes (see section 7.3.3)
7.1.3 DNA Extraction
DNA extraction of the blood and saliva samples was carried out by Fiona Middle 
(Molecular Psychiatry Group Laboratory, Birmingham University) and Detelina Grozeva 
(Psychiatric Genetics Laboratory, Cardiff University). The DNA extraction protocols 
followed for the two types of samples are provided in Appendix C.i pg. 313.
7.2 Detection o f Variants in ATP2A2 - Wales Gene Park
The detection of variants in ATP2A2 was carried out by the Wales Gene Park 
(http://www.walesgenepark.co.uk). The Wales Gene Park is an enterprise set up to advance 
genetics research and technology in Wales. The gene park has close links with Cardiff 
University and has a genomic facility that offers services to researchers with large-scale 
genomic projects. Two plates of extracted DNA samples were sent to the Gene Park, prepared
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by Detelina Grozeva and Dr. Elaine Green. The following sections describe briefly the three 
sequential techniques carried out by the Wales Gene Park to detect variants in ATP2A2.
7.2.1 Polymerase Chain Reaction (PCR)
Polymerase Chain Reaction (PCR) is a method of selectively amplifying small target 
fragments of DNA (usually a few hundred base pairs in length). This technique produces 
multiple copies (millions) of small fragments of DNA (PCR products), which can then be 
used in subsequent techniques used to detect DNA variants.
The Wales Gene Park attempted to amplify all 21 exons of A TP2A2 by PCR. The gene 
was divided up into fragments according to the exons apart from exon 8, a large exon, which 
was cut into two fragments and two fragments each of which contained two small exons, 2&3 
and 12&13 respectively. No PCR products could be generated for exon 1 therefore variants 
in this exon could not be detected in the present study. A further small number of fragments 
failed PCR amplification in some samples (an average of 3.6% of fragments across the two 
plates, excluding exon 1) although no more than four fragments failed in an individual 
sample.
7.2.2 Denaturing High Performance Liquid Chromatography (DHPLC) 
Analysis
Denaturing High Performance Liquid Chromatography (DHPLC) is a screening 
technique used to identify fragments of DNA that are likely to contain sequence variants. The 
first process in this technique involves heating double-stranded PCR products causing them to 
be denatured into single strands that are then slowly cooled allowing them to re-anneal into 
double-stranded products. A basic principle behind the technique is that if an individual has 
one normal allele and one variant-containing allele at a gene locus, the single strands of DNA 
re-anneal to form both homoduplexes and heteroduplexes, shown in Figure 7.1.
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Double Stranded PCR 
Products
Normal Variant - Heteroduplexes Homoduplexes
Wild-Type Containing (double-stranded (complementary
Allele Allele DNA containing 
mismatched bases)
matched bases)
Heat
Cool 
 ►
A T  G C  AC GT A T  G C
Individual in this case is heterozygous - has one normal allele containing the base A (and its 
paired base T) and one variant-containing allele which contains the base G (and its paired 
base C) at the same site. Heating and then cooling the double-stranded DNA leads to the 
formation of both homoduplexes (double-stranded DNA containing matched paired bases) 
and heteroduplexes (double stranded-DNA containing mismatched paired bases).
PCR; polymerase chain reaction.
Figure 7.1 Example of the Form ation of Heteroduplexes in an Individual Containing a DNA 
V ariant
Double-stranded homoduplexes have complementary sequences forming matched bases 
(i.e. A-T and G-C) whereas heteroduplexes have mismatched bases (i.e. A-C and G-T). Due 
to the mismatched bases, heteroduplexes are not as stable to heat as homoduplexes and 
denature at a lower temperature. DHPLC analysis involves heating the homoduplexes and 
heteroduplexes at a specified temperature, heteroduplexes, which will denature more 
completely, can then be distinguished from homoduplexes using high performance liquid 
chromatography. Therefore the DHPLC screening technique detects heteroduplexes in PCR 
products indicating the likely presence of a DNA variant. PCR products showing 
heteroduplexes can then be sequenced to identify the variant, described below. In the present 
study, excluding exon 1,96.4% (100-3.6% PCR amplification fails) of the DNA length of the 
ATP2A2 gene was successfully screened for DNA variants using DHPLC analysis.
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7.2.3 DNA Sequencing
Sequencing is the final stage of detecting DNA variants and involves identifying the 
complete DNA sequence in a fragment of DNA. Automated sequencing was carried out using 
an ABI 3100 automated sequencer. This is based upon Sanger dideoxynucleotide sequencing, 
with the four ddNTPs being labelled with four different fluorophors. Each fluorophor has a 
different emission wavelength when excited by the laser in the ABI 3100. The relative size of 
each terminated sequencing product is then determined by electrophoresis. Sequences are then 
compared to the known established human gene sequence in order to detect variants. It is 
expensive and labour intensive to sequence all fragments of a gene in a large number of 
individuals therefore sequencing is only carried out on PCR fragments showing 
heteroduplexes during DHPLC analysis i.e. fragments that have been identified as being 
likely to contain a DNA variant.
7.3 Further Mutational Analysis on Data Obtained From the Gene 
Wales Park
The Wales Gene Park provided a report listing the variants identified in ATP2A2 and the 
samples/individuals in whom they were detected, an example o f the format o f the data is 
shown in Table 7.2. Information was also provided indicating the small number o f fragments 
that failed PCR amplification and the samples/individuals in whom these fails occurred, an 
example of the format of these data is provided in Table 7.3.
Table 7.2 Format of Wales Gene Park Data Reporting Variants Detected in ATP2A2
Mutation ID Fragment Mutation (AA) Region SNP seq Sample
167 A>G X2 3 Q56R Coding GCTGGAACTTGTGATTGAGC R 13
219+179G>T X2 3 Intronic CAAAACACTTGAAGCCATTG K 27
1 0 0 0 0 T X8B R334. Stop CAAAGAAAAATGCCATTGTT Y 1 and 18
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Table 7.3 Form at of Wales Gene P ark  Data Reporting Fragments which Failed PCR 
Amplification
SAMPLE/INDIVIDUAL
FRAGMEN1
2 3 4 5 6 7 8A 8B 9 10 11 12 13 14 15 16 17 18 19 20A
1 F
2 F F
3 F
4 F F
PCR; Polymerase Chain Reaction, F; fragment failed PCR amplification.
The following sections describe the analyses I carried out on the data obtained from the 
Wales Gene Park. This firstly involved identifying which of the variants detected by the 
Wales Gene Park were likely to be pathogenic mutations.
7.3.1 Exclusion of Known Non-Pathogenic Polymorphisms
In order to identify which of the variants detected by the Wales Gene Park were likely to 
be pathogenic mutations it was important to initially identify and subsequently exclude any 
variants that were known non-pathogenic polymorphisms. All DNA variants identified by the 
Wales Gene Park were checked against a database of known single nucleotide polymorphisms 
(SNPs) in the human genome (http://www.ncbi.nlm.nih.gov/SNP/index.html). This database 
also contains known information on the population allele frequency of common 
polymorphisms. DNA variants were also checked against known non-pathogenic 
polymorphisms in ATP2A2 previously reported in the literature.
7.3.2 Identification of Pathogenic Mutations
After excluding any non-pathogenic polymorphisms it was necessary to decide which of 
the remaining variants were likely to be pathogenic mutations. This was achieved by ranking 
the variants according to how likely they were to be pathogenic. Mutations were ranked into 
nine categories ranging from the mutation types thought to be most likely to be causing DD to 
variants thought to be least likely to be causing DD, shown in Table 7.4. In order to decide
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whether each of the non-synonymous amino acid changes (missense mutations) detected were 
likely to be conservative or non-conservative, a program SIFT (Sorting Intolerant From 
Tolerant- website http://blocks.fhcrc.org/sifl/SIFT.html) was used. This is a sequence- 
homology-based programme that predicts whether an amino acid change will affect protein 
function. The program predicts the impact of all possible 20 amino acid changes at each 
amino acid position in a protein. Amino acid changes are predicted as being either not 
tolerated i.e. non-conservative and likely to affect protein function or tolerated i.e. 
conservative and not likely to affect protein function. An example of the SIFT program output 
is shown in Table 7.5.
A cut-off was decided above which mutations were thought to be highly likely to be 
pathogenic and below which mutations were thought to be less likely to be pathogenic. 
Mutation types already reported in the literature as being pathogenic mutations down to and 
including splice-site mutations were thought to be highly likely to be pathogenic. The three 
remaining mutation types, including conservative non-synonymous amino acid changes, 
synonymous amino acid changes (silent mutations) and intronic mutations were thought to be 
less likely to be pathogenic and were not included in any of the subsequent analyses.
Table 7.4 Ranking DNA V ariants Detected in ATP2A2
Rank Mutation Type
1 Reported in literature as a pathogenic mutation
2 Large insertion/deletions
3 Nonsense or Frameshift
4 Non-synonymous amino acid change (Missense): Non conservative
5 In-frame insertion/deletion
6 Splice site
7 Non-synonymous amino acid change (Missense): Conservative
8 Synonymous amino acid change (Silent)
9 Intronic
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Table 7.5 Example of SOFT Program Output
Predict Not Tolerated
Amino
Acid
Position
Predict Tolerated
d h g n e c s w r k y p q t a f v i 1M L M
c w f m i y  1 v h r g t n p a k S 2E D Q  E
3N w c m p  i g H f  v R Q L s Y k e T N A D
SIFT; Sorting Intolerant From Tolerant.
Example output predicts the impact of all possible 20 amino acid changes at three amino acid positions in a 
protein e.g. at position 1 of the protein, the amino acid change MIL is predicted as being tolerated, whereas the 
change Ml V is predicted as not being tolerated.
7.3.3 Quality Control
It was important to check the quality of the data regarding the detection of DNA variants 
wiJhin ATP2A2 and the subsequent identification of pathogenic mutations. This was carried 
out in a number of ways including:
• Comparing the frequencies of polymorphisms detected in the present study to the 
previously reported frequencies of these polymorphisms - it would be expected that 
the frequencies should be similar.
• Confirming that the pathogenic mutations already known for a small number of 
individuals in the study via Dr Susan Burge were identified in the same individuals in 
the current mutation detection.
• Confirming that, where DNA samples were collected from an index individual and an 
affected family member, the pathogenic mutation identified in the index individual 
was also detected in the affected family member.
• Confirming that, where DNA samples were collected from an index and an unaffected 
family member, the pathogenic mutation identified in the index individual was not 
detected in the unaffected family member.
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7.3.4 Comparison of Type and Location of Mutations Detected Compared 
to Previously Reported Mutations in ATP2A2
The type and location of the pathogenic mutations detected in the present sample were 
compared to the distribution of ATP2A2 mutations previously reported in the literature. The 
main purpose of this comparison was to ensure that the distribution of the pathogenic 
mutations detected in the present study was roughly similar to the distribution of previously 
reported mutations and therefore a representative sample of mutations.
7.4 Comparison o f the Clinical Features of DD and
Neuropsychiatric Phenotype In Individuals in whom a 
Pathogenic Mutation was and was not Detected
Before investigations into genotype-phenotype correlations were carried out, comparisons 
were made between index individuals with DD in whom a pathogenic mutation was and was 
not detected. Individuals in the two groups were compared on a number of clinical features of 
DD and neuropsychiatric features, summarised in Table 7.6. These have all previously been 
described in Chapter 3.
Table 7.6 Clinical Features of DD and Neuropsychiatric Features Compared in Individuals with 
DD in whom a Pathogenic M utation was and was not Detected
Clinical Features of DD_______________________________________________________________
Positive Family History of DD___________________________________________________
DD Severity_________________________________________________________________
DLQI -Worst Week Ever_______________________________________________________
Neuropsychiatric Phenotypes__________________________________________________________
Lifetime DSM-IV Diagnosis_____________________________________________________
BADDS Mania Dimension______________________________________________________
BADDS Depression Dimension__________________________________________________
Histoiy of Suicide Attempts_____________________________________________________
Contact with Psychiatric Services_________________________________________________
Histoiy of Learning Difficulties__________________________________________________
Investigations for Blackouts, Loss of Consciousness or Fainting Episodes___________________
DLQI; Dermatology Life Quality (described previously in Section 3.2.2.5 pg. 38), BADDS; Bipolar Affective 
Disorder Dimensional Scale (described previously in Section 3.2.5 pg. 42).
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7.5 Investigations o f Genotype-Phenotype Correlations
The following sections describe the approaches carried out to investigate possible 
genotype-phenotype correlations between the type and location of the pathogenic mutations 
detected within ATP2A2 and the neuropsychiatric phenotypes observed in individuals with 
DD. The neuropsychiatric phenotypes used in the genotype-phenotype correlation 
investigations are summarised in Table 7.7.
Table 7.7 Neuropsychiatric Phenotypes used in Genotype-Phenotype Correlation Investigations
Neuropsychiatric Phenotype Further Details
BADDS Mania Dimension Score from 0-100 reflecting the lifetime presence 
and severity of manic symptoms.
BADDS Depression Dimension Score from 0-100 reflecting the lifetime presence 
and severity of depressive symptoms.
Age of onset of psychiatric Illness Age of onset of any psychiatric illness causing 
impairment (years).
Any Lifetime DSM-IV Diagnosis Lifetime histoiy of any DSM-IV psychiatric 
disorder (yes or no).
Histoiy of Suicide Attempts Lifetime history of suicide attempts (yes or no).
History of Psychiatric Contact Lifetime histoiy of contact with secondary 
psychiatric services (yes or no).
Learning Difficulties Lifetime history of learning difficulties defined as 
having a diagnosis of dyslexia and/or receiving 
extra help at school and/or scoring 9 or more YES 
responses on the Adult Dyslexia Checklist, (yes 
or no).
Investigations for Blackouts, Loss of 
Consciousness or Fainting Episodes
Lifetime history of investigations for blackouts, 
loss of consciousness or fainting episodes (yes or 
no).
Personal History of Bipolar Disorder and/or 1st 
Degree Relatives with DD and Bipolar Disorder
The small number of index individuals with 
bipolar disorder would make genotype-phenotype 
correlation investigations uninterpretable. 
Therefore this phenotype was extended to include 
individuals with a 1st degree relative with DD and 
bipolar disorder.
Diagnosis of Epilepsy and/or 1st Degree Relatives 
with DD and a Diagnosis of Epilepsy
The small number of index individuals with 
epilepsy would make genotype-phenotype 
correlation investigations uninterpretable. 
Therefore this phenotype was extended to include 
individuals with a 1* degree relative with DD and 
epilepsy.
BADDS; Bipolar Affective Disorder Dimension Scale, DSM-IV; Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition.
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7.5.1 Schematic Diagram of the SERCA2b Protein
The pathogenic mutations identified in the present study were mapped onto schematic 
diagrams of the SERCA2b protein. The structure of the protein and its functional domains 
were based on the schematic diagram of the protein published by (Dode et al., 2003) and the 
domain structure of the protein provided by the Swiss-Prot Protein Database, a biological 
database of protein sequences (http:www.expasy.org). In each diagram the mutations were 
highlighted according to the absence or presence of a specific neuropsychiatric phenotype. In 
the case of the BADDS Mania score, this was converted into a categorical variable by 
highlighting mutations where individuals had BADDS mania scores greater or equal to 10 as 
a marker of mood bipolarity. The aim of this approach was to investigate whether clustering 
of mutations within the SERCA2b protein could be observed for any specific neuropsychiatric 
phenotype.
7.5.2 Mutation Type
As described in Chapter 6, different types of mutations are likely to have varying degrees 
of impact on protein structure and function. Therefore, the neuropsychiatric phenotypes of 
individuals with frameshift, in-frame (insertion and deletions), missense, nonsense, other 
(large insertions and deletions) and splice-site mutations were compared.
7.5.3 Mutation Location within Functional Domains of SERCA2b
As described in Chapter 6, the SERCA2 protein contains three cytoplasmic domains: 
Actuator (A), Nucleotide ATP-binding (N) and Phosphorylation (P) as well as 11 
transmembrane domains (Ml-Ml 1). The seven essential Ca -binding amino acids are located 
within four of the transmembrane domains (M4, M5, M6 and M8). The transmembrane 
regions M4 and M5 are connected to the stalk regions S4 and S5 respectively (see Figure 6.1 
pg. 137). It is possible that mutations within the S4 and S5 regions could have an impact on
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the Ca -binding functioning of the M4 and M5 transmembrane regions. Therefore, in the 
present analysis, the stalk regions S4 and S5 were included as part of the collective Ca2+- 
binding domains. The neuropsychiatric phenotypes of individuals with mutations in the A, N,
i
P and Ca -binding domains respectively were compared to the neuropsychiatric phenotypes 
of individuals not having mutations in these domains.
7.5.4 Mutation Location within ATP2A2
It is likely that the location of a mutation within a gene will influence the extent to which 
it has an impact on protein structure and function. For example, mutations at the beginning of 
a gene are more likely to have a detrimental impact than those occurring towards the end. 
However, as discussed in the previous chapter, investigations of genotype-phenotype 
correlations in 19 individuals with DD conducted by Jacobsen et a l (1999) found mutations 
among individuals with DD and neuropsychiatric features clustered in the last third of the 
gene. Therefore in the current study, the neuropsychiatric phenotypes of individuals with 
mutations located in the first third, middle third and last third of ATP2A2 were compared. The 
three sections were determined by dividing the total number of nucleotide bases within the 
ATP2A2 gene (3126) into three.
7.6 Statistical Analysis
Data were extracted from the study Access database into the statistical package SPSS 
version 12.0.1 (SPSS Inc., 2003). Normality of the data was assessed using the Kolmogorov- 
Smimov Test. The majority of the data were not normally distributed so non-parametric 
statistical tests were used, outlined below. Statistical tests were considered significant at the 
p<0.05 level, (two tailed).
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Continuous data:
• Differences between two groups were assessed using Mann-Whitney U tests.
• Differences between 3+ groups were assessed using Kruskal-Wallis Analysis of 
Variance. If a significant difference was found post hoc comparisons were 
performed on each pair of groups using Mann-Whitney U tests.
Categorical data
• Relationships between two categorical variables were assessed using 2x2 and 2x3 chi- 
square tests. In cases where 20% or more of the cells in a chi-square table had an 
expected count of less than five, Fisher’s Exact tests (2x2 tables) and exact 
significance tests for Pearson’s chi-square (2x3 tables) were used. For 2x3 chi-square 
tables, if a significant relationship was found post hoc comparisons were performed on 
each pair of variables using 2x2 chi-square tests.
Due to the modest size of the sample and limited power, corrections were not routinely made 
for multiple testing. Therefore, any significant findings were treated with caution and an 
emphasis was placed on looking for trends firstly, between the prevalence of neuropsychiatric 
features amongst individuals in whom a pathogenic mutation was and was not detected and 
secondly, between the neuropsychiatric phenotypes of individuals with specific mutation 
types and/or with mutations located in specific locations of the ATP2A2 gene.
The following chapter (Chapter 8) reports the results of the investigations carried out into 
the relationship between mutations detected in ATP2A2 and the neuropsychiatric phenotypes 
observed in individuals with DD.
8 GENOTYPE-PHENOTYPE CORRELATIONS BETWEEN 
MUTATIONS DETECTED IN ATP2A2 AND 
NEUROPSYCHIATRIC PHENOTYPES: RESULTS
This chapter reports investigations carried out into the relationship between mutations 
detected in ATP2A2 and the neuropsychiatric phenotypes observed in individuals with DD. First, 
the detection of non-pathogenic polymorphisms and pathogenic mutations in the sample is 
described. The type and location of mutations detected are then compared to the distribution of 
ATP2A2 mutations previously reported in the literature. This is followed by a comparison of the 
clinical features of DD and neuropsychiatric phenotypes in individuals in whom a pathogenic 
mutation was and was not detected. Finally, genotype-phenotype correlations between the type 
and location of the pathogenic mutations detected and the neuropsychiatric phenotypes observed 
are investigated. Additional information relating to this chapter can be found in section D of the 
Appendix starting at pg. 316, and will be referenced throughout the chapter.
8.1 Mutation Detection in Index Individuals with DD
93 unrelated index individuals with DD, 11 additional affected and 17 unaffected family 
members were screened for variants in 20 of the 21 exons of ATP2A2 including intron-exon 
boundaries (described in Chapter 7 section 7.2 pg. 146). As no PCR product could be generated 
for exon 1, this exon was not screened.
8.1.1 Frequencies of Non-Pathogenic Polymorphisms
The frequencies and percentages of previously reported non-pathogenic polymorphisms 
detected in the present sample are summarised in Table 8.1. One silent polymorphism in exon 15 
(A724A) was detected in 10 index individuals (11%), 2 affected family members (18%) and one
158
unaffected individual (6%). A further silent polymorphism in exon 15 (S765S) was identified in 
one index individual. The most common polymorphism located in intron 18 was detected in 34 of 
the 93 index individuals (37%), 3 affected individuals (27%) and 5 unaffected individuals (29%). 
The frequencies of this polymorphism in the present study are broadly consistent with the 
previously reported frequency of this polymorphism (16%).
Table 8.1 Frequencies of Previously Reported Non-Pathogenic Polymorphisms
Polymorphism
Sample Type 2172G—A 2295G— A 2741+54G—A
Exon 15 Exon 15 Intron 18
A724A S765S
N % N % N %
Index (n=93) 10 11 1 1 34 37
Affected (n=ll) 2 18 0 0 3 27
Unaffected (n=17) 1 6 0 0 5 29
8.1.2 Quality Control
Pathogenic mutations causing DD were already known for seven individuals in the present 
sample. Four of these mutations were detected in the same individuals in the current mutation 
detection. The three other mutations that were not detected were either located in exon 1, for 
which no PCR product could be generated or were located in a DNA fragment which failed PCR 
amplification in those particular individuals (as described in section 7.2.1 pg. 147). Eighteen 
variants detected in the current sample had previously been reported in the literature, including 
the four mutations mentioned above.
In the case of 12 index individuals, a variant was detected that was not detected in their 
unaffected relative without DD. In five cases a variant was not detected in either the index 
individual or their unaffected relative. Seven variants detected in seven index individuals were 
also detected in an affected relative. There was one case where a variant was detected in an index
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individual but not their affected relative. In this case the DNA fragment in which the variant was 
detected failed PCR amplification in the affected relative. In one case a DNA variant that was not 
detected in an index individual was detected in their affected relative, this is discussed later in the 
chapter. In four families, a variant was detected in an index and affected relative but not in an 
unaffected relative. These figures are summarised in Table 8.2
Table 8.2 Quality Control
N
Variant detected in index with DD that was not detected in 
their unaffected relative
12
Variant not detected in index or unaffected relative 5
Variant detected in index and an affected relative 7
Variant detected in index but not detected in affected 
relative
1
Variant detected in affected but not index 1
Variant detected in an index and affected but not in an 
unaffected relative
4
8.1.3 Identification of Pathogenic Mutations
For 66 index individuals a DNA variant that could be causing DD was detected. Five of these 
variants were identified in more than one individual. In total, 59 possible DD causing variants 
were detected in 66 individuals, reported in Table 8.3. In the case of six individuals, more than 
one variant was identified. In all cases, one variant was selected as the variant most likely to be 
causing DD in that individual. The variants not selected are listed at the end of the table. An 
intronic variant was identified in an individual who also had a large 86 base pair deletion in exon 
10 (Mutation ID 23), the latter was selected as the variant most likely to be causing DD. A 
missense mutation in exon 12 was identified in an individual with an in-frame deletion of one 
amino acid in exon 13 (Mutation ID 28). The latter mutation was also detected in an affected 
relative from the same family and was therefore selected as the mutation most likely to be 
causing DD in that family. Two mutations detected in the 3’ untranslated region were identified
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in 4 individuals in whom a DNA variation was also detected in the coding region of the gene. In 
all cases, the mutations detected in the coding region were selected as the mutations most likely 
to be causing DD (Mutation IDs 13,44, 50, 52).
Additional mutation information was known for seven index individuals, also summarised in 
Table 8.3. In two cases, no DNA could be collected from the index individuals, but another 
family member with DD provided a DNA sample. In these cases the mutation information from 
the affected relative has been used for the index individual (ID 21 and ID 38). A pathogenic 
mutation was already known for three individuals, although these mutations were not detected in 
the current screen (ID 59,62 and 63). In all three cases, the known pathogenic mutations were 
either in exon 1, for which no PCR product could be generated, (ID 62), or were in a DNA 
fragment in which failed PCR amplification in those particular individuals (ID 63 and 59). One of 
these mutations (ID 59) was also identified in another unrelated index individual. A further 
mutation was known for an individual from whom a DNA sample was not collected (ID 65). A 
frameshift variant in exon 13 was detected in the affected relative of an index individual, but not 
in the index individual (Mutation ID 64). However, PCR amplification of the fragment of DNA 
containing the variant did not fail in the index individual. One explanation for this could be that 
there was a further pathogenic variant not detected in either the index individual or affected 
relative causing DD in this family. However, the variant detected in the affected relative was a 
frameshift variant in a functional location (N domain) of the SERCA2 protein and therefore 
likely to be a pathogenic variant. There are no previous reports of more than one pathogenic 
variant in ATP2A2 being detected in individuals with DD. A further explanation could be that the 
frameshift mutation was not detected in the index individual in the current mutation detection 
process. As this explanation is more likely the variant was included in the following analyses.
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Table 8.3 Possible DD Causing DNA Variants Detected in ATP2A2
ID
Nucleotide
Change Exon/lntron
Amino
Acid
Change Type
SERCA2b Protein 
Domain 
(See Figure 8.1)
Number of 
individuals
1 137-3 OG Intron 2 Splice site SI 1
2 142 ins 18bp Exon 3 Large Insertion SI 1
3 167 A>G Exon 3 Q56R Missense Ml 1
4 194 T>C Exon 3 L 65 S Missense Ml 1
5 219+5 insert AA Intron 3 Intronic Ml-M2 lumenal 1
6 325-2 A>G Intron 4 Splice site M2 1
7 464-2 A>C Intron 5 Splice site A 1
8 490 A>G Exon 6 R164G Missense A 1
9 543delA Exon 6 Frameshift Deletion A 1
10 698 G>T Exon 8 G233V Missense A 1
11
826 15bp del Exon 8
IGHFN
del In-frame Deletion
M3-M4 lumenal
1
12 923 O A Exon 8 P308H Missense M4 1
13 925 G>A Exon 8 E309K Missense M4 1
14 929 G>T Exon 8 G310V Missense M4 1
15 948 del C Exon 8 Frameshift Deletion S4 1
16 949 7bp del Exon 8 Frameshift Deletion S4 1
17 958 G>C Exon 8 A320P Missense S4 1
18 10000T Exon 8 R334X Nonsense P
19 1043T>C Exon 8 I348T Missense P 1
20 1070 O G Exon 8 T357R Missense P 1
21 10700A Exon 8 T 357 K Missense P ]*
22 1095+1 G>C Exon 8 Splice site N 1
23 1228 del 86 bp Exon 10 Large Deletion N 1
24 1321A>C Exon 11 T 441 P Missense N 1
25 1413 O A Exon 11 C471X Nonsense N 1
26 1484 O T Exon 12 S495L Missense N
27 1508 delC Exon 12 Frameshift Deletion N 1
28 1628 del AGA Exon 13 Del K543 In-frame Deletion N 1
29 1713 del AA Exon 13 Frameshift Deletion N 1
30 1762-1 G>C Intron 13 Splice site N 1
31 1919 Ins T Exon 14 Frameshift Insertion P 1
32 2017 del C Exon 14 Frameshift Deletion P 1
33 2046 Ins C Exon 14 Frameshift Insertion P 1
34 2048 A>T Exon 14 K683M Missense P 1
35 2098-2 A>C Intron 14 Splice site P 1
36 2104G>A Exon 15 D 702 N Missense P 1
37 2116 G>A Exon 15 D706N Missense P
38 21230A Exon 15 P 708 H Missense P 1*
39 2249 G>A Exon 15 R750Q Missense S5 1
40 2287 OG Exon 15 L763V Missense M5 1
41 2294 O T Exon 15 S765L Missense M5
42 2300 A>G Exon 15 N767S Missense M5
43 2317 T>C Exon 15 C773R Missense M5 1
44 2319-1 G>A Intron 15 Splice site M5 1
45 2384 A>G Exon 16 N795S Missense M6 1
46 2405 O G Exon 16 P802R Missense M6 1
47 2406OT Exon 16 P 802 P Silent M6 1
48 2417 T>G Exon 16 L806R Missense M6 1
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Table 83 Continued.
ID
Nucleotide
Change Exon/lntron
Amino
Acid
Change Type
SERCA2b Protein 
Domain 
(See Figure 8.1)
Number of 
individuals
49 2527 G>T Exon 17 V843F Missense M7 1
50 2584 Ins G Exon 17 Frameshift Insertion M7-M8 1
51 2620 O T Exon 18 Q874X Nonsense M7-M8 1
52 2678dupC Exon 18 2678dupC Frameshift Insertion M7-M8 1
53 2684 O T Exon 18 P895L Missense M7-M8 1
54
2709 del 6bp Exon 18
Del V904 
and T905 In-frame Deletion
M8
1
55 2730 Ins C Exon 18 Frameshift Insertion M8 1
56 2741+1G>T Intron 18 Splice site M8 1
57 2741+5 G>C Intron 18 Intronic M8 1
58 2741+74 G>T Intron 18 Intronic M8 1
59 2759 O A Exon 19 S920Y Missense M8-M9 1 + 1*
60 2759 O T Exon 19 S920F Missense M8-M9 1
61 27770G Exon 19 P926R Missense M8-M9 1
62 1A>G Exon 1 M1V Missense N terminus 1*
63
1418delCA Exon 11
In-ftame exon (11) 
skipping
N domain
1*
64 1697dupA Exon 13 Frameshift Insertion N domain 1*
65 2258del3bp Exon 15 Del N755 In-frame Deletion S5 1*
Varia 
that ii
nts identified in indiv 
idividual
219+179 G>T
iduals with more thai 
Intron 3
n mutation - selected as the variant 1 
Intronic
east likely to be
M1-M2
lumenal
causing DD in 
1
1484 O T Exon 12 S495L Missense N 1
3126+238 A>G 3TJTR (20B) transl 3TJTR 1
3126+306 T>C 3TJTR (20B transl 3'UTR 3
Protein Domains: M« = transmembrane domains, Sn =stalk domains, A= Actuator Domain, P= Phosphorylation 
Domain, N= Nucleotide Binding Domain. * Mutation not detected in index individual in current mutation detection.
Figure 8.1 Schematic Diagram of Domains of SERCA2b Protein
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Including the mutation information known for the additional seven individuals, 65 
possible pathogenic DD causing variants were detected/known in 73 index individuals. In order 
to decide which of these variants were likely to be a pathogenic mutation, the variants were 
ranked in categories ranging from the mutation types most likely to be causing DD to variants 
less likely to be causing DD, shown in Table 8.4. Sixty of the 65 variants were ranked as likely to 
be pathogenic and the remaining five variants, including a non-synonymous amino acid change, a 
synonymous amino acid change and intronic variants were ranked as being less likely to be 
pathogenic.
In summary, 60 variants detected and/or known in 68 unrelated individuals were ranked 
as likely to be pathogenic. Genotype-phenotype correlations were carried out between the type 
and location of the pathogenic mutations detected and the neuropsychiatric phenotypes observed 
in these 68 individuals.
Table 8.4 Ranking of Possible DD Causing DNA Variants Detected in ATP2A2
Pathogenic Mutation Rank Mutation ID Total
1. Reported in literature as pathogenic 4 14 19 21 26 32 36 39 41 42 45 49 52 
53 59 62 63 65
18
2. Large insertion/deletions 2 23 2
3. Nonsense or Frameshift 9 15 16 18 25 27 29 31 33 50 51 55 64 13
4. Non-synonymous a.a change: Non 
conservative
(predicted as not tolerated with SIFT)
3 8 10 12 13 17 20 24 34 37 38 40 46 48 
60 61
16
5. In-frame insertion/deletion 11 28 54 3
6. Splice site 1 6 7 22 30 35 44 56 8
Mutations ranked as likely to be pathogenic —60
7. Non-synonymous a.a change: Conservative 
(predicted as tolerated with SIFT)
43 1
8. Synonymous a.a change (Silent) 47 1
9. Intronic 5 57 58 3
Mutations ranked as less likely to be pathogenic=5
SIFT; Sorting Intolerant From Tolerant, a.a; amino acid.
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8.2 Comparison of Type and Location of Mutations Detected 
Compared to Previously Reported Mutations in ATP2A2
This section compares the type and location of the 60 mutations detected/known in 68 
unrelated individuals in the present sample to the distribution of 143 ATP2A2 mutations 
previously reported in 175 unrelated individuals in the literature. Eighteen of the mutations 
detected/known in individuals in the present study had previously been reported in the literature. 
Therefore 42 novel pathogenic mutations in ATP2A2 were detected in the present study. The 
frequencies of mutations detected in the present sample were combined with mutations 
previously reported in the literature. Ten individuals in the present study whose mutations have 
previously been reported in the literature were counted only once. A total of 185 mutations in 
ATP2A2 have now been detected in 233 unrelated individuals with DD.
The frequencies and percentages of pathogenic mutations and individuals in the present 
study according to mutation type, ATP2A2 exon/intron mutation location and SERCA2 domain 
mutation location are summarised in Appendix D.i. pg 316 (Table D-l to D-6) where they are 
compared to the distribution of mutations and unrelated individuals previously reported in the 
literature. In all cases, the distribution of mutation types and locations were very similar to the 
distributions previously reported in the literature. The largest percentage difference in ATP2A2 
exon/intron mutation distribution was found in exon 8 , 20% of mutations in the present study 
were found in exon 8 compared to 10.5% previously reported in the literature and 19.1% of 
individuals in the present study had mutations in exon 8 compared to 10.9% of individuals in the 
literature (see Tables D-3 pg. 317 and D-4 pg. 318). Differences were also found in exon 1 (1.7% 
mutations in present study vs. 5% in literature and 1.5% of individuals vs. 7.4%). This was 
expected since no PCR product for this exon could be generated in the present study. One of the 
seven individuals in the present study with an already known pathogenic mutation had a mutation
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in exon 1. The largest percentage difference in SERCA2 domain mutation location was in the A 
domain (6.7% mutations vs. 21% and 5.9% individuals vs. 22.3%) (see Tables D-5 pg. 319 and 
D-6 pg. pg. 320). However, this difference would be expected as exon 1 is translated into part of 
the A domain.
8.3 Comparison of the Clinical Features of DD and Neuropsychiatric 
Phenotype in Individuals in whom a Pathogenic Mutation was and 
was not Detected/Known
This section compares the clinical features of DD and the neuropsychiatric phenotype in the 
68 individuals in whom a pathogenic mutation was detected /known to the 28 individuals where a 
pathogenic mutation was not detected/known. Four individuals from whom no DNA was 
collected and no mutation was known were not included in the following analyses. As 
highlighted in the previous section, 7.4% of individuals previously reported in the literature were 
found to have a mutation in Exon 1 for which no PCR product could be generated in the present 
study. One individual in the present sample was already known to have a pathogenic mutation in 
Exon 1 (Table 8.3 pg. 162). Therefore it would be expected that approximately six further 
individuals in the present sample would have a mutation in Exon 1. In addition, in 17 of the 28 
individuals in whom a pathogenic mutation was not detected, there were between one and three 
exon fragments for which no PCR product could be generated. Therefore one reason for a 
pathogenic mutation not being detected in individuals is that they had a pathogenic mutation in a 
fragment of DNA for which no PCR product could be generated. A further possibility is that for a 
subset of individuals, the clinical features similar to DD may be caused by factors other than a 
pathogenic mutation in ATP2A2 (i.e. individuals might be phenocopies of DD).
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8.3.1 Comparison of Clinical Features of DD
Comparisons of reported family history of DD, DD severity and Dermatology Life Quality 
Index (DLQI) worst week scores amongst individuals in whom a pathogenic mutation was and 
was not detected are shown in Appendix D.ii Table D-7 and D-8 pg. 321.The DLQI has been 
previously described in Chapter 3, section 3.2.2.5 pg. 38. Significantly more individuals in whom 
a pathogenic mutation was detected reported a definite or probable family history of DD (79% vs. 
57%; x 2 = 4 -4 6 5 , df=l, p=0.035). Within individuals in whom a pathogenic mutation was detected, 
18%, 72% and 10% were classified as having mild, moderate and severe DD respectively 
compared to 36%, 50% and 14% individuals in whom a pathogenic mutation was not detected. 
There was no significant relationship between a pathogenic mutation being identified and DD 
severity (x2 =4.571, df=2, p= 0.102). Individuals in whom a pathogenic mutation was and was not 
detected did not differ significantly in their median scores on the DLQI- worst week (15 vs. 15.5; 
U=849, n=95, p=0.467).
8.3.2 Comparison of Neuropsychiatric Features
Comparisons of positive lifetime DSM-IV diagnosis, lifetime history of suicide attempts, 
history of contact with psychiatric services, history of learning difficulties and history of 
investigations for blackouts, loss of consciousness or fainting episodes respectively amongst 
individuals in whom a pathogenic mutation was and was not detected are shown Appendix D.ii 
Table D-9 pg. 322 and summarised graphically in Figure 8.2 pg. 169. No significant relationships 
were found, although in all cases, there was a trend for the percentages of individuals to be higher 
amongst individuals in whom a pathogenic mutation was detected.
Comparisons of scores on the Bipolar Affective Disorder Dimensional Scale (BADDS) 
mania and depression dimensions and age of onset of psychiatric illness among individuals in
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whom a pathogenic mutation was and was not detected are shown in Table D-10 pg. 322. The 
BADDS has previously been described in Chapter 3, section 3.2.5 pg. 42. Individuals in whom a 
pathogenic mutation was detected had significantly higher median scores on the BADDS Mania 
Dimension (8 vs. 4; U=344.5, n=70, p=0.014) and non-significantly higher median scores on the 
BADDS depression dimension (54 vs. 45; U=148, n=45, p=0.132). The two groups did not 
significantly differ in their age of onset of psychiatric illness. The box plots in Figure 8.3 and 
Figure 8.4 represent the median, interquartile range and minimum and maximum scores on the 
BADDS mania and depression dimensions amongst individuals in whom a pathogenic mutation 
was and was not detected.
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Figure 8.2 Summary of the Neuropsychiatric Phenotype in Individuals in whom a Pathogenic Mutation was and was not Detected/Known
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Figure 8.4 BADDS Depression Dimension Scores among Individuals in whom a Pathogenic 
Mutation was and was not Detected
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8.3.3 Summary of Significant Relationships Between Individuals Having a 
Pathogenic Mutation Detected/Known and the Clinical Features of DD 
and Neuropsychiatric Phenotypes
A summary of the significant relationships between individuals having a pathogenic 
mutation detected/known and the clinical features of DD and neuropsychiatric phenotypes are 
summarised in Table 8.5.
Table 8.5 Significant Relationships between Individuals having a Pathogenic Mutation 
Detected/Known and the Clinical Features of DD and Neuropsychiatric Phenotypes
Significant Relationships with a Pathogenic Mutation 
Being Detected/Known
Clinical Features of DD
Family History of DD A significantly higher proportion of individuals in whom a 
pathogenic mutation was detected/known had a 
definite/probable family histoiy of DD compared to 
individuals in whom a pathogenic mutation was not 
detected/known
DD Severity -
DLQI -Worst Week Ever -
Neuropsychiatric Phenotypes
Lifetime DSM-IV Diagnosis -
History of Suicide Attempts -
Contact with Psychiatric Services *
History of Learning Difficulties -
Investigations for Blackouts, Loss of 
Consciousness or Fainting Episodes
-
BADDS Mania Dimension Individuals in whom a pathogenic mutation was 
detected/known had significantly higher scores in the 
BADDS Mania Dimension than individuals in whom a 
pathogenic mutation was not detected/known.
BADDS Depression Dimension -
Age of onset of psychiatric illness -
DLQI; Dermatology Life Quality, BADDS; Bipolar Affective Disorder Dimensional Scale.
* Relationship almost reached significance; a higher proportion of individuals in whom a pathogenic mutation 
was detected/known had a history of contact with psychiatric services compared to individuals in whom a 
pathogenic mutation was not detected/known (31% vs. 14%; p=0.085).
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8.4 Investigations o f Neuropsychiatric Genotype-Phenotype 
Correlations- Schematic Diagram o f SERCA2b
The neuropsychiatric phenotypes observed in the 68 individuals in whom a pathogenic 
mutation was detected/known are summarised in Table 8.6 pg. 173. Known neuropsychiatric 
features in individuals’ first-degree relatives with DD are also displayed in the table. The 
pathogenic mutations detected/known in the 68  individuals were mapped onto schematic 
diagrams of the SERCA2b protein and highlighted according to the presence of a specific 
neuropsychiatric phenotype. Two of these diagrams, highlighting the location of pathogenic 
mutations in individuals with a history of contact with psychiatric services and individuals with a 
personal history of bipolar disorder or first degree relative with DD and a histoiy of bipolar 
disorder, are shown below in Figure 8.5 pg. 177 and Figure 8.6 pg. 178 and the remainder are 
shown in Appendix D.iii pg 323 (Figures D-l to D-6). The numbering of the mutations 
corresponds to the ID numbers previously reported in Table 8.3 pg. 162. Mutations with the ID 
numbers 5,43,47,57 and 58 were not included in the diagrams as they were considered unlikely to 
be pathogenic (as discussed in section 8.1.3 pg. 160).
A summary of mutations detected within SERCA2b according to specific neuropsychiatric 
phenotypes is shown in Table 8.7 pg. 179 and observations of possible clustering of mutations are 
reported in Table 8.8 pg. 181.
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Table 8.6 Neuropsychiatric Features in 68 Individuals in whom a Pathogenic Mutation was Detected/Known and their First Degree 
Relatives with DD
Study ID ID** Neuropsychiatric Features (including DSM-IV Lifetime Main 
Diagnosis,
History of Suicide Attempts, Contact with Psychiatric Services, 
Learning Difficulties and Investigations for Blackouts, Loss of 
Consciousness or Fainting Episodes)
BADDS 
M Score
BADDS 
D Score
Neuropsychiatric Features 
in first-degree relatives with 
DD (n)
DAR36-1 1 Tonic clonic epilepsy, learning difficulties. - -
DAR91-1 2 Bipolar I Disorder*. Fit aged 10 months, CT and EEG investigations for 
periods of unconsciousness in late 20s.
81 50 Psychiatric treatment for 
depression and anxiety, 
possibly a bipolar illness (1)
DAR14-1 3 MDDR*, mild high mood after birth of children followed by episodes of 
depression.
30 64 ECT treatment for depression 
0)
DAR95-1 4 MDDR, learning difficulties. - 51 Mild form of epilepsy (1)
DAR75-1 6 - -
DAR81-2 7 Bipolar I Disorder*. 65 70 Depression and epilepsy (2), 
puerperal psychosis (1), 
depression (1)
DARI 1-1 8 MDDS*, learning difficulties. 8 60
DAR97-1 9 MDDR* - 53
DAR7-1 10 Depression NOS*, suicide attempt, diagnosis of dyslexia. - 39
DAR38-1 11 3 -
DAR6-1 12 Depression NOS. 11 -
DAR65-1 13 5 Bipolar Disorder (1) Seen by 
educational psychologist (1)
DAR3-1 14 17 - ***
DAR70-1 15 Unknown DSM-IV*, suicide attempt, cyclothymic personality, idiopathic 
epilepsy.
- •
DAR55-1 16 MDDR*, suicide attempt, extensive psychiatric histoiy, diagnosis of 
somatoform disorder. Brain scan to investigate a blackout.
16 74 Treated by psychiatrist for 
depression (1)
DAR43-1 17 1 Psychiatric hospital treatment 
for depression (1)
DARI-1 18a 1
DAR21-1 18b Unknown DSM-IV. 17
DAR77-1 19 -
DARIO-1 20 4
DAR76-1 21 MDDR, learning difficulties. “ 51
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Table 8.6 Continued
Study ID ID** Neuropsychiatric Features (including DSM-IV Lifetime Main 
Diagnosis,
History of Suicide Attempts, Contact with Psychiatric Services, 
Learning Difficulties and Investigations for Blackouts, Loss of 
Consciousness or Fainting Episodes)
BADDS 
M Score
BADDS 
DScore
Neuropsychiatric Features 
in first-degree relatives with 
DD(n)
DAR27-1 22 MDDR, possible symptoms of mania after birth of first child, query of 
epileptic fit in GP notes, learning difficulties.
17 41 Treated by psychiatrist for 
depression (1)
DAR30-1 23 MDDR*, suicide attempt, extensive psychiatric history, learning difficulties. - 69 Schizophrenia (1)
DAR99-1 24 EEG and CT scans for fainting episodes. 5
DAR4-1 25 MDDR*, multiple suicide attempts, extensive psychiatric history, brain scan 
investigations for blackouts, learning difficulties.
17 72
DAR39-1 26a MDDR, suicide attempt. - 65
DAR62-1 26b MDDS, chronic fatigue symptoms for 16 years. 9 50
DAR84-1 27 Panic Disorder Without Agoraphobia. 12 7
DAR51-2 28 5 Treated by psychiatrist for 
depression (1) psychiatric 
hospital treatment for 
depression (1)
DAR29-1 29 MDDR*. 0 61
DAR56-1 30 Unknown DSM-IV*. 6 - Treated by psychiatrist for 
depression (1)
DAR60-1 31 3 -
DAR28-1 32 MDDR, CT scan for syncopal attacks. 15 62 Treated by psychiatrist for 
depression and multiple 
suicide attempts (2)
DAR61-1 33 Anxiety Disorder NOS, learning difficulties - bom with hole in the heart. - -
DAR92-1 34 Two-five blackouts, investigated with CT scan. 17 39
DAR88-1 35
DARI 03- 
1
36 Dysthymic Disorder*, learning difficulties. 17 39 Seen by educational 
psychologist and mental 
health services (1)
DAR85-1 37a MDDS*, suicide attempt, learning difficulties. 7 60
DAR44-1 37b 3 - No details-adopted
DAR86-1 38 2
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Table 8.6 Continued
Study ID ID** Neuropsychiatric Features (including DSM-TV Lifetime Main 
Diagnosis,
History of Suicide Attempts, Contact with Psychiatric Services, 
Learning Difficulties and Investigations for Blackouts, Loss of 
Consciousness or Fainting Episodes)
BADDS 
M Score
BADDS 
D Score
Neuropsychiatric Features 
in first-degree relatives with 
DD(n)
DAR40-1 39 MDDS, fainting episodes for over 30 years. 8 60
DAR79-1 40 Depression NOS. 16 39 Suicide attempt (1)
DAR8-1 41a 1
DAR26-1 41b 7
DAR72-1 42a MDDR*, brain scan to investigate blackouts. 15 63
DAR41-1 42b Depression NOS. - 41
DAR74-1 42c MDDR, paranoia not reaching delusional intensity. 70 Diagnosis of schizophrenia, 
depression and suicide 
attempt (1)
DAR50-1 42d Unknown DSM-IV, learning difficulties. 14 -
DAR24-1 44 Depression NOS, CT for headache and fainting episodes. 10 30 Treated by mental health 
services (1)
DAR89-1 45 Anxiety Disorder NOS. 0
DAR90-1 46 Bipolar I Disorder*, puerperal psychosis following the birth of only child. 70 10
DAR47-1 48 MDDR - 51
DAR52-1 49 MDDR*, suicide attempt, two week period of blackouts investigated by a 
neurologist and brain scans.
5 66
DAR78-1 50 - -
DARI 6-1 51 MDDR*, described in medical notes as having “a curious affect”, learning 
difficulties, labile mood at interview.
- 55
DAR98-1 52 MDDR. - -
DAR19-1 53 Depression NOS, suicide attempt. 5 19
DAR9-1 54 16 -
DAR94-1 55 Depression NOS. 2 -
DAR83-1 56 - -
DAR68-1 59a Learning difficulties. 13 Learning disability and 
epilepsy (1)
DAR5-1 59b Unknown DSM-IV*, learning difficulties. - Depression and suicide 
attempt (1)
DAR53-1 60 Depression NOS. 7 30
DAR64-1 61 Cyclothymic Disorder*, learning difficulties 17
DAR54-1 62 Learning difficulties. -
DARI 5-1 63 GP investigations for fainting episodes since childhood. 1 - Learning disabilities (1).
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Table 8.6 Continued
Study ID ID** Neuropsychiatric Features (including DSM-IV Lifetime Main 
Diagnosis,
History of Suicide Attempts, Contact with Psychiatric Services, 
Learning Difficulties and Investigations for Blackouts, Loss of 
Consciousness or Fainting Episodes)
BADDS 
M Score
BADDS 
D Score
Neuropsychiatric Features 
in first-degree relatives with 
DD(n)
DARI 8-1 64 Bipolar I Disorder*, suicide attempt, learning difficulties.
EEG and CT investigations following an episode of loss of consciousness.
90 95
DAR69-1 65 Learning Difficulties. 2 -
**ID numbers correspond to those previously reported in Table 8.4 pg. 162.
* Contact with psychiatric services.
***Mother was admitted to psychiatric hospital with ‘high mood’ although neither parent was reported to have DD.
BADDS; Bipolar Affective Disorder Dimensional Scale Mania (M) and Depression (D) Dimensions, MDDR; Major Depressive Disorder Recurrent 
Episodes, MDDS; Major Depressive Disorder Single Episode, NOS; Not Otherwise Specified
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Figure 8.5 Genotype-Phenotype Correlation: History of Contact with Psychiatric Services
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37b o P
38 o P
65 o S5
39 o S5 i
40 o M5
41a o M5
41b o M5
42a O M5
42b o M5
42c o M5
42d o M5
44 A M5 1
45 i o M6
46 1 o M6
48 o M6
49 o M7
50 + M7-M8
51 X M7-M8
52 + M7-M8
53 o M7-M8
54 A M8
55 + M8 *------------
56 A M8
59a O M8-M9
________
59b ° M8-M9
________
■
60 o M8-M9 '61 O M8-M9 m m
**ID numbers correspond to those previously reported in Table 8.4 pg 164.
Protein Domains: Mn = transmembrane domains, Sn =stalk domains, A= Actuator Domain, P= 
Phosphorylation Domain, N= Nucleotide Binding Domain.
Coloured cells indicate the presence of a specific neuropsychiatric phenotype.
*  Large insertion, *** Splice site, O Missense , +  Frameshift insertion, O  Frameshift deletion, A  In­
frame Deletion, x Nonsense, x  Large Deletion, f t  In-frame Exon Skipping.
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Table 8.8 Observations of Possible Clustering of Mutations within the SERCA2b Protein 
according to Specific Neuropsychiatric Phenotypes
Figure;
Page
number
Neuropsychiatric
Phenotype
Observations
Figure
8.5;177
Contact with
Psychiatric
Services
All four individuals with mutations in the ‘A’ domain had a history of contact 
with psychiatric services (ID 7,8,9,10).
Other observed clusters of history of contact with psychiatric services:
• Two individuals with missense mutations four a.a apart in the ‘P’ 
domain (ID 36 and 37a).
• Two individuals with frameshift mutations only one base pair apart in 
the S4 (Stalk 4) domain (ID 15 and 16).
• Two individuals with missense mutations 6 a.a. apart in the M8-M9 
cytosolic loop (ID 59b and 61).
• Three individuals with mutations located close together in the ‘ N’ 
domain (ID 64, ID 29 and ID 30).
Figure
8.6;178
Personal History 
of BPAD or Is* 
Degree Relative 
with DD with a 
History of BPAD
• An individual with a missense mutation at one of the seven Ca2+ 
binding sites within the M4 domain (ID 13) had a 1st degree relative 
with DD and Bipolar Disorder. An individual with a missense 
mutation (ID 14) at an adjacent amino acid, with a BADDS mania 
score of 17, also had a parent who had been treated in a psychiatric 
hospital for ‘high mood’ on two occasions although there was no 
reported history of DD in the family.
• A further individual with bipolar disorder had a missense mutation in 
the M5 domain close another Ca2+ binding site.
Figure
D-l;
323
BADDS Mania 
Score
• Two individuals with BADDS mania scores of 81 and 30 (ID 2 and 3) 
respectively both had mutations in the Ml domain.
• Four individuals with mutations in the M5 domain had a BADDS 
Mania Score equal to or greater than 10 (ID 40,42a, 42d and 44). Two 
of these individuals had the same missense mutation.
• Two individuals with missense mutations in the M8-M9 cytosolic 
loop (ID 59a and 61) had BADDS mania scores of 13 and 17 
respectively.
Figure
D-2;
324
History of Suicide 
Attempts
• Two individuals with frameshift mutations only one base pair apart in 
the S4 domain had a history of suicide attempts (ID 15 and 16).
Figure
D-3;
325
Lifetime DSM-IV 
Diagnosis
• Three individuals with the same missense mutation at one of the seven 
Ca2+ binding sites in the M5 domain (ID 42a, b and c) all had a DSM- 
IV diagnosis of a mood disorder. An individual with the same 
mutation (ID 42d) and an unknown DSM-IV diagnosis.
• Two individuals with the same missense mutation in the N domain (ID 
26 a and b) had a lifetime DSM-IV diagnosis of major depression.
Figure
D-4;
326
Learning
Difficulties
• Three individuals with missense mutations in the M8-M9 cytosolic 
loop were classified as having learning difficulties (ID 59a, 59b, 61). 
Two of these individuals had the same mutation (ID 59).
Figure
D-6;
328
Diagnosis of 
Epilepsy or 1** 
Degree Relative 
with DD and a 
Diagnosis of 
Epilepsy
• Two individuals with mutations in the SI and Ml domains had a 
personal diagnosis of epilepsy (ID 1) or first degree relative with a 
diagnosis of epilepsy (ID 4).
a.a; amino acid, BADDS; Bipolar Affective Disorder Dimension Scale.
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8.5 Investigations of Genotype-Phenotype Correlations- Mutation 
Type
This section investigates possible relationships between the types of pathogenic 
mutations detected in ATP2A2 and the neuropsychiatric phenotypes observed in the 68  
individuals in whom a pathogenic mutation was detected. Comparisons of the percentages of 
neuropsychiatric phenotypes, BADDS mania and depression scores and age of onset of 
psychiatric illness among individuals with different mutation types are shown in Appendix 
D.iv Table D-l 1 pg. 329 to D-13 pg. 330 and summarised graphically in Figure 8.7 to Figure 
8.9 pg. 183 to 185. Table 8.9 summarises the relationships investigated between the types of 
mutation detected in ATP2A2 and specific neuropsychiatric phenotypes, no significant 
relationships were found.
Table 8.9 Summary of Relationships between Type of Pathogenic Mutation and 
Neuropsychiatric Phenotypes
Neuropsychiatric Phenotype Relationship with Type of 
Pathogenic Mutation
Table/
Figure
Any Lifetime DSM-IV Diagnosis V=9.291,df=5,p= 0.090 D-ll pg. 329 
Figure 8.7History of Suicide Attempts V  =4-817, df=5, p= 0.441
History of Psychiatric Contact *? =6.242, df=5, p= 0.284
Learning Difficulties =2.859, df=5,p= 0.760
Investigations for Blackouts, Loss of 
Consciousness or Fainting Episodes
=3.866, df=5,p= 0.527
Personal History of Bipolar Disorder and/or 1st 
Degree Relatives with DD and Bipolar 
Disorder
V  =3.570, df=5,p= 0.657 D-l 2 pg. 329 
Figure 8.7
Diagnosis of Epilepsy and/or 1st Degree 
Relatives with DD and a Diagnosis of Epilepsy
V  =4.753, df=5, p= 0.413
BADDS Mania Dimension **H=2.620, df=5, p=0.758 D-13 pg. 330 
Figure 8.8  
&Figure 8.9
BADDS Depression Dimension **H=3.369, df=4, p=0.498
Age of onset of psychiatric Illness **H=0.424, df=4,p=0.981
* Exact significance tests for Pearson’s chi-square, ** Kruskal-Wallis H tests.
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Figure 8.7 Percentages of Individuals with Specific Neuropsychiatric Phenotypes according to 
Mutation Types
Mutation Type
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Figure 8.9 BADDS Depression Scores according to Mutation Type
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8.6 Investigations of Genotype-Phenotype Correlations- Mutation 
Location
8.6.1 Mutations Located in Functional Domains of SERCA2b and 
Neuropsychiatric Phenotypes
This section investigates possible relationships between the location of pathogenic 
mutations within functional domains of the SERCA2b protein and the neuropsychiatric 
phenotypes observed. Comparisons of the percentages of neuropsychiatric phenotypes, 
BADDS mania and depression scores and age of onset of psychiatric illness among 
individuals with and without mutations in the functional A, N, P and Ca2+ binding domains 
are shown in Appendix D.v Table D-14 to D16 pg. 331-333. Table 8.10 summarises the two 
significant relationships found between mutations located in the functional domains of 
SERCA2b and neuropsychiatric phenotypes. Significantly more individuals with mutations in 
the A domain had a history of psychiatric contact compared to individuals without mutations 
in the A domain (100% vs. 27%; Fisher’s exact test, p= 0.008) and significantly fewer 
individuals with mutations in the Ca2+ binding domain had a history of learning difficulties 
compared to individuals without mutations in these domain (12% vs. 39 %; x2 =4.390, df=l, 
p=0.036). Further relationships that almost reached significance are also summarised in the 
table. Fewer individuals with mutations in the P domain had a lifetime DSM-IV diagnosis 
compared to individuals without a mutation in the P domain (38% vs. 6 6%). More individuals 
with mutations in the N domain had a history of suicide attempts (33% vs. 12%) and 
investigations for blackouts/loss of consciousness (40% vs. 15%).
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Table 8.10 Summary of Relationships between Mutations Located in Functional Domains of 
SERCA2b and Neuropsychiatric Phenotypes
A Domain N Domain P Domain Ca2+ Binding 
Domains
Lifetime DSM-IV 
Diagnosis
Lower % of 
individuals:
38 % vs. 66%
(X2 =3.3269, df=l, 
p= 0.071).
History of Suicide 
Attempts
Higher % of 
individuals:
33% vs. 12% 
(Fisher’s exact test,
p= 0.082)
History of Psychiatric 
Contact
Significantly 
higher % of 
individuals: 
100% vs. 27% 
(Fisher’s exact 
test, p=0.008)
Learning Difficulties Significantly 
lower % of 
individuals:
12% vs. 39 %
Gc2-4.390, df-l, 
p-0.036)
Investigations for 
Blackouts, Loss of 
Consciousness or 
Fainting Episodes
Higher % of 
individuals 
40% vs. 15% 
(Fisher’s exact test,
p=0.082)
Personal History of 
Bipolar Disorder 
and/or l1* Degree 
Relatives with DD 
and Bipolar Disorder
Diagnosis of Epilepsy 
and/or 1* Degree 
Relatives with DD 
and a Diagnosis of 
Epilepsy
BADDSM
BADDSD
Age of onset of 
psychiatric illness
Significant relationships are displayed in bold.
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8.6.2 Mutation Location within ATP2A2 and Neuropsychiatric 
Phenotypes
This section investigates possible relationships between the location of pathogenic 
mutations within the ATP2A2 gene and the neuropsychiatric phenotypes observed. 
Comparisons of the percentages of neuropsychiatric phenotypes, BADDS mania and 
depression scores and age of onset of psychiatric illness among individuals with mutations in 
the first, middle and last third of ATP2A2 are shown in Appendix D.vi Table D-17-19 pg.334 
and summarised graphically in Figure 8.10 and Figure 8.11 pg. 189 to 191. Table 8.11 
summaries the relationships between mutation location within A TP2A2 and neuropsychiatric 
phenotypes. A significantly higher proportion of individuals with mutations in the middle 
third of ATP2A2 had a history of investigations for blackouts, loss of consciousness or 
fainting episodes compared to individuals with mutations in the last third of the gene (34% vs. 
7%; Fisher’s exact test, p= 0.045) (Figure 8.10e) There was also a significant relationship 
between mutation location and diagnosis of epilepsy in index and/or 1st degree relatives with 
DD and a diagnosis of epilepsy (x2 =7.454, df=2, p=0.039) ( Figure 8.10g).
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Table 8.11 Summary of Relationships between Mutations Located in the First, Middle and Last 
Third of ATP2A2 and Neuropsychiatric Phenotypes
Neuropsychiatric Phenotype Relationship with Location 
of Pathogenic Mutation
Table/
Figure
Any Lifetime DSM-IV Diagnosis ^ = 0 .5 7 5 , df=2, p= 0.750 D-17 pg .334
History o f Suicide Attempts V  =0.754, d f= 2 ,p=  0.763
History o f Psychiatric Contact X =1.328, df=2, p= 0.515
Learning Difficulties V  =0.220, df=2, p= 0.939 Figure 8.10
Investigations for Blackouts, Loss o f  
Consciousness or Fainting Episodes
*X2 =6.039, df=2, p=0.048
Personal History o f Bipolar Disorder and/or 1st 
Degree Relatives with DD and Bipolar 
Disorder
V  =2.818, df=2, p= 0.371 D-18 pg .334
Diagnosis o f  Epilepsy and/or 1st Degree 
Relatives with DD and a Diagnosis o f  Epilepsy
Y  =7.454, df=2, p=0.039 Figure 8.10
BADDS Mania Dimension **H = 1.209, df=2, p=0.546 D-19 pg .335
BADDS Depression Dimension ** H=3.206, df=2, p=0.201 F igure 8.11
Age o f  onset o f  psychiatric Illness ** H=0.267, df=2, p=0.875
* Exact significance tests for Pearson’s chi-square, ** Kruskal-Wallis H tests.
Figure 8.10 Percentages of Individuals with Specific Phenotypes according to Mutation Location 
within A TP2A2
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Figure 8.11 BADDS Mania and Depression Scores according to A TP2A2 Mutation Location
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minimum and maximum BADDS Mania and Depression Dimension Scores.
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8.7 Summary of Chapter 8
This chapter has described investigations carried out into the relationship between 
mutations detected in ATP2A2 and the neuropsychiatric phenotypes observed in individuals 
with DD. The main findings of the chapter are summarised below.
Mutation Detection
• 20 of the 21 exons of ATP2A2 were screened for mutations. Exon 1 was not screened.
• Checks carried out on the data regarding the detection of DNA variants within 
ATP2A2 indicated that there were no major quality control issues. There were no cases 
in which an individual with an already known pathogenic mutation was found to have 
a different pathogenic mutation in the current study.
• In total, 60 pathogenic mutations were detected and/or known in 68  unrelated 
individuals.
• The mutation detection rate in the current study is 66% (61/93 individuals who were 
screened for mutations). This excludes the seven individuals in whom a pathogenic 
mutation was not identified in the current mutation detection.
• 42 mutations detected in the current study are novel mutations.
• The distribution of mutation types and locations of the mutations in the current sample 
was found to be very similar to the distributions previously reported in the literature.
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Comparison o f the Clinical Features o f DD and Neuropsychiatric Phenotype In Individuals in 
whom a Pathogenic Mutation Was and Was Not Detected/Known
• Significantly more individuals in whom a pathogenic mutation was detected reported a 
definite or probable family history of DD compared to individuals in whom a mutation 
was not detected.
• There was a consistent trend for the prevalence of lifetime neuropsychiatric 
phenotypes to be higher among individuals in whom a pathogenic mutation was 
detected.
Neuropsychiatric Genotype-Phenotype Correlations
1. Observations of possible clustering of mutations among individuals with certain 
neuropsychiatric phenotypes included:
• All four individuals with mutations in the functional ‘A’ domain of the protein had a 
history of contact with psychiatric services.
• Two individuals with frameshift mutations only one base pair apart in the S4 (Stalk 4)
domain of the protein both had a history of suicide attempts in addition to having a
cyclothymic personality and idiopathic epilepsy (ID 15) and an extensive psychiatric 
history including major depressive disorder, somatoform disorder and investigations 
for a blackout (ID 16).
• Three individuals with the same missense mutation at one of the seven Ca binding
sites in the M5 domain all had a DSM-IV diagnosis of a mood disorder.
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2. The main findings of genotype-phenotype investigations carried out between the type 
and location of pathogenic mutations detected in ATP2A2 and the prevalence and/or 
severity of the neuropsychiatric phenotypes are summarised in Table 8.12. For six of 
the seven neuropsychiatric phenotypes investigated, the highest or second highest 
prevalence of these phenotypes was found among individuals with frameshift 
mutations or other types of mutations (large deletions or insertions).
Table 8.12 Summary of Relationships between the Types and Locations o f M utation within 
ATP2A2 and Neuropsychiatric Phenotypes Observed in Individuals with DD
Mutation Types With 
Highest Prevalence
Mutations Located in 
Functional Domains of 
SERCA2b
Mutations Located in 
the First, Middle and 
Third of ATP2A2
Lifetime DSM-IV 
Diagnosis
1. Frameshift
2. Other/Nonsense
Least frequent among 
individuals with 
mutations in the 
P domain
History of Suicide 
Attempts
1. Other
2. Frameshift
Most frequent among 
individuals with 
mutations in the 
N domain
History of Psychiatric 
Contact
1. Other
2. Frameshift
Most frequent among 
individuals with 
mutations in the 
A domain
Learning Difficulties 1. Nonsense
2. Missense
Least frequent among 
individuals with 
mutations in the 
Ca2+ Bindine domain
Investigations for 
Blackouts, Loss of 
Consciousness or Fainting 
Episodes
1. Other/Nonsense
2. Frameshift
Most frequent among 
individuals with 
mutations in the 
N domain
Most frequent among 
individuate with 
mutations in the 
middle third
Personal History of 
Bipolar Disorder and/or 
1st Degree Relatives with 
DD and Bipolar Disorder
1. Other
2. Splice Site
Diagnosis of Epilepsy 
and/or 1M Degree Relatives 
with DD and a Diagnosis 
of Epilepsy
1. Splice Site
2. Frameshift
Most frequent among 
individuate with 
mutations in the 
first third
Significant relationships are reported in bold, relationships almost reaching significance are reported in italics.
The following chapter (Chapter 9) discusses these findings.
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9 GENOTYPE-PHENOTYPE CORRELATIONS BETWEEN 
MUTATIONS DETECTED IN ATP2A2 AND 
NEUROPSYCHIATRIC PHENOTYPES: DISCUSSION
This chapter will discuss the results presented in Chapter 8. These results and discussions 
relate to the second aim of the thesis, which was to investigate possible genotype-phenotype 
correlations between the type and/or locations of pathogenic mutations detected in the ATP2A2 
gene and the neuropsychiatric features observed in the current sample. Evidence for such 
correlations would support the hypothesis that mutations in the ATP2A2 gene may have 
pleiotropic effects in the skin and brain and therefore confer susceptibility to neuropsychiatric 
features in individuals with DD.
First, general issues concerning the detection of mutations in ATP2A2 in the current sample 
are discussed. This is followed by a discussion of the possible reasons for the consistent trend for 
the prevalence of lifetime neuropsychiatric features to be higher among individuals in whom a 
pathogenic mutation was detected compared to individuals in whom a pathogenic mutation was 
not detected. The findings of the investigations into genotype-phenotype correlations are then 
discussed and compared to the findings of the small number of previous genotype-phenotype 
correlation studies conducted in individuals with DD. A key finding reported in Chapter 8 was 
the observation of the clustering of mutations within the SERCA2b protein among individuals 
with similar neuropsychiatric phenotypes. These observations will be combined with the previous 
descriptions of individuals with known mutations in these regions of the protein to investigate 
whether this provides further support for the suggestion that certain mutations in ATP2A2 may 
confer susceptibility to certain types of neuropsychiatric illness in individuals with DD.
195
9.1 Detection of Mutations In A TP2A2
In the current study, 93 index individuals with DD and a smaller number of their affected 
and unaffected family members were screened for mutations in ATP2A2. The findings of the 
mutation detection screen are reported in section 8.1 pg. 158.Unfortunately, one of the exons 
(Exon 1) could not be screened for technical reasons. In addition, certain fragments failed PCR 
amplification in some samples. These technical difficulties are likely to explain why three 
previously known mutations in ATP2A2 were not detected during the current mutation screen. In 
total 60, pathogenic mutations were detected in 68 apparently unrelated individuals. The decision 
to classify a mutation as being pathogenic was based on ranking the mutations according to how 
likely they were to be pathogenic and deciding a cutoff above which mutations were thought to 
be highly likely to be pathogenic (see Table 8.4 pg. 164). It is possible that this method 
incorrectly classified mutations as non-pathogenic and vice versa. However, as a fairly 
conservative approach was used, it is more likely that pathogenic mutations may have been 
misclassified as non-pathogenic rather than non-pathogenic mutations being misclassified as 
pathogenic. Functional studies investigating the effects of specific mutations on the functioning 
of the SERCA2b protein would be needed to confirm whether a mutation was actually 
pathogenic. The criteria used to decide whether or not a mutation was likely to be pathogenic are 
very similar to those used in previous studies. Since the mutation types classified as being 
pathogenic in the current sample had all been reported as pathogenic mutations previously in the 
literature, this suggests that they were responsible for causing DD. This is also supported by the 
fact that the distributions of mutation types and locations of mutations in the current sample were 
very similar to the distributions previously reported in the literature.
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Eighteen of the pathogenic mutations detected in the current study were among the 143 
mutations previously reported in the literature, whereas 42 were novel. This study therefore 
greatly adds to the number of known mutations in DD and takes the worldwide known total from 
143 to 185. In the current study, only six of the 60 mutations (10%) were found in more than one 
unrelated individual and the majority of individuals were found to have a unique DD causing 
mutation. This finding is consistent with the previous literature in which 17% of the mutations 
reported have been found in more than one unrelated individual. Four individuals were found to 
have the same missense mutation (N767S) in the M5 (fifth transmembrane) domain of the 
SERCA2b protein (see Table 8.3 pg. 162 Mutation ID 42). This mutation is one of only four 
missense mutations that have been previously reported in three or more apparently unrelated 
families in the literature. The remaining five mutations found more than once were each found in 
two unrelated individuals. It is possible that these individuals may have shared a common 
ancestor, although this could only be known if extensive family history research and/or further 
genetic analysis were carried out.
9.2 Comparison of the Clinical Features of DD and Neuropsychiatric 
Phenotype In Individuals in whom a Pathogenic Mutation was and 
was not Detected/Known
The mutation detection rate in the current study is 66% with mutations not being detected in 
28 index individuals. This rate is consistent with those reported in larger scale mutation screens 
of the ATP2A2 gene, which have ranged from 50% (Ikeda et al., 2003) to 70% (Onozuka et a l , 
2004). In the current study, pathogenic mutations located in exon 1 would not have been detected 
(although this is only likely to account for six individuals, see section 8.3 pg. 166). Another 
possible explanation for mutations not being detected is poor DNA quality and/or technical
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reasons, for example, some individuals may have had a pathogenic mutation in a DNA fragment 
that failed PCR amplification. However since only a very small percentage of fragments failed 
amplification (3.6%), this explanation is not likely to account for many cases. It is also possible 
that undetected mutations may have been located in an unscreened region of the ATP2A2 gene 
such as the promoter region, although pathogenic mutations in DD have not previously been 
reported in this region. A final possibility could be that a proportion of individuals in the current 
sample had clinical features similar to DD caused by factors other than a pathogenic mutation in 
ATP2A2 i.e. they could be a phenocopy of DD. These individuals would be unlikely to report a 
family history of DD. Therefore, the suggestion that the sample may contain phenocopies of DD 
is supported by the finding that a significantly higher proportion of individuals in whom a 
pathogenic mutation was detected reported a family history of DD compared to individuals in 
whom a pathogenic mutation was not detected (see section 8.3.1 pg. 167).
The prevalence and severity of lifetime neuropsychiatric phenotypes, including suicide 
attempts, history of psychiatric contact, learning difficulties and investigations for periods of loss 
of consciousness, was higher among the individuals in whom a pathogenic mutation was detected 
compared to those in whom a pathogenic mutation was not detected (see Figure 8.2 to Figure 8.4 
pg. 169 to 170). Although only one significant relationship was found, for scores on the Bipolar 
Affective Disorder Dimensional Scale (BADDS) mania dimension, the small group sizes mean 
that power to detect significant differences between the two groups was limited.
A number of explanations could account for the increased prevalence of neuropsychiatric 
features among individuals in whom a pathogenic mutation was detected. This observation could 
be due to chance, although this seems unlikely due to the consistent trend seen across all of the 
neuropsychiatric phenotypes. However, there is a degree of overlap in the phenotypes measured,
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for example individuals with a history of suicide attempts are likely to have also had contact with 
psychiatric services. Another explanation could be that individuals within this group had a more 
severe form of DD and/or had experienced a greater impact of DD on their quality of life. The 
increased prevalence of psychiatric features seen in this group would therefore reflect a 
psychosocial reaction to the symptoms of DD. There was a trend for a higher percentage of 
individuals in whom a pathogenic mutation was not detected to have been classified as having 
mild DD. This difference did not reach statistical significance although it is possible that this 
could be due to limited power. The two groups however, did have very similar scores on the 
worst week version of the Dermatology Life Quality Index. This indicates that differences in the 
subjective impact DD had caused on quality of life could not account for the group differences in 
the prevalence and severity of psychiatric phenotypes.
A further explanation is that a proportion of the individuals in whom a pathogenic mutation 
was not detected are phenocopies of DD, i.e. they do not have a pathogenic mutation in ATP2A2. 
Based on the hypothesis that mutations in ATP2A2 have pleiotropic effects in the skin and brain, 
it would be expected that these individuals would have a lower prevalence of neuropsychiatric 
features than individuals with a confirmed mutation in ATP2A2. Comparison of the prevalence of 
reported family history of DD between the two groups described above, suggests that there is a 
possibility that individuals in whom a pathogenic mutation was not detected may be phenocopies 
of DD. However, this cannot be confirmed in the current study and it remains possible that all of 
the individuals in whom a pathogenic mutation was not detected did have a mutation in ATP2A2 
that was not detected in the current mutation screen.
In addition to potentially providing support for mutations in ATP2A2 having pleiotropic 
effects in the skin and brain, the increased prevalence of neuropsychiatric illness among
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individuals in whom a pathogenic mutation was detected has potential treatment implications for 
individuals with DD, particularly if this finding is replicated in future studies. DD is currently 
clinically diagnosed by a skin biopsy, however, it is possible that in the future, DNA samples will 
be routinely taken from individuals with biopsy proven clinical DD to be screened for a 
pathogenic mutation within ATP2A2. The findings of the present study highlight the need for the 
assessment and recognition of neuropsychiatric symptoms in DD particularly among individuals 
found to have pathogenic mutation in ATP2A2.
9.3 Investigations of Genotype-Phenotype Correlations in DD
The main findings of the genotype-phenotype investigations carried out between the type and 
location of pathogenic mutations detected in ATP2A2 and the prevalence and/or severity of the 
neuropsychiatric phenotypes measured in the current sample are summarised in Table 8.12 pg. 
194. A small number of significant findings were observed, although due to the number of 
investigations carried out these would not remain significant after corrections for multiple testing. 
Therefore these investigations, by looking at mutation types and locations, did not demonstrate 
statistically significant genotype-phenotype correlations. However, such correlations would not 
be expected given the very limited power due to the small group sizes.
The possible clustering of mutations within the SERCA2b protein among individuals with 
similar neuropsychiatric phenotypes was also examined in this study. This is a more useful way 
of looking for possible genotype-phenotype correlations as these associations are likely to be 
more complex than being related to just the type and/or location of mutations. The observation of 
the clustering of mutations among individuals with similar neuropsychiatric phenotypes,
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described in the following section, found evidence supporting the existence of genotype- 
phenotype correlations in DD.
9.3.1 Clustering of Mutations within SERCA2b and Neuropsychiatric 
Phenotypes
In the current sample, mutations found among individuals with similar neuropsychiatric 
phenotypes appeared to cluster in certain locations within the SERCA2b protein (see Table 8.8 
pg. 181 for a summary of these observations). The key observations are illustrated in Figure 9.1. 
Most evidence was found for a clustering of mutations among individuals with similar severe 
psychiatric phenotypes including suicide attempts and a lifetime history of contact with 
psychiatric services.
In the following sections the neuropsychiatric phenotypes of individuals with mutations in 
these highlighted domains of the SERCA2b protein will be combined with the previous 
descriptions of individuals with mutations in these regions. Dermatologists have carried out the 
majority of the previous mutation detection studies in DD. Therefore, a limitation of combining 
the findings of the current study with these previous studies is that they will not all have recorded 
and/or reported neuropsychiatric features. Similarly, where neuropsychiatric features have been 
reported previously in the literature, in many cases only brief descriptions are provided.
The neuropsychiatric features observed among individuals in the current sample and their 
first-degree relatives with DD are summarised in Table 8.6 pg. 173. Where individuals reported 
in this table are described in the following sections, their study ID (first column e.g. DAR36-1) 
and/or mutation ID (second column e.g. ID 1) will be provided for reference.
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_A domain
All four individuals with 
mutations in the ‘A’ domain 
had a history of contact with 
psychiatric services.
N domain
Three individuals with mutations 
located close together in the ‘ N’ 
domain had a history of 
psychiatric contact.
Actuator
‘A’
Nucleotide I 
I Binding ■
| ‘N’
Phosphorylation
Cytoplasm
ER
Lumen
ER; endoplasmic reticulum, Sn; stalk domains, Mn; transmembrane domains
Sl-M l Domain
Two individuals with 
mutations in the SI and Ml 
domains had a personal 
diagnosis of epilepsy or 
first degree relative with a 
diagnosis of epilepsy.
S4-M4 Domain
Two individuals with 
frameshift mutations only 
one base pair apart in the S4 
domain had a history of 
contact with psychiatric 
services and suicide 
attempts.
Ca2+ Binding Sites
An individual with a missense mutation at 
one of the seven Ca2+ binding sites within 
the M4 domain had a 1st degree relative with 
DD and bipolar disorder.
Three individuals with a missense mutation 
at another of the seven Ca2+ binding sites in 
the M5 domain all had a DSM-IV diagnosis 
of a mood disorder.
Figure 9.1 Key Observations of Evidence for Possible Clustering of Mutations within the SERCA2b 
Protein among Individuals In the Current Sample with Similar Neuropsychiatric Phenotypes
2 0 2
9.3.1.1 A Domain
All four individuals with mutations in the functional ‘A’ domain of the SERCA2b protein 
had a history of contact with psychiatric services (mutation IDs 7-10) (see Figure 8.5 pg. 177). 
This included an individual with a splice-site mutation who had a personal history of bipolar 
disorder (DAR81-2, ID 7) and a family history of multiple family members with DD and 
neuropsychiatric phenotypes including puerperal psychosis and epilepsy (see Figure 4.9 pg. 80).
In the previous literature, a further 22 mutations have been reported in this section of the ‘A 
domain* between the stalk 2 and stalk 3 domains. These include a missense mutation (P160L) 
which has been reported in a family with severe DD with a history of suicide attempts (Ringpfeil 
et al., 2001) and in an individual also with severe DD who “complained about learning 
difficulties and being moody” (Godic et al., 2004). A further individual with a frameshift 
mutation in the A domain is reported to have mild depression (Racz et al., 2004). However, the 
remaining 20 mutations previously reported in the A domain have not been associated with any 
neuropsychiatric features. These findings therefore do not provide robust support that mutations 
in the A domain of the SERCA2b confer susceptibility to severe psychiatric illness in individuals 
with DD
9.3.1.2 N Domain
Three individuals with mutations located close together in the ‘ N’ domain had a history of 
psychiatric contact (IDs 64, 29 and 30). These mutations along with the mutations previously 
reported in the literature in this section of the N domain are shown in Figure 9.2. Mutations 
identified in families where any family member with DD also had a known neuropsychiatric 
phenotype are highlighted in red. One of the individuals in the current study with a frameshift
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mutation in this region had a diagnosis of bipolar disorder (DARI 8-1, ID 64). Interestingly, a 
further missense mutation (C560R) in this region was previously reported in two unrelated 
individuals with mood disorders (Jacobsen et al., 1999). One of these individuals had bipolar 
disorder and another had a diagnosis of schizoid personality disorder not otherwise specified. Of 
the seven mutations that have been identified in this region of the N domain of the SERCA2b 
protein, six have been found in individuals with additional neuropsychiatric phenotypes. This 
includes two individuals with bipolar disorder and a further two individuals who have received 
treatment from secondary psychiatric services for depression. These findings therefore provide 
further strong support for the suggestion that mutations in this section of the N domain may 
confer susceptibility to mood disorders in individuals with DD.
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disorders including 
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Figure 9.2 Neuropsychiatric Phenotypes of all Known Individuals with DD Causing Mutations in the Last Segment of the N Domain
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9.3.1.3 S1-M1 Domain
Two individuals with mutations in the SI and Ml domains of the SERCA2b protein had a 
personal diagnosis of epilepsy (DAR36-1, ID 1) or first degree relative with a diagnosis of 
epilepsy (DAR95-1, ID 4). Both of these individuals were also classified as having learning 
difficulties. These mutations, along with those reported in the literature, are shown in Figure 9.3. 
There were no additional reported cases of epilepsy. However, of the 10 mutations that have been 
reported in this domain, six have been found in individuals with neuropsychiatric illness 
including bipolar disorder. A large insertion mutation was identified in the current study in an 
individual with a diagnosis of bipolar disorder (DAR91-1, ID 2). The mother of this individual 
with DD is also reported to possibly have a bipolar illness. A further individual in the current 
study with a missense mutation in this domain had a diagnosis of major depression and reported 
episodes of high mood after the birth of her children (DARI 4-1, ID 3). The father of this 
individual who also had DD had received ECT treatment for depression. A large insertion 
mutation located just outside the SI-Ml domain has also been reported in a family containing 
multiple members with affective disorder including bipolar disorder (Jones et al., 2002). These 
findings provide evidence to suggest that mutations in the SI-Ml region of the SERCA2b protein 
may confer susceptibility to more severe psychiatric phenotypes in DD, including bipolar 
disorder.
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individuals)
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family ID 
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current study
Exon. Nucleotide 
Change
(Amino Acid Change).
Multiple members with affective disorder including bipolar disorder (incomplete co­
segregation with DD)
Jones et al. 
(2002)
Intron 1/Exon 2.
Suicide in family, “emotional problems” (?n) Ringpfeil et al. 
(2001)
Exon 2.121 del 3bp 
(L41del)
Depression (?n) Ringpfeil et al 
(2001)
Exon 2.124 del 3bp 
(P42del)
Not reported Sakuntabhai et 
al. (1999a)
Exon 2 .130delG
Tonic clonic epilepsy, learning difficulties (1) DAR36-1 (1) Intron 2.137-3 OG
Not reported Sakuntabhai et 
al. (1999a)
Exon 3 .137-12ins 18bp
Bipolar disorder, fit aged 10 months, CT and EEG investigations for periods of 
unconsciousness in late 20s (1). Psychiatric treatment for depression and anxiety possibly 
a bipolar illness (1).
DAR91-1 (2) Exon 3.142 ins 18bp.
None Wada et al. 
(2003)
Exon 3. 160A>G (I54V)
Mild high mood after birth of children followed by episodes of depression (1) ECT 
treatment for depression (1).
DAR14-1 (3) Exon 3. 167 A>G 
(Q56R)
Depression and learning difficulties learning difficulties (1). Mild form of epilepsy (1). DAR95-1 (4) 
also reported in 
Ruiz-Perez et al. 
(1999)
Exon 3. 194 T>C (L 65 
S)
None Sakuntabhai et 
al. (1999a)
Intron 3.219+1G>A 
Splice-site
Mutation Type
*  Large insertion 
A Splice site 
O Missense 
O Frameshift deletion 
A In-frame Deletion
ER; Endoplasmic reticulum, S; stalk domain, M; transmembrane domain. Mutations labelled in red have been identified in families where 
any family member with DD also has a known neuropsychiatric phenotype.
Figure 9J Neuropsychiatric Phenotypes of all Known Individuals with DD Causing Mutations in the Sl-Ml Domain of SERCA2b
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9.3.14 S4-M4 Domain
Two individuals with frameshift mutations only one base pair apart in the S4 (Stalk 4) 
domain of the protein both had a history of suicide attempts in addition to having a cyclothymic 
personality and idiopathic epilepsy (DAR70-1, ID 15) and an extensive psychiatric history 
including major depressive disorder, somatoform disorder and investigations for a blackout 
(DAR55-1, ID 16). These mutations along with those previously reported are shown in Figure 
9.4.
Of the 10 mutations that have been reported in the M4-S4 domain, seven have been found in 
families with members with severe psychiatric phenotypes including bipolar disorder.
An individual in the current study with a missense mutation (E309K), at one of the Ca2+ binding 
sites (DAR65-1, ID 13) had a 1st degree relative with DD and bipolar disorder, although they 
themselves did not have a history of mood disorder.
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Reference/ Study 
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***Nucleotide
Change
Amino Acid Change).
Neuropsychiatric disorder and behaviour problems (2) Sato et al. (2004) (L321F)
Psychiatric hospital treatment for depression (1) DAR43 (ID 17) 958 G>C (A320P)
Mild mental retardation and psychiatric abnormality (1) (Wang et al., 2006). Ren et al. (2006) 
;Wang et al. (2006)
953G>T
(C318F)
None Onozuka et al. 
(2004);
Sakuntabhai et al. 
(1999a)
952T>C
(C318R)
Major depression, multiple suicide attempts, brain scan to investigate blackouts, 
somatoform disorder, BADDS mania score of 16 (1). Treated by psychiatrist for 
depression (1).
DAR55( ID 16) 949 7bp del
Cyclothymic personality described in medical notes, suicide attempt, idiopathic epilepsy 
(1)
DAR70 (ID 15) 948 del C
Bipolar disorder (1). Treated by psychiatrist for depression (1) (*) 935 O G  (P312R)
Below average IQ, BADDS Mania Score of 17 (1) (**) DAR3 (ID 14) 929 G>T (G310V)
Bipolar Disorder (1) Seen by educational psychologist for poor concentration (1) Seen by 
child psychiatrist and treated by psychiatrist for depression and heroin addiction as an 
adult, bipolar disorder not otherwise specified (1)
DAR65 (ID13) 925 G>A (E309K)
Depression NOS, BADDS Mania Score of 11 (1) DAR6 (ID 12) 923 O A  (P308H)
ER; Endoplasmic reticulum, S; stalk domain, M; transmembrane domain. Mutations have been found to be unique to families, except for 
mutations marked 2 where mutations have been reported in two unrelated families. Mutations labelled in red have been identified in 
families where any family member with DD also has a known neuropsychiatric phenotype. BADDS; Bipolar Affective Disorder 
Dimension Scale.
*Unpublished mutation identified in an individual seen by our research group who was not included in the current study.** Mother was 
admitted to psychiatric hospital with ‘high mood’ although neither parent was reported to have DD. *** All mutations are located in Exon 
8 .
Figure 9.4 Neuropsychiatric Phenotypes of all Known Individuals with DD Causing M utations in the S4-M4 Domain of SERCA2
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A further missense mutation three amino acids away (P312R) was identified in an individual 
with bipolar disorder who had previously been interviewed by our research team, although was 
not included in the current study. Interestingly, a missense mutation identified in between these 
two mutations (G310V) was identified in an individual with severe DD with a notable score of 
17 on the mania dimension of the Bipolar Affective Disorder Dimensional Scale. The mother of 
this individual had been admitted to a psychiatric hospital with high mood, although she was 
not known to have DD. Sato et al (2004) found a unique missense mutation (L321F) in the S4 
domain which led to a SERCA2b protein with markedly reduced sensitivity to feedback 
inhibition by ER Ca2+. This mutation was reported in a female and her daughter both with 
severe DD and severe neuropsychiatric disorders and behaviour problems.
These observations suggest that mutations within the S4-M4 domain may confer increased 
susceptibility to more severe neuropsychiatric phenotypes, in particular psychiatric symptoms 
and bipolar disorder, in individuals with DD. As this domain contains a Ca2+ binding site, 
mutations in this domain may be expected to have a more dramatic effect on the functioning of 
the protein. The neuropsychiatric phenotypes of individuals with mutations at the other Ca 
binding sites of the SERCA2b protein are discussed in the following section.
9.3.1.5 Ca2* Binding Sites
The SERCA2 protein has seven Ca2+ binding amino acids within four of the 
transmembrane domains (M4, M5, M6 and M8), which form two Ca binding sites (see 
Chapter 6 section 6.2.1 pg. 138 and Figure 6.1 pg. 137). In the current study, six individuals
i
were found to have missense mutations in a Ca binding amino acid. Four of these individuals 
had the same mutation in the M5 domain of the SERCA2b protein (N767S, ID 42). Three 
individuals with this mutation (DAR72-1, DAR41-1 and DAR74-1) all had DSM-IV diagnosis 
of a mood disorder including major depression and depression not otherwise specified. An
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individual with the same mutation (DAR50-1) had experienced possible symptoms of anxiety 
that did not reach diagnostic criteria. As described in the previous section, an individual with a 
missense mutation (E309K) at another of the Ca2+ binding sites within the M4 domain (DAR65- 
1, ID 13) had a 1st degree relative with DD and bipolar disorder. Two other members of this 
family with DD had been seen by a psychiatrist and an educational psychologist. A further 
missense mutation (N795S) at another Ca2* binding site was found in an individual in the 
current study who had a diagnosis of anxiety not otherwise specified (DAR89-1, ID 45). These 
findings suggest mutations in the Ca2+ binding sites may confer susceptibility to mood or 
anxiety symptoms. However, this is not supported by the previous literature. Of six further 
individuals/families reported to have mutations within one of the seven Ca binding sites, only 
one had a diagnosis of depression (Jacobsen et al., 1999). However, as discussed previously, the 
neuropsychiatric features of the remaining individuals may not have been recorded and/or 
reported.
9.3.2 Functional Genotype-Phenotype Studies in DD
The findings of the present study combined with the previous literature provide strong 
evidence to suggest genotype-phenotype correlations in DD. This is particularly evident in the 
S4-M4 region where a number of unrelated individuals have been found/reported to have severe 
psychiatric symptoms including multiple cases of bipolar disorder. In addition, unrelated 
individuals with the same DD causing mutation have been found to have similar 
neuropsychiatric phenotypes. However, replication of these findings is difficult since the 
majority of DD causing mutations are unique to families.
Site-directed mutagenesis functional studies are a further way of investigating genotype- 
phenotype correlations in DD. To date only a small number of these studies have been 
conducted, although the findings suggest that the variable neuropsychiatric phenotypes 
observed among individuals with DD may be accounted for by certain mutations having
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specific effects on the functioning of the SERCA2b protein. Ahn et al. (2003) indicated that the 
effects of DD mutations on Ca2+ transport activity could not account for the variable phenotypes 
observed in DD since the majority of mutations they examined (11 out of 12) had no Ca2+ 
pumping activity. Interestingly, they found that five of these mutations led to ‘mutant’
SERCA2b pumps that interact with, and subsequently reduce, the activity of the co-expressed 
wild-type normal SERCA2b pumps. Further functional studies have identified a small number 
of unique mutations leading to proteins with an enhanced Ca transport activity relative to the 
wild type SERCA2b and a reduced sensitivity to inhibition by lumenal Ca2+ (L321F and 
S920Y) ((Dode et al., 2003; Sato et al., 2004). It has been suggested that these unique types of 
mutations could account for the variable clinical features observed in individuals with DD 
including the presence of more severe neuropsychiatric features (Ahn et al., 2003; Sato et al., 
2004).
Of the 60 mutations in the current study, 11 had been previously examined in site-directed 
mutagenesis functional studies in DD. These mutations have been found to have varying effects 
on the levels of SERCA2b protein expression, Ca2+-ATPase activity and Ca2+-transport activity. 
The functional effects of specific mutations vary across the different studies making it difficult 
to summarise these findings. One of these 11 mutations (S920Y), has previously been shown to 
result in a ‘mutant’ pump that reduces activity of the wild-type normal pumps (Ahn et al.,
2003). A separate study found that this mutation leads to a protein that has a unique reduced 
sensitivity to inhibition by lumenal Ca2+ (Dode et al., 2003). This missense mutation (ID 59) is 
located in the cytoplasmic loop between M8 and M9 and was detected in two individuals in the 
current study (DAR68-1 and DAR5-1). Both of these individuals had severe DD and a personal 
and family history of neuropsychiatric features. The first of these individuals (DAR68-1) had a 
personal history of learning difficulties, according to the definition used in the present study, 
and had a sibling with DD who suffered from epilepsy and learning disabilities severe enough
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to require residential treatment. A further family member had committed suicide, which was 
reported as being a direct reaction to the severity of their DD. The neuropsychiatric features 
among members of this family had been reported previously in the literature (Jacobsen et al., 
1999; Sakuntabhai et al., 1999a). The second individual with this mutation in the present study 
(DAR5-1) also had learning difficulties and had received psychiatric treatment following a 
severe episode of septicaemia related to their DD. They had an adult child with DD with a 
diagnosis of major depression who had made a suicide attempt following relationship problems. 
Another family member with DD had been admitted to a psychiatric hospital.
These findings highlight the need for further site-directed mutagenesis functional studies in 
DD. These studies would enable further genotype-phenotype investigations into the association 
between the functional effects of certain ATP2A2 mutations and the presence of severe 
neuropsychiatric features in individuals with DD. Varied neuropsychiatric phenotypes have 
been observed among members of the same family with DD. Since these individuals will all 
have the same mutation in ATP2A2, this suggests that additional genetic and/or environmental 
susceptibility factors are likely to be involved in the development of neuropsychiatric features 
in individuals with DD.
9.3.3 Implications of Evidence for Genotype-Phenotype Correlations in DD
As discussed in the previous section, the current study has found evidence for possible 
genotype-phenotype correlations in DD. This provides support for the hypothesis that 
mutations in the ATP2A2 gene have pleiotropic effects in the skin and brain and therefore 
confer susceptibility to neuropsychiatric features, in particular psychiatric illness, in individuals 
with DD. This hypothesis is also supported by the small number of functional studies that have 
provided evidence of how certain mutations in ATP2A2 may have high penetrance with respect 
to neuropsychiatric phenotypes by their specific effects on the functioning of the SERCA2b 
protein.
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The suggestion of mutations in ATP2A2 being involved in conferring susceptibility to 
neuropsychiatric illness is highly plausible since the gene is widely expressed in the brain 
(Baba-Aissa et al., 1998). The dual role of the SERCA2b protein in intracellular Ca2+ 
signalling and in the synthesis and post-translational modification of proteins within the 
endoplasmic reticulum (ER) also provides support for this suggestion. Intracellular Ca2+ 
signalling has been shown to play a role in a range of neuronal functions including neuronal 
excitability, neurotransmitter release, gene expression, neuronal growth and synaptic plasticity 
(Berridge, 2002; Berridge et al., 1998; Verkhratsky, 2005). Furthermore, there is recent 
evidence suggesting the role of ER function in the pathophysiology and treatment of mood 
disorders (Shao et al., 2006; So et al., 2007).
It is possible that the function of SERCA2b pumps may be more critical in the skin and the 
brain than in other tissues. Both tissues may have a particular susceptibility to a reduction in 
SERCA2b activity possibly relating to changes in ER Ca2+ concentration and ER functioning 
such as the post-translational processing of proteins. For example, trafficking of desmoplakin, a 
plasma membrane protein involved in cell adhesion, has been found to be impaired in DD skin 
cells (Dhitavat et al., 2003a).
These findings have potential treatment implications for individuals with DD, particularly 
if future site-directed functional studies identify further mutations that appear to have high 
penetrance with respect to neuropsychiatric phenotypes. The findings also have implications for 
the identification of genetic factors involved in conferring susceptibility to psychiatric illness in 
individuals without DD. Other genes encoding proteins in the same biological system as and/or 
encoding proteins with a similar function to SERCA2b would be good candidates for 
involvement in predisposing individuals to developing psychiatric illness, in particular mood 
disorders. Further studies are needed to look for supportive evidence of the clustering of 
mutations among DD individuals with similar neuropsychiatric phenotypes. In addition further
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functional studies are needed to determine the likely biological plausibility that variation within 
the cluster domains can affect a neuropsychiatric phenotype.
The following chapters (Chapters 10-12) are concerned with addressing the third aim of the 
thesis, which was to compare the presence of neuropsychiatric features in individuals with DD 
and their first-degree relatives, unaffected by DD. These investigations were designed to allow 
the detection of milder neuropsychiatric phenotypes in DD and allow control for additional 
genetic and non-genetic factors that could influence the presence of these features.
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10 COMPARISON OF DEMOGRAPHICS, LIFETIME 
NEUROPSYCHIATRIC FEATURES AND QUESTIONNAIRE 
SCORES IN A SAMPLE OF INDIVIDUALS WITH DD AND 
THEIR UNAFFECTED RELATIVES: METHODS
Chapters 3 to 5 were concerned with investigating the neuropsychiatric phenotype in 100 
unrelated individuals with DD, looking at relationships between the clinical features of DD and 
the neuropsychiatric features observed and then comparing the prevalence of neuropsychiatric 
features observed in individuals with DD to normative data and literature regarding the 
prevalence of psychiatric illness in other dermatological conditions. This was then followed by 
investigations carried out into the relationship between DD causing mutations detected in 
ATP2A2 and the neuropsychiatric phenotypes observed in individuals with DD in Chapters 6 to 9.
It was also intended that the neuropsychiatric test battery previously described in Chapter 3 
would be administered to available and willing unaffected relatives without DD. Comparison of 
the presence of neuropsychiatric features in a sample of individuals with DD and their unaffected 
relatives allows control for additional genetic and non-genetic factors that could influence the 
presence of neuropsychiatric features in individuals with DD.
This chapter describes the recruitment and clinical assessment of 24 unaffected first- 
degree relatives with no history of DD. This is followed by a description of the measures and 
design used to compare the presence of neuropsychiatric features in individuals with DD and 
their unaffected relatives. Additional information relating to this chapter can be found in section 
E of the Appendix starting at pg. 336, and will be referenced throughout the chapter.
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10.1 Recruitment and Assessment of Unaffected Relatives
10.1.1 Available Unaffected Relatives
The 100 index individuals with DD described and discussed in Chapters 3 to 5 were asked 
whether they had an available unaffected first-degree relative, preferably a sibling, over the age 
of 18 whom they would ask to take part in the research. Thirty-one individuals did not have any 
available unaffected relatives who could be contacted to be asked to take part in the research, 
reasons are summarised in Table 10.1.
Table 10.1 Unavailable unaffected relatives
N
No unaffected 1st degree relatives 10
Not in contact with any I* degree relatives 8
1st degree unaffected relatives all under 18 or over 80 2
Did not want to ask 10
1* degree relatives not in the UK 1
Total 31
10.1.2 Approaches to Recruiting Available Unaffected Relatives
Sixty-nine index individuals with DD had a first-degree unaffected relative suitable to be 
asked to participate in the study. During the initial stages of interviewing the 100 index 
individuals with DD, it was also attempted to interview unaffected relatives, described below in 
section 10.1.2.1. However, due to the low number of unaffected relatives agreeing to be 
interviewed, a second approach was carried out in which index individuals were asked if they 
could pass on a questionnaire version of the interview to their unaffected relatives, described 
below in section 10.1.2.2.
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10.1.2.1 Approach 1-Interviewing Unaffected Relatives
I initially attempted to interview available unaffected relatives of the 100 index individuals 
with DD. Where possible, the unaffected relative was a sibling of the index individual, if an 
unaffected sibling was not available the unaffected relative was a parent or child of the index case 
over the age of 18. Individuals with available unaffected relatives were asked if they would pass 
on or post (envelopes and stamps provided) an invitation letter and information sheet to their 
unaffected relative (Appendix E.i pg. 336). Unaffected relatives willing to take part in the study 
or wishing to discuss taking part over the telephone were asked to complete an attached contact 
form, which could be returned in the SAE enclosed with the letter. For the first 40 index 
participants with DD, this approach was used to attempt to interview their unaffected relatives. 
Nine unaffected relatives agreed to participate in the study and were interviewed in their homes.
The clinical assessment of unaffected relatives was identical to the assessment of individuals 
with DD, described in Chapter 3 section 3.2 pg. 35 and summarised in Figure 3.2 pg. 36 with the 
exception of the section relating to the clinical features of DD. Unaffected relatives were asked if 
they had ever been treated by a dermatologist or had ever experienced any skin problems in case 
they might have had a mild case of DD that had not been diagnosed.
Reasons I thought could contribute to the low number of unaffected relatives willing to 
participate in the study included individuals being unable find the time to take part in the study 
due to work, family and other commitments, and individuals not feeling comfortable/willing to 
discuss personal details with a researcher. I also thought that the relationship individuals with DD 
had with their unaffected relative would influence the willingness of their unaffected relative to 
take part in the study.
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10.1.2.2 Approach 2 -Questionnaire Pack for Unaffected Relatives
Due to the low number of unaffected relatives agreeing to be interviewed a second approach, 
which involved asking unaffected relatives to complete a shortened questionnaire pack, was 
attempted (shown in Appendix E.ii pg. 340). The pack consisted of a covering letter, information 
sheet about the study, two copies of a consent form, a questionnaire version of the 
neuropsychiatric assessment and a set of personality, temperament and current mood state 
questionnaires (described later in section 10.1.3.3). Index individuals with DD with available 
unaffected relatives were asked if they would be willing to pass on or post (envelopes and stamps 
provided) the questionnaire pack to their unaffected relatives.
Where possible the unaffected relative was a sibling of the index individual, if an unaffected 
sibling was not available the unaffected relative was a parent or child over the age of 18. Willing 
unaffected relatives were asked to return the completed questionnaires in a SAE provided along 
with a signed consent form. Sixty index individuals with DD were given or sent a questionnaire 
pack to pass on to an available unaffected relative. Fifteen unaffected relatives returned a 
completed questionnaire pack. Therefore in total 24 unaffected relatives (35%) were recruited (9 
interviewed plus 15 completing a questionnaire pack).
10.1.2.3 Confirmation that Unaffected Relatives did not have a Pathogenic 
Mutation in ATP2A2
Blood or Oragene™ saliva samples were collected from 17 of the 24 unaffected relatives. 
The DNA extraction techniques, carried out by two members of the psychiatric genetics 
laboratories at Birmingham and Cardiff Universities, and the detection of variants in the ATP2A2 
gene, carried out by the Wales Gene Park, are previously described in Chapter 7 Section 7.1 and
7.2 respectively pg. 145. As reported in Chapter 8, section 8.1.1 pg. 158, no other possible DD 
causing variants in ATP2A2 were detected in any of these unaffected relatives.
10.1.2.4 Attempts to Match Individuals with DD and their Unaffected Relatives 
For Age and Gender
In addition to the 100 index individuals with DD and the 24 unaffected relatives, 16 
additional first-degree relatives with DD were also recruited as part of the study. This was usually 
because they had been present at the house when the index individual was interviewed and were 
also willing to participate in the study. In the case of four of these additional relatives, they were 
either closer in age to the unaffected relative than the index and/or were the same gender as the 
unaffected relative whereas the index was not. These four additional affected relatives were 
included in the DD comparison group instead of their four index relatives. These figures are 
summarised in Figure 10.1.
Figure 10.1 Comparison Groups- 24 Individuals with DD and their Unaffected Relatives
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16
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10.1.3 Comparison of Demographics, Lifetime Neuropsychiatric
Features and Scores on Personality, Temperament and Current Mood 
State Questionnaires
The demographic characteristics, prevalence of history of neuropsychiatric features and 
scores on a number of personality, temperament and current mood state questionnaires were 
compared in a group of individuals with DD and their unaffected first-degree relatives. These are 
described in the following sections.
10.1.3.1 Demographics
Demographic information was collected from all study participants including current age, 
gender, marital status, current social and employment circumstances, main lifetime occupation 
and highest level of educational qualifications.
10.1.3.2 Lifetime History of Neuropsychiatric Features
Individuals with DD and their unaffected relatives were compared on the following measures 
of lifetime history of neuropsychiatric features:
• Lifetime treatment for psychiatric illness (including GP consultation for psychiatric 
symptoms, being offered/receiving medication for psychiatric symptoms by their GP, 
being referred by their GP to psychiatric services, and receiving psychiatric inpatient 
treatment).
• Lifetime history of being referred to a neurologist and having neurological investigations 
and/or or being treated for a neurological condition.
• Lifetime history of being given a diagnosis of dyslexia and/ or a history of receiving extra 
help at school.
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10.1.3.3 Personality, Temperament and Current Mood State Questionnaires
As previously described in Chapter 3 section 3.2.9 pg 45, at the end of the clinical and 
neuropsychiatric assessment, individuals with DD were asked if they would be willing to have a 
pack of personality, temperament and current mood state questionnaires to be completed in their 
own time and returned in a stamped addressed envelope. Unaffected relatives were also asked to 
complete the same set of questionnaires. A brief description of each questionnaire is given below 
and their scoring is displayed in pg. 226. All of the questionnaires are self-rated and validated 
measures. Copies of all of the questionnaires are displayed in Appendix Eiii pg. 348.
Beck Depression Inventory (EDI) (Beck & Steer, 1987)
The Beck Depression Inventory (BDI) is a widely used measure of the presence and/or 
severity of current depressive symptoms. The questionnaire was included to investigate whether 
there were any significant differences in the current depression scores of individuals with DD and 
their unaffected relatives. As current depressive symptoms are known to affect scores on a 
number of personality and temperament questionnaires, the questionnaire was also included to 
enable differences between the groups on these measures to be investigated whilst controlling for 
individuals’ current level of depression.
Altman Self-Rating Scale for Mania (ASRM) (Altman et al., 1997)
The Altman Self-Rating Scale for Mania (ASRM) is a measure of the presence and/or 
severity of current manic symptoms. The questionnaire was included for the same reasons 
outlined above for the BDI.
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Rosenberg Self-Esteem Scale (RSE) (Rosenberg, 1965)
The Rosenberg Self-Esteem Scale (RSE) is a widely used measure of trait self-esteem. The 
scale has a total score and gives two subscale scores, a negative subscale relating to five 
statements including “At times I think I am no good at all” and a positive subscale relating to the 
remaining five statements including “On the whole I am satisfied with myself’. Studies have 
found lower self-esteem using the RSE among euthymic individuals with unipolar and bipolar 
disorder compared to controls (Jones et al., 2005; Scott et al., 2000). These studies, in addition to 
a number of others, suggest that low self-esteem reflects a vulnerability to affective illness. The 
RSE was included in the present study as significant differences in self-esteem scores may reflect 
differences between the groups in the prevalence of individuals with vulnerability to mood 
disorders.
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Eysenck Personality Questionnaire (EPQ) (Eysenck & Eysenck, 1975)
The Eysenck Personality Questionnaire (EPQ) is a widely used measure of personality. The 
questionnaire gives scores for three dimensions of personality: Extraversion, Neuroticism and 
Psychoticism. Similar to low self-esteem, numerous studies have shown that high neuroticism 
scores reflect an individual’s vulnerability to major depression (Duggan et al., 1995; Kendler et 
al., 2006). One study has suggested, that in women, EPQ neuroticism is a better reflection of 
vulnerability to depression than self-esteem measured using the RSE (Roberts & Kendler, 1999). 
Although neuroticism is most commonly reported as being associated with risk of developing 
unipolar depression, high neuroticism has also been associated with bipolar disorder (Solomon et 
al., 1996) and anxiety disorders including social phobia, agoraphobia and panic disorder 
(Bienvenu et al., 2001). The EPQ was included in the present study to compare scores on the 
personality dimensions between individuals with DD and their unaffected relatives. Significant 
differences in scores on the neuroticism dimension in particular may reflect differences between 
the groups in the prevalence of individuals with increased vulnerability to major depression and 
other mood and anxiety disorders.
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Temperament Evaluation o f Memphis, Pisa, Paris and San Diego-Autoquestionnaire version 
(TEMPS-A)(Akiskal et al., 2005)
The Temperament Evaluation of Memphis, Pisa, Paris and San Diego-Autoquestionnaire 
version (TEMPS-A) is designed to measure variations in individuals’ temperament. The 
questionnaire measures five temperaments/subscales: Cyclothymic, Dysthymic, Irritable, 
Hyperthymic and Anxious. It has been suggested by the author of the questionnaire that 
dysregulation of these temperaments may represent sub-clinical presentations of mood and 
anxiety disorders and reflect increased vulnerability to these disorders. This is supported by a 
study using the scale to compare the temperament scores of euthymic individuals with bipolar 
disorder, their healthy unaffected relatives (a sample of individuals at risk of developing mood 
disorders) and normal controls (Mendlowicz et al., 2005). Euthymic individuals with bipolar 
disorder and their unaffected relatives were found to have significantly higher scores on the 
cyclothymic and anxious temperament subscales than controls. The cyclothymic subscale 
includes the items/statements “my moods and energy are either high or low, rarely in between ” 
and “I  constantly switch between being lively and sluggish ” For each statement individuals are 
asked to indicate if this applies to them for much of their life.
The TEMPS-A questionnaire was included in the present study as significant differences 
between the groups on one or more of the subscales may reflect differences in the proportion of 
individuals with features of mood and anxiety disorders including sub-clinical features. Such 
differences may not be apparent when comparing the groups on objective measures such as 
lifetime history of treatment for psychiatric symptoms. An advantage of the TEMPS-A is that 
high scores on each of the temperaments/subscales may indicate vulnerability to specific types of 
mood and/or anxiety disorders.
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Kings Schizotypy Questionnaire (KSQ ) (Jones et al., 2000; Williams, 1993)
The Kings Schizotypy Questionnaire (KSQ) is a measure of schizotypy, a term used to 
describe a set of characteristics observed in the unaffected relatives of individuals with 
schizophrenia and suggested as reflecting liability to schizophrenia (Claridge, 1987; Meehl, 
1962). These characteristics include difficulty in close relationships, odd speech and behaviours 
and perceptual disturbances. The KSQ measures seven subscales: Social Isolation, Social 
Anxiety, Recurrent Illusions I, Recurrent Illusions II, Magical Thinking, Paranoid Ideation and 
Ideas of Reference. Scores on the KSQ have been found to be significantly higher in individuals 
with schizophrenia and bipolar disorder than controls (Heron et al., 2003). In addition the 
presence of schizotypal personality traits have been found to be similar in relatives of individuals 
with schizophrenia and affective psychosis (McGilvarry et al., 2001). These finding suggest that 
high schizotypy scores may reflect vulnerability to functional psychosis rather than just 
schizophrenia. The KSQ was included in the present study as significant differences in 
schizotypy may reflect difference between the groups in the prevalence of individuals with 
vulnerability to functional psychosis.
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Table 10.2 Current Mood State, Personality and Temperament Questionnaires
Questionnaire (Reference) Description Subscales Scoring
Beck Depression Inventory (BDI)
(Beck & Steer, 1987)
Widely used measure of the presence and/or 
severity of current depressive symptoms 
21 items each rated on a scale of 0 (absent) to 3 
(present and severe)
'"Total scores range from 0 (no 
depressive symptoms) to 63 
(severe depression)
Altman Self-Rating Scale for Mania 
(ASRM)
(Altman et al., 1997)
Measure of the presence and/or severity of 
current manic symptoms 
5 items each rated on a scale of 0 (absent) to 4 
(present and severe)
Total scores range from 0 (no 
manic symptoms) to 20 
(significant manic symptoms)
Rosenberg Self-Esteem Scale (RSE) 
(Rosenberg, 1965)
Widely used measure of global self esteem 
10 items/statements (5 positive, 5 negative) 
rated on a scale of 1-4 strongly disagree- 
strongly agree on the positive items/statements 
and strongly agree 
-strongly disagree on the negative 
items/statements
Positive Subscale 
Negative Subscale
Total score range from 10-40. 
Positive and negative subscale 
scores range from 5-20. Higher 
scores reflect higher self­
esteem.
Eysenck Personality Questionnaire 
(EPQ)
(Eysenck & Eysenck, 1975)
Widely used measure of personality. 
90 yes-no items
3 personality dimensions: 
Extraversion, Neuroticism, Psychoticism + 
Lie Scale
Subscale Scores 
Extraversion 0-21 
Neuroticism 0-23 
Psychoticism 0-25 
Lie 0-21
Temperament Evaluation of Memphis, 
Pisa, Paris and San Diego- 
Autoquestionnaire version (TEMPS- 
A)
(Akiskal et al., 2005)
Measure of temperament 
39 true-false items/statements -  true items are 
added up to give a score for each of the 5 
temperaments
5 temperaments:
Depressive, Cyclothymic, Hyperthymic, 
Irritable and Anxious
Cyclothymic 0-12 
Depressive 0-8 
Irritable 0-8 
Hyperthymic 0-8 
Anxious 0-3
Kings Schizotypy Questionnaire 
(Jones etaL, 2000; Williams, 1993)
Measure of schizotypal features 
63 yes-no items
7 subscales:
Social Isolation, Social Anxiety, Recurrent 
Illusions I, Recurrent Illusions II, Magical 
Thinking, Paranoid Thinking, Ideas of 
Reference
Total Score 0-63 
All 7 subscales 0-9
*BDI Cut off scores: <10; none or minima depression, 10-18; mild to moderate depression, 19-29; moderate to severe depression, 30-63; severe depression
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10.1.4 Pathogenic Mutation Detection in 24 Individuals with DD
In six of the 24 individuals with DD a pathogenic mutation was not detected in ATP2A2. 
As previously described in Chapter 9 section 9.2 pg. 197, it is possible that one or more of 
these individuals may have clinical features similar to DD that may be caused by factors other 
than a pathogenic mutation in ATP2A2 in other words a be a phenocopy of DD. As a result, 
two sets of analyses were carried out, one comparing all 24 individuals with a diagnosis of 
DD to their unaffected relatives and another excluding the six individuals in whom a 
pathogenic mutation was not detected in ATP2A2 and their unaffected relatives i.e. N=18 in 
each group.
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10.1.5 Summary of the Comparison of a Sample of Individuals with
DD and Their Unaffected Relatives
A summary of the measures and design used to compare a sample of individuals with DD 
and their unaffected relatives is shown in Figure 10.2.
Figure 10.2 Comparison of a Sample of Individuals with DD and their Unaffected Relatives- 
Measures and Design
MEASURES
Demographics
% Female
Lifetime Marital Status
Current Social and Employment Circumstances 
Main Lifetime Occupation 
Highest Level of Educational Qualifications 
Lifetime Neuropsychiatric Features 
Treatment for Psychiatric Illness 
Neurological Investigations and Treatments 
Learning Difficulties
Current Mood State, Personality and Temperament 
Questionnaires
Beck Depression Inventory (BDI)
Altman Mania Scale (AMS)
Rosenberg Self-Esteem Scale (RSE)
Eysenck Personality Questionnaire (EPQ)
TEMPS-A Temperament Questionnaire 
Kings Schizotypy Questionnaire (KSQ)
Study Database
Group 1: n=24 
Individuals with 
clinical DD
Group 2: n= 24 
Unaffected relatives
Group 1: n=18 
Individuals with 
genetically confirmed 
DD
Group 2: n=18 
Unaffected relatives
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10.2Statistical Approaches
Data were extracted from the study Access database into the statistical package SPSS 
version 12.0.1 (SPSS Inc., 2003). The statistical tests used to examine differences between the 
DD and unaffected relatives groups in both sets of analyses are outlined below. Statistical 
tests were considered significant at the p<0.05 level (two tailed).
Continuous data: Paired-samples t tests (normality of the differences between the two 
groups was assessed using the Kolmogorov-Smimov Test and were found to approximate 
normality on all measures)
Categorical data: Fisher’s exact tests (2x2 tables) and exact significance tests for 
Pearson’s chi-square (2x3 tables and greater).
Within-subject associations between scores on the BDI and the personality and 
temperament measures were assessed using Spearman’s rho correlations.
Binary logistic regression (forward stepwise likelihood ratio) was carried out to determine 
which combination of temperament and personality questionnaire measures best-predicted 
group membership (i.e. DD or unaffected relatives).
Due to the modest sample size of the groups and limited power, corrections were not 
routinely made for multiple testing. Therefore, any significant differences between the groups 
were treated with caution and an emphasis was placed on looking for trends in the differences 
between individuals with DD and their unaffected on the neuropsychiatric measures and 
scores on the personality and temperament questionnaires.
The following chapter (Chapter 11) compares the presence of neuropsychiatric features in 
a sample of individuals with DD and their unaffected first-degree relatives.
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11 COMPARISON OF DEMOGRAPHICS, LIFETIME 
NEUROPSYCHIATRIC FEATURES AND QUESTIONNAIRE 
SCORES IN A SAMPLE OF INDIVIDUALS WITH DD AND 
THEIR UNAFFECTED RELATIVES: RESULTS
This chapter describes and compares the demographic characteristics, prevalence of 
lifetime neuropsychiatric features and scores on a number of personality, temperament and 
current mood state questionnaires in a group of individuals with DD and a group of their 
unaffected relatives. Two sets of analyses were carried out, one comparing 24 individuals 
with a clinical diagnosis of DD to their unaffected relatives and another only comparing 18 of 
the original 24 individuals with genetically-confirmed DD to their unaffected relatives. 
Additional information relating to this chapter can be found in section F of the Appendix 
starting at pg. 363, and will be referenced throughout the chapter.
11.1 Comparison of Demographics
The demographic characteristics of all the groups are summarised in Table 11.1. In both 
sets of analyses, the DD group and unaffected relatives groups did not differ significantly on 
any of the demographic variables, which included current age, the proportion of females, 
lifetime marital status, current social circumstances, current employment status, main-lifetime 
occupation and highest level of educational qualifications (see Appendix F Table F-l pg.
363).
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Table 11.1 Comparison of Demographic Characteristics of Individuals with DD and their 
Unaffected Relatives - Descriptives and Frequencies
Individuals with Clinical 
DD and their unaffected 
relatives
Individuals with 
Genetically-confirmed 
DD and their unaffected 
relatives
DD (N=24) Unaffected
(N=24)
DD (N-18) Unaffected
(N-18)
Age (years)
Mean (95% Cl) 45.04
(39.34-
50.74)
43.50
(37.72-
49.28)
43.89
(37.73-
50.05)
44.22
(37.74-
50.71)
Standard Deviation 13.502 13.680 12.395 13.036
Range 20-67 19-74 21-61 19-74
% % •/• %
Female 67 71 67 72
Lifetime Marital Status
Has married/lived as married 75 79 78 83
Has never married/lived as married 25 21 22 17
Current Social Circumstances
Lives in own home with spouse and/or children 54.2 54.2 55.6 61.1
Lives alone 12.5 8.3 16.7 5.6
Lives in home of parents or children 25 29.2 22.2 27.8
Lives with partner at least one year but not married 8.3 8.3 5.6 5.6
Current Employment Status
Employed full time 41.7 37.5 50 38.9
Employed part time 20.8 33.3 22.2 33.3
Not working-receiving benefits 12.5 8.3 16.7 11.1
Full-time student 8.3 4.2 0 0
Homemaker 4.2 8.3 5.6 5.6
Retired 12.5 8.3 5.6 11.1
Main Lifetime Occupation
Legislator/senior officials, managers and 
professionals
25 41.7 16.7 33.4
Technicians & associate professionals (& civil 
servants)
8.3 12.5 11.1 16.7
Clerks 25 20.8 27.8 22.2
Service workers & shop & market workers 20.8 8.3 22.2 11.1
Craft & related trade workers 12.5 4.2 16.7 5.6
Elementary occupations 4.2 8.3 5.6 11.1
Full-time student 4.2 4.2 0 0
Highest Level of Educational Qualifications
No qualifications 20.8 20.8 27.8 22.2
Other qualifications* 20.8 4.2 16.7 5.6
GCSE A-C or equivalent 33.3 33.3 44.4 38.9
A Level or equivalent 12.5 12.5 5.6 11.1
Teaching, HND, Nursing, Degree 12.5 29.2 5.6 22.2
* Other qualifications include CSEs and GCSE grades D-G
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11.2 Comparison of Lifetime Neuropsychiatric Features
11.2.1 Comparison of Lifetime Treatment for Psychiatric Illness
Table 11.2 pg. 234 summarises the frequencies and percentages of individuals with DD 
and their unaffected relatives receiving treatment for psychiatric illness in their lifetime. 
Individuals who had received more than one type of treatment, for example had consulted 
their GP for symptoms of depression, received antidepressants and been referred to secondary 
psychiatric services, are included in more than one treatment category. In the first set of 
analyses, a significantly higher proportion of individuals with DD compared to their 
unaffected relatives had consulted their GP for psychiatric symptoms (62.5% vs. 25%; 
Fisher’s, p=0.019) and been referred by their GP to secondary psychiatric services (33.3% vs. 
4.2%; Fisher’s, p=0.023). In the second set of analyses, which only included individuals with 
genetically confirmed DD, there were greater differences in the proportions of individuals 
with DD and their unaffected relatives having a lifetime history of treatment for psychiatric 
illness. A significantly higher proportion of individuals with DD compared to their unaffected 
relatives had consulted their GP for psychiatric symptoms (66.7% vs. 16.7%; Fisher’s, 
p=0.006) and been referred by their GP to secondary psychiatric services (44% vs. 0%; 
Fisher’s, p=0.003).
11.2.2 Comparison of Lifetime History Neurological Investigations 
and Treatments
Table 11.3 pg. 234 summarises the frequencies and percentages of individuals with DD 
and their unaffected relatives with a lifetime history of being referred to a neurologist and 
having neurological investigations or being treated for a neurological condition. In both sets 
of analyses there were identical proportions of individuals with DD and their unaffected 
relatives having a lifetime history of neurological investigations and treatments.
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Table 11.2 Comparison of Lifetime Treatment for Psychiatric Illness amongst Individuals with 
DD and their Unaffected Relatives
Individuals with Clinical 
DD and their unaffected 
relatives
Individuals with 
Genetically-confirmed 
DD and their unaffected 
relatives
DD
N=24
Unaffected
N=24
DD
N-18
Unaffected
N-18
N(%) N(%) N(%) N(%)
GP consultation for psychiatric symptoms 15(62.5)
(p=C
6(25)
.019)
12 (66.7) 
(P*<
3(16.7)
1.006)
■“Offered/received medication for 
psychiatric symptoms by GP
10(41.7)
(p=(
6(25)
1.359)
9(50)
(p=C
3 (16.7) 
.075)
Referred by GP to psychiatric services 8 (33.3) | 1 (4.2) 
(p= 0.023)
8(44.4) | 0(0) 
(P- 0.003)
Psychiatric inpatient treatment 1(4.2) | 0(0) 
(P=1.0)
1(5.6) | 0(0) 
(P=10)
Fisher’s Exact Tests. * Includes antidepressants, anxiolytics or hypnotics.
Table 11.3 Comparison of Lifetime History of Neurological Investigations and Treatments 
amongst Individuals with DD and their Unaffected Relatives
Individuals with Clinical DD and 
their unaffected relatives
with Genetically* 
confirmed DD and their 
unaffected relatives
DD
N=24
Unaffected
N=24
DD
N-18
Unaffected
N«18
N (%) N (%) ..... N(%)
Neurological Treatments 
or Investigations
3* (12.5)
(p=
3** (12.5)
1.0)
3(16.7)
(P*
3 (16.7)
10)
Fisher’s Exact Tests. *Viral Encephalitis; syncope attacks; recurrent headaches. ** Multiple Sclerosis; recurrent 
headaches x2.
11.2.3 Comparison of Learning Difficulties
Table 11.4 summarises the frequencies and percentages of individuals with DD and their 
unaffected relatives with a lifetime history of being given a diagnosis of dyslexia and/or a 
history of receiving extra help at school. Individuals with a history of being given a diagnosis 
of dyslexia and receiving extra help at school are included in both categories. In the first set of 
analyses, a non-significantly higher proportion of individuals with DD compared to their 
unaffected relatives had previously been given a diagnosis of dyslexia (13% vs. 4.3%;
Fisher’s, p=0.608) and a history of receiving extra help at school (21.7% vs. 4.3%; Fisher’s,
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p=0.187). In the second set of analyses, there were greater differences in the proportions of 
individuals with genetically confirmed DD and their unaffected relatives having a lifetime 
history of a diagnosis of dyslexia (11.8% vs. 0%; Fisher’s, p=0.485) and a history of receiving 
extra help at school (24% vs. 0%; Fisher’s, p=0.103). These differences were not significant.
Table 11.4 Comparison of Learning Difficulties amongst Individuals with DD and their 
Unaffected Relatives
Individuals with Clinical DD 
and their unaffected relatives
Individuals w ith Genetically* 
confirmed DD and their 
unaffected relatives
DD Unaffected DD Unaffected
N=23* N=23* N-17* N-17*
N (%) N (%) N(%) N(%)
Diagnosis of Dyslexia 3(13) 1(4.3) 2(11.8) 0(0)
(p=0.608) (p=0.485)
♦♦Received extra help at school 5(21.7) 1 (4.3) 4(24) 0(0)
(p=0.187) (p*0.103)
Fisher’s Exact Tests. *Missing cases are one DD-Unaffected pair where information on either one individual or both was 
unknown. ** Includes extra help with reading and/or writing and/or spelling and/or maths.
11.3 Comparison of Current Mood State, Personality and  
Temperament Questionnaires
The following sections compare the DD and unaffected relatives groups on a number 
of personality, temperament and current mood state questionnaires. A brief description of 
each questionnaire and their scoring is displayed in Chapter 10 Table 10.2 pg. 227.
11.3.1 Current Mood State Questionnaires
Descriptives for scores on the Beck Depression Inventory (BDI) and Altman Self-Rating 
Scale for Mania (ASRM) among individuals with DD and their unaffected relatives are 
displayed in Table 11.5. In the first set of analyses, there was a very small difference in the 
mean BDI scores of individuals with DD and their unaffected relatives (6.95 vs. 6.86; 
t=0.042, df=20, p=0.967). In the second set of analyses, only including individuals with 
genetically confirmed DD, there was a greater difference in the mean BDI scores, which 
almost reached significance (7.93 vs. 4.20; t=1.813, df=14, p=0.091). In both sets of analyses,
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there were very small non-significant differences in the mean ASRM scores (2.90 vs. 3.62; 
t=0.821, df=20, p=0.422) and (3.27 vs. 3.73; t=0.450, dfi=14, p=0.660).
Table 11.5 Comparison of BDI and ASRM Scores in Individuals with DD and their Unaffected 
Relatives
Individuals with Clinical DD and 
their unaffected relatives
Individuals with Genetically-confirmed 
DD and their unaffected relatives
DD
*N=21
Unaffected
*N=21
DD
♦N-15
Unaffected
*N-15
BDI Mean/ Median 6.95/5.00 6.86/3.00 7.93/5.00 420/1.00
Standard Deviation 7.018 9.074 7.411 6.700
Range (IqR) 0-24 (10.00) 0-31 (10.50) 0-24(9) 0-25 (6)
(t=0.042, df=20, p=0.967) (*=1.813, dfH4, p=0.091)
ASRM Mean/ Median 2.90/2.00 3.62/3.00 3.27/2.00 3.73/3.00
Standard Deviation 2.528 4.080 2.658 4.511
Range (IqR) 0-9 (3) 0-15(7) 0-9(2) 0-15(8)
(t=0.821, df=20, p=0.422) (t=0.450, df=14, p=0.660)
Paired Samples T Tests. BDI; Beck Depression Inventory, ASRM; Altman Self-Rating Scale for Mania. IqR; 
Interquartile Range. "‘Missing cases are three DD-Unaffected pairs where either one individual or both did not 
complete the questionnaires.
11.3.2 Personality and Temperament Questionnaires 
11.3.2.1 Rosenberg Self-Esteem Scale (RSE)
Descriptives for total and subscale scores on the Rosenberg Self-Esteem Scale (RSE) 
among individuals with DD and their unaffected relatives are displayed in Table 11.6. A 
similar pattern of results was observed in both sets of analyses. Both groups of individuals 
with DD had lower mean total scores on the RSE (indicating lower self esteem) than their 
unaffected relatives. In the second set of analyses, this difference was statistically significant 
(26.44 vs. 31.50; t=2.219, df=15, p=0.042). Mean scores on the positive subscale of the RSE 
were not significantly different in both sets of analyses. Individuals with DD had significantly 
lower mean scores on the negative scale of the RSE (indicating lower self-esteem) than their 
unaffected relatives in both sets of analyses (13.38 vs. 15.81; t=2.112, df=20, p=0.047) and 
(12.38 vs. 15.69; t=2.374, df=15, p=0.031). In the three sets of analyses where individuals 
with DD had significantly lower self-esteem scores than their unaffected relatives, 
correlations between self-esteem scores and individuals’ current level of depression were
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investigated (see Table F-2 pg. 363). In all cases there was a non significant negative 
correlation between self-esteem and current depressive symptoms, individuals with lower 
self-esteem reported more current depression. To investigate whether the significant 
differences in self-esteem between individuals with DD and their unaffected relatives still 
existed once current level of depression was controlled for, further analyses were carried out 
only including individuals with DD and their unaffected relatives where both individuals had 
a score of less than 10 on the BDI (the cut-off for none or minimal depression) (see Table F-3 
pg 364). The trend for individuals with DD to have lower self-esteem scores than their 
unaffected relatives remained but these differences did not reach statistical significance. This 
trend was also found when a linear regression model was used to adjust RSE scores for 
variation in BDI scores and the corrected total RSE scores of individuals with DD and their 
unaffected relatives were compared using a paired sample t- test (mean RSE scores; 24.46 vs. 
27.93; t=2.085, d£=14, p=0.056).
Table 11.6 Comparison of Rosenberg Self-Esteem Scale Total and Subscale Scores in Individuals 
with DD and their Unaffected Relatives
Individuals with Clinical DD and their 
unaffected relatives
Individuals with Genetically-confirmed 
DDand their unaffected relatives
DD
*N=21
Unaffected
*N=21
DD
**N«16
Unaffected
**N*16
Total . • :
Mean/Median 28.10/28.00 31.62/32.00 26.44/27.00 31.50/31.50
Standard Deviation 6.123 6.407 5.656 6.303
Range 17-39 16-40 17-39 16-40
Interquartile Range 10 9 8 10
(t= 1.874, df=20, p=0.076) Ct-2.219, df»s15, p-0.042)
Positive subscale
Mean/Median 14.71/15.00 15.81/15.00 14.06/15.00 15.81/15.00
Standard Deviation 3.068 2.462 3.043 2.287
Range 7-19 11-20 7-19 11-20
Interquartile Range 5 3 ' ' -S' ■ ' 3
(t= 1.263, df=20,p=0.221) (**1.635,0*15, p* 0.123)
Negative subscale
Median/ Mean 13.38/13.00 15.81/17.00 12.38/12.00 15.69/16.00
Standard Deviation 3.653 4.167 3364 4.254
Range 9-20 5-20 9-20 5-20
Interquartile Range 6 6 6
(t=2.112, df=20, p=0.047) (t=2374, df=15, p=0.031)
Paired Samples T Tests. Missing cases are three* and two** DD-Unaffected pairs where either one individual or both did not 
complete the questionnaire.
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11.3.2.2 Eysenck Personality Questionnaire (EPQ)
Descriptives for subscale scores on the Eysenck Personality Questionnaire (EPQ) 
among individuals with DD and their unaffected relatives are displayed in Table 11.7. In both 
sets of analyses there were no significant differences in the mean scores of individuals with 
DD and their unaffected relatives on the extroversion, psychoticism and lie subscales. The 
groups also did not significantly differ in their mean scores on the neuroticism subscale in the 
first set of analyses. However, in the second set of analyses, the mean neuroticism score of the 
genetically confirmed DD group was significantly higher than the mean score of the 
unaffected relatives group (12.80 vs. 8.13; t=3.883, df=14, p=0.002). In these two groups 
there was a positive correlation between neuroticism scores and individuals’ current level of 
depression (see Table F-2 pg. 363). Individuals with DD still had significantly higher mean 
EPQ neuroticism scores than their unaffected relatives when current level of depressive 
symptoms was controlled for by only including individuals with DD and their unaffected 
relatives where both individuals had a score of less than 10 on the Beck Depression Inventory, 
(12.25 vs. 7; t=3.656, df=7, p=0.008) (see Table F-3 pg. 364).
The frequencies and percentages of individuals responding yes or no to EPQ item 68 
“Have you ever wished you were dead? ” are shown in Table 11.8. In the first set of analyses, 
a non-significantly higher proportion of individuals with DD responded .yes to the item than 
their unaffected relatives (48% vs. 38%; Fisher’s, p=0.687). In the second set of analyses the 
difference was greater with nearly twice as many individuals with genetically confirmed DD 
reporting they had wished they were dead compared to their unaffected relatives. This 
relationship remained non-significant (60% vs. 33%; Fishers, p= 0.143).
I 238
Table 11.7 Comparison of EPQ Subscale Scores in Individuals with DD and their Unaffected 
Relatives
Individuals with Clinical DD and their 
unaffected relatives
Individuals with Genetically-confirmed 
DD and their unaffected relatives
DD
*N=21
Unaffected
*N=21
DD
*N-15
Unaffected
*N«15
Extraversion
Mean/Median 12.90/13.00 13.00/13.00 13.00/13.00 13.73/15.00
Standard Deviation 4.898 4.461 4.957 4.574
Range (IqR) 5-21(9) 6-20 (8) 5-21(8) 6-20(9)
(t=0.091, df=20,p=0.928) (t*0.615, df“14, p“0.549)
Neuroticism
Mean/Median 10.43/11.00 9.52/8.00 12.80/15.00 8.13/7.00
Standard Deviation 7.011 5.988 5.943 5.514
Range (IqR) 0-22 (14) 1-22(10) 3-22(11) 1-18(10)
(t=0.548, df=20, p= 0.590) (t-3.883, df-14,0=0.002)
Psychoticism
Mean/Median 2.00/2.43 2.29/2.00 2.73/3.00 2.73/2.00
Standard Deviation 1.832 1.848 1907 1.981
Range (IqR) 0-7 (3) 0-8 (2) 0-7(3) 1-8(2)
(t=0.260, df=20, p=0.797) (t**0.0, dfH 4,0*1.0)
Lie
Mean/Median 10.00/10.24 10.43/9.00 1033/9.00 10.93/11.00
Standard Deviation 4.242 4.154 4.353 4.131
Range 4-19 (7) 4-18(7) 6-19(8) 5-18(6)
(t=0.159, df=20, p=0.875) ^ ft^0s399, df»14, p*0.696)
Paired Samples T Tests. EPQ; Eysenck Personality Questionnaire. IqR; Interquartile Range.
♦Missing cases are three DD-Unaifected pairs where either one individual or both did not complete the questionnaire.
Table 11.8 Comparison of Response to EPQ  Item 68 'Have you ever wished you were dead?* in 
Individuals with DD and their Unaffected Relatives
Individuals with Clinical DD and 
their unaffected relatives
Individuals with Genetically-confirmed 
DD and their unaffected relatives
No Yes No Yes
FAMILY MEMBER N % N % N n  | % N % N
DD 11 52 10 48 21 6 40 9 60 15
Unaffected 13 62 8 38 21 10 1 67 5 33 15
‘Total N 24 18 42 16 14 30
(Fisher’s, p=0.756) (Fisher’s, p=0.143)
Fisher’s Exact Tests. EPQ; Eysenck Personality Questionnaire.
* Missing cases are six individuals from three DD-Unaffected pairs where either one individual or both did not 
complete the questionnaire.
11.3.2.3 TEMPS-A Temperament Questionnaire
Descriptives for scores on the temperament dimensions of the TEMPS-A among 
individuals with DD and their unaffected relatives are displayed in Table 11.9. In both sets of
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analyses, individuals with DD had higher mean scores on the depressive dimension than their 
unaffected relatives but these differences were not significant. In the first set of analyses, 
individuals with DD had non-significantly higher mean scores on the cyclothymic dimension 
than their unaffected relatives (3.32 vs. 2.36; t=l .233, df=21, p=0.231). This difference in 
mean cyclothymic scores became significant when only individuals with genetically 
confirmed DD were compared to their unaffected relatives (4.06 vs. 2.06; t=2.309, df=15, 
p=0.036). In both sets of analyses individuals with DD had lower mean scores on the 
hyperthymic temperament dimension than their unaffected relatives. This difference was only 
significant in the first set of analyses (3.27 vs. 4.55; t=2.096, df=21, p=0.048). There were no 
significant differences between the groups on the irritable and generalized anxious 
temperament dimension in both sets of analyses. In the case of the cyclothymic and 
hyperthymic temperament dimensions where significant differences were found between 
individuals with DD and their unaffected relatives, correlations between the temperament 
scores and individuals current level of depressive symptoms were investigated (see Table F-2 
pg. 363). In both the DD and unaffected relatives groups there was a positive correlation 
between individuals' cyclothymic temperament scores and their current level of depressive 
symptoms. This relationship was significant in the DD group (rho=0.779, n=15, p=0.001). In 
the DD group there was also a significant negative correlation between individuals’ 
hyperthymic temperament scores and their current level of depressive symptoms (rho=-0.552, 
n=21, p=0.01) but there was no significant correlation in the unaffected relatives group.
When current depression was controlled for there were no significant differences between 
individuals with DD and their unaffected relatives in their mean scores on the cyclothymic and 
hyperthymic temperament dimensions of the TEMPS-A questionnaire (see Table F-3 pg.
364).
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Table 11.9 Comparison of TEMPS-A Subscale Scores in Individuals with DD and their 
Unaffected Relatives
Individuals with Clinical DD 
and their unaffected relatives
Individuals with Genetically* 
confirmed DD and their 
unaffected relatives
DD
*N=22
Unaffected
*N=22
DD
*N-16
Unaffected
*N-16
Depressive Mean/Median 2.00/1.00 1.18/0.00 2.38/1.50 1.00/0.00
Standard Deviation 2.545 1.680 2.680 1.366
Range (IqR) 0-8 (3) 0-6(2) 0-8(4) 0-4(2)
(t= 1.328, df=21, p=0.198) (t*1.752,df*15,p*0.100)
Cyclothymic Mean/Median 3.32/2.50 2.36/2.00 4.06/3.00 2.06/1.50
Standard Deviation 3.272 2.592 3.45 2.46
Range (IqR) 0-11(5) 0-7(5) 0-11(5) 0-7(4)
(t=l.233, df=21, p=0.231) (t-3.309, df~15, p-0.036)
Hyperthymic Mean/Median 3.27/3.00 4.55/5.00 3.19/3.00 4.50/5.00
Standard Deviation 2.354 2.041 2.482 2.19
Range (IqR) 0-8(4) 1-8(3) 0-8(4) 1-8(4)
(t=2.096, df=:21, p=0.048) (t-1.774,dM5,p-0.096)
Irritable Mean/Median 1.64/1.00 1.68/1.00 2.00/1.50 1.81/1.00
Standard Deviation 1.620 1.961 1.633 2.228
Range (IqR) 0-5(3) 0-8 (2) 0-5(3) 0-8(3)
(t=0.110, df=21 ,p=0.913) (t«0.362,df*15,P“0.723)
Generalized Anxious Mean/Median 1.05/1.00 0.77/0.00 1.19/1.00 0.88/0.00
Standard Deviation 1.174 1.193 1.276 1.204
Range (IqR) 0-3 (2) 0-3(1) v . 0-3 (3) , 0-3(2)
(t=0.810, df=21,p=0.427) \ (t^):847, df*15, p-0,410)
Paired Samples T Test. TEMPS-A; Temperament Evaluation of Memphis, Pisa, Paris and San Diego- 
Autoquestionnaire version. IqR; Interquartile Range. ’"Missing cases are two DD-Unaffected pairs where either 
one individual or both did not complete the TEMPS-A questionnaire.
11.3.2.4 Kings Schizotypy Questionnaire (KSQ)
Descriptives for the total and subscale scores on the Kings Schizotypy Questionnaire 
(KSQ) among individuals with DD and their unaffected relatives are displayed in Table 
11.10. In the first set of analyses, individuals with DD and their unaffected relatives did not 
significantly differ in their total scores on the KSQ or any of the subscales. In the second set 
of analyses individuals with DD had significantly higher mean Total KSQ scores (11.09 vs. 
7.64; t=3.121, df=10, p=0.011) and significantly higher mean scores on the Ideas o f Reference 
(1.82 vs. 0.91; t=3.194, df=10, p=0.010) and Recurrent Illusions 1 subscales (1 vs. 0.36; t= 
2.609, df=10, p= 0.026). In both groups there was a non-significant positive correlation 
between individuals’ Total, Ideas o f Reference and Recurrent Illusions 1 scale scores and 
their current level of depressive symptoms (see Table F-2 pg. 363). When current level of
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depressive symptoms was controlled for, individuals with DD still had significantly higher 
mean scores on the KSQ total scale (10.17 vs. 6.33; t=3.005, df=5, p=0.030) and the Ideas o f 
Reference subscale (1.83 vs. 0.50; t=4.00, df=5, p=0.010) (shown in Table F-3 pg. 364).
Table 11.10 Comparison of KSQ Scores in Individuals with DD and their Unaffected Relatives
Individuals with Clinical DD 
and their unaffected relatives
Individuals wil 
confirmed E 
unaffected
th Genetically* 
ID and their 
relatives
DD
*N=16
Unaffected
*N=16
DD
*N-11
Unaffected
*N*11
Total Mean/Median 10.56/10.00 9.50/7.00 11.09/10.00 7.64/7.00
Standard Deviation 6.077 9.839 6.172 6.021
Range 1-21 1-41 3-21 1-23
Interquartile Range 11 6 12 5
(t= 0.577, df=15, p=0.572) (t-3.121, df*=10, p-0.011)
Ideas of Reference Mean /Median 1.63/1.00 1.19/0.00 1.82/1.00 0.91/0.00
Standard Deviation 1.408 1.797 1.471 1.446
Range 0-4 0-6 <W 0-4
Interquartile Range 3 2 2 2
(t= 1.385, df=15, p=0.186) (t*3.194, df»10,11*0.010)
Magical Thinking Mean/Median 1.31/1.00 1.06/1.00 1.00/1.00 0.82/1.00
Standard Deviation 1.138 1.389 1.000 0.982
Range 0-3 0-5 0-3 0-3
Interquartile Range 2 2 2. , 1 .
(t=0.745, dfH5, p=0.468) (t*0.690, df*10, p*=0.506)
Paranoid Thinking Mean/Median 1.25/1.00 1.06/1.00 1.45/1.00 1.09/1.00
Standard Deviation 1.571 0.929 1.809 0.831
Range 0-5 0-3 0-5 0-2
Interquartile Range 2 2 3 2
(t=0.467, df=15, p=0.654) ^ ^<tf0.649,d^l0,|H).53I)
Recurrent Illusions 1 Mean/Median 0.81/0.00 0.94/0.00 ; t.oo/d.oo 0.36/0.00
Standard Deviation 1.424 2.081 1.012 0.924
Range 0-5 0-8 0-5 0-3
Interquartile Range 1 1 1 0
(t=0.212, df=15, p=0.835) (t» 2.609, df»10, p« 0.026)
Recurrent Illusions 2 Mean/Median 1.38/1.00 0.94/0.00 1.73/1.00 0.55/0.00
Standard Deviation 1.857 1.652 2.102 0.820
Range 0-7 0-6 0-7 0-2
Interquartile Range 2 2 2 1
(t=0.835 , df=15, p=0.417) 0*2.137, dfMO, p=0.058)
Social Anxiety Mean/Median 2.75/3.00 2.50/2.00 3.00/3.00 2.18/2.00
Standard Deviation 1.571 1.932 1.673 1.471
Range 1-6 1-8 , 1-6 - 1-6
Interquartile Range 3 2 3 2
(t=0.522, df=15, p=0.609) (t-1.695. df»10, p-0.121)
Social Isolation Mean/Median 1.44/1.00 1.81/1.50 1.09/1.00 1.73/1.00
Standard Deviation 1.590 1.759 1.044 1.794
Range 0-6 0-6 0-3 0-6
Interquartile Range 2 3 2 3
(t=0.972, df=15, p=0.347) 0*=1.249, df=10, p=0.240)
Paired Samples T Tests. KSQ; Kings Schizotypy Questionnaire.
♦Missing cases are eight DD-Unaffected pairs where either one individual or both did not complete the questionnaire.
242
11.3.3 Temperament and Personality Predictors of Individuals with 
DD vs. Unaffected Relatives
Logistic regression (forward stepwise) was carried out to determine which combination 
of temperament and personality questionnaire measures best-predicted group membership 
(i.e. DD or unaffected relative). All total questionnaire scores and/or questionnaire subscales 
where there were large differences between the scores of individuals with DD and their 
unaffected relatives were selected as predictor variables in addition to total scores on the two 
current mood state questionnaires (Beck Depression Inventory and Altman Self-Rating Scale 
for Mania), these are summarised in Table 11.11.
Table 11.11 Personality and Temperament Measures Selected as Predictor Variables for 
Logistic Regression
Beck Depression Inventory Total Score (BDI)
Altman Self-Rating Scale for Mania Total Score (ASRM)
Rosenberg Self - Esteem Scale Total Score (RSE)
Eysenck Personality Questionnaire - Neuroticism Subscale (EPQ-N) 
TEMPS-A- Depressive Subscale 
TEMPS-A- Cyclothymia Subscale 
TEMPS-A-Hyperthymia Subscale
Kings Schizotypy Questionnaire Total Score (KSQ)_____________________
TEMPS-A; Temperament Evaluation of Memphis, Pisa, Paris and San Diego-Autoquestionnaire 
version.
In the first set of analyses, 35 individuals with no missing values for any of the 
questionnaire variables were included in the analysis. None of the questionnaire variables had 
a significance value of less than 0.05 and were therefore not significantly predictive of DD vs. 
unaffected relative status. In the second set of analyses, which only included individuals with 
genetically confirmed DD, 25 individuals, with no missing values for any of the questionnaire 
predictor variables, were included in the analysis. The best solution correctly classified 72% 
of individuals. The significant variable in this solution was EPQ neuroticism (OR=l .202,95% 
Cl = 1.014-1.424, p= 0.034).
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11.4 Summary
This chapter has described and compared the demographic characteristics, prevalence of 
lifetime neuropsychiatric features and questionnaires scores in a group of individuals with DD 
and a group of their unaffected relatives. A key finding was that the differences between the 
two groups were greater in the set of analyses that only included individuals with genetically 
confirmed DD. Table 11.12 summaries the lifetime neuropsychiatric features and 
questionnaire scores amongst individuals with genetically confirmed DD and their unaffected 
relatives.
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Table 11.12 Summary of Comparison of Lifetime Neuropsychiatric Features and Questionnaire 
Scores amongst Individuals with Genetically-Confirmed DD and their Unaffected Relatives
Individuals with 
genetically- 
confirmed DD
Unaffected
Relatives
P
% %
GP consultation for psychiatric symptoms 66.7 16.7 0.006
Referred by GP to psychiatric services 44.4 0 0.003
Psychiatric inpatient treatment 5.6 0 1.0
Neurological Treatments or Investigations 16.7 16.7 1.0
Diagnosis of Dyslexia 11.8 0 0.485
Received extra help at school 24 0 0.103
EPQ Item 68- Have you ever wished you were 
dead?
60 33 0.143
Mean (Median*) Mean (Median*) P(P**)
BDI 7.93 (5.00) 4.20(1.00) 0.091
ASRM 3.27 (2.00) 3.73 (3.00) 0.660
RSE Total 26.44 31.50 0.042 (0.175)
Positive subscale 14.06 15.81 0.123
Negative subscale 12.38 15.69 0.031 (0.206)
EPQ Extraversion 13.00 13.73 0.549
Neuroticism 12.80 8.13 0.002 (0.008)
Psychoticism 2.73 2.73(2.00) 1.0
Lie 10.33 10.93 0.696
TEMPS-A Depressive 2.38(1.50) 1.00(0.00) 0.100
Cyclothymic 4.06 2.06(1.50) 0.036 (0.794)
Hyperthymic 3.19 4.50 0.096
Irritable 2.00(1.50) 1.81 (1.00) 0.723
Generalized Anxious 1.19(1.00) 0.88 (0.00) 0.410
KSQ Total 11.09 7.64 (7.00) 0.011 (0.030)
Ideas of Reference 1.82(1.00) 0.91 (0.00) 0.010 (0.010)
Magical Thinking 1.00 0.82(1.00) 0.506
Paranoid Thinking 1.45 1.09 0.531
Recurrent Illusions 1 1.00(0.00) 0.36 (0.00) 0.026 (0.203)
Recurrent Illusions 2 1.73(1.00) 0.55 (0.00) 0.058
Social Anxiety 3.00 2.18/2.00 0.121
Social Isolation 1.09 1.73 0.240
Fisher’s Exact Tests and Paired Samples T Tests. BDI; Beck Depression Inventory, ASRM; Altman Self-Rating 
Scale for Mania, RSE; Rosenberg Self-Esteem Scale, EPQ; Eysenck Personality Questionnaire, TEMPS-A; 
Temperament Evaluation of Memphis, Pisa, Paris and San Diego-Autoquestionnaire, KSQ; Kings Schizotypy 
Questionnaire. Median* reported where data are not normally distributed. P** Significance after controlling for 
current depression. Significant P values are reported in bold.
The following chapter (Chapter 12) discusses the finding summarised in Table 11.12
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12 COMPARISON OF DEMOGRAPHICS, LIFETIME 
NEUROPSYCHIATRIC FEATURES AND QUESTIONNAIRE 
SCORES IN A SAMPLE OF INDIVIDUALS WITH DD AND 
THEIR UNAFFECTED RELATIVES: DISCUSSION
This chapter will discuss the results presented in Chapter 11. These results and 
discussions relate to the third aim of the thesis, which was to compare the presence of 
neuropsychiatric features in a sample of individuals with DD and their unaffected first-degree 
relatives. First, the possible reasons for the consistent finding that differences between the two 
groups were greater when the analysis only included individuals with genetically confirmed 
DD are discussed. This is followed by a discussion of the comparison of the demographic 
characteristics, lifetime neuropsychiatric features and questionnaire scores among the group 
of 18 individuals with genetically confirmed DD and their unaffected relatives.
12.1 Comparisons o f Individuals with Clinical DD and Genetically 
Confirmed DD
In the majority of cases there was a trend for the prevalence of neuropsychiatric 
features/questionnaire scores among individuals with genetically confirmed DD to indicate a 
greater degree of psychopathology compared to the sample containing all individuals with a 
clinical diagnosis of DD. This pattern was observed for all of the lifetime treatment for 
psychiatric illness measures, for example 33% of the “clinical diagnosis of DD” sample had 
been referred to psychiatric services compared to 44% of the “genetically confirmed DD” 
sample. This is consistent with the finding, reported and discussed in Chapters 8 and 9, that 
individuals in whom a pathogenic mutation was detected in ATP2A2 had a higher lifetime 
prevalence of neuropsychiatric illness. In 18 of the 21 questionnaire total and subscale scores 
(excluding the EPQ lie scale) there was a trend for scores indicating more psychopathology to 
be observed in the “genetically confirmed DD” sample compared to the “clinical DD” sample.
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Explanations for the increased prevalence of neuropsychiatric features among individuals 
with genetically confirmed DD have previously been discussed in Chapter 9 section 9.2 pg. 
197). It is possible that a proportion of the individuals in whom a pathogenic mutation was 
not detected are phenocopies of DD, i.e. they do not have a pathogenic mutation in ATP2A2. 
Based on the hypothesis that mutations in ATP2A2 have pleiotropic effects in the skin and 
brain, it would be expected that these individuals would have a lower prevalence of 
neuropsychiatric features. Due to the possibility that individuals in the “clinical DD” sample 
may not have a pathogenic mutation in ATP2A2, the following sections discuss just the 
comparisons of individuals with genetically confirmed DD and their unaffected relatives.
12.2 Comparison of Individuals With Genetically-Confirmed DD and 
Their Unaffected Relatives
This is the first case series study of DD to compare the presence of neuropsychiatric 
features in individuals with DD and their first-degree unaffected relatives. Unaffected family 
members have only previously been examined in studies reporting the neuropsychiatric 
features in single families with multiple family members with DD (summarised in Table 2.3 
pg. 13). These studies have consistently reported a greater prevalence of neuropsychiatric 
features in family members with DD compared to family members without DD.
As discussed in Chapter 5, comparison of the prevalence of lifetime neuropsychiatric 
features in the current sample to the reported rates in the general population suggested a 
potential population-level association between DD and mood disorders, specifically major 
depression, suicide attempts and suicidal thoughts. The added advantage of having an 
unaffected relatives comparison group is that this method allows control for additional genetic 
and non-genetic factors that could influence the presence of neuropsychiatric features.
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12.2.1 Demographics
The two groups were well matched for age (mean age 44 in both groups) and gender 
(proportion of women; 67% vs. 72%). A very similar proportion of individuals with DD and 
their unaffected relatives were married and the majority of individuals in both groups were 
living with a spouse and/or children. A higher proportion of individuals with DD were living 
on their own compared to their unaffected relatives (16.7% vs. 5.6%). In both groups most 
individuals were either employed full time or part time (72%).
A very slightly higher proportion of DD individuals reported that they had no formal 
qualifications compared to their unaffected relatives (27.8% vs. 22.2%). As reported in 
Chapter 4,41% of individuals in the current study reported having no qualifications, 
indicating that the DD group was unrepresentative of the whole sample. A possible 
explanation for this is that individuals with no qualifications were more likely to be older, and 
therefore their first-degree relatives may not have been well enough/available to take part in 
the study.
There was a non-significant trend for individuals with DD to have not reached as high 
occupational and educational levels as their unaffected relatives. A lower proportion of the 
DD group reported their main lifetime occupation as being a professional/associate 
professional (27.8% vs. 50.1%) and a lower proportion had higher education qualifications 
(5.6% vs. 22%). This finding is consistent with a report in the literature of an individual with 
DD (as a result of a spontaneous mutation) who left school aged 15 without any 
qualifications, and had a genetically identical but unaffected twin brother who completed 
secondary school education and achieved a senior position (Ruiz-Perez et al., 1999). The 
potential effects of DD on individuals’ occupation and educational performance needs to be 
examined in a larger samples. Individuals with DD may have to take time off from school 
and/or work due to the severity of their symptoms also, as discussed in Chapter 5, a
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proportion of individuals with DD may be impaired in specific aspects of learning. Both of 
these factors could potentially affect the educational and occupational performance of 
individuals with DD.
12.2.2 Lifetime Neuropsychiatric Features
Treatment for Psychiatric Illness
As shown in Table 11.2 pg. 234, a significantly higher proportion of individuals with DD 
had a lifetime history of consulting their GP for psychiatric symptoms and being referred by 
their GP to psychiatric services compared to their unaffected relatives. This is consistent with 
the findings in the whole DD sample, reported and discussed in Chapters 4 and 5. The 
explanations for the increased prevalence of psychiatric features among individuals with DD 
compared to their unaffected relatives have previously been discussed in Chapter 5, section 
5.4 pg. 123 These include psychosocial factors and the pleiotropy hypothesis.
The prevalence of past psychiatric treatment in the DD group differed from that observed 
in the whole genetically confirmed DD sample. Among DD individuals with a participating 
unaffected relative there was a non-significantly higher prevalence of lifetime history of GP 
consultation (66.7% vs. 46.0%; Fisher’s, p=0.173) and being referred by a GP to psychiatric 
services (44.4% vs. 29.2%; Fisher’s, p=0.257) compared to individuals without a participating 
relative. However this bias does not fully account for the differences between the DD and 
unaffected groups. It is possible that individuals with a past history of psychiatric illness may 
have been more likely to encourage their unaffected relatives to participate in the current 
study. In addition, unaffected relatives may have been more likely to participate if they felt 
their relatives had experienced psychiatric symptoms as a consequence of DD. In contrast 
there was a lower prevalence of lifetime history of receiving psychiatric inpatient treatment 
among individuals with a participating unaffected relative compared to individuals without
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(5.6% vs. 16.3%; Fisher’s, p=0.238). This suggests that individuals with a lifetime history of 
more severe psychiatric symptoms were less likely to have an unaffected relative participating 
in the study. Finally, it is also possible that the unaffected relatives group may be an 
unrepresentative sample. Unaffected relatives with a history of psychiatric illness may not 
have felt comfortable discussing any treatment they had received with a researcher and/or 
reporting these symptoms/treatments in a questionnaire version of the interview.
Overall the findings of the current study indicate that individuals with DD had a greater 
prevalence of lifetime treatment for psychiatric illness than their unaffected relatives. Ideally 
this needs to be examined in larger samples. In the current study every effort was made to 
recruit unaffected relatives. It is therefore likely that future attempts to collect larger samples 
would encounter similar difficulties.
Neurological Investigations and Treatments
The DD and unaffected relatives groups had an identical proportion of individuals with a 
lifetime history of being referred to a neurologist and having neurological investigations 
(16.7%). However, the prevalence of lifetime treatment for neurological symptoms in the DD 
group is unrepresentative of the whole DD sample. DD individuals with a participating 
relative had a significantly lower prevalence of treatment for neurological symptoms than 
individuals without a participating relative (16.7% vs. 46.0%; Fisher’s; p=0.046). In the 
current study one of the main reasons for DD individuals being referred to a neurologist was 
for investigations of periods of loss of consciousness. As discussed in Chapter 5 (section 5.5 
pg. 125) in some of these individuals, the episodes of loss of consciousness might have 
formed part of a psychiatric condition or somatization disorder. These individuals may have 
been less likely to ask their unaffected relatives to participate and/or to have an unaffected 
relative willing to participate in the current study. Due to this bias in the DD group it is not
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possible to make any conclusions regarding prevalence of neurological features in the two 
groups
Learning Difficulties
As reported in Chapter 5 (section 5.3.4 pg. 121) difficulties were encountered comparing 
the prevalence of learning difficulties in the current sample to general population figures. The 
mean age in the DD and unaffected groups was identical, making comparisons between these 
two groups more meaningful. A non-significantly higher proportion of the DD group had 
been given a diagnosis of dyslexia and had a history of receiving extra help at school. The 
small group sizes are likely to have limited the power to detect a significant difference.
Individuals with a participating unaffected relative had a higher prevalence of receiving 
extra help at school (22% vs. 11%; Fisher’s, p= 0.248) and having a diagnosis of dyslexia 
(11% vs. 4.1%; Fisher’s, p= 0.291) compared to individuals without a participating relative. 
This indicates a possible bias in the DD group. It is also possible that the unaffected relatives 
group may have been unrepresentative. Unaffected relatives with learning difficulties may 
have been less likely to complete the written questionnaires. The current study suggests an 
increased prevalence of learning difficulties in individuals with DD. However, group biases 
are likely to partially explain these differences.
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12.2.3 Comparison of Current Mood State, Personality and 
Temperament Questionnaires
This final section discusses the group differences on the current mood state, personality 
and temperament questionnaires. A number of these measures have previously been 
completed by large samples of individuals with bipolar disorder and major recurrent 
depression participating in our research into mood disorders. These data have been collected 
by researchers within the Department of Psychiatry at the University of Birmingham and 
Department of Psychological Medicine at Cardiff University. The scores on the Eysenck 
Personality Questionnaire (EPQ) and Rosenberg Self-Esteem Scale (RSE) in these samples 
and a control sample at low risk developing mood disorders have previously been reported 
(Jones et a l , 2005). Particular patterns of scores on the EPQ and RSE have been associated 
with increased risk of developing mood disorders (Duggan et a l , 1995; Jones et a l, 2005; 
Kendler et a l, 2006; Scott et a l, 2000; Solomon et a l, 1996). Similarities in the personality 
characteristics of individuals with DD and individuals with mood disorders may suggest that 
individuals with DD have an increased vulnerability to developing these disorders compared 
to their unaffected relatives.
12.2.3.1 Current Mood State Questionnaires
Individuals with DD had non-significantly higher current mean scores on the Beck 
Depression Inventory (BDI) than their unaffected relatives although the small group sizes are 
likely to have limited the power to detect a significant difference. Both groups had scores of 
less than 10 on the BDI, which is in the range reflecting none or minimal depression. 
Individuals with a participating unaffected relative had lower scores on the BDI than DD 
individuals without a participating relative (median BDI score; 5 vs. 13; U=196, n=50,
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p=0.083). This suggests individuals’ current level of depressive symptoms may have affected 
the likelihood of them encouraging an unaffected relative to participate in the research.
There were very small group differences in the mean scores on the Altman Self-Rating 
Scale for Mania (ASRM). DD individuals with and without a participating unaffected relative 
did not differ in their ASRM scores (median ASRM score; 2 vs. 2; U= 194.4, n=47, p=0.173). 
This suggests that the ASRM scores of DD group were representative of the whole DD 
sample. These findings indicate that the presence of current manic symptoms was similar 
among individuals with DD and their unaffected relatives.
12.2.3.2 Rosenberg Self-Esteem Scale (RSE)
DD individuals had significantly lower score total and negative subscale scores on the 
RSE reflecting lower self-esteem (shown in Table 11.6 pg. 237). The group differences did 
not remain significant after controlling for current depression, although the trend for DD 
individuals to have lower self-esteem remained. It is likely that due to the small group sizes 
there was not enough power to detect a significant difference. DD individuals with a 
participating unaffected relative had similar RSE scores to individuals without a participating 
relative (mean total RSE scores; 26.44 vs. 26.09; t=0.198, df=46, p=0.844) and (mean 
negative scale scores; 14.06 vs. 13.84; t=0.255, df=46, p=0.800). This indicates that the DD 
group RSE scores were representative of the scores of individuals in the current study.
The total RSE score among the DD group (26.44) is similar to the mean scores found 
among our large samples of individuals with bipolar disorder (26.81) and major depression 
(23.67) (Jones et al., 2005). The mean self-esteem score of the control group in this study 
(34.48) was higher than the score of the current unaffected group (31.50). This suggests that 
the unaffected group was not particularly biased towards containing individuals with high
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self-esteem. Overall these findings indicate that the lower self-esteem scores in the DD group 
cannot be explained by group biases.
12.2.3.3 Eysenck Personality Questionnaire (EPQ)
Individuals with DD had significantly higher EPQ neuroticism (N) scores, a measure of 
emotional instability, compared to their unaffected relatives (see Table 11.7 pg. 239). This 
difference remained significant after controlling for current depression. Logistic regression 
analysis also indicated that EPQ-N was the only questionnaire variable to be significantly 
predictive of DD vs. unaffected relative group membership. These findings would not remain 
significant after corrections for multiple testing although the analyses did have limited power 
due to the small group sizes. DD individuals with a participating unaffected relative had 
similar EPQ-N scores to individuals without a participating relative (mean EPQ-N Score;
12.80 vs. 13.53; t=0.370, df=45, p=0.713). This indicates that the EPQ-N scores of the DD 
group were representative of the scores of DD individuals in the current study.
The mean EPQ-N score of the DD group (12.80) is lower than the mean EPQ-N scores 
found in our bipolar sample (14.96) and major depression sample (17.49) (figures not 
reported in the Jones et al. (2005) paper). The mean EPQ-N score of the control sample in this 
study was 4.81. However, individuals in this sample were selected partially on the basis of 
having low EPQ-N scores and comparisons with this sample would not be meaningful. No 
normative data could be obtained for the version of the EPQ used in this study. It is therefore 
difficult to elicit whether the significant differences between the DD and unaffected groups 
are due to the unaffected group having particularly low EPQ-N scores. However, the EPQ-N 
scores of the DD group were closer to the mean scores of our bipolar sample than the 
unaffected relatives group (8.31). Higher neuroticism scores have been previously been 
found in euthymic individuals with bipolar disorder compared to controls (Solomon et al., 
1996). Therefore overall these finding suggests that the group differences are due to elevated
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neuroticism scores in the DD group rather than the unaffected relatives group being biased 
towards individuals with low levels of neuroticism.
Group Differences in Responses to Item 68
Almost twice as many individuals with DD responded yes to item 68 of the EPQ, 
indicating that they had wished that they were dead at some point in their life compared to 
their unaffected relatives (60% vs. 33%) (see Table 11.8 pg. 239). This group difference did 
not reach statistical significance although the small group sizes are likely to have limited the 
power to detect a significant difference. The proportion of individuals responding yes to this 
item was similar among individuals with and without a participating unaffected relative (60% 
vs. 50%; Fisher’s, p= 0.550). This indicates responses to this item were representative of the 
whole DD sample.
The prevalence of positive responses to item 68 in the DD group (60%) was closer to that 
in our bipolar sample (71%) and major depression sample (80%) (figures not reported in the 
Jones et al (2005) paper) than in the unaffected relatives group (33%). The vast majority of 
individuals in the mood disorders sample had a past history of depression (excluding 
individuals with bipolar disorder who had only experienced manic episodes). Recurrent 
thoughts of death, suicidal ideation and suicide attempts are a diagnostic symptom of major 
depression. This suggests that the group differences are due to individuals with DD having a 
higher prevalence of past thoughts of wishing they were dead rather than the unaffected 
relatives group being biased towards individuals with no history of such thoughts. This 
finding is consistent with previous studies reporting a high prevalence of suicidal ideation and 
attempts among individuals with DD (Denicoff et al., 1990; Ringpfeil et a l , 2001).
12.2.3.4 TEMPS-A Temperament Questionnaire
Individuals with DD had significantly higher scores on the cyclothymic subscale of the 
TEMPS-A temperament questionnaire compared to their unaffected relatives (see Table 11.9 
pg. 241). However this group difference disappeared after controlling for current depression. 
Individuals with DD also had non-significantly higher scores on the depressive dimension and 
lower scores on the hyperthymic dimension compared to their unaffected relatives. Scores on 
the irritable and generalised anxious dimensions were similar in both groups. The TEMPS-A 
questionnaire was included in the current study to investigate whether individuals with DD 
had a particular vulnerability to any specific type of mood and/or anxiety disorder compared 
to their unaffected relatives. Although initial comparisons suggested individuals with DD had 
higher scores on the temperaments measuring mood, in particular the cyclothymic 
temperament, this difference did not remain significant after controlling for current 
depression. It is therefore not possible to make any conclusions from the comparisons of 
TEMPS-A scores in the current study.
12.2.3.5 Kings Schizotypy Questionnaire (KSQ)
Individuals with DD had significantly higher scores on the total, ideas o f reference and 
recurrent illusions 1 scales of the KSQ than their unaffected relatives (see Table 11.10 pg. 
242). After controlling for current depression, the differences between the groups on the total 
and ideas o f reference scales remained significant, although would not after corrections for 
multiple testing. Individuals with a participating unaffected relative had lower KSQ scores 
than individuals without a participating relative (median total scores; 10 vs. 13; U=119, n=41, 
p=0.175), (median ideas o f reference scores; 1 vs. 2; U=131, n=41, p=0.310) and (median 
recurrent illusion scores; 0 vs. 1; U=97.5, n=41, p=0.040). This suggests the KSQ scores of
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the DD group may not be representative of the scores of the whole DD sample. It is also 
possible that the unaffected relatives group was biased towards individuals with lower KSQ 
scores. This is supported by the fact that the mean KSQ score of the unaffected relatives in the 
current study (7.64) is lower than the mean KSQ scores of a previously reported sample of 
controls without a personal or family history of psychiatric illness (10.18) (Jones et al., 2000). 
Despite these potential group biases, the findings do indicate individuals with DD had higher 
total, ideas o f reference and recurrent illusions 1 scale scores than their unaffected relatives. 
However, it is possible that individuals with DD may have related a small number of the KSQ 
items directly to their DD, for example, item 10 “ Do you feel self-conscious in public?” and 
item 24 “ Do people look at you strangely?”. These responses may have contributed to the 
higher total score in the DD group. These items form part of the social anxiety subscale and 
there was a trend for individuals with DD to have higher scores on this scale. DD individuals 
also had significantly higher scores on the ideas o f reference subscale. A higher proportion of 
individuals with DD compared to their unaffected relatives responded yes to item 7 in this 
subscale “Do you quite often get the feeling that other people are taking notice of you in the 
street or on a bus or in a restaurant?” (54.5% vs. 9.1%, Fisher’s p=0.063). In contrast, an 
equal proportion of individuals within the two groups responded yes to the item 14 in the 
subscale “Do people often seem to drop hints about you or say things with a double 
meaning?” (9.1% vs. 9.1%; Fisher’s, p=1.00). These findings suggests the higher KSQ scores 
among the DD group are reflecting feelings of self consciousness around others rather than a 
vulnerability to functional psychosis.
12.2.4 Low Self-Esteem, Neuroticism and Mood Disorders
The current findings suggest individuals with DD have lower self-esteem and higher 
levels of neuroticism compared to their unaffected relatives. These personality characteristics 
have been identified as risk factors for developing mood disorders (Brown et al., 1990;
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Duggan et al., 1995; Kendler et al., 2006). Neuroticism in particular has been shown to reflect 
a genetically determined trait underlying vulnerability to develop major depression (Duggan 
et al., 1995; Kendler et al., 2006). Associations between self-esteem, neuroticism and 
depression may also be due to these features being a consequence or symptom of past or 
current depression. For example, Farmer et al. (2002) suggest neuroticism mainly reflects 
residual symptoms of depression. The group differences in neuroticism and self-esteem 
remained after controlling for current depression, suggesting this did not account for the 
group differences. Thirty-nine percent of the DD group had a lifetime diagnosis of major 
depression. However, the prevalence in the unaffected relatives group is unknown since a 
proportion of the sample were not interviewed. It is possible that a higher prevalence of past 
depression in the DD group could contribute to the increased neuroticism and lower self­
esteem in this group. Low self-esteem may also be a consequence of the distressing symptom 
of malodour experienced by individuals with DD in addition to the detrimental impact the 
disorder has on many aspects of individuals’ personal and social lives. These findings suggest 
that individuals with DD may benefit from psychological therapy since feelings of low self­
esteem in particular are likely to have a long-term detrimental impact on many aspects of their 
lives.
Due to the cross-sectional design of the study, it is not possible to determine whether the 
increased neuroticism and lowered self-esteem scores in the DD group reflect an increased 
genetic predisposition to these personality characteristics or whether they are a consequence 
of past episodes of depression and/or the symptoms of DD. Ideally, longitudinal studies 
assessing these personality characteristics in the children of individuals with DD before they 
may or may not develop DD themselves should be carried out. Such studies would greatly 
improve the understanding of the association between neuroticism, self-esteem, mood 
disorders and DD.
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12.2.5 Summary of Comparisons of Individuals with DD and their 
Unaffected Relatives
The findings of the current study show an overall trend for an increased prevalence of 
neuropsychiatric features and psychopathology among individuals with DD compared to their 
unaffected relatives. Key findings are that a much higher proportion of individuals with DD 
had received treatment for psychiatric illness and reported that they had wished that they were 
dead at some point in their life. In addition they had lower self-esteem and higher levels of 
neuroticism. It is possible that the group differences are due to group biases. In particular, 
unaffected relatives with a history of psychiatric illness may have been less likely to 
participate in the study. However, this is difficult to assess. The group differences may also 
reflect the psychosocial consequences of DD or an increased genetic vulnerability to low self­
esteem, neuroticism and psychiatric illness in individuals with DD.
This study has a number of limitations. Firstly the small group sizes mean that power to 
detect significant difference was limited. Secondly, as mentioned above, it is possible that the 
unaffected relatives group was biased towards individuals with fewer neuropsychiatric 
features. Finally the majority of unaffected relatives were not interviewed face to face, which 
affects the quality of the data obtained. The findings of the study require replication in larger 
samples. However, obtaining such samples may be difficult.
The following chapter (Chapter 13) is the final chapter. This chapter will summarise the 
key findings of the investigations, discuss the limitations and implications of these findings, 
and makes suggestions for further research.
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13 FINAL CONCLUSIONS, IMPLICATIONS, LIMITATIONS 
AND SUGGESTIONS FOR FURTHER RESEARCH
This final chapter summarises the main findings and final conclusions of the 
investigations into the neuropsychiatric phenotype in DD presented in this thesis. This is 
followed by a discussion of the implications of these findings and the limitations of the study. 
Finally, suggestions for further research are described.
13.1 Main Findings and Final Conclusions
The presence of neuropsychiatric features among individuals with DD has long been 
reported and discussed in the literature. Explanations for this association have also been 
debated, particularly following the discovery that the disorder is caused by mutations in the 
ATP2A2 gene (Sakuntabhai et al., 1999b). One important possibility requiring thorough 
investigation is that mutations in ATP2A2 have pleiotropic effects in the skin and brain. This 
suggestion would be supported by firstly, a population-level association between 
neuropsychiatric features and DD and secondly, genotype-phenotype correlations between 
mutations in A TP2A2 and the presence of neuropsychiatric phenotypes. These relationships 
have not been consistently or robustly found in previous studies of DD. However, these 
studies have had methodological problems as well as small sample sizes. The limitations of 
these previous studies led to the three main aims of this thesis. The main findings of the 
investigations relating to each of these aims are summarised below.
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13.1.1 First Aim
To conduct a systematic investigation o f the neuropsychiatric characteristics in a sample o f 
100 unrelated individuals with DD using a battery o f standardised neuropsychiatric 
measures.
This thesis reported the findings of the first systematic investigation into the 
neuropsychiatric phenotype in DD using a battery of standardised neuropsychiatric measures. 
The results of the investigation found that the prevalence of mood disorders, including major 
depression, suicide attempts and suicidal thoughts are significantly higher in individuals with 
DD than in the general population. This finding is consistent with previous studies reporting 
an increased prevalence of depression and suicidal ideation in DD (Denicoff et al., 1990; 
Ringpfeil et al., 2001). The prevalence of bipolar disorder and epilepsy in the sample was also 
found to be non-significantly higher than the prevalence in the general population suggesting 
that a subset of individuals/families with DD may have an increased risk of developing these 
disorders.
Further investigations indicated that psychosocial factors alone could not account for the 
observed increased prevalence of mood disorders, suicidal thoughts and suicide attempts.
Only a small proportion of individuals reported that they felt all the episodes of psychiatric 
illness they had experienced were due to the symptoms of DD. Furthermore, among 12 out of 
the 13 individuals who had made a suicide attempt, there was no subjective or objective 
temporal relationship between their suicide attempts and the symptoms of DD. A further 
interesting finding was the increased prevalence of psychiatric illness and history of suicidal 
thoughts and attempts among individuals reporting a positive family history DD, which
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potentially provides support for the hypothesis that mutations in ATP2A2 have pleiotropic 
effects in the skin and brain.
There was also a high prevalence of soft neurological symptoms in the sample, in 
particular episodes of loss of consciousness and headaches. However, no general population 
comparison data for the prevalence of these soft neurological features could be obtained. A 
large proportion of the sample was found to have no qualifications. There are a number of 
possible reasons for this finding including the possibility that individuals with DD may be 
impaired in specific aspects of learning. However, difficulties were encountered in assessing 
true prevalence of learning difficulties in the sample. Individuals were not found to differ 
from the general population in terms of their general level of intellectual functioning.
13.1.2 Second Aim
To investigate possible genotype-phenotype correlations between the type and/or locations o f 
pathogenic mutations detected in the ATP2A2 gene and neuropsychiatric features observed in 
a large sample o f unrelated individuals with DD.
The main finding of these investigations was that mutations found among individuals 
with similar neuropsychiatric phenotypes clustered in certain locations within the SERCA2b 
protein. A number of these observations were further supported when the findings of the 
current study were combined with the previous literature. In particular, strong evidence was 
found to suggest that mutations within the S4-M4 domain of the protein may confer increased 
susceptibility to more severe psychiatric symptoms and bipolar disorder. Another interesting
04 -finding was that three individuals with the same mutation at one of the Ca binding sites of 
the protein all had a diagnosis of a mood disorder. A mutation previously shown to result in a
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‘mutant’ SERCA2b pump with unique functioning was found in two individuals both with 
severe DD and a personal and family history of neuropsychiatric features.
A further main finding of these investigations was that the prevalence and severity of all 
the lifetime neuropsychiatric phenotypes measured was higher among individuals with 
genetically confirmed DD compared to those in whom a pathogenic mutation was not 
detected. A number of explanations could account for this finding including the possibility 
that a proportion of the individuals in whom a pathogenic mutation was not detected were 
phenocopies of DD, i.e. they did not have a pathogenic mutation in ATP2A2.
13.1.3 Third Aim
To compare the presence o f neuropsychiatric features in a sample o f individuals with DD and 
their first-degree relatives, unaffected by DD.
There was an increased prevalence of neuropsychiatric features and psychopathology 
among individuals with DD compared to their unaffected relatives. Key findings were that a 
much greater proportion of individuals with DD had received treatment for psychiatric illness 
and reported that they had wished that they were dead at some point in their life. In addition, 
individuals in the DD group had lower self-esteem and higher levels of neuroticism than their 
unaffected relatives.
13.1.4 Final Conclusions
In conclusion, investigations into the neuropsychiatric phenotype in DD presented in this 
thesis have found evidence to suggest a potential population-level association between DD 
and mood disorders, specifically major depression, suicide attempts and suicidal thoughts.
The findings of the genotype-phenotype investigations provide strong support for the
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hypothesis that mutations in the ATP2A2 gene have pleiotropic effects in the skin and brain 
and therefore confer susceptibility to neuropsychiatric features, in particular psychiatric 
illness, in individuals with DD.
It is highly plausible that mutations in ATP2A2 could be involved in conferring 
susceptibility to neuropsychiatric illness since the gene is widely expressed in the brain. The 
suggestion is also supported by the dual role of the SERCA2b protein in intracellular Ca2+ 
signalling and in the synthesis and post-translational modification of proteins within the ER. 
It is possible that the skin and brain may have a particular susceptibility to a reduction in 
SERCA2b activity possibly relating to changes in ER Ca concentration and ER functioning.
13.2 Implications
The findings of the investigations presented in this thesis have implications for 
understanding of the treatment needs of individuals with DD and the identification of genetic 
factors involved in conferring susceptibility to neuropsychiatric features, in particular 
psychiatric illness, in individuals without DD.
13.2.1 Treatment Implications for Individuals with DD
The high prevalence of mood disorders, suicidal thoughts and suicide attempts observed 
in the current sample highlights the need for assessment and recognition of psychiatric 
symptoms in DD. This is particularly important in individuals reporting a positive family 
history of DD since these individuals were found to have an increased prevalence of 
psychiatric illness. The lowered self-esteem and higher levels of neuroticism found among 
individuals with DD compared to their unaffected relatives suggests that individuals with DD 
may also benefit from psychological therapy. Feelings of low self-esteem in particular are 
likely to have a long-term detrimental impact on many aspects of individuals’ lives.
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The current investigations have highlighted the possibility that a proportion of individuals 
with a clinical diagnosis of DD may be phenocopies of DD. The findings suggest that a lack 
of family history and having mild clinical features of DD might indicate that an individual is a 
phenocopy of DD. Further research into this area is needed as the findings of such 
investigations may have important diagnostic and treatment implications.
13.2.2 Neuropsychiatric Features in Individuals without DD
Support for the suggestion that mutations in A TP2A2 are involved in conferring 
susceptibility to neuropsychiatric illness in individuals with DD has implications for the 
identification of genetic factors involved in conferring susceptibility to these illnesses in 
individuals without the disorder. Other genes encoding proteins in the same biological system 
as and/or encoding proteins with a similar function to SERCA2b would be good candidates 
for involvement in predisposing individuals to developing psychiatric illness, in particular 
mood disorders.
13.3 Limitations
13.3.1 Lack of Control Group
The main limitation of the current investigations is the lack of a control sample of 
individuals with another skin disorder of a similar severity to DD. Collecting a control sample 
was considered when the study was first being designed, however due to time constrictions 
this was not possible.
13.3.2 Potential Sample Biases
Despite the fact that the majority of individuals in the current study were recruited on 
the basis of having DD, it is possible that there could be a recruitment bias towards
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individuals who had experienced psychiatric symptoms as a consequence of their DD. 
Conversely, individuals with more severe neuropsychiatric features, including severe 
psychiatric illness and learning difficulties may have been underrepresented in the sample. 
Although DD is reported to be equally prevalent among males and females, participants in the 
current study were predominantly female. It is likely that this female bias will have inflated 
the prevalence of psychiatric illness in the sample, although this was taken into account when 
comparisons were made to the reported prevalence of these illnesses in the general 
population. Finally, it is possible that the sample of unaffected relatives was biased towards 
individuals with fewer neuropsychiatric features.
13.3.3 Modest Sample Size
A further limitation of these investigations was the modest sample size, which limited the 
power to detect significant relationships especially when subgroup analysis was carried out. 
Since DD is rare and individuals with the disorder live all across the UK, it was not possible 
to collect a larger sample in the given timeframe. As a result, a greater emphasis was placed 
on looking for trends in the data. A number of statistical tests were carried out however, 
correcting for multiple testing using the Bonferroni method was felt to be too conservative 
given the nature of this exploratory study.
13.4 Future Research
Further research into the neuropsychiatric phenotype in DD is required in larger samples 
of individuals. Because DD is so rare, it is likely that collaborative research will be needed to 
obtain such samples. The predominance of females in the current study highlights the need for 
future studies to make an additional effort to recruit male participants. This would enable 
potential gender differences in the neuropsychiatric phenotype in DD to be investigated.
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In order to confirm the suggestion that there is a population-level association between 
DD and psychiatric illness, a control sample of individuals with another skin disorder of a 
similar severity to DD needs to be collected. This sample will need to be assessed using a 
similar battery of standardised neuropsychiatric measures including a psychiatric clinical 
interview.
Further research is needed into the apparently high prevalence of soft neurological 
symptoms in the current sample. This needs to be investigated using specific neurological 
tests including audiograms and neuroimaging, which may confirm the presence of 
neurological abnormalities in individuals with DD. Further studies are also required into the 
true prevalence of specific learning difficulties among individuals with DD using standardised 
neuropsychological measures, such as memory and attention tests. These investigations need 
to be carried out in a sample of individuals with DD and a suitable age-matched control 
group, which would ideally be a sample of unaffected relatives.
Evidence that the variable neuropsychiatric phenotypes observed among individuals with 
DD may be accounted for by certain mutations having specific effects on the functioning of 
the SERCA2b protein highlights the need for further site-directed mutagenesis functional 
studies in DD. These studies would enable further genotype-phenotype investigations to be 
carried out into the association between the functional effects of certain A TP2A2 mutations 
and the presence of severe neuropsychiatric features in individuals with DD.
Certain regions of the ATP2A2 gene were not screened for mutations in the current study 
including the promoter. This may in part account for the mutation detection rate of 66%. 
Future research should involve the screening of these regions of the ATP2A2 gene for 
pathogenic mutations.
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13.5 Summary
This thesis has presented the findings of the first systematic investigation into the 
neuropsychiatric phenotype in DD. Evidence has been found to support the suggestion that 
mutations in ATP2A2, in addition to causing DD, confer susceptibility to neuropsychiatric 
features, in particular psychiatric illness in individuals with DD. These findings have 
implications for management and treatment of individuals with DD as well as the 
identification of genetic factors involved in conferring susceptibility to these features in 
individuals without DD. Further research in larger samples using specific neurological and 
neuropsychological measures is required. There is also a need for more functional studies to 
be carried out in DD. The findings of such studies are likely to have important clinical and 
research implications.
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APPENDICES
A Appendices for Chapter 3
A.i Study Invitation Letters, Website, Information Sheet & Consent Form
D e r m a t o l o g is t  In v it a t io n  L e t t e r
BRIEF INFORMATION SHEET ABOUT 
RESEARCH INTO DARIER’S DISEASE
I am writing to ask whether you may be willing to participate in research being conducted by 
members of the Department of Psychological Medicine at Cardiff University and the Department 
of Psychiatry at the University of Birmingham. Their aim is to investigate clinical features that 
may be associated with Darier’s Disease. We hope that their study will improve understanding of 
Darier’s Disease and related conditions.
Taking part in the study will involve an interview, a series of short memory and problem-solving 
tasks, completing some questionnaires and, in some cases, giving a small blood sample from your 
arm or a saliva sample. In total, this should take approximately 2 and a half hours. A researcher 
would be more then willing to visit you in your own home. If you would like to receive further 
information about the study from a member of the research team, I would be extremely grateful if 
you would complete the enclosed form and return it in the enclosed stamped envelope. If you do 
decide to participate, I would like to assure you that all the information you provide will be 
strictly confidential.
Also, you do not have to take part in the study. If you decline, it will not alter the care you 
receive. If you would like to contact the team directly for further details about the research their 
telephone number is XXX XXXX
Yours sincerely
Dr
Consultant Dermatologist
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D a r ie r ’s  S u p p o r t  G r o u p  I n f o r m a t io n  L e t t e r
DARIER’S DISEASE RESEARCH
I am writing to inform you about research that is currently being conducted by members of the 
Department of Psychological Medicine at the University of Wales College of Medicine and 
University of Birmingham. Their aim is to investigate clinical features that may be associated 
with Darier’s Disease and hope their study will improve understanding of the disease itself and 
related conditions.
Taking part will involve an interview which asks participants about their Darier’s Disease and the 
impact it has had on their everyday lives, a short series of memory and problem solving tasks, 
completing some questionnaires and in some cases giving a blood sample. If you would be 
interested in receiving more information about the study from a member of the research team, 
please fill in the enclosed form and return it in the enclosed stamped envelope. If you do wish to 
participate, a researcher will be more than willing to visit you in your home at a time convenient 
for you including evenings and weekends.
If you would like to contact the team directly, please telephone Katherine Gordon-Smith on 0121 
678 2352 or email k.m.gordonsmith@bham.ac.uk
Thank you for your time
Jenny Davies
Darier’s Disease Support Group
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St u d y  W e b sit e
Research into D arie r 's  Disease
Department of Psychological Medicine, Cardiff University 
Department of Psychiatry, University of Birmingham
W hat is D arie r 's  Disease?
Darier's disease is a rare inherited skin condition affecting both men and women. The first signs 
of the condition usually appear somewhere between the ages of 6 and 20. The disease is 
characterised by a rash which is often present on the chest, neck or upper back at the start but 
warty bumps may occur on any part of the body. The severity of the condition varies a lot and is 
unpredictable. The fmger nails are usually affected. They tend to be rather fragile and split easily 
and there may be very obvious long red or white lines running the length of the nails. Nail 
changes and/or flat "warts" on the backs of the hands are often present in childhood, well before 
there are any other skin changes. (Adapted from British Association of Dermatologists patient 
information on Darier's disease)
W hat is the R esearch about?
We have funding for 3 years (July 2003-2006) from the Wellcome Trust to conduct research to 
learn more about features which may be associated with Darier's disease and learn more about the 
impact that it has on individuals everyday lives. We hope this research will improve 
understanding of the disease itself and related conditions.
We are hoping to interview a sample of at least 100 individuals who suffer from Darier's disease. 
We would also be interested in seeing other available family members, whether they suffer from 
Darier's disease or not.
Taking p a r t will involve:
An interview asking individuals about their Darier's disease and the impact it has on their 
everyday lives
A short series of memory and problem solving tasks 
Completing some questionnaires 
Giving a small blood sample
If you do wish to participate a researcher will be more than willing to visit you in your home at a 
time convenient to you.
If you would like to receive more information about the study from a member of the research 
team, please contact:
Katherine Gordon-Smith
University of Birmingham, Department of Psychiatry, Queen Elizabeth Psychiatric Hospital, 
Mindelsohn Way, Edgbaston, Birmingham, B15 2QZ, United Kingdom.
Tel: +44 (0)121 678 2352
E-mail: k.m.gordonsmith@bham.ac.uk
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P a r t ic ip a n t  In f o r m a t io n  S h e e t
IN FO R M A TIO N  A BOUT R ESEA R C H  IN TO  D A R IE R ’S DISEASE
Version 2- 21.03.03
In t r o d u c t io n
I am a member of a team of researchers who work in the Department of Psychological Medicine at Cardiff 
University and the Department of Psychiatry at the University of Birmingham. We are conducting 
research (funded by the Wellcome Trust) to learn more about features that may be associated with 
Darier’s Disease.
W hat  is  th e  research  a b o u t?
It is known that sometimes disorders affecting the nervous system (such as epilepsy or depression) occur 
in individuals with Darier’s Disease. However, such disorders are common in the general population and it 
is not known whether this is just a coincidence or whether there is any relationship to the Darier’s Disease 
itself. The idea of this study is to compare individuals with Darier’s Disease with other individuals who do 
not have the illness in order to discover whether there are any problems that are specifically related to 
Darier’s Disease and also to try to find out what influences their occurrence. This research will help us 
understand more about Darier’s Disease itself and, importantly, the treatment needs of people suffering 
with the illness. As a sufferer of Darier’s Disease, we would be extremely grateful if you would be kind 
enough to help us with this study.
WHAT DOES TAKING PART INVOLVE?
We are hoping to recruit a sample of at least 100 individuals who suffer from Darier’s Disease. We would 
also be very interested in seeing other available family members, whether they suffer from Darier’s 
Disease or not. Participation involves:
an interview (lasting around 1 Vi hours) asking you about your Darier’s Disease and any medical, 
neurological and psychiatric conditions you have experienced
a series of short tasks designed to assess cognitive abilities e.g. memory, problem solving skills and 
attention (% hour) completing a set of questionnaires (Vi hour) giving a small blood sample from your arm 
(approximately lOmls)
If you agree to take part, a researcher will arrange a suitable time to visit you in your home or another 
place convenient for you. We will only need to see you the once but may ask if you would like to take part 
in future research. We will keep you informed of any interesting results and of future studies into Darier’s 
Disease.
With your permission, we would like to look at your medical records in strict confidence.
W h a t  a r e  th e  b e n e f it s  o f  t a k in g  p a r t  ? A r e  t h e r e  a n y  r is k s ?
By taking part in the study you will not gain any direct benefit. However, your help will be of great value 
in allowing us to learn more about Darier’s Disease and this is likely to help improve treatments.
As this study does not include any treatment changes or invasive techniques, there are no real risks of 
taking part. You may experience mild bruising on you arm after giving a blood sample.
We may check with the doctors involved in your care to ensure it would be appropriate for you to take 
part in the study.
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DECLINING AND WITHDRAWING FROM THE STUDY
Taking part in the research is entirely voluntary. It is up to you to decide whether or not to take 
part. If you decide to take part you are still free to withdraw at any time and without giving a 
reason.
A decision to withdraw at any time, or a decision not to take part, will not affect the standard of 
care you receive.
CONFIDENTIALITY
All interviews and results will be strictly confidential.
Your blood cells may be kept growing in the laboratory in order to provide samples for future use in this 
research, by us and by other researchers working with us. The results of your blood test are for research 
purposes only and will not be available to anybody on an individual basis.
All information given is kept in an anonymous format.
If you have any further questions about this research, we would be delighted to answer them in person or 
over the telephone. Our address appears above, our telephone number is 0121 678 2352, and our e-mail 
address is k.m.gordonsmith@bham.ac.uk
Katherine Gordon-Smith - Research Psychologist
Professor Nick Craddock - Head of Department Dr Lisa Jones- Research Psychologist
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P a r t ic ip a n t  C o n s e n t  F o r m
AGREEMENT TO TAKE PART IN THE STUDY OF DARIER’S DISEASE
I have read the attached information sheet (version 2, dated 21.03.03) on the above project and have been given a 
copy to keep. I have had the opportunity to ask questions about the project and understand why the research is being 
done.
I agree to give a sample of blood for research in the above project.
I understand that participation in this project is voluntary and that I am free to withdraw from the study without 
giving a reason and without my medical treatment being affected.
I give permission for my medical records to be looked at in strict confidence by responsible people from the research 
group.
I understand that the tests done as part of this research are not clinically diagnostic and I will not be informed of any 
specific results.
I understand that I will not benefit personally from taking part in this research.
I understand that the information and blood sample I have donated for this study will be held in a confidential and 
coded form by the research team and may be made available to researchers at other centres who are carrying out 
similar work.
I agree that my general practitioner can be told that I am taking part in the research.
I agree that I may be contacted again, in connection with the research, in the future.
I know how to contact the research team if I need to.
NAME_________________ SIGNED_________________ DATE.
WITNESSED ___________ SIGNED________________DATE
I also agree that other members of my family can be asked to take part in the study.
SIGNED ______________________ DATE _______________________
THANK YOU FOR PARTICIPATING IN OUR RESEARCH 
YOU WILL BE GIVEN A COPY OF THIS CONSENT FORM TO KEEP
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A.ii Clinical Assessment of Darier’s Disease
C ontact details o f derm atologist
Age o f onset ______  Site o f onset_________________________________
D a r ie r ’s  S e v e r it y _______________________________________________________________________
Mild: keratotic papules scattered sparsely over the trunk or flexures or disease limited to one or two areas (e.g. 
hands)
Moderate: more extensive papular lesions or localized verruous plaques
Severe: coalescent verrucous plaques involving most of the trunk or grossly hypertrophic flexured disease
Disease freq/pattern ________________________________
Current status ________________________________
Other Physical symptoms ________________________________
TREATMENT FOR DARIER’S
Ever used 
[Y/NJ
Helpful
[Y/NJ
Currently 
using 
[Y/N]
Current
nnco
Past dose
Side Effects 
0 -  no, 1-min prob 
2  -  major problem 
3- stopped due to 
(note side effects)
Years used
Acitretin / Neotigason
Roaccutane /
Isotretinoin
Ever used [Y/N] Helpful [Y/N] Currently using 
[Y/N]
Name if known
Emollients
Sunscreens
Antihistamines
Topical Corticosteroids
Antiseptics
Topical retinoids
Topical antibiotics
Oral antibiotics
Topical antiviral
Surgery
X ray
Other
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DARIER'S CLINICAL FEATURES
[Y/N/DK/
N/A]
SITES INVOLVED [PAST 
AND PRESENT]
[Y/N/DK/
N/A]
Past Cur
Precipitating factors Scalp
Stress Hair loss
Heat or sweating Face
Sun Neck
Friction Chest
Cold Upper back
Pregnancy Abdomen
Menstrual cycle Legs
Any drug- specify Low back
Other Buttock
Dairy Arm
Clinical Features
Fluctuation in severity Flexures
Static Groin
Improving with age Perineum
Worse with age Genitalia
Sometimes the skin looks normal Axilla
Umbilicus
Symptoms Behind Ear
Itching Inside Ear
Pain Beneath Breasts
Papules
Blisters Hands
Boils or cysts Acrokeratosis on back of hand
Hypo- pigmentation Finger nail lines (red/white)
Hyper- pigmentation Finger nail notches
Malodour Palmar Pits
2ndy infection Bumps on palms
Viral
Bacterial
LIFETIME RELATED EFFECTS OF DARIER’S DISEASE 
Time off work due to Darier’s
None  Days   Weeks  Months  > 1 year  Stopped work due to_
N/A_
Number of Admissions to hospital due to Darier’s __
Lifetime subjective effect of Darier’s on [none/mild/mod/severe/N/A] [0/1//2/3/8]
School _ Social Activities _
Work/Career _ Relationships _
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A.iii Dermatology Life Quality Index
The aim of this questionnaire is to measure how much your skin problem has affected your life 
OVER THE LAST WEEK. Please tick one answer for each question
1. Over the last week, how itchy, sore, Very Much
painful or stinging has your skin A lot
been? A little
Not at all
—
2. Over the last week, how embarrassed Veiy much
or self conscious have you been because A lot
of your skin ? A little
Not at all
—
3. Over the last week, how much has your Very much
skin interfered with you going A lot
shopping or looking after your home A little
or garden? Not at all
—
Not relevant_
4. Over the last week, how much has your Very much
skin influenced the clothes A lot
you wear? A little
Not at all
—
Not relevant_
5 Over the last week, how much has your Very much
skin affected any social or leisure A lot
activities ? A little
Not at all
—
Not relevant_
6. Over the last week, how much has your Very much
skin made it difficult for you to do A lot
any sport ? A little
Not at all
—
Not relevant_
7. Over the last week, has your skin prevented Yes
you from working or studying ? No
—
Not relevant_
If “No”, over the last week, how much has A lot
your skin been a problem at work or studying ? A little
Not at all
—
8. Over the last week, how much has your Very Much
skin created problems with your A lot
partner or any of your close friends A little
or relatives ? Not at all — Not relevant_
9. Over the last week, has your Very Much
skin caused any sexual A lot
difficulties ? A little
Not at all Not relevant_
10. Over the last week, how much of a Much
problem has the treatment for your A lot
skin been, for example by making A little
your home messy, or by taking up time? Not at all __ Not relevant_
The aim of this questionnaire is to measure how much your skin problem has affected your life 
IN THE WORST WEEK EVER. Please tick one answer for each question
1. In the worst week, how itchy, sore, 
painful or stinging was your skin?
Very Much 
A lot 
A little 
Not at all
In the worst week, how embarrassed 
or self conscious have you been because 
of your skin ?
Very much 
A lot 
A little 
Not at all
In the worst week, how much did your 
skin interfere with you going 
shopping or looking after your home 
or garden?
In the worst week, how much did your 
skin influenced the clothes 
you wear?
Very much 
A lot 
A little 
Not at all
Very much 
A lot 
A little 
Not at all
Not relevant
Not relevant
In the worst week, how much did your 
skin affect any social or leisure 
activities ?
Very much 
A lot 
A little 
Not at all Not relevant
In the worst week, how much did your 
skin made it difficult for you to do 
any sport ?
Very much 
A lot 
A little 
Not at all Not relevant
7. In the worst week, did your skin prevent 
you from working or studying ?
If “No”, in the worst week, how much was 
your skin a problem at work or studying ?
Yes
No
A lot 
A little 
Not at all
Not relevant
In the worst week, how much did your 
skin create problems with your 
partner or any of your close friends 
or relatives ?
Very Much 
A lot 
A little 
Not at all Not relevant
In the worst week, did your 
skin cause any sexual 
difficulties ?
Very Much 
A lot 
A little 
Not at all Not relevant
10. In the worst week, how much of a 
problem was the treatment for your 
skin , for example by making 
your home messy, or by taking up time?
Much 
A lot 
A little 
Not at all Not relevant
A.iv Psychiatric History Screening Questions
l.Have you ever experienced mental health problems in your life? -  even i f  very mild
Y/N Sought help from  
GP/other health 
professional
Received
counselling
Prescribed
medication
Seen psychiatrist 
+ contact details, 
Hospital 
admission
Current
symptoms
Anxious or panic attacks
Feeling very low in spirits, depression or 
low mood
Feeling much too high in spirits or elated 
or very irritable without reason, manic 
depression or bipolar disorder
Experiencing things that are difficult to 
explain or understand like hearing voices 
or seeing things, psychosis or 
schizophrenia
OCD- checking things you know you have 
done, keeping things in a special order
Eating disorders
Other
SECTION 11& 12 -ALCOHOL AND SUBSTANCE
11.001 Screen- ever used alcohol at all [1 -  never used, 2 -  once or twice in lifetime, 3 -  used more than twice] _
Other probes- about how often do/did you take a drink, would it be difficult to do without, have you ever felt you had problems with alcohol
11.002 How often did you take a drink in heaviest year period [0 -  not at all, 1 -  less and once a month, 2 -  once a month,4- 2-3days a month, 4 -  1-2 days a 
week, 5 -  approx. daily any time within one year, 6 - approx. daily repeatedly within one year, 7 -  approx, daily for at least one month, 8 - NK, 9 -  NA_
11.003 Estimated usual daily amounts [ enter number of standard drinks] _
12.001 Screen- [1- never used drugs, 2 -  once or twice in a lifetime, 3 -  drugs used more than twice]_
12.006-14 Frequency of drug use in year period [0=no use, l=up to 5 times in period, 2=6-12 times or less than once a month,3=approx. monthly, 4=approx. 
weekly, 5=approx. daily any time within one year period, 6= approx. daily repeatedly within one year, 7=approx. daily for at least one month
Opioids  Cannabinoids Sedatives, Hypnotics, Anxiolytics  Cocaine  Stimulants  Hallucinogens PCP  Volatile
Substances Other and unknown
286
A.v Psychiatric Consensus Rating Form
Study ID  Initials  DOB
R a te r   D a te _____
Main Diagnosis
DSM -IV ICD - RDC
O ther diagnosis
DSM -IV ICD - RD C
DSM -IV ICD - RD C
DSM -IV ICD - RD C
DSM -IV ICD - RD C
BADDS Dimension Scores: M
D
P
I
GAS scores L ifetim e w orst ever episode ___
Lifetim e w orst in depressive episode ___
Lifetim e w orst in m anic episode ___
P ast w eek ___
Section 2 f e a tu r e s   M ood C o n g ru e n c e ____ N ear Section 2
Predom inant m anic a f f e c t   D ysphoric m ania ___
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No. Episodes: M ania___  Depression ___  Anxiety
Longest Duration: M ania___ Depression ____ Anxiety
Age of onset: any psychiatric disorder
Symptom  Impairment  Contact  Admission__
Age of First
First Depression  First Mania____  First Psychosis
First anxiety/panic/phobia _ First obsessional illness
First Eating disorder   First alcohol or substance
Suicidal ideation Rapid Cycling Puerperal
A vi The Bipolar Affective Disorder Dimensional Scale, version 3.0 
(BADDS 3.0).
G eneral inform ation
The Bipolar Affective Disorder Dimension Scale (BADDS) has been developed in order to 
address some of the disadvantages of a purely categorical approach to diagnostic classification of 
Bipolar Spectrum Disorders.
BADDS is a dimensional rating scheme that retains and builds upon current categorical 
classifications. It is intended for use in clinical samples from populations over-represented by 
Bipolar Spectrum illness. It was not developed for use in general population samples.
BADDS has been under development since 1996 and has now been used by a variety of 
researchers within our group on more than 1100 cases. It has proved to be user friendly and has 
excellent reliability, even on sets of diagnostically challenging cases.
BADDS comprises 4 dimensions: M: Mania; D: Depression; P: Psychosis; I: Incongruence. Each 
dimension is rated using integer scores on a 0 -  100 scale. Ratings are made after review of all 
available clinical data on a subject (eg. case records, semi-structured psychiatric interview and 
information from an informant) and can be performed as a simple addition to the conventional 
consensus lifetime psychiatric diagnostic procedures already in use by many research groups. 
Each rating reflects a mixture of severity and frequency of clinical features. Guidelines are 
provided that define anchor points in the rating scales and specify how ratings should be made.
Researchers and clinicians are welcome to use BADDS providing that an appropriate literature 
citation acknowledging its use is included in any published work that arises.
W e welcome com m ents and  suggestions ab o u t BADDS and  will consider these when making 
revisions to  the scale and  ra ting  guidelines. P lease d irec t any correspondence to:
Professor Nick Craddock 
Neuropsychiatric Genetics Unit 
Department of Psychological Medicine 
University of Wales College of Medicine 
Heath Park 
Cardiff CF14 4XN 
United Kingdom 
Email: craddockn@cardiff.ac.uk
289
BADDS: General rating guidelines
1) Do not rate a dimension if there is insufficient information - just leave the dimension blank.
2) Use all available information to make the best judgement for each rating.
3) It is expected that when used for research BADDS will be used within the accepted framework 
of the lifetime best-estimate consensus diagnostic procedure.
4) All ratings should be made using integers in the range 0-100.
5) Ratings for M and D are a mixture of severity and frequency. Generally the severity of the 
most severe episode identifies a range in which the rating will be made and the frequency 
determines the score assigned within the range. In assigning a rating, start at the lowest score in 
the range and then add points according to any relevant psychopathology over and above that of 
the most severe episode according to the following guidelines:
a) In general each additional episode o f that level o f severity will add a score of 2 in a 20 point 
range and 1 in a 10 point range.
b) Scores in the identified severity range can and should be modified according to severity and 
duration of total episodes -  but with a substantial down-weighting for episodes of lower severity.
c) For episodes that are one level of severity lower than the rating range, add 0.25 points for each 
episode of lower severity for a score in a 10 point range and 0.5 points for each episode of lower 
severity for a score in a 20 point range.
d) For episodes that are more than one level of severity lower than the rating range the total 
adjustment should not normally exceed 1 or 2 points.
6) For the P and I dimensions anchor points are given in these guidelines. Judgment is used to 
assign scores between anchor points.
7) Under very exceptional circumstances a score can be rated outside the severity range. 
However, this should always be agreed by at least two raters and the rating should lie in the 
interval 0-100. Such a rating should be indicated by an asterisk (*) following the rating for that 
dimension. An example of the applicability of this rule is the rating up of an episode in which the 
balance of evidence clearly suggests a severe illness that is not adequately supported by the 
documented evidence because o f poor documentation. Another example would be the rating 
down of an episode if the balance of evidence strongly suggests that the formal evidence clearly 
over-represents the clinical significance of the episode.
290
1) Mania dimension (M)
The rating reflects severity and frequency.
Use ICD10 to define symptom and duration criteria for hypomanic and manic syndromes. 
Sub-hypomanic features in the ranges 1-19 and 20 - 39 should be rated using judgement 
according to the balance of number and duration of symptoms.
No impairment criterion is used for hypomania.
The impairment criteria for mania are one or more of:
Disrupts work or social life more or less completely
Markedly inappropriate overspending that is reckless within the context of the 
Subject’s financial position 
Fights 
Lost job
Police involvement 
Family split up
Received specific treatment (including dose increase of mood stabilizer) for acute mania 
Psychotic features
Incapacitating mania refers to a severe manic episode that includes the presence of one or more 
of the following features: incoherence, disorientation, loss of contact with reality (which includes 
psychotic features), frenzied or bizarre psychomotor activity.
Mixed episodes are rated on the M dimension. If all manic episodes are mixed, add “m” to the 
rating (eg. 65m).
Key points and ranges on the M  dimension 
0 No manic features.
1-19 Mild sub-hypomanic features. Elation/irritability and less than 3
symptoms.
20 - 39 Sub-hypomanic features. Elation/irritability and 3+ symptoms for at
least 1 day.
40 - 59 Hypomanic features. At least one hypomanic episode.
60 - 79 Manic features. At least one manic episode.
80-100 Severe manic features. At least one episode of incapacitating mania.
2) Depression (D)
Rating reflects severity and duration.
Use ICD10 to define depressive syndromes. This includes 10 symptoms of depression that count 
for the purposes of diagnosis:
A Depressed mood
Loss of interest/pleasure 
Loss of energy
B Suicidal ideation
Pathological guilt 
Loss of confidence/self esteem 
Loss of concentration 
Slowed activity 
Change of appetite or weight 
Change in sleep pattern
Depression severity: Mild - 4+ symptoms (2+ from A); moderate - 6+ symptoms (2+ from A); 
severe - 8+ symptoms (3 from A). Refer to 1CD10 for full definition of syndromes and 
symptoms.
Duration criterion for Major Depressive Episode is 2 + weeks. If 1- 2 weeks, classify as Minor 
Depression.
Rate depression as severe if (a) ICD10 criteria fulfilled, or (b) criteria for major depression are 
fulfilled and there has been a serious suicide attempt, ECT treatment or hospital admission for 
depression.
Minor depression refers to at least 1 week of low mood accompanied by 2 or more depression 
items or to brief episodes that would otherwise meet criteria for Major Depression.
Incapacitating depression refers to severe major depression that includes presence of one or more 
of the following features: stupor; mutism; loss of contact with reality (including psychotic 
features).
If psychotic features are present, a depressive episode can be rated as incapacitating if the 
minimum criteria for major depression are satisfied (ie. 4 items).
Key points and ranges on D dimension
0 No features of depression during lifetime.
1-19 Sub-Minor depression.
20-39 Minor depression.
40-49 Mild major depression.
50-59 Moderate major depression.
60-79 Severe depression.
80 -100 Incapacitating depression
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3) Psychotic features (P)
Psychotic features refers to delusions, hallucinations, positive formal thought disorder, catatonia 
or grossly disorganized behaviour (but see exclusions below).
Ratings on this dimension exclude stupor or excitement during an affective episode or positive 
formal thought disorder during mania.
Lifetime occurrence of psychotic features is rated.
Near psychotic schizotypal features refers to the following DSMIV schizotypal items: ideas of 
reference; odd beliefs or magical thinking that influences behaviour and is inconsistent with sub­
cultural norms; unusual perceptual experiences including bodily illusions; odd thinking and 
speech; suspiciousness or paranoid ideation; behaviour or appearance that is odd eccentric or 
peculiar. Depersonalization and derealization are not classified as near psychotic features.
The period of illness considered refers to all affective and non-affective periods of 
psychopathology.
Rating should take account of both number and duration of episodes with and without psychotic 
features. If in doubt, “rate up” the psychotic features. Examples:
If there have been two 1 week long affective psychotic episodes and a 1 year non-psychotic 
depressive episode, rate 60 (ie. approx. 2/3 of illness episodes).
If there have been nine 1 month non-psychotic affective episodes, one 1 month psychotic 
affective episode and 4 years of chronic hallucinations outside affective episodes, rate 80 (ie. 
approx. 80% of illness duration).
The Uncertain category (P = 1) is used for situations in which insufficient information is 
available to determine if sign or symptom meets criteria for near psychotic feature.
Key points and ranges on P dimension
0 Absent.
1 Uncertain.
2 -9  Near psychotic features: occasional at low end of range, frequent at
high end of range. Occurrence of true psychotic symptoms should not 
be rated in this range.
10-20 Brief clear-cut psychotic symptom that are not a prominent
feature of illness.
10-Single.
20 -  Multiple.
21-100 Psychotic symptoms that are a prominent feature in one of more
episodes of illness.
25 - present for 25% of illness.
50 - present for 50% of illness.
75 - present for 75% of illness.
100 - prominent psychotic features present throughout illness.
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4) M ood incongruence (I)
DSMIV definitions of congruence and incongruence are used.
Rate incongruence of lifetime occurrence of psychotic features.
For convenience, the set of psychotic symptoms recognized as having special weight in the 
diagnosis of schizophrenia and schizoaffective disorder (thought echo, insertion, withdrawal or 
broadcasting; passivity experiences; hallucinatory voices giving running commentary, discussing 
subject in third person or originating in some part of the body; bizarre delusions; catatonia) are 
denoted in the guidelines as the “S set”.
If Psychosis Features dimension, P < 10, leave I blank.
Key points on I dim ension
0 -40 Psychotic symptoms occur only during affective episodes and do not include any of the S 
set.
Rating 0 -  virtually completely mood congruent.
Rating 20 -  approximate balance between mood congruent and incongruent.
Rating 40- virtually completely mood incongruent
43 Psychotic symptoms occur only during affective episodes and include one or more of the
S set which have not definitely been present for 2 weeks.
47 Psychotic symptoms occur only during affective episodes and include one or more of the
S set which have definitely been present for 2 weeks.
50 - 59 Psychotic symptoms probably present for at least 2 weeks either side of an affective 
episode.
Rating 50 -  on at least one occasion.
Ratings of 51-59 used to reflect recurrence and/or certainty.
60- 100 Psychotic symptoms definitely present for at least 2 weeks either side of an 
affective episode.
Rating 60 -  on at least one occasion.
Rating 80- on many occasions.
Rating 100 -  Psychotic symptoms predominate illness and occur chronically outside (or in 
absence of) affective episodes.
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A.vii Neurological Screen
Ask if experienced symptoms from the list- if respond yes complete table
Head injury _________________________________________ ___________
Headaches __________________________________________
Fits, faints, funny turns, epilepsy or seizure, lost consciousness/ seem to loose contact with reality/Strange 
feelings in behaviour/perception/ feelings
Memory difficulties or diagnosis of “dementia”
Weaknesses of the limbs________________
Loss of sensation in the limbs____________
Tremors or shaking____________________
Difficulty walking_____________________
Giddiness or difficulty with balance________
Strokes, brain haemorrhages, (TIAs)_______
Brain tumour or cancer affecting brain or NS _
Infections of the brain or NS ___________
Problems with vision _____________________________________________
Problems with hearing _____________________________________________
Developmental delay or development problem relating to the brain or nervous system
Any other symptoms or treatment related to problems with the brain or nervous system
Treatments or investigations
Ever been seen by a neurologist? [0/1] __
Ever had neurological procedures such as Brain scans (CT, MRI), brain wave recordings (EEG), 
lumbar punctures? [0/1]
Details
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Neurological
Problem
B rie f
details
Dates- Seen G P R eferred
to
specialist
T rea tm en t Im pairm ent-
m ild/m oderate/
severe
I
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A.viii Adult Dyslexia Checklist
Please tick Yes or No to each question. If in doubt, tick the answer that you feel is true 
often
most
Yes No
Do you find difficulty telling left from right?
Is map reading or finding your way to a strange place confusing?
Do you dislike reading aloud?
Do you take longer than you should to read a page of a book?
Do you find it difficult to remember the sense [gist/general idea] of what 
you have read?
Do you dislike reading long books?
Is your spelling poor?
Is your writing difficult to read?
Do you get confused if you have to speak in public?
Do you find it difficult to take messages on the telephone and 
pass them on correctly?
When you say a long word, do you sometimes find it difficult to get all the 
sounds in the right order?
Do you find it difficult to do sums in your head without using your fingers 
or paper?
When using the telephone, do you tend to get the numbers mixed up 
when you dial?
Do you find it difficult to say the months of the year forwards quickly and 
without mistakes?
Do you find it difficult to say the months of the year backwards?
Do you mix up dates and times and miss appointments?
When writing cheques do you frequently find yourself making mistakes?
Do you find forms difficult and confusing?
Do you mix up bus numbers like 95 and 59?
Did you find it hard to leam your multiplication tables at school?
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B Appendices for Chapter 4
Table B-l DLQI Last Week and Worst Week Median Domain Scores as a Percentage of Total 
Domain Scores
DLQI Last Week DLQI Worst Week
Domain Score out 
o f
Median % of total 
domain score
Median % of total 
domain score
Symptoms and 
feelings
6 2 33 5 83
Daily Activities 6 1 17 4 67
Leisure 6 0 0 3 50
Work and School 3 0 0 1 33
Personal
relationships
6 0 0 2 33
Treatment 3 0 0 1 33
Table B-2 Lifetime DSM-IV Diagnosis and History of Suicidal Thoughts and Attempts
No DSM-IV Any DSM- 
IV
Unknown
DSM-IV
Total
No suicidal ideation or 
suicide attempts 37 (100%) 20 (36%) 6 (75%) 63
Suicidal Thoughts 0 (0%) 17(31%) 1 (12.5%) 18
Suicide Attempts 0 (0%) 12 (22%) 1 (12.5%) 13
Unknown 0 (0%) 6 (11%) 0 (0%) 6
Total 37 55 8 100
Table B-3 Age of Onset of Psychiatric Illness -Descriptives
N Median Range Interquartile Range
Age of onset of any 
psychiatric illness
39 25.00 14-58 15
Age of onset of depressive 
disorder
35 25.00 14-58 14
Age of onset of bipolar 
disorder
4 23.00 15-52 32
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Table B-4 Number of Episodes of Depression (D) and Mania (M) among Individuals with a Lifetime
DSM-IV Mood Disorder-Descriptives
N Median Range Inter-quartile Range
Major Depressive Disorder 
(N-30)
D 30 4.00 1-20 4
M* 2 1.50 1-2 -
Dysthymic Disorder 
(N-2)
D* 2 1 1-1 -
M 0 - - -
Depression NOS 
(N-13)
D* 9 2.00 1-130 10
M 0 - - -
Bipolar Disorder 
(N=4)
D 3 10.00 1-50 -
M 4 6.00 1-20 14
Cyclothymia
(N -l)
D* ** - - -
M* ** - - -
* Episodes did not reach full DSM-IV criteria an episode hypomania/mania (M) or major depression (D), ** number 
of episodes could not be determined.
Table B-5 Longest Duration of Episodes of Depression (D) and Mania (M) in Weeks among 
Individuals with a Lifetime DSM-IV Mood Disorder -Descriptives
N Median Range Inter-quartile
Range
Major Depressive Disorder 
(N-30)
D 29 26.00 2-260 42
M* 2 2.50 2-3 -
Dysthymic Disorder (N=2) D* 2 546.00 312-780 -
Depression NOS 
(N-13)
D* 9 3.00 0.4-130 18
Bipolar I Disorder 
(N=4)
D 2 13.50 12-15 -
M 4 5.00 2-50 37
*Episodes did not reach full DSM-IV criteria an episode hypomania/mania (M) or major depression (D).
Table B-6 IQ Scores and Gender
Male Female t* P
Mean 100.62 100.27 0.111 0.912
Std. Deviation 14.873 12.441
95% Cl 94.61-106.62 97.03-103.51
Range 70-125 67-125
N 26 59
*T test.
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Table B-7 First-degree Relatives with a History of Psychiatric Illness and DD-Frequencies
First-degree Relatives with 
Psychiatric History and DD
First-degree Relatives with 
Psychiatric History Without DD
First-degree Relatives with 
Psychiatric History Unsure DD
N % N % N %
34 53.1 23 1 35.9 7 10.9
Figures are the numbers and percentages of first-degree relatives.
Table B-8 First-degree Relatives with a History of Epilepsy and DD - Frequencies
First-degree Relatives Epilepsy 
and DD
First -degree Relatives with 
Epilepsy without DD
First-degree Relatives with 
Epilepsy unsure DD
N % N % N %
6 75 1 12.5 1 12.5
Figures are the numbers of first-degree relatives.
Table B-9 Relationship between Lifetime Neuropsychiatric Features, IQ Scores and Family History 
of Psychiatric Illness
Investigations for 
Blackouts, Loss 
of Consciousness 
or Fainting 
Episodes 
|No=81, Yes=131
Lifetime 
Diagnosis of 
Epilepsy 
[No=97, Yes=3J
Family History 
of Psychiatric 
Illness 
[No=52, Yes=43J
IQ Score Below 
Average 
[No=68, Yes=171
Learning 
Difficulties 
[No=79, Yes=21J
x2 df P df P x2 df P x2 df P x2 df P
Lifetime 
DSM-IV 
Diagnosis 
|No*37, 
Yes= 551
4.411 1 0.036 ** 1 0.159 2.051 1 0.152 0.002 1 0.960 0.743 1 0.389
Learning
Difficulties
** 1 0.722 ** 1 0.511 1.077 1 0.299 ** 1 0.003
IQ Score 
Below 
Average
** 1 0.341 ** 1 0.493 0.047 1 0.828
FH of 
Psychiatric 
Illness
3.781 1 0.052 ** 1 0.249
Lifetime 
Diagnosis 
of Epilepsy
** 1 1.000
Chi-square tests, ♦♦Fisher’s exact tests. Significant relationships are reported in bold.
Table B-10 Relationship between History of Investigations for Blackouts, Loss of Conscious or
Fainting Episodes and Lifetime DSM-IV Diagnosis and Family History of Psychiatric Illness
Any Lifetime DSM-IV Diagnosis
Family History of 
Psychiatric Illness TotalNo Yes No Yes
N % N % N N % N %
Investigations 
for blackouts, 
loss of
consciousness 
or fainting 
episodes
NO
34 47 39 53 73 46 60 31 40 77
YES
2 15 11 85 13 4 31 9 69 13
Total N 36 50 86 50 40 90
(**= 4.411, df=l, p=0.036) = 3.781, df=l, p=0.052)
Chi-square tests.
Table B -ll Relationship between Below Average IQ Scores and Learning Difficulties
IQ Score Below Average
TotalNo Yes
N % N % N
Learning Difficulties No 57 88 8 12 65
Yes 11 55 9 45 20
Total N 68 17 85
(Fishers, p=0.003)
Fisher’s exact tests.
Table B-12 Subjective Lifetime and Temporal Relationships between DD and Depression- 
Frequencies and Percentages
Yes N0 Unsure Total
N % N % N % N
Lifetime Relationship 3 6 39 78 8 16 50
Temporal Relationship 19 38 24 48 7 14 50
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Table B-13 Age of Onset and Duration of DD and Lifetime DSM-IV Diagnosis and History of
Suicidal Thoughts and Attempts
Any Lifetime DSM-IV Diagnosis History of Suicidal Thoughts and Suicide Attempts
No Yes U* P None Suicidal
Thoughts
Suicide
Attempts
H** P
Age of onset 
of DD
Median 14.00 13.00 840.5 0.250 14.00 14.00 14.50 0.783 0.676
Range 6-48 0-48 0-48 0-48 6-37
Interquartile
Range
9 10 11 8 15
N*** 37 53 61 17 12
Duration of 
DD
Median 30.00 31.00 911.5 0.571 29.00 36.00 32.00 2.262 0.323
Range
Interquartile
Range
5-53
20
3-60
22
5-59
23
3-60
16
5-49
18
N*** 37 53 61 17 12
*Mann-Whitney U Tests, ♦♦ Kruskal-Wallis H Tests.
♦♦♦ Missing cases are individuals where age of onset of DD and/or lifetime DSM-IV diagnosis was unknown and/or 
history of suicidal thoughts and suicide attempts was unknown.
Table B-14 Age of Onset and Duration of DD-Correlations with Key Psychiatric Clinical Variables
Age of Onset Of DD Duration of DD
Age of onset of any psychiatric illness
*rho -0.034 -
P 0.843 -
N** 37 -
Number of Episodes of Depression
♦rho 0.234 0.113
P 0.136 0.476
N** 42 42
Longest Duration of Depression
♦rho -0.139 0.157
P 0.394 0.334
N " 40 40
♦Spearman’s rho correlation coefficients. **Missing cases are individuals where age of onset of DD was unknown 
and/or cases where there was not enough information to make a rating on the key psychiatric clinical variables.
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Table B-15 Relationship between DD Severity and Lifetime DSM-IV Diagnosis and History of
Suicidal Thoughts and Suicide Attempts
Any Lifetime DSM-IV Diagnosis History of Suicidal Th 
Attem
Dughts and Suicide 
pts
No Yes None SuicidalThoughts
Suicide
Attempts
DD Severity N % N % N N % N % N % N
Mild 10 50 10 50 20 16 80 2 10 2 10 20
Moderate 23 37 39 63 62 42 67 11 17 10 16 63
Severe 4 40 6 60 10 5 45.5 5 45.5 1 9 11
Total N* 37 55 92 63 18 13 94
**“ 1.047, df=2, p=0.592 *V= 6.79, df=4,p=0.143
Chi-square tests, ** exact significance test for Pearson’s chi-square.
* Missing cases are individuals where lifetime DSM-IV diagnosis was unknown and/or where history of suicidal 
thoughts and suicide attempts was unknown.
Table B-16 DD Severity and Key Psychiatric Clinical Variables
DD Severity
Mild Moderate Severe H* P
Age of onset 
of any 
psychiatric 
illness
Median 25.00 26.00 26.50 0.229 0.892
Range 17-44 14-58 19-40
Interquartile Range 10 17 18
N** 7 28 4
Number of 
Episodes of 
Depression
Median 2.50 3.00 5.00 0.030 0.985
Range 1-9 1-130 1-6
Interquartile Range 6 8 4
N** 8 31 5
Longest 
Duration of 
Depression
Median 11.00 21.00 3.50 2.525 0.283
Range 1-52 0.4-780 2-104
Interquartile Range 41 41 77
N** 8 30 4
*Kruskal-Wallis H Tests. ** Missing cases are individuals where there was not enough information to make a rating 
on the key psychiatric clinical variables.
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Table B-17 Relationship between Pain and Malodour Reported as a Symptom of DD and Lifetime 
DSM-IV Diagnosis and History of Suicidal Thoughts and Attempts
Any Lifetime DSM-IV Diagnosis History of Suicidal Thoughts and Suicide 
Attempts
No Yes Total None SuicidalThoughts
Suicide
Attempts
Total
N % N % N N % N % N % N
Pain No 19 50 19 50 38 27 73 5 13.5 5 13.5 37
Yes 15 30 35 70 50 32 60 13 25 8 15 53
Total N 34 54 88* 59 18 13 90**
X2=3.643, df=l, p=0.056 X2 = 1.887, d£=2, p= 0.389
Malodour No 15 45 18 55 33 26 79 4 12 3 9 33
Yes 19 34.5 36 65.5 55 33 58 14 24.5 10 17.5 57
Total N 34 54 88* 59 18 13 90**
X2= 1.035, df=l,p= 0.309 Xz = 4.043 df=2,p= 0.132
Chi-square tests. * Missing cases are individuals where lifetime DSM-IV diagnosis was unknown and/or where 
individuals were unsure whether they had experienced pain and/or malodour as symptom of DD. "“"Missing cases are 
individuals where history of suicidal thoughts and suicide attempts was unknown and/or where individuals were 
unsure whether they had experienced pain and/or malodour as symptom of DD.
Table B-18 Pain and Malodour Reported as Symptom of DD and Key Psychiatric Clinical Variables
Pain Reported as a Symptom of DD Malodour Reported as a Symptom of 
DD
No Yes U* P No Yes U* P
Age of onset of any 
psychiatric illness
Median 25.00 27.00 145.00 0.590 25.00 26.00 131.00 0.431
Range 15-52 14-58 15-44 14-58
Interquartile Range 
N**
15
13
18
25
12
12
21
26 -
Number of Episodes 
of Depression
Median 5.00 3.00 157.50 0.232 2.50 4.00 182 0.913
Range 1-50 1-130 1-10 1-130
Interquartile Range 7 4 7 5
N** 14 29 12 31
Longest Duration of 
Depression
Median 15.50 13.00 167.00 0.543 12.00 26.00 151.500 0.425
Range 1-156 0.4-780 1-104 0.4-780
Interquartile Range 21 49 34.5 47.3
N** 14 27 12 30
*Mann-Whitney U Tests. ** Missing cases are individuals who were unsure whether they had experienced pain 
and/or malodour as a symptom of DD and/or where there was not enough information to make a rating on the key 
psychiatric clinical variables.
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Table B-19 Relationship between Subjective Impact of having DD on School, Work/Career, 
Relationships and Social Activities and Lifetime DSM-IV Diagnosis and History of Suicidal 
Thoughts and Suicide Attempts
Any Lifetime DSM-IV Diagnosis History of Suicidal Thoughts and Suicide 
Attempts
No Yes Total None SuicidalThoughts
Suicide
Attempts
Total
N % N % N N % N % N % N
School None 14 46.7 16 53.3 30 24 77.4 4 12.9 3 9.7 31
Mild 4 36.4 7 63.6 11 5 50.0 3 30.0 2 20.0 10
Mod/Sv 4 23.5 13 76.5 17 10 58.8 5 29.4 2 11.8 17
N/A 15 44.1 19 55.9 34 24 66.7 6 16.7 6 16.7 36
Total N* 37 55 92 63 18 13 94
X2 = 2.771, df=3, p= 0.428 **X2= 4.325 df=6,p= 0.653
Work/
Career
None 25 43.1 33 56.9 58 43 76.8 9 16.2 4 7.1 56
Mild 5 50 5 50 10 6 54.5 1 9.1 4 36.4 11
Mod/Sv 6 28.6 15 71.4 21 12 50 8 33.3 4 16.7 24
Total N* 36 53 89 61 18 12 91
X2 = 1.778, df=2,p= 0.411 11.595, df=4,p= 0.021
Relation­
ships
None 26 41.9 36 58.1 62 43 68.3 13 20.6 7 11.1 63
Mild 8 53.3 7 46.7 15 12 80 2 13.3 1 6.7 15
Mod/Sv 3 23.1 10 76.9 13 7 50 3 21.4 4 28.6 14
Total N* 37 53 90 62 18 12 92
X2= 2.689, df=2, p= 0.261 **X2= 4.585, df=4,p= 0.337
Social
Activities
None 20 50 20 50 40 34 79.1 4 9.3 5 11.6 43
Mild 11 36.7 19 63.3 30 17 60.7 7 25 4 14.3 28
Mod/Sv 6 28.6 15 71.4 21 12 54.5 7 31.8 7 13.6 22
Total N* 37 54 91 63 18 12 93
X2^ 2.916, df=2,p= 0.233 **X2= 6.161, df=4,p= 0.193
Chi-square tests, *exact significance tests for Pearson’s chi-square. Mod/Sv; moderate/severe DD.
’Missing cases are individuals where DSM-IV diagnosis was unknown and/or where history of suicidal thoughts and 
suicide attempts was unknown and/or where the effects of DD on the domain of life could not be established and/or 
where the lifetime effect on the domain of life was not applicable.
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Table B-20 Scores on the Dermatology Life Quality Index and Lifetime DSM-IV Diagnosis and
History of Suicidal Thoughts and Suicide Attempts
Any Lifetime DSM-IV Diagnosis History of Suicidal Thoughts and Suicide Attempts
No Yes U* P None Suicidal
Thoughts
Suicide
Attempts
H** P
DLQI- Last 
Week
Median 3.00 5.00 846.000 0.215 3.00 5.00 5.00 2.146 0.342
Range 0-20 0-28 0-26 0-28 0-12
Iq R 6 7 7 11 6
N*** 37 54 63 17 13
DLQI-
Worst
Week
Median 14.00 16.50 841.500 0.203 14.00 20.00 16.00 7.120 0.028
Range 0-30 2-30 0-30 2-30 10-30
Iq R 10 14 11 11 12
N*** 37 54 63 17 13
♦Mann-Whitney U Tests, ♦♦ Kruskal-Wallis H Tests. Iq R; interquartile range.
♦♦♦ Missing cases are individuals where age of onset of DD and/or lifetime DSM-IV diagnosis was unknown and/or 
history of suicidal thoughts and suicide attempts was unknown and one individual who did not complete the DLQI.
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Table B-21 Subjective Impact of Having DD on School and Work/ Career and Key Psychiatric Variables
Subjective Impact of DD on School Subjective Impact of DD on Work/Career
None Mild Moderate/
Severe
Not
Applicable
*H P None Mild Moderate/
Severe
*H P
Age of onset of any 
psychiatric illness
Median 28.50 16.00 29 24.50 1.790 0.617 25.00 17.00 29.40 1.310 0.519
Range 15-52 14-48 15-41 18-58 15-52 14-58 15-41
Interquartile Range 9 25 22 10 12 34 22
N 12 7 8 12 24 4 10
Number of 
Episodes of 
Depression
Median 4.00 4.00 1.5 3.50 4.160 0.245 2.50 5.00 3.00 0.581 0.748
Range 1-50 1-6 1-10 1-130 1-50 1-9 1-130
Interquartile Range 8 5 9 7 7 7 5
N 12 6 10 16 26 4 13
Longest Duration 
of Depression
Median 9.00 65.00 19 14.50 6.241 0.10 12.50 19.50 26.00 0.581 0.748
Range 1.0-
104.0
13.0-
260.0 1-780 0.4-156.0 1.0-780 13.0-52
0.4-312
Interquartile Range 20.0 139.8 238.3 35.0 45 32.5 102
N 12 6 8 16 26 4 11
♦Kruskal-Wallis H Tests.
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Table B-22 Subjective Impact of Having DD on Relationships and Social Activities and Key Psychiatric Variables
Subjective Impact of having DD on Relationships Subjective Impact of having DD on Social Activities
None Mild Moderate/Severe *H P None Mild Moderate/Severe *H P
Age of onset of any 
psychiatric illness
Median 25.00 20.50 31.00 1.588 0.542 29.50 25.00 23.00 4.01 0.135
Range 15-58 15-29 14-52 15-58 14-48 15-40
Interquartile Range 14 13 24 18 12 14
N 27 4 7 14 14 10
Number of Episodes 
of Depression
Median
Range
2.50
1-20
5.50
2-10
3.00
1-130
1.514 0.469 2.50
1-130
2.00
1-10
5.00
1-20
0.456 0.796
Interquartile Range 4 6 27 7 6 5
N 30 4 9 16 16 11
Longest Duration of 
Depression
Median 13.00 26.00 15.00 0.652 0.722 21.00 12.00 26.00 1.276 0.528
Range 1.0-780 12.0-52 0.4-312 0.4-780 1.0-130 1-312
Interquartile Range 47.3 30 25.0 36.8 48.0 139
N 30 4 7 16 15 10
♦Kruskal-Wallis H Tests.
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Table B-23 DLQI Last Week and Worst Week Scores - Correlations with Key Psychiatric Clinical
Variables
DLQI Last Week DLQI Worst Week
Age of onset of any psychiatric illness
♦rho 0.087 -0.202
P 0.604 0.223
n 38 38
Number of Episodes of Depression
♦rho 0.080 .082
P 0.611 0.601
n 43 43
Longest Duration of Depression
♦rho 0.130 0.086
P 0.418 0.591
n 41 41
Spearman’s rho correlation coefficients.
Table B-24 Relationship between having a Family History of DD and Lifetime DSM-IV Diagnosis 
and History of Suicidal Thoughts and Suicide Attempts
Any Lifetime DSM-IV Diagnosis History of Suicidal Thoughts and Suicide 
Attempts
No Yes Total None SuicidalThoughts
Suicide
Attempts
Total
N % N % N N % N % N % N
Family History of 
DD
No 15 60 10 40 25 23 92 0 0 2 8 25
Yes 19 31 42 69 61 36 57 17 27 10 16 63
Total 34 52 ♦86 59 17 12 ♦♦88
g*-6.175, df=l, p=0.013 " xMO.803, df=2, p=0.003
Chi-square test, ♦♦ exact significance test for Pearson’s chi-square. * Missing cases are individuals where lifetime 
DSM-IV diagnosis was unknown and/or where history of suicidal thoughts or suicide attempts was unknown and/or 
family history of DD was unknown.
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Table B-25 Family History of DD and Key Psychiatric Clinical Variables
Negative Family 
History of DD
Positive Family 
History of DD
U* P
Age of onset of any psychiatric illness
Median 18.50 27.00 74.000 0.433
Range 16-39 14-58
Interquartile Range 18 9
N** 6 31
Number of Episodes of Depression
Median 2.00 3.00 89.500 0.562
Range 1-6 1-130
Interquartile Range 4 8
N " 6 35
Longest Duration Depression
Median 10.00 16.00 80.500 0.470
Range 1-780 0.4-312
Interquartile Range 211 43
N " 6 33
♦Mann-Whitney U Tests. ♦♦ Missing cases are individuals where family history of DD was unknown and/or where 
there was not enough information to make a rating on the key psychiatric clinical variables.
Table B-26 Age of Onset of DD and History of Learning Difficulties
Learning Difficulties
No Yes U* P
Age of onset of DD
Median 14.00 13.00 605.0 0.244
Range 0-48 5-33
Interquartile Range 10 5
N” 77 19
♦Mann-Whitney U Test. ♦♦ Missing cases are individuals where age of onset of DD was unknown.
Table B-27 Relationship between DD Severity and History of Learning Difficulties
Learning Difficulties
TotalNo Yes
N % N % N
Severity index Mild 17 77.3 5 22.7 22
Moderate 54 80.6 13 19.4 67
Severe 8 72.7 3 27.3 11
Total N 79 21 100
X2=0.403, df=2, p=0.805
Exact significance test for Pearson’s chi-square.
Table B-28 Relationship between Subjective Impairment of DD on School Life and History of 
Learning Difficulties
Learning Difficulties
No Yes Total
N % N % N
Impact on School None 25 76 8 24 33
Mild 8 73 3 27 11
Mod/Sv 13 76 4 24 17
N/A 33 85 6 15 39
Total N 79 21 100
X2= 1.277, df=3,p= 0.758
Exact significance tests for Pearson’s chi-square. Mod/Sv; moderate/severe DD.
Table B-29 Relationship between Family History of DD and History of Learning Difficulties
Learning Difficulties
TotalNo Yes
N 1 % N % N
Family History of DD No 22 84.6 4 15.4 26
Yes 52 | 76.5 16 23.5 68
Total N* 74 20 94
X2=0.745, df=l, p=0.:188
Chi-square test. *Missing cases are individuals where family history of DD was unknown.
Table B-30 DD Severity and IQ Scores
DD Severity
Mild Moderate Severe H* P
Median 106.50 101.50 92.00 5.256 0.072
Range 70-118 67-125 76-108
Interquartile Range 14 19 13
N** 20 56 9
*Kruskal-Wallis H Test. ** Missing cases are individuals who did not complete the IQ measurement.
Table B-31 Relationship between Subjective Impairment of DD on School Life
Subjective Impact of DD on School
None Mild Moderate/Severe Not Applicable *H P
IQ
Median 105.00 99.50 96.00 105.00 2.955 0.399
Range 70-118 84-18 67-114
Interquartile
Range 20 15 14 23
N** 28 10 14 33
*Kruskal-Wallis H Tests. ** Missing cases are individuals who did no complete the IQ measurement
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Table B-32 Family History of DD and IQ Scores
Negative Family 
History of DD
Positive Family 
History of DD
U* P
IQjScore
Median 102.00 104.00 636.500 0.935
Range 70-118 67-125
Interquartile Range 19 21
N** 23 56
*Mann-Whitney U Test. ** Missing cases are individuals where family history of DD was unknown and/or 
individuals who did not complete the IQ measurement.
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C Appendices fo r Chapter 7
C.i DNA Extraction Protocols for Blood and Oragene Saliva Samples
P h e n o l -C h l o r o f o r m  D N A  E x t r a c t i o n  p r o t o c o l  f o r  10m l  h u m a n  p e r ip h e r a l  b l o o d :
First label 50ml centrifuge tubes (Elkay Laboratory Products Ltd) with the same IDs used on the tubes 
with the blood (Greiner Bio-one).
1. Put the blood in the 50ml centrifuge tubes adding Lysis buffer to a total volume of 40 ml.
The lysis buffer removes the erythrocytes from the peripheral blood by lysing them.
2. Place the blood-lysis mix on ice for 30 minutes.
3. Centrifuge the samples in the centrifuge (Sorvall® LegendK7\ Kendro Laboratory products) at 3000 
rpm for 15 minutes.
4. Tip off the supernatant retaining the cell pellet (the pellet should consist of leucocytes) at the bottom of 
the tube. The supernatant should be disposed off into a Virkon solution (Antec International Ltd) for 
decontamination before disposal down the sink.
5. Add lysis buffer to the cell pellet to a total volume of 30 ml.
6. Vortex the samples until the cell pellet is resuspended.
7. Centrifuge the samples at 3000 rpm for 15 minutes.
8. Tip off most of the supernatant.
9. Invert the tubes on to a tissue paper to remove the excess liquid.
The pellets are ready for digestion.
Cells (leukocytes from the blood) have to be digested overnight with:
-500 pi SET buffer
-50 pi 10% SDS (Sodium Dodecyl Sulfate Solution, Gibco™)
Adding the 10% SDS (strong anionic detergent) helps to disrupt the cell membranes, distributes the 
extraction buffer through the tissue, and helps the Proteinase K to denature the proteins.
-50 pi Proteinase K (from Tritirachium album, Sigma®)
Proteinase K is added to remove the proteins bound to the DNA and to destroy the cellular enzymes that 
would otherwise digest the DNA, thus maximizing the amount of intact DNA that is extracted.
Incubate overnight at 55°C in a water bath (Grant Instruments Cambridge Ltd.).
The 2ml tubes (Bioquote Limited) that will be used must be labelled before the beginning of the 
extraction.
1. Transfer the sample from the 50ml centrifuge tube to a 2ml tube (already labelled).
Add 1ml Tris-saturated Phenol (pH 8.0, Sigma®).
Vortex vigorously and centrifuge at 3000rpm for 5 minutes (Biofuge 13, Heraeus Sepatech).
Phenol is an organic solvent, hydrophobic and it disrupts the 3D structure of the proteins, precipitates 
and denatures them. The denatured proteins become soluble in the organic interphase, while the DNA 
remains in the aqueous phase.
Phenol does not denature the DNA because it is hydrophobic and DNA is hydrophilic.
2. Transfer the top (aqueous) layer to fresh prelabelled 2ml tube containing 500ul chloroform (BDH 
Laboratoiy Supply)/isoamyl (24:1) alcohol (BDH Laboratory Supply) and 500pl Tris-saturated phenol 
(pH8.0). Vortex and spin at 3000rpm for 5 minutes.
The chloroform helps the phenol in the denaturing of the proteins. It aids in the removal of the lipids as 
well, thus improving separation of nucleic acid into the aqueous phase. Phase separation is also
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enhanced, which assists in the removal o f  the aqueous phase with minimal cross contamination from the 
organic phase. The isoamyl alcohol is added to the phenol and the chloroform to reduce foaming.
3. Transfer the top layer trying not to disturb the white interface (it predominantly consists of proteins) to 
a fresh tube containing 1ml chloroform.
Vortex and spin at 3000rpm for 5 minutes.
The chloroform is used to remove residual phenol from the aqueous phase, which is slightly soluble and a 
known PCR inhibitor.
4. Transfer the top layer without the interface to a fresh 2ml tube. Add 1ml ethanol (cold, absolute, Fischer 
scientific) to precipitate the DNA.
5. Spool the DNA, rinse it with 70% ethanol and put it into 1ml 1% TE buffer.
The tubes with the DNA must be put on a rotator (VWR International Ltd) at 4°C at least for 3 days in 
order the DNA to be diluted entirely in the TE buffer.
6. Measure the concentration of the DNA, using Quant-it ™ PicoGreen® ds DNA assay kit (Invitrogen).
7. Test if the DNA is degraded.
8. Prepare PCR for known working assay and test if the DNAs are viable on 0.8% agarose gel (Sigma®).
Lvsis buffer:
Ammonium chloride (BDH Laboratory Supply)-8g 
Potassium bicarbonate (Sigma®)-lg
0.5 M EDTA-200pl
Make up to 11 with sterile ddH20  (Fresenius Kabi Ltd)
SET buffer:
NaCl-1.461 g (10ml 5MNaCl)
1M TRIS-C1 (pH 8.0)-10ml
0.5M EDTA (pH 8.0>5ml
Make up to 500 ml with sterile ddH20  (Fresenius Kabi Ltd)
TE buffer-1 % :
1MTRIS-C1 (pH 8.0)-10ml 
ImM EDTA (pH 8.0)-2 ml
Make up to 11 with sterile ddH2Q (Fresenius Kabi Ltd)
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Oracene  K its for  purifying  DNA from  saliva  (DNA Genotek  Inc):
DNA purification steps:
1. Incubate overnight the Oragene/saliva sample in the Oragene vial at 5S°C in a water bath (Grant 
Instruments Cambridge Lid.).
2. Divide the total 4 ml Oragene/saliva sample into four 1.5 ml centrifuge tubes (Bioquote Limited), each 
containing approximately 1 ml of sample.
3. Add 40 pi (l/25th volume) of Oragene Purifer (supplied with the kit) to each tube and mix gently by 
inversion. The sample will become turbid as impurities are precipitated.
4. Incubate the four tubes on ice for 10 minutes.
5. Centrifuge the four tubes for 3 minutes at 15,000 * g (13,000 rpm) (centrifuge-Biofuge 13, Heraeus 
Sepatech) at room temperature. Carefully pipet the clear supernatant from each tube and combine them all 
into one 15 ml centrifuge tube (Elkay Laboratory Products Ltd) without disturbing the pellets. Discard the 
pellets.
6. Add 4 ml (equal volume) of room-temperature 95% ethanol (Sigma®) to the supernatant and mix 
gently by inversion. Invert at least 5 times. A clot of DNA may be visible.
7. Let the solution stand for 10 minutes at room temperature, so that the DNA is fully precipitated. Do not 
incubate at -20°C because impurities may co-precipitate with the DNA.
8. Centrifuge for 10 minutes at 1,100 x g (3,500 rpm) at room temperature (Sorvall® Legend^T, Kendro 
Laboratory products).
9. Discard the supernatant without disturbing the DNA pellet (may or may not be visible). Remove 
ethanol as thoroughly as possible.
10. Once all of the ethanol has been removed, dissolve the DNA pellet in 500 pi of 1% TE buffer. The 
expected concentration of the rehydrated DNA is 20 to 200 ng/pl.
11. The tubes with the DNA must be put on a rotator (VWR International Ltd) at 4°C at least for 3 days in 
order the DNA to be diluted entirely in the TE buffer.
12. Measure the concentration of the DNA, using Quant-it ™ PicoGreen® ds DNA assay kit (Invitrogen).
13. Test if the DNA is degraded.
14. Prepare PCR for known working assay and test if the DNAs are viable on 0.8% agarose gel (Sigma®).
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D Appendices for Chapter 8
D.i Comparison of Type and Location of Mutations Detected Compared to 
Previously Reported Mutations in ATP2A2
Table D-l Frequencies and Percentage of Types of Pathogenic Mutations in the Present Study 
Compared to Mutations Previously Reported in the Literature
Mutation Type Frequencies of m utations 
in present study
All m utations previously in 
literature
ALL MUTATIONS
N % N % N %
Nonsense 3 5 14 10 16 9
Frameshift
(insertion/deletion)
12 20 33 23 43 23
Missense (non- 
synonomous)
30 50 71 50 87 47
In-frame
(insertion/deletion)
4 7 9 6 13 7
Splice Site 8 13 12 8 20 11
Other 3 5 4 3 6 3
Total number o f 
mutations
60 100 143 100 185 100
18 mutations detected/known in the present study that had previously been reported in the literature are counted in 
both the first two columns but only counted once in the ALL MUTATIONS column.
Table D-2 Frequencies and Percentages of Individuals in the Present Study according to Mutation 
Type Compared to Unrelated Individuals Previously Reported in the Literature
Mutation Type Frequencies of unrelated 
individuals in present 
study
Frequencies of unrelated 
individuals previously in 
the literature
ALL UNRELATED 
INDIVIDUALS
N % N % N %
Nonsense 4 6 15 9 19 8.1
Frameshift
(insertion/deletion)
12 18 34 19.4 45 19.3
Missense (non- 
synonomous)
37 54 98 56 128 54.9
In-frame
(insertion/deletion)
4 6 11 6 14 6
Splice Site 8 12 13 7.4 21 8.7
Other 3 4 4 2 6 2.6
Total number o f  
unrelated individuals
68 100 175 100 233 100
10 individuals in the present study whose mutations had previously been reported in the literature are counted in both
the first two columns but only counted once in the ALL UNRELATED INDIVIDUALS column.
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Table D-3 Frequencies and Percentages of the Exon/Intron Locations of Pathogenic Mutations in
the Present Study Compared to Mutations Previously Reported in the Literature
Mutation
Location
Frequencies of Mutations in 
present study
All mutations previously in 
the literature
ALL MUTATIONS
N % N % N %
Exon 1 1 1.7 7 5 7 3.8
Intron 1 0 0 1 0.7 1 0.5
Exon 2 0 0 5 3.5 5 2.7
Intron 2 1 1.7 0 0 1 0.5
Exon 3 3 5 4 2.8 6 3.2
Intron 3 0 0 0 0 0 0
Exon 4 0 0 2 1.4 2 1.1
Intron 4 1 1.7 0 0 1 0.5
Exon 5 0 0 6 4 6 3.24
Intron 5 1 1.7 0 0 1 0.5
Exon 6 2 33 5 3.5 7 3.8
Intron 6 0 0 1 0.7 1 0.5
Exon 7 0 0 7 5 7 3.8
Intron 7 0 0 1 0.7 1 0.5
Exon 8 12 20 15 10.5 24 13
Intron 8 1 1.7 0 0 1 0.5
Exon 9 0 0 3 2 3 1.6
Intron 9 0 0 0 0 0 0
Exon 10 1 1.7 2 1.4 3 1.6
Intron 10 0 0 1 0.7 1 0.5
Exon 11 3 5 2 1.4 4 2.2
Intron 11 0 0 0 0 0 0
Exon 12 2 33 7 5 8 43
Intron 12 0 0 1 0.7 1 0.5
Exon 13 3 5 6 4 9 4.9
Intron 13 1 1.7 1 0.7 2 1.1
Exon 14 4 6.7 11 7.7 14 7.6
Intron 14 1 1.7 1 0.7 2 1.1
Exon IS 8 13.3 19 13 22 11.9
Intron 15 1 1.7 0 0 1 0.5
Exon 16 3 5 8 5.6 10 5.4
Intron 16 0 0 0 0 0 0
Exon 17 2 33 1 0.7 2 1.1
Intron 17 0 0 1 0.7 1 0.5
Exon 18 6 10 10 7 14 7.6
Intron 18 0 0 0 0 0 0
Exon 19 3 5 8 5.6 10 5.4
Intron 19 0 0 1 0.7 1 0.5
Exon 20 0 0 2 1.4 2 1.1
Intron 20 0 0 1 0.7 1 0.5
Exon 20b 0 0 3 2 3 1.6
Total number 
of mutations
60 100 143 100 185 100
18 mutations detected/known in the present study that had previously been reported in the literature are counted in
both the first two columns but only counted once in the ALL MUTATIONS column.
Table D-4 Frequencies and Percentages of Individuals in the Present Study according to
Exon/Intron Mutation Location Compared to Unrelated Individuals Previously Reported in the
Literature
Mutation
Location
Frequencies of unrelated 
individuals in present study
Frequencies of unrelated 
individuals previously in the 
literature
ALL UNRELATED 
INDIVIDUALS
N % N % N %
Exon 1 1 1.5 13 7.4 14 6.0
Intron 1 0 0 1 0.6 1 0.4
Exon 2 0 0 5 2.9 5 2.1
Intron 2 1 1.5 0 0.0 1 0.4
Exon 3 3 4.4 4 2.3 6 2.6
Intron 3 0 0 0 0.0 0 0.0
Exon 4 0 0 2 1.1 2 0.9
Intron 4 1 1.5 0 0.0 1 0.4
Exon 5 0 0 9 5.1 9 3.9
Intron 5 1 1.5 0 0.0 1 0.4
Exon 6 2 2.9 7 4.0 9 3.9
Intron 6 0 0 1 0.6 1 0.4
Exon 7 0 0 7 4.0 7 3.0
Intron 7 0 0 1 0.6 1 0.4
Exon 8 13 19.1 19 10.9 31 13.3
Intron 8 1 1.5 0 0.0 1 0.4
Exon 9 0 0 3 1.7 3 13
Intron 9 0 0 0 0.0 0 0.0
Exon 10 1 1.5 2 1.1 3 13
Intron 10 0 0 2 1.1 2 0.9
Exon 11 3 4.4 2 1.1 4 1.7
Intron 11 0 0 0 0.0 0 0.0
Exon 12 3 4.4 8 4.6 10 4.3
Intron 12 0 0 1 0.6 1 0.4
Exon 13 3 4.4 7 4.0 10 4 3
Intron 13 1 1.5 1 0.6 2 0.9
Exon 14 4 5.9 14 8.0 17 7 3
Intron 14 1 1.5 1 0.6 2 0.9
Exon 15 13 19.1 26 14.9 37 15.9
Intron 15 1 1.5 0 0.0 1 0.4
Exon 16 3 4.4 9 5.1 12 5.2
Intron 16 0 0 0 0.0 0 0.0
Exon 17 2 2.9 2 1.1 3 1 3
Intron 17 0 0 1 0.6 1 0.4
Exon 18 6 8.8 10 5.7 16 6.9
Intron 18 0 0 0 0.0 0 0.0
Exon 19 4 5.9 10 5.7 12 5.2
Intron 19 0 0 1 0.6 1 0.4
Exon 20 0 0 2 1.1 2 0.9
Intron 20 0 0 1 0.6 1 0.4
Exon 20b 0 0 3 1.7 3 1.3
Total number 
o f  unrelated 
Individuals
68 100 175 100 233 100
10 individuals in the present study whose mutations had previously been reported in the literature are counted in both
the first two columns but only counted once in the ALL UNRELATED INDIVIDUALS column.
318
Table D-5 Frequencies and Percentages of the Protein Domain Locations of Pathogenic Mutations
in the Present Study Compared to Mutations Previously Reported in the Literature
Frequencies of 
mutations in present 
study
All mutations 
previously in the 
literature
ALL MUTATIONS
N % N % N %
N Terminus 1 1.7 1 0.7 1 0.5
MI transmembrane/S 1 4 6.7 8 5.6 11 5.9
Ml-M2 lumenal 0 0.0 0 0.0 0 0.0
M2 transmembrane/ S2 1 1.7 3 2.1 4 2.2
A domain 4 6.7 30 21.0 34 18.4
M3 transmembrane/S3 0 0.0 1 0.7 1 0.5
M3-M4- lumenal 1 1.7 1 0.7 2 1.1
M4 transmembrane/ S4 6 10.0 4 2.8 9 4.9
P domain 12 20.0 25 17.5 33 17.8
N domain 11 18.3 25 17.5 34 18.4
M5 transmembrane/S5 6 10.0 10 7.0 12 6.5
MS-M6 lumenal 0 0.0 0 0.0 0 0.0
M6 transmembrane 3 5.0 6 4.2 8 4.3
M6-M7 cytoplasmic 0 0.0 1 0.7 1 0.5
M7 transmembrane 1 1.7 2 1.4 2 1.1
M7-M8 lumenal 4 6.7 8 5.6 10 5.4
M8 transmembrane 3 5.0 4 2.8 7 3.8
M8-M9 cytoplasmic 3 5.0 4 2.8 6 3.2
M9 transmembrane 0 0.0 3 2.1 3 1.6
M9-10 lumenal 0 0.0 2 1.4 2 1.1
M10 transmembrane 0 0.0 2 1.4 2 1.1
M10-M11 cytoplasmic 0 0.0 0 0.0 0 0.0
Mil transmembrane 0 0.0 3 2.1 3 1.6
Lumenal 0 0.0 0 0.0 0 0.0
Total Number/Percentage of 
Mutations
60 100 143 100 185 100
18 mutations detected/known in the present study that had previously been reported in the literature are counted in 
both the first two columns but only counted once in the ALL MUTATIONS column.
Protein Domains: = transmembrane domains, Sn =stalk domains, A= Actuator Domain, P= Phosphorylation
Domain, N= Nucleotide Binding Domain.
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Table D-6 Frequencies and Percentages of Individuals in the Present Study according to SERCA2b
Protein Domain Compared to the Frequencies Previously Reported in the Literature
Frequencies of 
unrelated individuals 
in present study
Frequencies of 
unrelated individuals 
previously in the 
literature
ALL UNRELATED 
INDIVIDUALS
N % N % N %
N Terminus 1 1.5 3 1.7 4 1.7
MI transmembrane/S 1 4 5.9 8 4.6 11 4.7
M1-M2 lumenal 0 0.0 0 0.0 0 0.0
M2 transmembrane /S2 1 1.5 3 1.7 4 1.7
A domain 4 5.9 39 22.3 43 18.5
M3 transmembrane/S3 0 0.0 1 0.6 1 0.4
M3-M4- lumenal 1 1.5 1 0.6 2 0.9
M4 transmembrane /S4 6 8.8 6 3.4 11 4.7
P domain 14 20.6 31 17.7 44 18.9
N domain 12 17.6 28 16.0 38 16 3
M5 transmembrane/SS 10 14.7 16 9.1 24 10 3
M5-M6 lumenal 0 0.0 0 0.0 0 0.0
M6 transmembrane 3 4.4 6 3.4 9 3.9
M6-M7 cytoplasmic loop 0 0.0 1 0.6 1 0.4
M7 transmembrane 1 1.5 4 2.3 4 1.7
M7-M8 lumenal loop 4 5.9 8 4.6 12 5.2
M8 transmembrane 3 4.4 4 23 7 3.0
M8-M9 cytoplasmic loop 4 5.9 5 2.9 7 3.0
M9 transmembrane 0 0.0 4 23 4 1.7
M9-10 lumenal 0 0.0 2 1.1 2 0.9
M10 transmembrane 0 0.0 2 1.1 2 0.9
M10-M11 cytoplasmic 0 0.0 0 0.0 0 0.0
Ml 1 transmembrane 0 0.0 3 1.7 3 1.3
Lumenal 0 0.0 0 0.0 0 0.0
Total Number/Percentage of 
unrelated Individuals
68 100 175 100 233 100
10 individuals in the present study whose mutations had previously been reported in the literature are counted in both 
the first two columns but only counted once in the ALL UNRELATED INDIVIDUALS column.
Protein Domains: Mn = transmembrane domains, Sn =stalk domains, A= Actuator Domain, P= Phosphorylation 
Domain, N= Nucleotide Binding Domain.
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D.ii Comparison of Clinical Features of DD and Neuropsychiatric Phenotypes In Individuals in whom a 
Pathogenic Mutation Was and Was Not Detected/Known
Table D-7 Relationship between Detection of Pathogenic Mutation, Reported Family History of DD and DD Severity
Family History of DD DD Severity
No Definite/Probable Total Mild Moderate Severe Total
N % N % N N % N % N % N
Pathogenic Mutation 
Detected
No 10 43 13 57 23 10 36 14 50 4 14 28
Yes 14 21 53 79 67 12 18 49 72 7 10 68
Total N* 24 66 90 22 63 11 96
**=4.465, df=l, p=0.035 **=4.571, df=2, p= 0.102
Chi-square tests. *Missing cases are 4 individuals where no DNA was collected and no mutation information was known and/or individuals where family history 
of DD was unknown.
Table D-8 Pathogenic Mutation Detection and Scores on the Dermatology Life Quality Index (DLQI) -Worst Week Ever
No Pathogenic Mutation 
Detected
Pathogenic Mutation 
Detected
U* P
DLQI Worst Week Ever Score (Max. =30)
Median 15.50 15.00 849.000 0.467
Range 2-30 0-30
Interquartile Range 13 14
N** 28 67
* Mann-Whitney U Test. ** Missing cases are 4 individuals where no DNA was collected and no mutation information was known and 1 case where the DLQI 
was not completed.
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Table D-9 Relationship Between Detection of Pathogenic Mutation and Presence of Neuropsychiatric Phenotypes
Any Lifetime DSM-IV 
Diagnosis
History of Suicide 
Attempts
History of Psychiatric 
Contact
Learning Difficulties Investigations for 
Blackouts, Loss of 
Consciousness or Fainting 
Episodes
No Yes No Yes No Yes No Yes No Yes
Pathogenic
Mutation
Detected N % N % N N % N % N N % N % N N % N % N N % N % N
No 11 44 14 56 25 25 96 1 4 26 24 86 4 14 28 24 86 4 14 28 24 92 2 8 26
Yes 25 40 38 60 63 54 84 10 16 64 46 69 21 31 67 51 75 17 25 68 54 84 10 16 64
Total N* 36 52 88 79 11 90 70 25 95 75 21 96 78 12 90
X^ =0.138, df=l, p=0.710 Fisher’s, p=0.166 yf =2.963, df=l,p= 0.085 y?=1.332, df=l,p= 0.248 Fisher’s, p=0.497
Chi-square tests, Fisher’s; Fisher’s exact test. ♦Missing cases are 4 individuals where no DNA was collected and no mutation information was known and/or 
cases where lifetime history of a specific neuropsychiatric phenotype was unknown.
Table D-10 Relationship between Detection of Pathogenic and BADDS Mania (M) and Depression (D) Scores and Age of First Psychiatric 
Contact
No Pathogenic Mutation Detected Pathogenic Mutation Detected U* P
BADDS M Median (Iq R) 4.00(10) 8.00(14) 344.500 0.014
Range 0-40 0-90
N** 23 47
BADDS D Median (Iq R) 45.00 (40) 54.00 (25) 148.0 0.132
Range 10-70 7-95
N " 13 32
Age of onset of Psychiatric Illness (Years) Median (Iq R) 25.00(19) 27.00(14) 115 0.696
Range 18-44 15-58
N " 9 28
♦Mann-Whitney U Tests. BADDS; Bipolar Affective Disorder Dimensional Scale, Iq R; Interquartile Range.
♦♦Missing cases are 4 individuals where no DNA was collected and no mutation information was known and/or individuals not given a BADDS M and/or D 
score and/or individuals with no psychiatric illness or where age of onset of psychiatric illness was unknown.
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D.lii Investigations of Neuropsychiatric Genotype-Phenotype Correlations- Schematic Diagram of 
SERCA2b
Figure D-l Genotype-Phenotype Correlation: BADDS Mania Scores
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Figure D-2 Genotype-Phenotype Correlation: History of Suicide Attempts
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Figure D-3 Genotype-Phenotype Correlation: History of DSM-IV Lifetime Diagnosis
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Figure D-4 Genotype-Phenotype Correlation: Learning Difficulties
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Figire D-5 Genotype-Phenotype Correlation: Investigations for Blackouts, Loss of Consciousness or Fainting Episodes
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Figure D-6 Genotype-Phenotype Correlation: Diagnosis of Epilepsy or 1st Degree Relative with DD and a Diagnosis of Epilepsy
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D.iv Investigations of Genotype-Phenotype Correlations- Mutation Type
Table D-ll Relationship Between Mutation Type and Neuropsychiatric Phenotypes (1)
Any Lifetime DSM-IV 
Diagnosis
History of Suicide 
Attempts
History of Psychiatric 
Contact
Learning Difficulties Investigations for 
Blackouts, Loss of 
Consciousness or 
Fainting Episodes
No Yes No Yes No Yes No Yes No Yes
MUTATION N % N % N N % N % N N % N % N N % N % N N % N % N
Frameshift 2 18 9 82 11 7 70 3 30 10 5 50 5 50 10 10 83 2 17 12 8 73 3 27 11
In-frame 4 100 0 0 4 4 100 0 0 4 4 100 0 0 4 3 75 1 25 4 4 100 0 0 4
Missense 13 37 22 63 35 30 86 5 14 35 27 73 10 27 37 27 73 10 27 37 32 89 4 11 36
Nonsense 1 33 2 67 3 3 75 1 25 4 2 50 2 50 4 2 50 2 50 4 2 67 1 33 3
Other 1 33 2 67 3 2 67 1 33 3 1 33 2 67 3 3 100 0 0 3 2 67 1 33 3
Splice Site 4 57 3 43 7 8 100 0 0 8 6 75 2 25 8 6 75 2 25 8 6 86 1 14 7
Total N* 25 38 63 54 10 64 45 21 66 51 17 68 54 10 64
3^=9.291, df=5,p= 0.090 X? =4.817, df=5, p= 0.441 yf=6.242, df=5,p= 0.284 =2.859, df=5, p= 0.760 =3.866, df=5, p= 0.527
Exact significance tests for Pearson’s chi-square. *Missing cases are individuals where lifetime history of a specific neuropsychiatric phenotype was unknown.
Table D-12 Relationship between Mutation Type and Neuropsychiatric Phenotypes (2)
Index with Bipolar Disorder or 1*‘ Degree Relative with 
DD and Bipolar Disorder
Index with Epilepsy or 1*‘ Degree Relative with DD and 
Epilepsy
No Yes No Yes
MUTATION N % N % N N % N % N
Frameshift 11 92 1 8 12 11 92 1 8 12
In-frame 4 100 0 0 4 4 100 0 0 4
Missense 35 95 2 5 37. 35 95 2 5 37
Nonsense 4 100 0 0 4 4 100 0 0 4
Other 2 67 1 33 3 3 100 0 0 3
Splice Site 7 88 1 12 8 6 75 2 25 8
Total N 63 5 68 63 5 68
^ =3.570, df=5, p= 0.657 3^=4.753. df=5, p= 0.413
Exact significance tests for Pearson’s chi-square.
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Table D-13 Relationship between Mutation Types and BADDS Mania (M) and Depression (D) Scores and Age of First Psychiatric Illness
Frameshift In-frame Missense Nonsense Other Splice Site H* P
BADDS M Median (Iq R) 12.00(14) 4.00(11) 8.00(11) 17.00 41.00 13.50(46) 2.620 0.758
Range 0-90 2-16 0-70 1-17 1-81 6-65
N** 7 4 27 3 2 4
BADDS D Median (Iq R) 61.50(38) - 51.00(24) 63.50 59.50 41.00 3.369 0.498
Range 7-95 - 10-70 55-72 50-69 30-70
N** 6 0 19 2 2 3
First Psychiatric Illness (years) Median (Iq R) 27 (29) 27(16) 29.5 24.5 25 0.424 0.981
Range 15-52 - 15-58 29-30 18-31 15-48
N** 4 0 17 2 2 3
*Kruskal-Wallis H Tests. BADDS; Bipolar Affective Disorder Dimensional Scale, Iq R; Interquartile Range.
♦♦Missing cases are 4 individuals where no DNA was collected and no mutation information was known and/or individuals not given a BADDS M and/or D 
score and/or individuals with no psychiatric illness or where age of onset of psychiatric illness was unknown.
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D.v Investigations of Genotype-Phenotype Correlations -Mutations Located in Functional Domains of 
SERCA2b and Neuropsychiatric Phenotypes
Table D-14 Relationship between Mutation Location in the A, N, P and Ca2+ Binding Domains of SERCA2b and Neuropsychiatric 
Phenotypes (1)
Any Lifetime DSM-IV 
Diagnosis
History of Suicide 
Attempts
History of Psychiatric 
Contact
Learning Difficulties Investigations for 
Blackouts, Loss of 
Consciousness or 
Fainting Episodes
No Yes No Yes No Yes No Yes No Yes
DOMAIN N % N % N N % N % N N % N % N N % N % N N % N % N
A No 25 42 34 58 59 51 85 9 15 60 45 73 17 27 62 48 94 3 6 51 50 93 4 7 54
Yes 0 0 4 100 4 3 75 1 25 4 0 0 4 100 4 16 94 1 6 17 10 100 0 0 10
Total N* 25 38 63 54 10 64 45 21 66 64 4 68 60 4 64
Fisher’s, p= 0.145 Fisher’s, p= 0.502 Fisher’s, p= 0.008 Fisher’s, p=l Fisher’s, P=1
N No 22 42 30 58 52 46 88 6 12 52 38 70 16 30 54 42 82 9 18 51 46 85 8 15 54
Yes 3 27 8 73 11 8 67 4 33 12 7 58 5 42 12 14 82 3 18 17 6 60 4 40 10
Total N* 25 38 63 54 10 64 45 21 66 56 12 68 52 12 64
Fisher’s, p= 0.503 Fisher’s, p= 0.082 Fisher’s, p=0.499 Fisher’s, p=l Fisher’s, p=0.082
P No 17 34 33 66 50 41 82 9 18 50 33 63 19 37 52 41 80 10 20 51 43 80 11 20 54
Yes 8 62 5 38 13 13 93 1 7 14 12 86 2 14 14 13 76 4 24 17 8 80 2 20 10
Total N* 25 38 63 54 10 64 45 21 66 54 14 68 51 13 64
t =3.3269, df=l, p= 
0.071 Fisher’s, p= 0.437 Fisher’s, p=0.127 Fisher’s, p=0.737 Fisher’s, p=l
Ca2+ binding No 17 40 26 60 43 37 82 8 18 45 28 62 17 38 45 31 61 20 39 51 36 67 18 33 54
Yes 8 40 12 60 20 17 89 2 11 19 17 81 4 19 21 15 88 2 12 17 8 80 2 20 10
Total N* 25 38 63 54 10 64 45 21 66 46 22 68 44 20 64
=0-001, dP=l, p= 
0.972 Fisher’s, p= 0.451 X2 =2.315, df=l, p=0.128 X2 =4.390, df=l, p=0.036 Fisher’s, p=0.486
Chi-square tests, Fisher’s; Fisher’s exact tests. *Missing cases are where the lifetime history of a specific neuropsychiatric phenotype was unknown.
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Table D-15 Relationship between Mutation Location in the A, N, P and Ca2+ Binding Domains of SERCA2b and Neuropsychiatric 
Phenotypes (2)
Index with Bipolar Disorder or 1st Degree Relative with 
DD and Bipolar Disorder
Index with Epilepsy or 1st Degree Relative with DD 
and Epilepsy
No Yes No Yes
SERCA2b Domain N % N % N N % N % N
A No 60 95 3 5 63 60 95 3 5 63
Yes 4 80 1 20 5 4 80 1 20 5
Total *N 64 4 68 64 4 68
Fisher’s, p=0.269 Fisher’s, p=0.269
N No 52 83 11 17 63 51 81 12 19 63
Yes 4 80 1 20 5 5 100 0 0 5
Total *N 56 12 68 56 12 68
Fisher’s, df=l, p=l Fisher’s, p=0.577
P No 49 78 14 22 63 49 78 14 22 63
Yes 5 100 0 0 5 5 100 0 0 5
Total *N 54 14 68 54 14 68
Fisher’s, p=0.575 Fisher’s, p=0.575
Ca2+ binding No 43 68 20 32 63 42 67 21 33 63
Yes 3 60 2 40 5 4 80 1 20 5
Total *N 46 22 68 46 22 68
Fisher’s, p=0.656 Fisher’s, df=l, p=l
Fisher’s; Fisher’s exact tests. "'Missing cases are where lifetime histoiy of a specific neuropsychiatric phenotype was unknown.
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Table D-16 Relationship between Mutation Location in the A, N, P and Ca2+ Binding Domains of 
SERCA2b and BADDS Mania (M) and Depression (D) Scores and Age of First Psychiatric Contact
Functional Domain Individuals with 
mutations 
within domain
Individuals with 
mutations not 
within domain
U* P
BADDS Mania Scores
N  domain Median (Iq R) 36.5 (-) 8(14) 25.5 0.303
Range 8-65 0-90
N* 2 45
N  domain Median (Iq R) 7.5 (13) 8(14) 180 0.908
Range 0-90 0-81
N* 10 37
P  domain Median (IqR) 5.5 (14) 9(12) 162 0.549
Range 1-17 0-90
N* 10 37
Ca binding domains Median (Iq R) 10(14) 7.5 (13) 235.5 0.649
Range 0-70 0-90
N* 17 30
BADDS Depression Scores
A domain Median (IqR) 56.5 (25) 53 (25) 51.5 0.797
Range 39-70 7-95
N* 4 28
N  domain Median (IqR) 63 (28) 52(24) 71 0.276
Range 7-95 10-74
N* 8 24
P  domain Median (IqR) 55.5 (20) 54 (26) 52 0.819
Range 39-62 7-95
N* 4 28
Ca binding domains Median (IqR) 51 (32) 55 (24) 93.5 0.675
Range 10-74 7-95
N* 9 23
Age of Onset of Psychiatric Illness 
(Years)
A domain Median (IqR) 23 (22) 27(13) 40.5 0.622
Range 15-40 15-58
N* 4 24
N  domain Median (IqR) 34 (-) 27(13) 72 0.936
Range 22-41 15-58
N* 3 25
P  domain Median (IqR) 28 (12) 27 (16) 24 0.315
Range 15-52 15-58
N* 7 21
Ca binding domains Median (IqR) 24 (25) 28(12) 75.5 0.622
Range 15-58 15-52
N* 9 19
*Mann-Whitney U Tests. BADDS; Bipolar Affective Disorder Dimensional Scale, Iq R; Interquartile Range. 
♦•Missing cases are 4 individuals where no DNA was collected and no mutation information was known and/or 
individuals not given a BADDS M and/or D score and/or individuals with no psychiatric illness or where age of 
onset of psychiatric illness was unknown.
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D.vi Mutation Location within ATP2A2 and Neuropsychiatric Phenotypes
Table D-17 Relationship between Mutation Location in ATP2A2 and Neuropsychiatric Phenotypes (1)
Any Lifetime DSM-IV 
Diagnosis
History of Suicide 
Attempts
History of Psychiatric 
Contact
Learning Difficulties Investigations for 
Blackouts, Loss of 
Consciousness or Fainting 
Episodes
No Yes No Yes No Yes No Yes No Yes
ATP2A2
Position N % N % N N % N % N N % N % N N % N % N N % N % N
First Third 8 47 9 53 17 16 84 3 16 19 11 58 8 42 19 15 79 4 21 19 17 89 2 11 19
Middle 7 39 11 61 18 15 79 4 21 19 14 74 5 26 19 14 74 5 26 19 12 67 6 34 18
Last Third 10 36 18 64 28 23 88 3 12 26 20 71 8 29 28 22 73 8 27 30 25 93 2 7 27
Total N* 25 38 63 54 10 64 45 21 66 51 17 68 54 10 64
X2=0.575, df=2,p= 0.750 X2=0.754, df=2,p= 0.763 X*=1.328, df=2, p= 0.515 X2 =0.220, df=2,p= 0.939 X2 =6.039, df=2, p=0.048
Exact significance tests for Pearson’s chi-square. *Missing cases are where lifetime history of a specific neuropsychiatric phenotype was unknown.
Table D-18 Relationship between Mutation Location in ATP2A2 and Neuropsychiatric Phenotypes (2)
Index with Bipolar Disorder or 1st Degree Relative with 
DD and Bipolar Disorder
Index with Epilepsy or 1st Degree Relative with DD and 
Epilepsy
No Yes No Yes
ATP2A2
Position N % N % N N % N % N
First Third 16 84 3 16 19 15 79 4 21 19
Middle 18 95 1 5 19 19 100 0 0 19
Last Third 29 97 1 3 30 29 97 1 3 30
Total N 63 5 68 63 5 68
X2 =2.818, df=2, p= 0.371 X2 =7.454, df=2, p=0.039
Exact significance tests for Pearson’s chi-square.
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Table D-19 Relationship between Mutation Location and BADDS Mania and Depression Domains
First
Third
Middle
Third
Last
Third
H* P
BADDS Mania Median (Iq R) 13.5 (23) 7.5(13) 7(15) 1.209 0.546
Range 1-81 0-90 0-70
N** 12 14 21
BADDS Depression Median (Iq R) 56.50(18) 61.50(22) 46.00(31) 3.206 0.201
Range 39-74 7-95 10-70
N** 8 10 14
Age of Onset of Psychiatric Illness (years) Median (Iq R) 27(15) 29(13) 25 (19) 0.267 0.875
Range 15-40 15-52 15-58
N** 7 8 13
*Kruskal-Wallis H Tests. BADDS; Bipolar Affective Disorder Dimensional Scale, Iq R; Interquartile Range.
** Missing cases are 4 individuals where no DNA was collected and no mutation information was known and/or individuals not given a BADDS M and/or 
D score and/or individuals with no psychiatric illness or where age of onset of psychiatric illness was unknown.
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E  Appendices fo r Chapter 10
E.i Unaffected Relatives Invitation Letter, Information Sheet and Consent 
Form
U n a ff e c t e d  R e l a t iv e s  In v it a t io n  L e t t e r
Dear
I am a member of a team of psychiatrists and psychologists who work in the Department of 
Psychological Medicine at Cardiff University and Department of Psychiatry at the University of 
Birmingham. We are conducting research into features that may be associated with Darier’s 
Disease. I enclose with this letter a short information sheet about our study.
If you may be interested in taking part, or would like further details, I would be very grateful if 
you would complete the enclosed form and return it in the enclosed stamped addressed envelope.
Many thanks in anticipation of your help,
Katherine Gordon-Smith 
Research Psychologist
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U n a f f e c t e d  R e l a t iv e s  I n f o r m a t io n  Sh e e t
IN FO R M A TIO N  ABOUT RESEA RCH  INTO D A RIER’S DISEASE
In t r o d u c t io n
I am a member of a team of researchers who work in the Department of Psychological Medicine 
at Cardiff University and Department of Psychiatry at the University of Birmingham. We are 
conducting research (funded by the Wellcome Trust) to learn more about features that may be 
associated with Darier’s Disease.
W h a t  is  t h e  r e s e a r c h  a b o u t ?
It is known that sometimes disorders affecting the nervous system (such as epilepsy or 
depression) occur in individuals with Darier’s Disease. However, such disorders are common in 
the general population and it is not known whether this is just a coincidence or whether there is 
any relationship to the Darier’s Disease itself. The idea of this study is to compare individuals 
with Darier’s Disease with other individuals who do not have the illness in order to discover 
whether there are any problems that are specifically related to Darier’s Disease and also to try to 
find out what influences their occurrence. This research will help us understand more about 
Darier’s Disease itself and, importantly, the treatment needs of people suffering with the illness. 
As an unaffected family member of a sufferer of Darier’s Disease, we would be extremely 
grateful if you would be kind enough to help us with this study.
WHAT DOES TAKING PART INVOLVE?
We are hoping to recruit a sample of at least 100 individuals who suffer from Darier’s Disease. 
We would also be very interested in seeing other available family members, whether they suffer 
from Darier’s Disease or not. Participation as an unaffected family member involves: 
an interview (lasting around 1 V% hours) asking you about any medical, neurological and 
psychiatric conditions you have experienced
a series of short tasks designed to assess cognitive abilities e.g. memory, problem solving skills
and attention (% hour)
completing a set of questionnaires (lA hour)
giving a small blood sample from your arm (approximately lOmls).
If you agree to take part, a researcher will arrange a suitable time to visit you in your home or 
another place convenient for you. We will only need to see you the once but may ask if you 
would like to take part in future research. We will keep you informed of any interesting results 
and of future studies into Darier’s Disease.
With your permission, we may ask to look at your medical records in strict confidence.
W h a t  a r e  t h e  b e n e f it s  o f  t a k in g  p a r t  ? A r e  t h e r e  a n y  r is k s ?
By taking part in the study you will not gain any direct benefit. However, your help will be of 
great value in allowing us to learn more about Darier’s Disease and this is likely to help improve 
treatments.
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As this study does not include any treatment changes or invasive techniques, there are no real 
risks of taking part. You may experience mild bruising on you arm after giving a blood sample.
DECLINING AND WITHDRAWING FROM THE STUDY
Taking part in the research is entirely voluntary. It is up to you to decide whether or not to take 
part. If you decide to take part you are still free to withdraw at any time and without giving a 
reason.
A decision to withdraw at any time, or a decision not to take part, will not affect the standard of 
any care you may receive.
CONFIDENTIALITY
All interviews and results will be strictly confidential.
Your blood cells may be kept growing in the laboratory in order to provide samples for future use 
in this research, by us and by other researchers working with us. The results of your blood test are 
for research purposes only and will not be available to anybody on an individual basis.
All information given is kept in an anonymous format.
If you have any further questions about this research, we would be delighted to answer them in 
person or over the telephone. Our address appears above, our telephone number is 0121 678 
2352, and our e-mail address is k.m.gordonsmith@bham.ac.uk
Katherine Gordon-Smith - Research Psychologist 
Professor Nick Craddock - Head of Department 
Dr Lisa Jones- Research Psychologist
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U n a ff e c t e d  R e l a t iv e s  C o n s e n t  F o r m
A GREEM EN T TO  TA KE PART IN TH E STUDY O F D A RIER’S DISEASE
I have read the attached information sheet (Version 4 07.06.05) on the above project and have 
been given a copy to keep. I have had the opportunity to ask questions about the project and 
understand why the research is being done.
I understand that participation in this project is voluntary and that I am free to withdraw from the 
study without giving a reason.
I understand that the tests done as part of this research are not clinically diagnostic and I will not 
be informed of any specific results.
I understand that I will not benefit personally from taking part in this research.
I understand that the information I have donated for this study will be held in a confidential and 
coded form by the research team and may be made available to researchers at other centres who 
are carrying out similar work.
I know how to contact the research team if I need to.
NAME SIGNED
DATE
THANK YOU FOR PARTICIPATING IN OUR RESEARCH 
THIS COPY IS FOR YOU TO KEEP
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E.ii Unaffected Relatives Questionnaire
A. GENERAL INFORMATION
Name ______________________________  Sex Male □  Female □  (please
tick)
Date of Birth (DD/MM/YY)_____________
Name of family member who passed on this questionnaire pack
What is your relationship to this family member (brother, sister, mother, father, son, 
daughter)
Please give your address if you are willing to be sent a saliva collection kit in the post (it 
should take less than 5 minutes to do)
Please tick the following box if you would be willing to receive a brief follow up telephone 
call to discuss your some of the information you have provided in this questionnaire pack □
Telephone num ber____________________________
Please state any days or times when it would be most convenient to contact you
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B . Pe r s o n a l  M e d ic a l  a n d  P s y c h ia t r ic  H is t o r y
1. Have you ever been diagnosed w ith D arier’s disease y e s__ n o ___(please tick
one)
2. Have you ever experienced any o ther skin conditions/problems (e.g. eczema, psoriasis) 
yes  no (please tick  one)
I f  yes please give b rie f d e ta i ls ____________________________________________________
3.Do you currently  suffer from  any physical illnesses y e s__ n o ___(please tick
one)
I f  yes please give b rie f d e ta i ls ____________________________________________________
4. A re you currently  on any medication y e s__ n o ___(please tick  one)
I f  yes please give b rie f d e ta i ls ____________________________________________________
5. Have you ever been a regu lar sm oker: (please tick one)
□ No □ Yes in past now stopped
□ Yes, currently
6. Have you ever experienced any of the following problems in your life? -  even if very mild 
(please tick one for each)
Yes No
Anxiety or panic attacks □ □
Feeling very low in spirits, depression or low mood □ □
Feeling much too high in spirits or elated or very irritable
without reason, manic depression or bipolar disorder □ □
Experiencing things that are difficult to explain or understand
like hearing voices or seeing things, psychosis or schizophrenia □ □
Checking things you know you have done 
keeping things in a special order,
obsessive compulsive disorder □ □
Eating disorders □ □
Problems due to alcohol or □ □
other substances
7. I f  you answ ered YES to any o f the items above, please could you indicate any treatm ent 
you have had: 
(tick as m any as a re  relevant)
Sought help from  Prescribed Received Seen H ospital None
GP or other health M edication Counselling Psychiatrist Adm ission 
professional
Anxiety or panic attacks □ □ □ □ □ □
Depression or low mood □ □ □ □ □ □
Feeling much too high in 
spirits or elated or very irritable 
without reason, manic depression
or bipolar disorder □ □ □ □ □ □
Experiencing things that are difficult 
to explain or understand like hearing 
voices or seeing things,
psychosis or schizophrenia □ □ □ □ □ □
Checking things you know 
you have done, keeping things 
in a special order, 
obsessive compulsive
disorder □ □ □ □ □ □
Eating disorders □ □ □ □ □ □
Problems due to alcohol or
other substances □ □ □ □ □ □
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8. If you have responded ‘yes’ to any of items in question 6 or ticked any of the items in question 7 
please could you provide brief details such as the symptoms you have experienced, how often they 
have occurred, how long they lasted, how severe they have been and the treatment you have 
received.
343
C. N eurological  Sym pto m s
1. Have you ever experienced any of the following symptoms? (please tick)
Head injury □ Severe Headaches □
Fits, faints, funny turns, epilepsy Memory difficulties or diagnosis
or seizure, loss of consciousness □ “dementia" □
Weaknesses of the limbs □ Loss of sensation in the limbs □
Tremors or shaking □ Difficulty walking □
Giddiness or difficulty with balance □ Stokes, brain haemorrhages, (TIAs) □
Brain tumour or cancer affecting brain
or nervous system □ Infections of the brain or nervous system □
Problems with vision □ Problems with hearing □
Developmental delay or development problem relating to the brain or nervous system □
Any other symptoms or treatment related to problems with the brain or nervous system □
2. Have you ever been seen by a neurologist? Please tick No □ Yes □ Unsure
□
3. Have you ever had neurological procedures such as brain scans (CT, MRI), brain wave 
recordings (EEG), lumbar punctures? Please tick No □ Yes □ Unsure □
If  you have ticked any of the items in question 1 or answered YES to either question 2 or 3 
please could you provide brief details of the symptoms and procedures you have had
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D. PARTICIPANT QUESTIONNAIRE
1. Please tick  w hich o f the  following qualifications you have obtained (please tick as many as 
necessary):
□ None
□ 11+
□ O-Level/GCSE
□ A-Level/HND/BTEC
□ Degree
□ Post-graduate degree
2. Please tick w hich o f the  following types o f jobs have you have had (tick as many as 
necessary):
□ Never worked
□ Never worked due to sickness/disablement
□ Legislator/senior official/manager
□ Technician/associate professional/civil servant
□ Service worker/shop worker/market worker
□ Skilled agricultural /fishery worker
□ Plant & machinery operator/assembler
□ Other (please specify)___________________
3. Please tick  w hich o f the  following types o f jobs vour father has had (tick as many as 
necessary):
□ Unknown
□ Never worked
□ Never worked due to sickness/disablement
□ Legislator/senior official/manager □
□ Technician/associate professional/civil servant □
□ Service worker/shop worker/market worker □
□ Skilled agricultural /fishery worker □
□ Plant & machinery operator/assembler □
□ Other (please specify)________________________
Other professional 
Clerk
Craft and related trade worker 
Armed forces 
Homemaker
□ Other professional
□ Clerk
□ Craft and related trade worker
□ Armed forces
□ Homemaker
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4. Please tick  w hich o f the following types of jobs vour m other has had (itick as many as 
necessary):
□ Unknown
□ Never worked
□ Never worked due to sickness/disablement
□ Legislator/senior official/manager □ Other professional
□ Technician/associate professional/civil servant □ Clerk
□ Service worker/shop worker/market worker □ Craft and related trade worker
□ Skilled agricultural /fishery worker □ Armed forces
□ Plant & machinery operator/assembler □ Homemaker
□ Other (please specify)
5. Please tick which of the following best describes your current occupational status:
□ Employed full time □ Homemaker
□ Employed part time □ Student
□ Unemployed -  receiving benefits □ Retired
□ Unemployed -  not receiving benefits
6. Have you been married/ lived with a partner as though married?
□ Yes
□ No
7. Please tick  w hich o f the  following best describes your cu rren t social circum stances:
□ Living alone
□ Living with partner at least one year but not married
□ Living in own home with spouse and /or children
□ Living in home with parents or children
□ Living in home of siblings
□ Living in shared home with other relatives or friends
□ Living in residential treatment facility
□ Other
8. Place of birth (please tick)
□ England -  Midlands □ Other Europe
□ England -  North □ Asia
□ England -  South □ Africa
□ Wales -  North □ North America
□ Wales -  South □ South America
□ Scotland -  North □ Australasia
□ Scotland -  South □ Other
□ Northern Ireland □ Unknown
□ Republic of Ireland
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9. Ethnic Origin (please tick)
□ UK/Irish Caucasian □ Asian
□ West European Caucasian □ Mixed race
□ Other Caucasian □ Unknown
□ Afro-Caribbean
10. Which hand do you write with (please tick) Right □ Left □ Ambidextrous □
11. Did you experience any problems in the following areas at school (Please tick)
Reading No □ Mild problems □ Major Problems □ Unsure □
Spelling No □ Mild problems □ Major Problems □ Unsure □
Writing No □ Mild problems □ Major Problems □ Unsure □
Sums/numbers No □ Mild problems □ Major Problems □ Unsure □
Coordination/
clumsiness No □ Mild problems □ Major Problems □ Unsure □
12. Have you ever had any of the following diagnoses (Please tick)
Dyslexia No □ Yes □ Unsure □
Dyspraxia No □ Yes □ Unsure □
13. Did you receive any help extra help at school (Please tick)
No □ Yes □ Unsure □
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E.iii Personality and Temperament Questionnaires
1.B E C K  D EPRESSION  INVENTORY fBDD
On this questionnaire are groups of statements. Please read each group of statements carefully, circle the 
number (0, 1, 2 or 3) next to the one statement in each group which best describes how you feel today. If 
several statements within a group seem to apply equally well, circle each one. Be sure to read all the
1 0 I do not feel sad. 8 0 1 don’t feel I am worse than anyone
else.
1 I feel sad. 1 I am critical of myself for my
weaknesses
2 I am sad all the time and I can’t snap or mistakes.
out of it. 2 I blame myself all the time for my
faults.
3 I am so sad or unhappy that I can’t 3 I blame myself for eveiything bad that
stand it. happens.
2 0 I am not particularly discouraged about 9 0 1 don’t have any thoughts of killing
the future. 1 myself.
I have thoughts of killing myself, but I
1 I feel discouraged about the future. would not carry them out.
2 I feel I have nothing to look forward to. 2 I would like to kill myself.
3 I feel that the future is hopeless and that 3 1 would kill myself if I had the chance.
things cannot improve.
10 0 I don’t cry any more than usual.
3 0 I do not feel like a failure. 1 I cry more now than I used to.
1 I feel I have failed more than the 2 I cry all the time now.
average person. 3 I used to be able to cry, but now I can’t
cry
2 As I look back on my life, all I can see even though I want to.
is a lot of failures.
3 I feel I am a complete failure as a 11 0 I am no more irritated now than I ever
person. am.
1 I get annoyed or irritated more easily
than I
4 0 I get as much satisfaction out of things used to.
as I used to. 2 I feel irritated all the time now.
1 I don’t enjoy things the way I used to. 3 I don’t get irritated at all by the things
that
2 I don’t get real satisfaction out of used to irritate me.
anything anymore.
3 I am dissatisfied or bored with 12 0 I have not lost interest in other people.
everything.
1 I am less interested in other people than
I
5 0 I don’t feel particularly guilty.
1
used to be.
1 I feel guilty a good part of the time. 2 I have lost most of my interest in other
2 I feel quite guilty most of the time. people.
3 I feel guilty all of the time. 3 I have lost all of my interest in other
people.
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6 0 1 don’t feel I am being punished.
1 I feel I may be punished.
2 I expect to be punished.
3 I feel I am being punished.
7 0 1 don’t feel disappointed in myself.
1 I am disappointed in myself.
2 I am disgusted with myself.
3 I hate myself.
14 0 I don’t feel I look any worse than I used 
to.
1 I am worried that I am looking old or 
unattractive.
2 I feel that there are permanent changes 
in
my appearance that make me look 
unattractive.
3 I believe that I look ugly.
15 0 I can work about as well as before.
1 It takes an extra effort to get started at 
doing something.
2 I have to push myself very hard to do
anything.
3 I can’t do any work at all.
16 0 I can sleep as well as usual.
1 I don’t sleep as well as I used to.
2 I wake up 1-2 hours earlier than usual
and
find it hard to get back to sleep.
3 I wake up several hours earlier than I 
used
to and cannot get back to sleep.
17 0 I don’t get more tired than usual.
1 I get tired more easily than I used to.
2 I get tired from doing almost anything.
3 I am too tired to do anything.
13 0 I make decisions about as well as I ever 
could.
1 I put off making decisions more than I 
used
to.
2 I have greater difficulty in making 
decisions than before.
3 I can’t make decisions at all anymore.
19 0 I haven’t lost much weight, if any,
lately.
1 I have lost more than 5 pounds.
2 I have lost more than 10 pounds.
3 I have lost more than 15 pounds.
I am purposely trying to lose weight by 
eating less. Yes No (please 
circle)
20 0 I am no more worried about my health 
than 
usual.
1 I am worried about physical problems 
such as aches and pains; or upset 
stomach;
or constipation.
2 I am very worried about physical 
problems
and it’s hard to think of much else.
3 I am so worried about my physical 
problems that I cannot think of 
anything
else.
21 0 I have not noticed any recent change in 
my
interest in sex.
1 I am less interested in sex than I used to 
be.
2 I am much less interested in sex now.
3 I have lost interest in sex completely.
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18 0 My appetite is no worse than usual.
1 My appetite is not as good as it used to
be.
2 My appetite is much worse now.
3 I have no appetite at all anymore.
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2.A LTM A N  SELF-RA TIN G  SCALE FO R  MANlA(ARSIVf>
1. On this questionnaire are groups of five statements. Please read each group of statements 
carefully.
2. Choose one statement in each group that best describes how you feel today.
3. Circle the number next to the statement you have picked.
4. Please not the word *occasionally’ when used here means once or twice. ‘ Often’ means 
several times or more. *Frequently * means most of the time._______________________
1 0 I do not feel happier or more cheerful than usual.
1 I occasionally feel happier or more cheerful than usual.
2 I often feel happier or more cheerful than usual.
3 I feel happier or more cheerful than usual most of the time.
4 I feel happier or more cheerful than usual all of the time.
2 0 I do not feel more self-confident than usual.
1 I occasionally feel more self-confident than usual.
2 I often feel more self-confident than usual.
3 I feel more self-confident than usual most of the time.
4 I feel more self-confident than usual all of the time.
3 0 1 do not need less sleep than usual.
1 I occasionally need less sleep than usual.
2 I often need less sleep than usual.
3 I frequently need less sleep than usual.
4 I can go all day and night without any sleep and still do not feel tired.
4 0 I do not talk more than usual.
1 1 occasionally talk more than usual.
2 I often talk more than usual.
3 I frequently talk more than usual.
4 I talk constantly and cannot be interrupted.
5 0 1 have not been more active (either socially, sexually, at work, home or school) than usual.
1 I have occasionally been more active than usual.
2 I have often been more active than usual.
3 I have frequently been more active than usual.
4 I am constantly active or on the go all the time.
351
3. R O SEN B ERG  SELF-ESTEEM  SCA LEtRSEl
This is a short questionnaire to measure thoughts about yourself.
Please indicate whether you strongly agree, agree, disagree or strongly disagree with each 
statement by ticking the appropriate box.
Strongly
agree
Agree Disagree Strongly
disagree
1. On the whole I am satisfied with myself.
2. At times I think 1 am no good at all.
3. I feel I have a number of good qualities.
4. I am able to do things as well as most 
people.
5. I feel I do not have much to be proud of.
6. 1 certainly feel useless at times.
7. I feel I am a person of worth, at least 
equal to others.
8. 1 wish I could have more respect for 
myself.
9. All in all, I am inclined to feel 1 am a 
failure.
10. I take a positive attitude towards 
myself.
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4. EYSENCK PERSONALITY QUESTIONNAIRE (EPOl
Please answer each of the following questions by ticking the ‘yes’ or ‘no’ box following the 
question.
There are no right or wrong answers, and no trick questions.
Work quickly and do not think too long about the exact meaning of the questions.
Please complete all questions.
Yes No
1. Do you have many different hobbies? □  □
2. Do you stop to think things over before doing anything? □  □
3. Does your mood often go up and down? □  □
4. Have you ever taken the praise for something you knew someone else
had really done? □  □
5. Are you a talkative person? □  □
6. Would being in debt worry you? □  □
7. Do you ever feel ‘just miserable’ for no reason? □  □
8. Were you ever greedy by helping yourself to more than your fair share
of anything? □  □
9. Do you lock up your house carefully at night? □  □
10. Are you rather lively? □  □
11. Would it upset you a lot to see a child or animal suffer? □  □
12. Do you often worry about things you should not have done or said? □  □
13. If you say you will do something, do you always keep your promise
no matter how inconvenient it might be? □  □
14. Can you usually let yourself go and enjoy yourself at a lively party? □  □
15. Are you an irritable person? □  □
16. Have you ever blamed someone for doing something you knew was
really your fault? E  □
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17. Do you enjoy meeting new people?
18. Do you believe insurance schemes are a good idea?
19. Are your feelings easily hurt?
20. Are all your habits good and desirable ones?
21. Do you tend to keep in the background on social occasions?
22. Would you take drugs which may have strange or dangerous effects?
23. Do you often feel ‘fed-up’?
24. Have you ever taken anything (even a pin or button) that belonged 
to someone else?
25. Do you like going out a lot?
26. Do you enjoy hurting people you love?
27. Are you often troubled about feelings of guilt?
28. Do you sometimes talk about things you know nothing about?
29. Do you prefer reading to meeting new people?
30. Do you have enemies who want to harm you?
31. Would you call yourself a nervous person?
32. Do you have many friends?
33. Do you enjoy practical jokes that can sometimes really hurt people?
34. Are you a worrier?
35. As a child, did you do as you were told immediately and without 
grumbling?
36. Would you call yourself happy-go-lucky?
37. Do good manners and cleanliness matter much to you?
38. Do you worry about awful things that might happen?
39. Have you ever broken or lost something belonging to someone else?
40. Do you usually take the initiative in making new friends? □ □
41. Would you call yourself tense or ‘highly-strung’? □ □
42. Are you mostly quiet when you are with other people? □ □
43. Do you think marriage is old-fashioned and should be done away with? □ □
44. Do you sometimes boast a little? □ □
45. Can you easily get some life into a rather dull party? □ □
46. Do people who drive carefully annoy you? □ □
47. Do you worry about your health? □ □
48. Have you ever said anything bad or nasty about anyone? □ □
49. Do you like telling jokes and funny stories to your friends? □ □
50. Do most things taste the same to you? □ □
51. As a child, were you ever cheeky to your parents? □ □
52. Do you like mixing with people? □ □
53. Does it worry you if you know there are mistakes in your work? □ □
54. Do you suffer from sleeplessness? □ □
55. Do you always wash before a meal? □ □
56. Do you nearly always have a ‘ready answer’ when people talk to you? □ □
57. Do you like to arrive at appointments in plenty of time? □ □
58. Have you often felt listless and tired for no reason? □ □
59. Have you ever cheated at a game? □ □
60. Do you like doing things in which you have to act quickly? □ □
61. Is (or was) your mother a good woman? □ □
62. Do you often feel that life is very dull? □ □
63. Have you ever taken advantage of someone? □ □
64. Do you often take on more activities than you have time for?
65. Are there several people who keep trying to avoid you?
66. Do you worry a lot about your looks?
67. Do you think people spend too much time safeguarding their future 
with savings and insurances?
68. Have you ever wished you were dead?
69. Would you dodge paying taxes if you were sure you could never be 
found out?
70. Can you get a party going?
71. Do you try not to be rude to people?
72. Do you worry too long after an embarrassing experience?
73. Have you ever insisted on having your own way?
74. When you catch a train do you often arrive at the last minute?
75. Do you suffer from ‘nerves’?
76. Do your friendships break up easily without it being your fault?
77. Do you often feel lonely?
78. Do you always practise what you preach?
79. Do you sometimes like teasing animals?
80. Are you easily hurt when people find fault with you or the work you do?
81. Have you ever been late for an appointment or work?
82. Do you like plenty of bustle and excitement around you?
83. Would you like people to be afraid of you?
84. Are you sometimes bubbling over with energy and sometimes very sluggish?
85. Do you sometimes put off until tomorrow what you ought to do today?
86. Do other people think of you as being very lively?
87. Do people tell you a lot of lies?
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
□ □
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88. Are you touchy about some things?
89. Are you always willing to admit it when you have made a mistake?
90. Would you feel very sorry for an animal caught in a trap?
5. T E M P E R A M E N T  EV A LU A TIO N  O F M EM PH IS. PISA. PA R IS AND SAN DIEGO- 
A UTOO UESTIONN A1RE VERSION (TEM PS-A)
Please read the following statements and
Circle T true for all the items that are true about you for much of your life 
Circle F false for all the rest that don’t apply to you for much of vour life
T F My ability to think varies greatly from sharp to dull for no apparent reason 
T F I constantly switch between being lively and sluggish 
T F I get sudden shifts in mood and energy
T F The way I see things is sometimes vivid, but at other times lifeless 
T F My mood often changes for no reason
T F I go back and forth between being outgoing and being withdrawn from others 
T F My moods and energy are either high or low, rarely in between 
T F I go back and forth between feeling overconfident and feeling unsure of myself 
T F My need for sleep varies a lot from just a few hours to more than 9 hours 
T F I sometimes go to bed feeling great, and wake up in the morning feeling life is not 
worth living.
T F I can really like someone a lot, and then completely lose interest in them 
T F I am the kind of person who can be sad and happy at the same time 
T F People tell me I am unable to see the lighter side of things 
T F I’m the kind of person who doubts everything 
T F I am a very skeptical person 
T F I am by nature a dissatisfied person 
T F I’m a sad, unhappy person 
T F I think things often turn out for the worst 
T F I give up easily 
T F I complain a lot
T F People tell me I blow up out of nowhere 
T F I can get so furious I could hurt someone 
T F I often get so mad that I will just trash everything 
T F When crossed, I could get into a fight
T F When I disagree with someone, I can get into a heated argument 
T F When angry, I snap at people 
T F I am known to swear a lot
T F I have been told that I become violent with just a few drinks 
T F I have a gift for speech, convincing and inspiring to others 
T F I often get many great ideas 
T F I love to tackle new projects, even if risky 
T F I like telling jokes, people tell me I am humorous 
T F I have abilities and expertise in many areas 
T F I am totally comfortable, even with people I hardly know 
T F I love to be with a lot of people 
T F I am the kind of person who likes to be the boss
T F I am often fearful of someone in my family coming down with a serious disease 
T F I am always thinking someone might break bad news to me about a family member 
T F When someone is late coming home, I fear they have had an accident
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IK IN G S SCH IZO TY PY  OUESTIONNAIREOCSQ1
INSTRUCTIONS: The following questions are about the way you feel or act. Please answer each 
question
by putting a circle around the ‘yes’ or ‘no’ following the question. There are no right or wrong answers. 
Please work quickly and do not spend too long on any one question.
1. Do you ever get the feeling that familiar
surroundings seem strange? Yes No
2. Given the choice would you prefer to live
with other people than by yourself? Yes No
3. Are you a friendly, outgoing person? Yes No
4. Would you say you’re a superstitious person? Yes No
5. Have you ever felt that you looked unreal when
you looked at yourself in the mirror? Yes No
6. Do you like authority? Yes No
7. Do you quite often get the feeling that other people 
are taking notice of you in the street or on a bus
or in a restaurant? Yes No
8. Do you often feel muddled or unable to think
clearly for long periods of time for no reason? Yes No
9. Do you like mixing with people socially? Yes No
10. Do you feel self-conscious in public? Yes No
11. Do you have a sixth sense? Yes No
12. Have you ever felt unreal, that you were not a real
person, not in the living world? Yes No
13. Are there several people who keep trying to avoid you? Yes No
14. Do people often seem to drop hints about you or say
things with a double meaning? Yes No
15. Are your thoughts often in a fog? Yes No
16. D o  y o u  feel remote from other people? Yes No
17. Do people say they find it easy to get on with you? Yes No
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)18. Are you clairvoyant or able to see into the future? Yes No
19. Do you often feel puzzled for an hour or more
for no apparent reason? Yes No
20. Do people tell you a lot of lies? Yes No
21. Are there people about who are not what they
seem to be? Yes No
22. Have you ever had the feeling for hours at a time
that things around you were unreal? Yes No
23. Do people find you easy to get to know? Yes No
24. Do people often look at you strangely? Yes No
25. Can other people read your mind? Yes No
26. Do you ever get the feeling that something odd
is going on around you that you cannot explain? Yes No
27. Have you ever felt that someone was after you
trying to hurt you either mentally or physically? Yes No
28. Do you quite often get the feeling you are being 
blamed unjustifiably for something or even
accused of something? Yes No
29. Do you ever have strange lifeless feelings? Yes No
30. Do you usually want to stay away from other people? Yes No
31. Are you relaxed about meeting people? Yes No
32. Do you ever wonder if other people or forces can
influence your actions? Yes No
33. Do you ever hear muttering or whispering when
there is no-one there? Yes No
34. Do you feel got at by people in authority such as
the police or your superiors at work? Yes No
35. Does there ever seem to be a special meaning in the
way things are arranged? Yes No
36. Do parts of your body feel changed or distorted
in a way that puzzles you? Yes No
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37. Do you prefer having only 1 or 2 close friends? Yes No
38. Are you the type of person who can accept
criticism easily? Yes No
39. Do you think other people can feel your feelings? Yes No
40. Have you ever had visions or seen things that
other people could not see? Yes No
41. Are some of your neighbours against you? Yes No
42. Does eveiyone seem to gossip about you? Yes No
43. Do things often seem as though they are
almost an imitation of reality? Yes No
44. Are you a quiet, solitary person? Yes No
45. Do you avoid arguments? Yes No
46. Do you often think that there is something like
telepathy going on which is directed towards you? Yes No
47. Do you ever hear noises like tapping or music
that other people might not hear? Yes No
48. Have you frequently feared that other people
might harm you? Yes No
49. Do you ever seem to see special meanings in 
advertisements or shop windows or on the
radio or on T.V.? Yes No
50. Do your surroundings ever feel unreal for
hours at a time? Yes No
51. Do your friendships break up easily without
it being your fault? Yes No
52. Do you look forward to going out to parties? Yes No
53. Do you sometimes get the idea that other people
or forces can control your feelings or your thinking? Yes No
54. Have you ever felt that some part of your body
did not belong to you? Yes No
55. Do you have enemies who want to harm you
without cause? Yes No
56. Did you ever believe that certain things that
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happened around you were connected to you, 
like people talking about you in the streets 
or following you?
Does the appearance of things or people ever 
change in a puzzling way?
Do you usually keep yourself to yourself?
Do people have to push you into going out?
Are you in full control of your thoughts?
Do other people seem to be acting instead of 
being themselves?
Are you suspicious of other people and their 
intentions?
Do people ever seem to laugh at you or talk 
about you critically behind your back?
F Appendices for Chapter 11
Table F-l Demographic Characteristics of Individuals with DD and their Unaffected Relatives- 
Significance of Differences
Individuals with Clinical DD and 
their unaffected relatives 
N=24 in each group
Individuals with Genetically- 
confirmed DD and their unaffected 
relatives 
N=18 in each group
P P
♦Age 0.638 0.919
♦♦Female 0.755 0.717
♦♦Lifetime Marital Status 0.731 0.673
♦♦♦Current Social Circumstances 1.00 0.882
♦♦♦Current Employment Status 0.875 0.882
♦♦♦Main Lifetime Occupation 0.479 0.565
♦♦♦ Highest Level of Educational 
Qualifications
0.125 0.195
* Paired samples T Tests, ♦♦chi-square tests, ♦♦♦ exact significance tests for Pearson’s chi-square.
Table F-2 Correlations Personality and Temperament Questionnaire Scores and Current BDI 
Scores
♦Correlation with current 
BDI Scores
Total RSE 
Scores
Individuals w ith Genetically-confirm ed DD 
and the ir unaffected relatives
DD rho= -0.512, n=14, p=0.061
Unaffected rho=-0.236, n=14,p=0.417
Negative
RSE
subscale
Score
Individuals with Clinical DD and their 
unaffected relatives
DD rho= -0.425, n=18, p=0.079
Unaffected rho= -0.350, n= 18, p=0.155
Individuals w ith Genetically-confirm ed DD 
and the ir unaffected relatives
DD rho= -0.414, n=14, p=0.141
Unaffected rho=-0.714, n=14, p=0.522
EPQ
Neuroticism
Individuals w ith Genetically-confirm ed DD 
and the ir unaffected relatives
DD rho=0.340, n=14, p=0.234
Unaffected rho=0.519, n=14, p=0.057
TEMPS-A 
Cyclothymic
Individuals w ith Genetically-confirm ed DD 
and the ir unaffected relatives
DD rho=0.779, n=15, p=0.001
Unaffected rho=0.152, n=15, p=0.589
TEMPS-A 
Hyperthymic
Individuals w ith Clinical DD and their 
unaffected relatives
DD rho=-0.552, n=21, p=0.01
Unaffected rho=-0.098, n=21,p=0.672
Total KSQ Individuals with Genetically-confirm ed DD 
and the ir unaffected relatives
DD rho= 0.155, n=10, p=0.668
Unaffected rho=0.508, n=10, p=0.134
KSQ Ideas 
of Reference
Individuals with Genetically-confirm ed DD 
and the ir unaffected relatives
DD rho=0.107, n=10, p=0.768
Unaffected rho=0.506, n=10, p=0.135
KSQ
R ecurrent 
Illusions 1
Individuals with Genetically-confirm ed DD 
and the ir unaffected relatives
DD rho=0.322, n=10, p=0.364
Unaffected rho=0.158, n=10, p=0.663
♦Spearman’s rho correlation coefficients. Individuals were included where both individuals from a DD-Unaffected 
pair had completed the BDI and the personality/temperament questionnaire.
BDI; Beck Depression Inventory, RSE; Rosenberg Self-Esteem Scale, EPQ; Eysenck Personality Questionnaire, 
TEMPS-A; Temperament Evaluation of Memphis, Pisa, Paris and San Diego-Autoquestionnaire version, KSQ; 
Kings Schizotypy Questionnaire.
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Table F-3 Comparison of Temperament and Personality Questionnaire Score of Individuals with 
DD and Their Unaffected Relatives (analysis of individuals with scores of <10 on the BDI)
Mean Standard
Deviation
*t P
Total RSE
Scores
Individuals with Genetically- 
confirm ed DD and the ir unaffected 
relatives
DD**N=8 27.13 4.970
1.510 0.175Unaffected**N=8 31.38 5.181
Negative Individuals with Clinical DD and DD**N=10 13.60 3.062
RSE
subscale
Score
the ir unaffected relatives Unaffected**N=10 16.00 3.333 1.686 0.126
Individuals with Genetically- 
confirm ed DD and the ir unaffected 
relatives
DD**N=8 13.00 3.117
0.1394 0.206Unaffected**N=8 15.50 3.423
EPQ
Neuroticism
Individuals with Genetically- 
confirm ed DD and the ir unaffected 
relatives
DD**N=8 12.25 5.994
3.656 0.008Unaffected* *N=8 7.00 4.840
TEMPS-A
Cyclothymic
Individuals with Genetically- 
confirm ed DD and the ir unaffected 
relatives
DD**N=8 2.00 1.690
0.271 0.794Unaffected**N=8 2.25 2.053
TEMPS-A
Hyperthymic
Individuals with C linical DD and 
th e ir unaffected relatives
DD**N=10 3.30 1.829
1.285 0.231Unaffected* *N= 10 4.60 2.221
Total KSQ Individuals w ith Genetically- 
confirm ed DD and the ir unaffected 
relatives
DD**N=6 10.17 5.636
3.005 0.030Unaffected* *N=6 6.33 4.179
KSQ Ideas 
of Reference
Individuals with Genetically- 
confirm ed DD and the ir unaffected 
relatives
DD**N=6 1.83 1.472
4.00 0.010U naffected * *N=6 0.50 0.837
KSQ
Recurrent 
Illusions 1
Individuals with Genetically- 
confirm ed DD and th e ir unaffected 
relatives
DD**N=6 0.67 1.211
1.464 0.203Unaffected**N=6 0.17 0.408
♦Paired Samples T Tests. **DD-Unaffected pairs were included where both individuals completed the BDI 
questionnaire and the personality/temperament questionnaire and had a score of <10 on the BDI.
BDI; Beck Depression Inventory, DD; Darier’s Disease, RSE; Rosenberg Self-Esteem Scale, EPQ; Eysenck 
Personality Questionnaire, TEMPS-A; Temperament Evaluation of Memphis, Pisa, Paris and San Diego- 
Autoquestionnaire version, KSQ; Kings Schizotypy Questionnaire.
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